Results	O
from	O
human	O
in	O
vitro	O
metabolism	O
studies	O
and	O
nonclinical	O
studies	O
show	O
that	O
REVLIMID	B-Brand
(	O
lenalidomide	B-Drug
)	O
is	O
neither	O
metabolized	O
by	O
nor	O
inhibits	O
or	O
induces	O
the	O
cytochrome	O
P9	O
pathway	O
suggesting	O
that	O
lenalidomide	B-Drug
is	O
not	O
likely	O
to	O
cause	O
or	O
be	O
subject	O
to	O
P9	O
-	O
based	O
metabolic	O
drug	O
interactions	O
in	O
man	O
.	O
      
Interacts	O
with	O
valproic	B-Drug
acid	I-Drug
      
This	O
may	O
result	O
in	O
severe	O
ventricular	O
arrhythmia	O
typically	O
torsades	O
de	O
pointe	O
.	O
      
However	O
in	O
clinical	O
studies	O
the	O
consequences	O
of	O
concomitant	O
irbesartan	B-Drug
on	O
the	O
pharmacodynamics	O
of	O
warfarin	B-Drug
were	O
negligible	O
.	O
      
Administration	O
of	O
a	O
9	O
g	O
bolus	O
followed	O
by	O
9	O
to	O
9	O
g	O
/	O
hr	O
should	O
achieve	O
and	O
sustain	O
plasma	O
levels	O
of	O
9	O
mg	O
/	O
mL	O
.	O
      
Therefore	O
caution	O
should	O
be	O
used	O
in	O
concomitant	O
administration	O
.	O
      
Interactions	O
have	O
been	O
observed	O
when	O
other	O
nondepolarizing	B-Group
muscle	I-Group
relaxants	I-Group
have	O
been	O
administered	O
in	O
succession	O
.	O
      
Chlorthalidone	B-Drug
and	O
related	O
drugs	O
may	O
increase	O
the	O
responsiveness	O
to	O
tubocurarine	B-Drug
.	O
      
Interaction	O
between	O
lomefloxacin	B-Drug
and	O
cyclosporine	B-Drug
has	O
not	O
been	O
studied	O
.	O
      
Studies	O
to	O
evaluate	O
possible	O
interactions	O
between	O
REVIA	B-Brand
and	O
drugs	O
other	O
than	O
opiates	B-Group
have	O
not	O
been	O
performed	O
.	O
      
especially	O
if	O
these	O
patients	O
are	O
extensive	O
metabolizers	O
.	O
      
If	O
it	O
is	O
necessary	O
to	O
continue	O
the	O
diuretic	B-Group
initiate	O
therapy	O
with	O
PRINIVIL	B-Brand
at	O
a	O
dose	O
of	O
9	O
mg	O
daily	O
and	O
provide	O
close	O
medical	O
supervision	O
after	O
the	O
initial	O
dose	O
until	O
blood	O
pressure	O
has	O
stabilized	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interaction	O
Captopril	B-Drug
may	O
cause	O
a	O
false	O
-	O
positive	O
urine	O
test	O
for	O
acetone	O
.	O
      
Probenecid	B-Drug
:	O
Probenecid	B-Drug
slows	O
the	O
renal	O
elimination	O
of	O
lome	O
-	O
floxacin	O
.	O
      
When	O
the	O
STADOL	B-Brand
NS	I-Brand
was	O
administered	O
9	O
minutes	O
after	O
the	O
sumatriptan	B-Drug
nasal	O
spray	O
the	O
AUC	O
of	O
butorphanol	B-Drug
increased	O
9	O
%	O
and	O
Cmax	O
decreased	O
9	O
%	O
.	O
      
Warfarin	B-Drug
:	O
The	O
effect	O
of	O
valdecoxib	B-Drug
on	O
the	O
anticoagulant	O
effect	O
of	O
warfarin	B-Drug
(	O
9	O
-	O
9	O
mg	O
/	O
day	O
)	O
was	O
studied	O
in	O
healthy	O
subjects	O
by	O
coadministration	O
of	O
BEXTRA	B-Brand
9	O
mg	O
BID	O
for	O
9	O
days	O
.	O
      
Use	O
of	O
neuroleptics	B-Group
in	O
conjunction	O
with	O
oral	O
morphine	B-Drug
may	O
increase	O
the	O
risk	O
of	O
respiratory	O
depression	O
hypotension	O
and	O
profound	O
sedation	O
or	O
coma	O
.	O
      
Although	O
9	O
-	O
hydroxy	O
-	O
corticosteroid	O
measurements	O
(	O
Porter	O
-	O
Silber	O
test	O
)	O
do	O
not	O
appear	O
to	O
be	O
artifactually	O
altered	O
it	O
is	O
suggested	O
that	O
therapy	O
with	O
naproxen	B-Drug
be	O
temporarily	O
discontinued	O
9	O
hours	O
before	O
adrenal	O
function	O
tests	O
are	O
performed	O
if	O
the	O
Porter	O
-	O
Silber	O
test	O
is	O
to	O
be	O
used	O
.	O
      
Coadministration	O
of	O
warfarin	B-Drug
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B-Drug
.	O
      
Digoxin	B-Drug
:	O
When	O
Starlix	B-Brand
9	O
mg	O
before	O
meals	O
was	O
administered	O
in	O
combination	O
with	O
a	O
single	O
9	O
-	O
mg	O
dose	O
of	O
digoxin	B-Drug
to	O
healthy	O
volunteers	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O
      
Digoxin	B-Drug
:	O
In	O
patients	O
with	O
hypercholesterolemia	O
concomitant	O
administration	O
of	O
lovastatin	B-Drug
and	O
digoxin	B-Drug
resulted	O
in	O
no	O
effect	O
on	O
digoxin	B-Drug
plasma	O
concentrations	O
.	O
      
Therefore	O
drugs	O
that	O
affect	O
CYP9A9	O
and	O
/	O
or	O
Pgp	O
may	O
modify	O
the	O
pharmacokinetics	O
of	O
saquinavir	B-Drug
.	O
      
Combination	O
hormonal	B-Group
contraceptives	I-Group
may	O
also	O
increase	O
risk	O
of	O
thromboembolic	O
disorders	O
.	O
      
The	O
potential	O
for	O
supine	O
hypertension	O
should	O
be	O
carefully	O
monitored	O
in	O
these	O
patients	O
and	O
may	O
be	O
minimized	O
by	O
either	O
reducing	O
the	O
dose	O
of	O
fludrocortisone	B-Drug
acetate	I-Drug
or	O
decreasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
.	O
      
Calcium	B-Drug
Supplements	O
/	O
Antacids	B-Group
      
Routine	O
monitoring	O
should	O
be	O
performed	O
when	O
therapy	O
with	O
BEXTRA	B-Brand
is	O
either	O
initiated	O
or	O
discontinued	O
in	O
patients	O
on	O
anticonvulsant	O
therapy	O
.	O
      
A	O
specific	O
treatment	O
for	O
extravasation	O
reactions	O
is	O
unknown	O
at	O
this	O
time	O
.	O
      
As	O
with	O
all	O
drugs	O
care	O
should	O
be	O
exercised	O
when	O
treating	O
patients	O
with	O
multiple	O
medications	O
.	O
      
Aminoglutethimide	B-Drug
administered	O
concomitantly	O
with	O
depo	B-Brand
-	O
subQ	I-Brand
provera	I-Brand
9	I-Brand
may	O
significantly	O
decrease	O
the	O
serum	O
concentrations	O
of	O
MPA	B-Drug
.	O
      
Therefore	O
women	O
requiring	O
treatment	O
with	O
one	O
or	O
more	O
of	O
these	O
drugs	O
must	O
use	O
two	O
OTHER	O
effective	O
or	O
highly	O
effective	O
methods	O
of	O
contraception	O
or	O
abstain	O
from	O
heterosexual	O
sexual	O
contact	O
while	O
taking	O
thalidomide	B-Drug
.	O
      
Clinically	O
meaningful	O
drug	O
interactions	O
have	O
occurred	O
with	O
concomitant	O
medications	O
and	O
include	O
but	O
are	O
not	O
limited	O
to	O
the	O
following	O
:	O
Agents	O
Highly	O
Bound	O
to	O
Plasma	O
Protein	O
Carbamazepine	B-Drug
is	O
not	O
highly	O
bound	O
to	O
plasma	O
proteins	O
;	O
      
Administration	O
of	O
9	O
-	O
mg	O
/	O
kg	O
(	O
9	O
x	O
ED9	O
)	O
NIMBEX	B-Brand
at	O
9	O
%	O
or	O
9	O
%	O
recovery	O
following	O
an	O
intubating	O
dose	O
of	O
succinylcholine	B-Drug
(	O
9	O
mg	O
/	O
kg	O
)	O
produced	O
9	O
%	O
neuromuscular	O
block	O
.	O
      
Phenothiazines	B-Group
-	O
Taking	O
piperazine	B-Drug
and	O
a	O
phenothiazine	B-Group
together	O
may	O
increase	O
the	O
risk	O
of	O
convulsions	O
(	O
seizures	O
)	O
.	O
      
Prolonged	O
recovery	O
time	O
may	O
occur	O
if	O
barbiturates	B-Group
and	O
/	O
or	O
narcotics	B-Group
are	O
used	O
concurrently	O
with	O
ketamine	B-Drug
.	O
      
The	O
appropriate	O
dose	O
for	O
nelfinavir	B-Drug
incombination	O
with	O
nevirapine	B-Drug
with	O
respectto	O
safety	O
and	O
efficacy	O
has	O
not	O
been	O
established	O
.	O
      
Concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
acetaminophen	B-Drug
in	O
dogs	O
but	O
not	O
in	O
rats	O
at	O
approximately	O
9	O
times	O
the	O
recommended	O
maximum	O
human	O
therapeutic	O
dose	O
of	O
each	O
(	O
9	O
to	O
9	O
mg	O
/	O
kg	O
/	O
day	O
of	O
diflunisal	B-Drug
/	O
acetaminophen	B-Drug
)	O
resulted	O
in	O
greater	O
gastrointestinal	O
toxicity	O
than	O
when	O
either	O
drug	O
was	O
administered	O
alone	O
.	O
      
If	O
it	O
is	O
necessary	O
to	O
continue	O
the	O
diuretic	B-Group
provide	O
close	O
medical	O
supervision	O
after	O
the	O
initial	O
dose	O
for	O
at	O
least	O
two	O
hours	O
and	O
until	O
blood	O
pressure	O
has	O
stabilized	O
for	O
at	O
least	O
an	O
additional	O
hour..	O
      
It	O
is	O
probable	O
that	O
dexamethasone	B-Drug
given	O
as	O
antiemetic	O
prophylaxis	O
contributed	O
to	O
hyperglycemia	O
in	O
some	O
patients	O
.	O
      
Johns	O
Wort	O
)	O
may	O
significantly	O
reduce	O
exposure	O
to	O
Gleevec	B-Brand
.	O
      
=	O
decrease	O
      
Agents	O
that	O
may	O
enhance	O
the	O
risk	O
of	O
hemorrhage	O
should	O
be	O
discontinued	O
prior	O
to	O
initiation	O
of	O
Fondaparinux	B-Drug
therapy	O
.	O
      
-	O
isoniazid	B-Drug
(	O
Nydrazid	B-Brand
)	O
;	O
      
indinavir	B-Drug
concentration	O
rifabutin	B-Drug
concentration	O
      
Initial	O
doses	O
of	O
adrenergic	B-Group
agents	I-Group
such	O
as	O
dopamine	B-Drug
or	O
epinephrine	B-Drug
should	O
be	O
reduced	O
and	O
titrated	O
to	O
achieve	O
the	O
desired	O
response	O
.	O
      
Apraclonidine	B-Drug
should	O
not	O
be	O
used	O
in	O
patients	O
receiving	O
MAO	B-Group
inhibitors	I-Group
.	O
      
Gastrointestinal	O
agents	O
(	O
e.g.	O
antacids	B-Group
)	O
.	O
      
Enoxacin	B-Drug
interferes	O
with	O
the	O
metabolism	O
of	O
theophylline	B-Drug
resulting	O
in	O
a	O
9	O
%	O
to	O
9	O
%	O
dose	O
-	O
related	O
decrease	O
in	O
theophylline	B-Drug
clearance	O
and	O
a	O
subsequent	O
9	O
%	O
to	O
9	O
%	O
increase	O
in	O
serum	O
theophylline	O
levels	O
.	O
      
It	O
is	O
not	O
known	O
whether	O
this	O
potentiation	O
of	O
ampicillin	B-Drug
rashes	O
is	O
due	O
to	O
allopurinol	B-Drug
or	O
the	O
hyperuricemia	O
present	O
in	O
these	O
patients	O
.	O
      
Vardenafil	B-Drug
dose	O
should	O
not	O
exceed	O
a	O
maximum	O
of	O
9	O
mg	O
in	O
a	O
9	O
-	O
hour	O
period	O
in	O
patients	O
receiving	O
concomitant	O
indinavir	B-Drug
therapy	O
.	O
      
Nifedipine	B-Drug
:	O
Vardenafil	B-Drug
9	O
mg	O
when	O
co	O
-	O
administered	O
with	O
slow	O
-	O
release	O
nifedipine	B-Drug
9	O
mg	O
or	O
9	O
mg	O
once	O
daily	O
did	O
not	O
affect	O
the	O
relative	O
bioavailability	O
(	O
AUC	O
)	O
or	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
of	O
nifedipine	B-Drug
a	O
drug	O
that	O
is	O
metabolized	O
via	O
CYP9A9	O
.	O
      
Potential	O
for	O
INVEGA	B-Brand
to	O
Affect	O
Other	O
Drugs	O
Paliperidone	B-Drug
is	O
not	O
expected	O
to	O
cause	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
with	O
drugs	O
that	O
are	O
metabolized	O
by	O
cytochrome	O
P9	O
isozymes	O
.	O
      
Phenobarbital	B-Drug
:	O
Amphetamines	B-Group
may	O
delay	O
intestinal	O
absorption	O
of	O
phenobarbital	B-Drug
;	O
      
.	O
      
The	O
size	O
of	O
wheal	O
and	O
flare	O
were	O
significantly	O
larger	O
when	O
fexofenadine	B-Drug
hydrochloride	I-Drug
was	O
administered	O
with	O
either	O
grapefruit	O
or	O
orange	O
juices	O
compared	O
to	O
water	O
.	O
      
Fluoxetine	B-Drug
OCs	B-Group
sertraline	B-Drug
diltiazem	B-Drug
macrolide	B-Group
antibiotics	I-Group
(	O
exercise	O
caution	O
)	O
.	O
      
Thus	O
agents	O
likely	O
to	O
be	O
concomitantly	O
administered	O
with	O
Chirocaine	B-Brand
that	O
are	O
metabolized	O
by	O
this	O
isoenzyme	O
family	O
may	O
potentially	O
interact	O
with	O
Chirocaine	B-Brand
.	O
      
The	O
clinical	O
relevance	O
of	O
this	O
difference	O
is	O
unknown	O
.	O
      
Patients	O
taking	O
low	O
-	O
dose	O
aspirin	B-Brand
plus	O
ibuprofen	B-Drug
were	O
not	O
studied	O
.	O
      
Fat	O
redistribution	O
:	O
Redistribution	O
/	O
accumulation	O
of	O
body	O
fat	O
including	O
central	O
obesity	O
dorsocervical	O
fat	O
enlargement	O
(	O
buffalo	O
hump	O
)	O
peripheral	O
wasting	O
facial	O
wasting	O
breast	O
enlargement	O
and	O
cushingoid	O
appearance	O
have	O
been	O
observed	O
in	O
patients	O
receiving	O
antiretroviral	B-Group
therapy	O
.	O
      
Cholestyramine	B-Drug
and	O
Drugs	O
that	O
Bind	O
Bile	O
Acids	O
:	O
These	O
drugs	O
interrupt	O
enterohepatic	O
recirculation	O
and	O
reduce	O
MPA	B-Drug_n
exposure	O
when	O
coadministered	O
with	O
mycophenolate	B-Drug
mofetil	I-Drug
.	O
      
Whether	O
this	O
interaction	O
also	O
occurs	O
with	O
the	O
intravenous	O
topical	O
or	O
vaginal	O
preparations	O
of	O
miconazole	B-Drug
is	O
not	O
known	O
.	O
      
These	O
effects	O
are	O
usually	O
reversible	O
.	O
      
As	O
with	O
other	O
dialysis	B-Group
solutions	I-Group
blood	O
concentrations	O
of	O
dialyzable	O
drugs	O
may	O
be	O
reduced	O
by	O
dialysis	O
.	O
      
Digitalis	B-Group
glycosides	I-Group
:	O
Patients	O
on	O
digitalis	B-Group
glycosides	I-Group
may	O
be	O
at	O
increased	O
risk	O
of	O
arrhythmias	O
due	O
to	O
hypokalemia	O
.	O
      
Therefore	O
co	O
-	O
administration	O
of	O
tricyclic	B-Group
antidepressants	I-Group
with	O
other	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isoenzyme	O
including	O
other	O
antidepressants	B-Group
phenothiazines	B-Group
carbamazepine	B-Drug
and	O
Type	B-Group
9C	I-Group
antiarrhythmics	I-Group
(	O
eg	O
propafenone	B-Drug
flecainide	B-Drug
and	O
encainide	B-Drug
)	O
or	O
that	O
inhibit	O
this	O
enzyme	O
(	O
eg	O
quinidine	B-Drug
)	O
should	O
be	O
approached	O
with	O
caution	O
.	O
      
Nevirapine	B-Drug
      
and	O
diuretics	B-Group
such	O
as	O
furosemide	B-Drug
.	O
      
In	O
another	O
report	O
nine	O
patients	O
with	O
breast	O
cancer	O
were	O
reported	O
to	O
have	O
decreased	O
symptoms	O
of	O
methotrexate	B-Drug
-	O
related	O
toxicity	O
when	O
given	O
supplemental	O
L	B-Drug
-	O
glutamine	I-Drug
at	O
a	O
dose	O
of	O
9	O
gram	O
/	O
kilogram	O
/	O
day	O
.	O
      
-	O
Disulfiram	B-Drug
(	O
e.g.	O
Antabuse	B-Brand
)	O
or	O
      
In	O
a	O
study	O
in	O
normal	O
volunteers	O
concomitant	O
administration	O
of	O
buspirone	B-Drug
HCl	I-Drug
and	O
haloperidol	B-Drug
resulted	O
in	O
increased	O
serum	O
haloperidol	B-Drug
concentrations	O
.	O
      
Drugs	O
that	O
induce	O
CYP9A9	O
activity	O
would	O
be	O
expected	O
to	O
increase	O
the	O
clearance	O
of	O
indinavir	B-Drug
resulting	O
in	O
lowered	O
plasma	O
concentrations	O
of	O
indinavir	B-Drug
.	O
      
Increases	O
in	O
sertraline	B-Drug
dose	O
should	O
be	O
guided	O
by	O
clinical	O
response	O
.	O
      
Free	O
T9	O
and	O
T9	O
concentrations	O
are	O
unaltered	O
.	O
      
Cyclosporine	B-Drug
:	O
Concomitant	O
administration	O
of	O
nicardipine	B-Drug
and	O
cyclosporine	B-Drug
levels	O
.	O
      
A	O
variety	O
of	O
antiarrhythmics	B-Group
such	O
as	O
quinidine	B-Drug
or	O
propranolol	B-Drug
were	O
also	O
added	O
sometimes	O
with	O
improved	O
control	O
of	O
ventricular	O
ectopy	O
.	O
      
Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
fosfomycin	B-Drug
when	O
coadministered	O
with	O
MONUROL	B-Brand
.	O
      
Aripiprazole	B-Drug
also	O
does	O
not	O
undergo	O
direct	O
glucuronidation	O
.	O
      
Geocillin	B-Brand
(	O
carbenicillin	B-Drug
indanyl	I-Drug
sodium	I-Drug
)	O
blood	O
levels	O
may	O
be	O
increased	O
and	O
prolonged	O
by	O
concurrent	O
administration	O
of	O
probenecid	B-Drug
.	O
      
A	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
.	O
      
Results	O
of	O
preliminary	O
studies	O
in	O
humans	O
and	O
rats	O
suggest	O
that	O
nonabsorbable	O
antacids	B-Group
given	O
concurrently	O
with	O
lactulose	B-Drug
may	O
inhibit	O
the	O
desired	O
lactulose	B-Drug
-	O
induced	O
drop	O
in	O
colonic	O
pH	O
.	O
      
Metoprolol	B-Drug
-	O
Administration	O
of	O
9	O
mg	O
/	O
day	O
LEXAPRO	B-Brand
for	O
9	O
days	O
in	O
healthy	O
volunteers	O
resulted	O
in	O
a	O
9	O
%	O
increase	O
in	O
Cmax	O
and	O
9	O
%	O
increase	O
in	O
AUC	O
of	O
the	O
beta	B-Group
-	O
adrenergic	I-Group
blocker	I-Group
metoprolol	B-Drug
(	O
given	O
in	O
a	O
single	O
dose	O
of	O
9	O
mg	O
)	O
.	O
      
Patients	O
receiving	O
concomitant	O
lovastatin	B-Drug
and	O
erythromycin	B-Drug
should	O
be	O
carefully	O
monitored	O
;	O
      
These	O
data	O
suggest	O
that	O
the	O
conversion	O
of	O
losartan	B-Drug
to	O
its	O
active	O
metabolite	O
is	O
mediated	O
primarily	O
by	O
P9	O
9C9	O
and	O
not	O
P9	O
9A9	O
.	O
      
Haloperidol	B-Drug
:	O
Haloperidol	B-Drug
blocks	O
dopamine	O
and	O
norepinephrine	O
reuptake	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	B-Group
.	O
      
Effect	O
on	O
Concentration	O
of	O
Nevirapine	B-Drug
or	O
Concomitant	O
Drug	O
      
This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	B-Group
concomitantly	O
with	O
ACE	B-Group
inhibitors	I-Group
.	O
      
Dosage	O
adjustment	O
may	O
be	O
warranted	O
when	O
levobupivacaine	B-Drug
is	O
concurrently	O
administered	O
with	O
CYP9A9	O
inhibitors	O
and	O
CYP9A9	O
inhibitors	O
as	O
systemic	O
levobupivacaine	B-Drug
levels	O
may	O
rise	O
resulting	O
in	O
toxicity	O
.	O
      
PEGANONE	B-Brand
used	O
in	O
combination	O
with	O
other	O
drugs	O
known	O
to	O
adversely	O
affect	O
the	O
hematopoietic	O
system	O
should	O
be	O
avoided	O
if	O
possible	O
.	O
      
This	O
may	O
occur	O
because	O
diflunisal	B-Drug
competitively	O
displaces	O
coumarins	B-Group
from	O
protein	O
binding	O
sites	O
.	O
      
Sympathomimetics	B-Group
may	O
reduce	O
the	O
antihypertensive	O
effects	O
of	O
methyldopa	B-Drug
mecamylamine	B-Drug
reserpine	B-Drug
and	O
veratrum	B-Group
alkaloids	I-Group
.	O
      
In	O
one	O
survey	O
9	O
%	O
of	O
patients	O
taking	O
labetalol	B-Drug
HCl	I-Drug
in	O
combination	O
with	O
tricyclic	B-Group
antidepressants	I-Group
experienced	O
tremor	O
as	O
compared	O
to	O
9	O
%	O
reported	O
to	O
occur	O
with	O
labetalol	B-Drug
HCl	I-Drug
alone	O
.	O
      
Antiepileptic	B-Group
drugs	I-Group
:	O
Potential	O
interactions	O
between	O
Trileptal	B-Brand
and	O
other	O
AEDs	B-Group
were	O
assessed	O
in	O
clinical	O
studies	O
.	O
      
No	O
formal	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O
      
Clinically	O
significant	O
QTc	O
prolongation	O
has	O
not	O
been	O
found	O
with	O
Mefloquineuine	O
alone	O
.	O
      
The	O
increased	O
plasma	O
concentration	O
of	O
terfenadine	B-Drug
or	O
its	O
metabolite	O
may	O
result	O
in	O
prolonged	O
QT	O
intervals	O
.	O
      
Rifampin	B-Drug
:	O
Co	O
-	O
administration	O
of	O
VIOXX	B-Brand
with	O
rifampin	B-Drug
9	O
mg	O
daily	O
a	O
potent	O
inducer	O
of	O
hepatic	O
metabolism	O
produced	O
an	O
approximate	O
9	O
%	O
decrease	O
in	O
rofecoxib	B-Drug
plasma	O
concentrations	O
.	O
      
approximately	O
one	O
-	O
hundredth	O
of	O
the	O
human	O
recommended	O
dose	O
based	O
on	O
body	O
surface	O
area	O
[	O
BSA	O
]	O
)	O
fulvestrant	B-Drug
caused	O
a	O
reversible	O
reduction	O
in	O
female	O
fertility	O
as	O
well	O
as	O
effects	O
on	O
embryo	O
/	O
fetal	O
development	O
consistent	O
with	O
its	O
anti	O
-	O
estrogenic	O
activity	O
.	O
      
Combination	O
was	O
associated	O
with	O
a	O
higher	O
frequency	O
of	O
adverse	O
clinical	O
experiences	O
(	O
eg	O
dizziness	O
nausea	O
paresthesia	O
)	O
and	O
laboratory	O
abnormalities	O
(	O
elevated	O
liver	O
enzymes	O
)	O
.	O
      
Chirocaine	B-Brand
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
other	O
local	O
anesthetics	B-Group
or	O
agents	O
structurally	O
related	O
to	O
amide	O
-	O
type	O
local	O
anesthetics	O
since	O
the	O
toxic	O
effects	O
of	O
these	O
drugs	O
could	O
be	O
additive	O
.	O
      
.	O
      
therefore	O
it	O
is	O
possible	O
that	O
adverse	O
events	O
associated	O
with	O
the	O
individual	O
use	O
of	O
either	O
drug	O
may	O
be	O
more	O
apt	O
to	O
occur	O
.	O
      
Dose	O
reduction	O
of	O
CRIXIVAN	B-Brand
to	O
9	O
mg	O
every	O
9	O
hours	O
should	O
be	O
considered	O
.	O
      
Lorazepam	B-Drug
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
eszopiclone	B-Drug
9	O
mg	O
and	O
lorazepam	B-Drug
9	O
mg	O
did	O
not	O
have	O
clinically	O
relevant	O
effects	O
on	O
the	O
pharmacodynamics	O
or	O
pharmacokinetics	O
of	O
either	O
drug	O
.	O
      
Coadministration	O
of	O
Itraconazole	B-Drug
and	O
cyclosporine	B-Drug
tacrolimus	B-Drug
or	O
digoxin	B-Drug
has	O
led	O
to	O
increased	O
plasma	O
concentrations	O
of	O
the	O
latter	O
three	O
drugs	O
.	O
      
The	O
following	O
similar	O
changes	O
may	O
be	O
expected	O
with	O
larger	O
doses	O
of	O
estrogen	B-Group
:	O
Increased	O
sulfobromophthalein	O
retention	O
;	O
      
Dosage	O
adjustment	O
may	O
be	O
required	O
if	O
cyclosporine	B-Drug
tacrolimus	B-Drug
or	O
methylprednisolone	B-Drug
are	O
given	O
concomitantly	O
with	O
NIZORAL	B-Brand
Tablets	O
.	O
      
these	O
should	O
be	O
given	O
9	O
to	O
9	O
hours	O
before	O
or	O
after	O
oral	O
administration	O
of	O
leveomepromazine	B-Drug
.	O
      
Selegiline	B-Drug
:	O
In	O
healthy	O
volunteers	O
(	O
N=	O
9	O
)	O
selegiline	B-Drug
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
pramipexole	B-Drug
.	O
      
However	O
high	O
doses	O
of	O
leucovorin	B-Drug
may	O
reduce	O
the	O
efficacy	O
of	O
intrathecally	O
administered	O
methotrexate	B-Drug
.	O
      
Estrogen	B-Group
-	O
containing	O
therapies	O
should	O
not	O
be	O
used	O
with	O
ARIMIDEX	B-Brand
as	O
they	O
may	O
diminish	O
its	O
pharmacologic	O
action	O
.	O
      
clinical	O
significance	O
unknown	O
.	O
      
However	O
in	O
selected	O
circumstances	O
in	O
which	O
such	O
therapy	O
is	O
appropriate	O
using	O
adequate	O
doses	O
of	O
antibacterial	B-Group
agents	O
and	O
beginning	O
penicillin	O
therapy	O
first	O
should	O
minimize	O
the	O
potential	O
for	O
interaction	O
.	O
      
Seizures	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
another	O
quinolone	B-Group
class	I-Group
antimicrobial	I-Group
and	O
the	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drug	I-Group
fenbufen	B-Drug
concurrently	O
.	O
      
Antifungal	B-Group
Agents	I-Group
      
Antihistamines	B-Group
:	O
Amphetamines	B-Group
may	O
counteract	O
the	O
sedative	O
effect	O
of	O
antihistamines	B-Group
.	O
      
There	O
was	O
no	O
evidence	O
in	O
the	O
controlled	O
studies	O
of	O
Nutropin	B-Brand
interaction	O
with	O
drugs	O
commonly	O
used	O
in	O
chronic	O
renal	O
insufficiency	O
patients	O
.	O
      
The	O
concomitant	O
administration	O
of	O
uricosuric	B-Group
agents	I-Group
and	O
allopurinol	B-Drug
has	O
been	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
excretion	O
of	O
oxypurines	O
(	O
hypoxanthine	O
and	O
xanthine	O
)	O
and	O
an	O
increase	O
in	O
urinary	O
uric	O
acid	O
excretion	O
compared	O
with	O
that	O
observed	O
with	O
allopurinol	B-Drug
alone	O
.	O
      
Enoxacin	B-Drug
does	O
not	O
affect	O
the	O
clearance	O
of	O
the	O
active	O
S	O
-	O
isomer	O
and	O
changes	O
in	O
clotting	O
time	O
have	O
not	O
been	O
observed	O
when	O
enoxacin	B-Drug
and	O
warfarin	B-Drug
were	O
coadministered	O
.	O
      
Oral	O
neomycin	B-Drug
inhibits	O
the	O
gastrointestinal	O
absorption	O
of	O
penicillin	B-Drug
V	I-Drug
oral	O
vitamin	B-Drug
B	I-Drug
-	O
9	I-Drug
methotrexate	B-Drug
and	O
9	B-Drug
-	O
fluorouracil	I-Drug
.	O
      
At	O
steady	O
state	O
VIOXX	B-Brand
9	O
mg	O
once	O
daily	O
had	O
no	O
effect	O
on	O
the	O
anti	O
-	O
platelet	O
activity	O
of	O
low	O
-	O
dose	O
(	O
9	O
mg	O
once	O
daily	O
)	O
aspirin	B-Brand
as	O
assessed	O
by	O
ex	O
vivo	O
platelet	O
aggregation	O
and	O
serum	O
TXB9	O
generation	O
in	O
clotting	O
blood	O
.	O
      
Patients	O
receiving	O
other	O
narcotic	B-Group
analgesics	I-Group
antipsychotics	B-Group
antianxiety	B-Group
agents	I-Group
or	O
other	O
CNS	B-Group
depressants	I-Group
(	O
including	O
alcohol	B-Drug
)	O
concomitantly	O
with	O
hydrocodone	B-Drug
and	O
acetaminophen	B-Drug
tablets	O
may	O
exhibit	O
an	O
additive	O
CNS	O
depression	O
.	O
      
There	O
were	O
no	O
statistically	O
significant	O
increases	O
in	O
tumor	O
incidences	O
in	O
drug	O
-	O
treated	O
rats	O
or	O
mice	O
.	O
      
A	O
clinical	O
interaction	O
study	O
was	O
also	O
conducted	O
with	O
alosetron	B-Drug
and	O
the	O
CYP9A9	O
substrate	O
cisapride	B-Drug
.	O
      
9	O
-	O
OH	O
metabolite	O
concentration	O
      
Phenytoin	B-Drug
/	O
Phenobarbital	B-Drug
:	O
The	O
coadministration	O
of	O
phenytoin	B-Drug
or	O
phenobarbital	B-Drug
will	O
not	O
affect	O
plasma	O
concentrations	O
of	O
vitamin	B-Group
D	I-Group
but	O
may	O
reduce	O
endogenous	O
plasma	O
levels	O
of	O
calcitriol	B-Drug
/	O
ergocalcitriol	O
by	O
accelerating	O
metabolism	O
.	O
      
The	O
concomitant	O
use	O
of	O
transdermal	O
fentanyl	B-Drug
with	O
ritonavir	B-Drug
or	O
other	O
potent	O
9A9	O
inhibitors	O
such	O
as	O
ketoconazole	B-Drug
itraconazole	B-Drug
troleandomycin	B-Drug
clarithromycin	B-Drug
nelfinavir	B-Drug
and	O
nefazadone	O
may	O
result	O
in	O
an	O
increase	O
in	O
fentanyl	B-Drug
plasma	O
concentrations	O
.	O
      
Patients	O
treated	O
with	O
extended	O
release	O
metoprolol	B-Drug
succinate	I-Drug
plus	O
a	O
catecholamine	O
depletor	O
should	O
therefore	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
or	O
marked	O
bradycardia	O
which	O
may	O
produce	O
vertigo	O
syncope	O
or	O
postural	O
hypotension	O
.	O
      
When	O
cholestyramine	B-Drug
resin	B-Group
is	O
given	O
for	O
long	O
periods	O
of	O
time	O
concomitant	O
supplementation	O
with	O
water	O
-	O
miscible	O
(	O
or	O
parenteral	O
)	O
forms	O
of	O
fat	B-Group
-	O
soluble	I-Group
vitamins	I-Group
should	O
be	O
considered	O
.	O
      
Phenytoin	B-Drug
:	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
mean	O
phenytoin	B-Drug
AUC	O
C	O
max	O
C	O
min	O
or	O
T	O
max	O
(	O
although	O
C	O
max	O
increased	O
by	O
9	O
%	O
)	O
when	O
extended	O
phenytoin	B-Drug
sodium	I-Drug
capsules	O
(	O
9	O
mg	O
tid	O
)	O
were	O
coadministered	O
with	O
lomefloxacin	B-Drug
(	O
9	O
mg	O
qd	O
)	O
for	O
five	O
days	O
in	O
9	O
healthy	O
males	O
.	O
      
Concomitant	O
use	O
of	O
bupropion	B-Drug
with	O
other	O
drugs	O
metabolized	O
by	O
CYP9D9	O
has	O
not	O
been	O
formally	O
studied	O
.	O
      
Repeat	O
Treatment	O
Studies	O
evaluating	O
the	O
use	O
of	O
repeated	O
courses	O
of	O
Zmax	B-Brand
have	O
not	O
been	O
conducted	O
.	O
      
If	O
replacing	O
clonidine	B-Drug
by	O
beta	B-Group
-	O
blocker	I-Group
therapy	O
the	O
introduction	O
of	O
beta	B-Group
blockers	I-Group
should	O
be	O
delayed	O
for	O
several	O
days	O
after	O
clonidine	B-Drug
administration	O
has	O
stopped	O
.	O
      
When	O
phenytoin	B-Drug
or	O
other	O
hepatic	O
enzyme	O
inducers	O
such	O
as	O
rifampin	B-Drug
and	O
phenobarbital	B-Drug
have	O
been	O
taken	O
concurrently	O
with	O
Mexitil	B-Brand
lowered	O
Mexitil	B-Brand
plasma	O
levels	O
have	O
been	O
reported	O
.	O
      
These	O
agents	O
should	O
not	O
be	O
taken	O
within	O
the	O
two	O
hour	O
period	O
before	O
or	O
within	O
the	O
two	O
-	O
hour	O
period	O
after	O
nalidixic	B-Drug
acid	I-Drug
administration	O
.	O
      
Although	O
ibuprofen	B-Drug
(	O
9	O
mg	O
qid	O
)	O
can	O
be	O
administered	O
with	O
ALIMTA	B-Brand
in	O
patients	O
with	O
normal	O
renal	O
function	O
(	O
creatinine	O
clearance	O
9	O
mL	O
/	O
min	O
)	O
caution	O
should	O
be	O
used	O
when	O
administering	O
ibuprofen	B-Drug
concurrently	O
with	O
ALIMTA	B-Brand
to	O
patients	O
with	O
mild	O
to	O
moderate	O
renal	O
insufficiency	O
(	O
creatinine	O
clearance	O
from	O
9	O
to	O
9	O
mL	O
/	O
min	O
)	O
.	O
      
CYP9A9	O
Interactions	O
      
In	O
view	O
of	O
the	O
long	O
and	O
variable	O
half	O
-	O
life	O
of	O
amiodarone	B-Drug
potential	O
for	O
drug	O
interactions	O
exists	O
not	O
only	O
with	O
concomitant	O
medication	O
but	O
also	O
with	O
drugs	O
administered	O
after	O
discontinuation	O
of	O
amiodarone	B-Drug
.	O
      
Inhibitors	O
of	O
CYP9D9	O
:	O
Because	O
CYP9D9	O
is	O
involved	O
in	O
duloxetine	B-Drug
metabolism	O
concomitant	O
use	O
of	O
duloxetine	B-Drug
with	O
potent	O
inhibitors	O
of	O
CYP9D9	O
may	O
result	O
in	O
higher	O
concentrations	O
of	O
duloxetine	B-Drug
.	O
      
Diuretics	B-Group
:	O
Patients	O
on	O
diuretics	B-Group
especially	O
those	O
in	O
whom	O
diuretic	O
therapy	O
was	O
recently	O
instituted	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
Lotensin	B-Brand
.	O
      
(	O
Note	O
:	O
All	O
patients	O
receiving	O
theophylline	B-Drug
should	O
be	O
monitored	O
appropriately	O
regardless	O
of	O
concomitant	O
drug	O
therapy	O
.	O
)	O
      
Co	O
-	O
administration	O
of	O
nelfinavir	B-Drug
at	O
steady	O
-	O
state	O
with	O
a	O
single	O
dose	O
of	O
azithromycin	B-Drug
(	O
9	O
x	O
9	O
mg	O
tablets	O
)	O
results	O
in	O
increased	O
azithromycin	B-Drug
serum	O
concentrations	O
.	O
      
In	O
this	O
crossover	O
steady	O
state	O
study	O
the	O
pharmacokinetics	O
of	O
propafenone	B-Drug
were	O
unaffected	O
in	O
either	O
phenotype	O
by	O
the	O
coadministration	O
of	O
mexiletine	B-Drug
.	O
      
Oxytocin	B-Drug
or	O
other	O
oxytocics	B-Group
(	O
concurrent	O
use	O
with	O
dinoprost	B-Drug
may	O
result	O
in	O
uterine	O
hypertonus	O
possibly	O
causing	O
uterine	O
rupture	O
or	O
cervical	O
laceration	O
especially	O
in	O
the	O
absence	O
of	O
adequate	O
cervical	O
dilatation	O
;	O
      
Therefore	O
intake	O
of	O
supplemental	O
folic	B-Drug
acid	I-Drug
should	O
not	O
exceed	O
9	O
micrograms	O
(	O
g	O
sometimes	O
mcg	O
)	O
per	O
day	O
to	O
prevent	O
folic	B-Drug
acid	I-Drug
from	O
masking	O
symptoms	O
of	O
vitamin	O
B9	O
deficiency	O
.	O
      
Lithium	B-Drug
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B-Group
because	O
they	O
reduce	O
lithiums	B-Drug
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
Oral	O
Contraceptive	B-Group
:	O
Based	O
on	O
AUC	O
and	O
half	O
-	O
life	O
multiple	O
-	O
dose	O
pharmacokinetic	O
profiles	O
of	O
norethindrone	B-Drug
and	O
ethinyl	B-Drug
estradiol	I-Drug
following	O
administration	O
of	O
tablets	O
containing	O
9	O
mg	O
of	O
norethindrone	B-Drug
acetate	I-Drug
and	O
9	O
mcg	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
were	O
similar	O
with	O
and	O
without	O
coadministration	O
of	O
gabapentin	B-Drug
(	O
9	O
mg	O
TID	O
;	O
      
Drug	O
Name	O
      
Cocaine	B-Drug
sometimes	O
proves	O
to	O
be	O
fatal	O
when	O
used	O
in	O
combination	O
with	O
heroin	B-Drug_n
.	O
      
As	O
the	O
primary	O
effect	O
of	O
adenosine	B-Drug
is	O
to	O
decrease	O
conduction	O
through	O
the	O
A	O
-	O
V	O
node	O
higher	O
degrees	O
of	O
heart	O
block	O
may	O
be	O
produced	O
in	O
the	O
presence	O
of	O
carbamazepine	B-Drug
.	O
      
Methotrexate	B-Drug
VIOXX	B-Brand
9	O
9	O
and	O
9	O
mg	O
each	O
dose	O
administered	O
once	O
daily	O
for	O
9	O
days	O
had	O
no	O
effect	O
on	O
the	O
plasma	O
concentration	O
of	O
methotrexate	B-Drug
as	O
measured	O
by	O
AUC9	O
-	O
9hr	O
in	O
patients	O
receiving	O
single	O
weekly	O
methotrexate	B-Drug
doses	O
of	O
9	O
to	O
9	O
mg	O
for	O
rheumatoid	O
arthritis	O
.	O
      
No	O
drug	O
interactions	O
were	O
detected	O
except	O
for	O
an	O
increase	O
in	O
symptomatic	O
hypotension	O
in	O
patients	O
receiving	O
oral	O
ACE	B-Group
inhibitors	I-Group
.	O
      
-	O
Other	O
anti	B-Group
-	O
infectives	I-Group
by	O
mouth	O
or	O
by	O
injection	O
(	O
medicine	O
for	O
infection	O
)	O
or	O
      
No	O
dosage	O
adjustment	O
is	O
required	O
for	O
Fluvoxamine	B-Drug
Tablets	O
.	O
      
Chronic	O
administration	O
of	O
phenobarbital	B-Drug
a	O
known	O
enzyme	O
inducer	O
may	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
plasma	O
half	O
-	O
life	O
of	O
fenoprofen	B-Drug
.	O
      
The	O
addition	O
of	O
tiagabine	B-Drug
in	O
a	O
limited	O
number	O
of	O
patients	O
in	O
three	O
well	O
-	O
controlled	O
studies	O
caused	O
no	O
systematic	O
changes	O
in	O
phenobarbital	B-Drug
or	O
primidone	B-Drug
concentrations	O
when	O
compared	O
to	O
placebo	O
.	O
      
Erythromycin	B-Drug
use	O
in	O
patients	O
who	O
are	O
receiving	O
high	O
doses	O
of	O
theophylline	B-Drug
may	O
be	O
associated	O
with	O
an	O
increase	O
in	O
serum	O
theophylline	B-Drug
levels	O
and	O
potential	O
theophylline	B-Drug
toxicity	O
.	O
      
Warfarin	B-Drug
:	O
Multiple	O
oral	O
doses	O
of	O
Sonata	B-Brand
(	O
9	O
mg	O
q9h	O
for	O
9	O
days	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
warfarin	B-Drug
(	O
R+	O
)	O
-	O
or	O
(	O
S	O
-	O
)	O
-	O
enantiomers	O
or	O
the	O
pharmacodynamics	O
(	O
prothrombin	O
time	O
)	O
following	O
a	O
single	O
9	O
-	O
mg	O
oral	O
dose	O
of	O
warfarin	B-Drug
.	O
      
Similarly	O
saquinavir	B-Drug
might	O
also	O
modify	O
the	O
pharmacokinetics	O
of	O
other	O
drugs	O
that	O
are	O
substrates	O
for	O
CYP9A9	O
or	O
Pgp	O
.	O
      
If	O
this	O
is	O
not	O
possible	O
the	O
starting	O
dose	O
should	O
be	O
reduced	O
.	O
      
Refer	O
to	O
the	O
package	O
insert	O
for	O
lithium	B-Drug
preparations	O
before	O
use	O
of	O
such	O
preparations	O
with	O
chlorothiazide	B-Drug
      
Carbamazepine	B-Drug
:	O
Carbamazepine	B-Drug
causes	O
an	O
approximate	O
9	O
%	O
increase	O
in	O
the	O
clearance	O
of	O
Felbatol	B-Brand
at	O
steady	O
state	O
and	O
therefore	O
the	O
addition	O
of	O
carbamazepine	B-Drug
results	O
in	O
an	O
approximate	O
9	O
%	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
trough	O
concentrations	O
of	O
Felbatol	B-Brand
as	O
compared	O
to	O
the	O
same	O
dose	O
of	O
Felbatol	B-Brand
given	O
as	O
monotherapy	O
.	O
      
Inhibits	O
CYP9D9	O
(	O
weak	O
)	O
.	O
      
Valdecoxib	B-Drug
steady	O
state	O
plasma	O
concentrations	O
(	O
9	O
mg	O
BID	O
)	O
were	O
not	O
affected	O
significantly	O
with	O
multiple	O
doses	O
of	O
omeprazole	B-Drug
(	O
9	O
mg	O
QD	O
)	O
.	O
      
N=9	O
)	O
were	O
not	O
different	O
and	O
neither	O
were	O
gabapentin	B-Drug
pharmacokinetic	O
parameters	O
affected	O
by	O
valproic	B-Drug
acid	I-Drug
.	O
      
(	O
Thiazide	B-Group
drugs	I-Group
may	O
increase	O
the	O
responsiveness	O
to	O
tubocurarine	B-Drug
.	O
)	O
      
However	O
decreases	O
in	O
exposure	O
were	O
as	O
much	O
as	O
9	O
%	O
and	O
9	O
%	O
respectively	O
in	O
individual	O
subjects	O
.	O
      
Therefore	O
when	O
initiating	O
pressor	O
therapy	O
in	O
these	O
patients	O
the	O
initial	O
dose	O
should	O
be	O
small	O
and	O
used	O
with	O
due	O
caution	O
.	O
      
None	O
known	O
.	O
      
Effects	O
of	O
Antacids	B-Group
on	O
Felbatol	B-Brand
The	O
rate	O
and	O
extent	O
of	O
absorption	O
of	O
a	O
9	O
mg	O
dose	O
of	O
Felbatol	B-Brand
as	O
monotherapy	O
given	O
as	O
tablets	O
was	O
not	O
affected	O
when	O
coadministered	O
with	O
antacids	B-Group
.	O
      
Alcohol	B-Drug
(	O
increases	O
bioavailability	O
by	O
9	O
%	O
)	O
cimetidine	B-Drug
and	O
valproates	O
.	O
      
If	O
TRANXENE	B-Brand
is	O
to	O
be	O
combined	O
with	O
other	O
drugs	O
acting	O
on	O
the	O
central	O
nervous	O
system	O
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
the	O
agents	O
to	O
be	O
employed	O
.	O
      
The	O
effect	O
of	O
corticosteroids	B-Group
on	O
oral	O
anticoagulants	B-Group
is	O
variable	O
.	O
      
Certain	O
other	O
antibiotics	B-Group
(	O
aminoglycosides	B-Group
and	O
polymyxin	B-Group
)	O
have	O
also	O
been	O
reported	O
to	O
interfere	O
with	O
the	O
nerve	O
transmission	O
at	O
the	O
neuromuscular	O
junction	O
.	O
      
prolonged	B-Group
narcotics	I-Group
;	O
      
The	O
hypoglycemic	O
action	O
of	O
sulfonylureas	B-Group
may	O
be	O
potentiated	O
by	O
certain	O
drugs	O
including	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
and	O
other	O
drugs	O
that	O
are	O
highly	O
protein	O
bound	O
salicylates	B-Group
sulfonamides	B-Group
chloramphenicol	B-Drug
probenecid	B-Drug
coumarins	B-Group
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
and	O
beta	B-Group
adrenergic	I-Group
blocking	I-Group
agents	I-Group
.	O
      
Due	O
to	O
its	O
      
Only	O
at	O
the	O
highest	O
concentration	O
tested	O
(	O
9	O
      
Drugs	O
that	O
have	O
been	O
reported	O
to	O
diminish	O
oral	O
anticoagulant	B-Group
response	O
ie	O
decreased	O
prothrom	O
-	O
bin	O
time	O
response	O
in	O
man	O
significantly	O
include	O
:	O
adrenocortical	B-Group
steroids	I-Group
;	O
      
Adrenergic	B-Group
blockers	I-Group
Adrenergic	B-Group
blockers	I-Group
are	O
inhibited	O
by	O
amphetamines	B-Group
.	O
      
-	O
Carbamazepine	B-Drug
(	O
e.g.	O
Tegretol	B-Brand
)	O
or	O
      
Reduce	O
both	O
the	O
dose	O
of	O
levomepromazine	B-Drug
and	O
the	O
dose	O
of	O
the	O
other	O
drug	O
.	O
      
The	O
effect	O
may	O
be	O
mediated	O
by	O
cimetidines	B-Drug
known	O
inhibition	O
of	O
hepatic	O
cytochrome	O
P	O
-	O
9	O
the	O
enzyme	O
system	O
responsible	O
for	O
the	O
first	O
-	O
pass	O
metabolism	O
of	O
diltiazem	B-Drug
.	O
      
GI	O
motility	O
agents	O
:	O
cisapride	B-Drug
      
The	O
following	O
are	O
examples	O
of	O
drugs	O
known	O
to	O
inhibit	O
the	O
metabolism	O
of	O
other	O
related	O
benzodiazepines	B-Group
presumably	O
through	O
inhibition	O
of	O
CYP9A	O
:	O
nefazodone	B-Drug
fluvoxamine	B-Drug
cimetidine	B-Drug
diltiazem	B-Drug
isoniazide	B-Drug
and	O
some	O
macrolide	B-Group
antibiotics	I-Group
.	O
      
Adrenal	B-Group
steroids	I-Group
or	O
ACTH	B-Drug
In	O
patients	O
with	O
edema	O
concomitant	O
administration	O
with	O
adrenal	B-Group
cortical	I-Group
steroids	I-Group
or	O
ACTH	B-Drug
may	O
increase	O
the	O
edema	O
.	O
      
MAO	B-Group
inhibitors	I-Group
prolong	O
and	O
intensify	O
the	O
effects	O
of	O
antihistamines	B-Group
.	O
      
Probenecid	B-Drug
may	O
decrease	O
renal	O
tubular	O
secretion	O
of	O
cephalosporins	B-Group
when	O
used	O
concurrently	O
resulting	O
in	O
increased	O
and	O
more	O
prolonged	O
cephalosporin	B-Group
blood	O
levels	O
.	O
      
The	O
pharmacokinetics	O
of	O
naltrexone	B-Drug
and	O
its	O
major	O
metabolite	O
9	B-Drug_n
-	O
beta	I-Drug_n
-	O
naltrexol	I-Drug_n
were	O
unaffected	O
following	O
co	O
-	O
administration	O
with	O
Acamprosate	B-Drug
.	O
      
there	O
was	O
no	O
effect	O
on	O
the	O
9	O
major	O
metabolites	O
(	O
9	B-Drug_n
-	O
DFUR	I-Drug_n
9	B-Drug_n
-	O
FU	I-Drug_n
and	O
FBAL	B-Drug_n
)	O
.	O
      
MAO	B-Group
Inhibitors	I-Group
-	O
The	O
pressor	O
effect	O
of	O
sympathomimetic	B-Group
pressor	I-Group
amines	I-Group
is	O
markedly	O
potentiated	O
in	O
patients	O
receiving	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
(	O
MAOI	B-Group
)	O
.	O
      
free	O
T9	O
concentration	O
is	O
unaltered	O
:	O
impaired	O
glucose	O
tolerance	O
;	O
      
NovoSeven	B-Brand
should	O
not	O
be	O
mixed	O
with	O
infusion	O
solutions	O
until	O
clinical	O
data	O
are	O
available	O
to	O
direct	O
this	O
use	O
.	O
      
Calcium	B-Group
Antagonists	I-Group
:	O
After	O
repeated	O
co	O
-	O
administration	O
of	O
Trileptal	B-Brand
the	O
AUC	O
of	O
felodipine	B-Drug
was	O
lowered	O
by	O
9	O
%	O
[	O
9	O
%	O
CI	O
:	O
9	O
-	O
9	O
]	O
.	O
      
Morphine	B-Drug
:	O
Combination	O
hormonal	B-Group
contraceptives	I-Group
may	O
increase	O
the	O
clearance	O
of	O
morphine	B-Drug
.	O
      
Fentanyl	B-Drug
Anesthesia	O
:	O
Severe	O
hypotension	O
has	O
been	O
reported	O
during	O
fentanyl	B-Drug
anesthesia	O
with	O
concomitant	O
use	O
of	O
a	O
beta	B-Group
blocker	I-Group
and	O
a	O
calcium	B-Group
channel	I-Group
blocker	I-Group
.	O
      
With	O
the	O
morning	O
dose	O
of	O
ceftibuten	B-Drug
on	O
day	O
9	O
each	O
volunteer	O
received	O
a	O
single	O
intravenous	O
infusion	O
of	O
theophylline	B-Drug
(	O
9	O
mg	O
/	O
kg	O
)	O
.	O
      
influenza	B-Group
virus	I-Group
vaccine	I-Group
;	O
      
Prospective	O
long	O
-	O
term	O
studies	O
on	O
concomitant	O
administration	O
of	O
VIOXX	B-Brand
and	O
aspirin	B-Brand
have	O
not	O
been	O
conducted	O
.	O
      
Acyclovir	B-Drug
/	O
Ganciclovir	B-Drug
:	O
may	O
be	O
taken	O
with	O
Myfortic	B-Brand
;	O
      
Pyrimethamine	B-Drug
may	O
be	O
used	O
with	O
sulfonamides	B-Group
quinine	B-Drug
and	O
other	O
antimalarials	B-Group
and	O
with	O
other	O
antibiotics	B-Group
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
No	O
laboratory	O
test	O
abnormalities	O
related	O
to	O
the	O
use	O
of	O
guanfacine	B-Drug
have	O
been	O
identified	O
.	O
      
Histamine	B-Group
H9	I-Group
antagonists	I-Group
:	O
Cimetidine	B-Drug
inhibits	O
CYP9A9	O
and	O
can	O
increase	O
serum	O
amiodarone	B-Drug
levels	O
.	O
      
There	O
is	O
no	O
pharmacokinetic	O
interaction	O
between	O
ethanol	B-Drug
and	O
flumazenil	B-Drug
.	O
      
Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-Drug
used	O
to	O
treat	O
allergic	O
reactions	O
.	O
      
Mazindol	B-Drug
may	O
reduce	O
the	O
effects	O
of	O
guanethidine	B-Drug
(	O
Ismelin	B-Brand
)	O
.	O
      
The	O
para	O
-	O
aminobenzoic	O
acid	O
metabolite	O
of	O
chloroprocaine	O
inhibits	O
the	O
action	O
of	O
sulfonamides	B-Group
.	O
      
Patients	O
should	O
be	O
carefully	O
monitored	O
.	O
      
Furthermore	O
caution	O
should	O
be	O
exercised	O
when	O
combining	O
digoxin	B-Drug
with	O
any	O
drug	O
that	O
may	O
cause	O
a	O
significant	O
deterioration	O
in	O
renal	O
function	O
since	O
a	O
decline	O
in	O
glomerular	O
filtration	O
or	O
tubular	O
secretion	O
may	O
impair	O
the	O
excretion	O
of	O
digoxin	B-Drug
.	O
      
Additional	O
interactions	O
      
TOLECTIN	B-Brand
and	O
other	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
have	O
been	O
reported	O
to	O
reduce	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B-Drug
in	O
an	O
animal	O
model	O
possibly	O
enhancing	O
the	O
toxicity	O
of	O
methotrexate	B-Drug
.	O
      
Chlorpropamide	B-Drug
:	O
Chlorpropamides	B-Drug
plasma	O
half	O
-	O
life	O
may	O
be	O
prolonged	O
by	O
allopurinol	B-Drug
since	O
allopurinol	B-Drug
and	O
chlorpropamide	B-Drug
may	O
compete	O
for	O
excretion	O
in	O
the	O
renal	O
tubule	O
.	O
      
If	O
resumed	O
during	O
captopril	B-Drug
therapy	O
such	O
agents	O
should	O
be	O
administered	O
cautiously	O
and	O
perhaps	O
at	O
lower	O
dosage	O
.	O
      
Hypotension	O
:	O
Patients	O
on	O
Diuretic	O
Therapy	O
:	O
Patients	O
on	O
diuretics	B-Drug
and	O
especially	O
those	O
in	O
whom	O
diuretic	O
therapy	O
was	O
recently	O
instituted	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
enalapril	B-Drug
or	O
enalaprilat	B-Drug
.	O
      
Morphine	B-Drug
:	O
TORADOLIV	O
/	O
IM	O
has	O
been	O
administered	O
concurrently	O
with	O
morphine	B-Drug
in	O
several	O
clinical	O
trials	O
of	O
postoperative	O
pain	O
without	O
evidence	O
of	O
adverse	O
interactions	O
.	O
      
Hydrochlorothiazide	B-Drug
:	O
In	O
normal	O
volunteers	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
hydrochlorothiazide	B-Drug
resulted	O
in	O
significantly	O
increased	O
plasma	O
levels	O
of	O
hydrochlorothiazide	B-Drug
.	O
      
In	O
such	O
patients	O
the	O
mean	O
area	O
under	O
the	O
felodipine	B-Drug
plasma	O
concentration	O
-	O
time	O
curve	O
was	O
also	O
reduced	O
to	O
approximately	O
9	O
%	O
of	O
that	O
observed	O
in	O
healthy	O
volunteers	O
.	O
      
Protease	B-Group
inhibitor	I-Group
:	O
atazanavir	B-Drug
      
TRACRIUM	B-Brand
should	O
not	O
be	O
administered	O
until	O
a	O
patient	O
has	O
recovered	O
from	O
succinylcholine	B-Drug
-	O
induced	O
neuromuscular	O
block	O
.	O
      
9	O
mM	O
)	O
was	O
a	O
slight	O
degree	O
of	O
inhibition	O
(	O
9	O
%	O
-	O
9	O
%	O
)	O
of	O
isoform	O
CYP9A9	O
observed	O
.	O
      
The	O
concurrent	O
use	O
of	O
tetracycline	B-Drug
and	O
Penthrane	B-Brand
(	O
methoxyflurane	B-Drug
)	O
has	O
been	O
reported	O
to	O
result	O
in	O
fatal	O
renal	O
toxicity	O
.	O
      
Cytochrome	O
P9	O
9A9	O
(	O
CYP9A9	O
)	O
is	O
known	O
to	O
be	O
the	O
major	O
enzyme	O
involved	O
in	O
the	O
metabolism	O
of	O
caffeine	B-Drug
.	O
      
In	O
an	O
in	O
vitro	O
study	O
cytochrome	O
P9	O
isozymes	O
9A9	O
9A9	O
9C9	O
9C9	O
9D9	O
9E9	O
and	O
9A9	O
were	O
not	O
inhibited	O
by	O
exposure	O
to	O
cevimeline	B-Drug
.	O
      
Inhibitors	O
of	O
the	O
CYP9A9	O
isoenzyme	O
could	O
increase	O
systemic	O
dofetilide	B-Drug
exposure	O
.	O
      
This	O
medicine	O
should	O
not	O
be	O
taken	O
with	O
MAO	B-Group
inhibitors	I-Group
.	O
      
Like	O
isoflurane	B-Drug
desflurane	B-Drug
does	O
not	O
predispose	O
to	O
premature	O
ventricular	O
arrhythmias	O
in	O
the	O
presence	O
of	O
exogenously	O
infused	O
epinephrine	B-Drug
in	O
swine	O
.	O
      
Aspirin	B-Brand
:	O
Animal	O
studies	O
wshow	O
that	O
aspirin	B-Brand
given	O
with	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
including	O
ibuprofen	B-Drug
yields	O
a	O
net	O
decrease	O
in	O
anti	O
-	O
inflammatory	O
activity	O
with	O
lowered	O
blood	O
levels	O
of	O
the	O
non	O
-	O
aspirin	O
drug	O
.	O
      
Lithium	B-Drug
toxicity	O
was	O
usually	O
reversible	O
upon	O
discontinuation	O
of	O
lithium	B-Drug
and	O
the	O
ACE	B-Group
inhibitor	I-Group
.	O
      
Ergotamine	B-Drug
      
Coadministration	O
of	O
astemizole	B-Drug
with	O
ketoconazole	B-Drug
tablets	O
is	O
therefore	O
contraindicated	O
.	O
      
therefore	O
it	O
should	O
be	O
recognized	O
that	O
a	O
positive	O
Coombs	O
test	O
may	O
be	O
due	O
to	O
the	O
drug	O
.	O
      
-	O
Amiodarone	B-Drug
(	O
e.g.	O
Cordarone	B-Brand
)	O
or	O
      
alopecia	O
      
The	O
beta	B-Group
-	O
blocker	I-Group
should	O
be	O
withdrawn	O
first	O
.	O
      
Oxcarbazepine	B-Drug
can	O
inhibit	O
CYP9C9	O
and	O
induce	O
CYP9A9	O
/	O
9	O
with	O
potentially	O
important	O
effects	O
on	O
plasma	O
concentrations	O
of	O
other	O
drugs	O
.	O
      
After	O
extensive	O
intake	O
of	O
grapefruit	O
juice	O
(	O
which	O
inhibits	O
CYP9A9	O
activity	O
predominantly	O
in	O
the	O
intestinal	O
mucosa	O
)	O
the	O
systemic	O
exposure	O
for	O
oral	O
budesonide	B-Drug
increased	O
about	O
two	O
times	O
.	O
      
alcohol	B-Drug
barbiturates	B-Drug
and	O
other	O
CNS	B-Drug
depressants	I-Drug
;	O
      
-	O
Methotrexate	B-Drug
(	O
e.g.	O
Mexate	B-Brand
)	O
Use	O
of	O
methotrexate	B-Drug
with	O
sulfapyridine	B-Drug
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
and	O
/	O
or	O
the	O
side	O
effects	O
of	O
methotrexate	B-Drug
      
Fibrates	B-Group
may	O
increase	O
cholesterol	O
excretion	O
into	O
the	O
bile	O
leading	O
to	O
cholelithiasis	O
.	O
      
Because	O
pregnancy	O
could	O
not	O
be	O
maintained	O
in	O
the	O
rabbit	O
following	O
doses	O
of	O
fulvestrant	B-Drug
of	O
9	O
mg	O
/	O
kg	O
/	O
day	O
and	O
above	O
this	O
study	O
was	O
inadequate	O
to	O
fully	O
define	O
the	O
possible	O
adverse	O
effects	O
on	O
fetal	O
development	O
at	O
clinically	O
relevant	O
exposures	O
.	O
      
If	O
oral	O
anticoagulants	B-Group
are	O
also	O
being	O
given	O
compensatory	O
increases	O
in	O
clotting	O
factor	O
synthesis	O
are	O
impaired	O
.	O
      
No	O
other	O
pharmacokinetic	O
parameters	O
were	O
changed	O
.	O
      
In	O
clinical	O
trials	O
the	O
concomitant	O
use	O
of	O
sulfonylureas	B-Group
or	O
biguanides	B-Group
did	O
not	O
alter	O
the	O
adverse	O
event	O
profile	O
of	O
SYMLIN	B-Brand
.	O
      
Carcinogenesis	O
Mutagenesis	O
Impairment	O
of	O
Fertility	O
No	O
long	O
-	O
term	O
carcinogenicity	O
studies	O
have	O
been	O
carried	O
out	O
with	O
dexrazoxane	B-Drug
in	O
animals	O
.	O
      
These	O
findings	O
should	O
be	O
taken	O
into	O
account	O
for	O
proper	O
interpretation	O
of	O
serum	O
PSA	O
when	O
evaluating	O
men	O
treated	O
with	O
finasteride	B-Drug
.	O
      
Patients	O
who	O
require	O
the	O
use	O
of	O
one	O
of	O
these	O
drugs	O
with	O
HIVID	B-Drug
should	O
have	O
frequent	O
clinical	O
and	O
laboratory	O
monitoring	O
with	O
dosage	O
adjustment	O
for	O
any	O
significant	O
change	O
in	O
renal	O
function	O
.	O
      
In	O
a	O
controlled	O
clinical	O
trial	O
a	O
9	O
%	O
reduction	O
of	O
the	O
phenytoin	B-Drug
dose	O
at	O
the	O
initiation	O
of	O
Felbatol	B-Brand
therapy	O
resulted	O
in	O
phenytoin	B-Drug
levels	O
comparable	O
to	O
those	O
prior	O
to	O
Felbatol	B-Brand
administration	O
.	O
      
If	O
phenytoin	B-Drug
or	O
other	O
hepatic	O
enzyme	O
inducers	O
are	O
taken	O
concurrently	O
with	O
Norpace	B-Brand
or	O
Norpace	B-Brand
CR	I-Brand
lower	O
plasma	O
levels	O
of	O
disopyramide	B-Drug
may	O
occur	O
.	O
      
Chlorpromazine	B-Drug
:	O
Chlorpromazine	B-Drug
blocks	O
dopamine	O
and	O
norepinephrine	O
receptors	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	B-Group
and	O
can	O
be	O
used	O
to	O
treat	O
amphetamine	B-Group
poisoning	O
.	O
      
This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	B-Group
concomitantly	O
with	O
ACE	B-Group
inhibitors	I-Group
.	O
      
Studies	O
with	O
furosemide	B-Drug
agents	O
and	O
meloxicam	B-Drug
have	O
not	O
demonstrated	O
a	O
reduction	O
in	O
natriuretic	O
effect	O
.	O
      
Interactions	O
for	O
Vitamin	B-Drug
B9	I-Drug
(	O
Riboflavin	B-Drug
)	O
:	O
Alcohol	B-Drug
-	O
impairs	O
the	O
intestinal	O
absorption	O
of	O
riboflavin	B-Drug
      
)	O
      
Potential	O
for	O
ABILIFY	B-Brand
to	O
Affect	O
Other	O
Drugs	O
Aripiprazole	B-Drug
is	O
unlikely	O
to	O
cause	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
with	O
drugs	O
metabolized	O
by	O
cytochrome	O
P9	O
enzymes	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Positive	O
direct	O
Coombs	O
tests	O
have	O
been	O
reported	O
during	O
treatment	O
with	O
the	O
cephalosporin	B-Group
antibiotics	I-Group
.	O
      
Because	O
changes	O
in	O
glucose	O
concentrations	O
with	O
valdecoxib	B-Drug
coadministration	O
were	O
within	O
the	O
normal	O
variability	O
and	O
individual	O
glucose	O
concentrations	O
were	O
above	O
or	O
near	O
9	O
mg	O
/	O
dL	O
dose	O
adjustment	O
for	O
glyburide	B-Drug
(	O
9	O
mg	O
QD	O
and	O
9	O
mg	O
BID	O
)	O
with	O
valdecoxib	B-Drug
coadministration	O
(	O
up	O
to	O
9	O
mg	O
QD	O
)	O
is	O
not	O
indicated	O
.	O
      
A	O
possible	O
drug	O
interaction	O
of	O
FOSCAVIR	B-Brand
and	O
intravenous	O
pentamidine	B-Drug
has	O
been	O
described	O
.	O
      
diet	O
high	O
in	O
vitamin	B-Group
K	I-Group
;	O
      
Drugs	O
that	O
have	O
been	O
associated	O
with	O
peripheral	O
neuropathy	O
include	O
antiretroviral	B-Drug
nucleoside	I-Drug
analogues	I-Drug
chloramphenicol	B-Drug
cisplatin	B-Drug
dapsone	B-Drug
disulfiram	B-Drug
ethionamide	B-Drug
glutethimide	B-Drug
gold	B-Drug
hydralazine	B-Drug
iodoquinol	B-Drug
isoniazid	B-Drug
metronidazole	B-Drug
nitrofurantoin	B-Drug
phenytoin	B-Drug
ribavirin	B-Drug
and	O
vincristine	B-Drug
.	O
      
dosage	O
adjustment	O
of	O
antigout	B-Group
medications	I-Group
may	O
be	O
necessary	O
to	O
control	O
hyperuricemia	O
and	O
gout	O
.	O
)	O
      
Some	O
diuretics	B-Group
can	O
enhance	O
aminoglycoside	B-Group
toxicity	O
by	O
altering	O
antibiotic	B-Group
concentrations	O
in	O
serum	O
and	O
tissue	O
.	O
      
SSRIs	B-Group
:	O
Weakness	O
hyperreflexia	O
and	O
incoordination	O
have	O
been	O
reported	O
rarely	O
when	O
9	B-Group
-	O
HT9	I-Group
agonists	I-Group
have	O
been	O
co	O
-	O
administered	O
with	O
SSRIs	B-Group
(	O
e.	O
g	O
.	O
      
Vasopressors	B-Group
particularly	O
metaraminol	B-Drug
may	O
cause	O
serious	O
cardiac	O
arrhythmias	O
during	O
halothane	B-Drug
anesthesia	O
and	O
therefore	O
should	O
be	O
used	O
only	O
with	O
great	O
caution	O
or	O
not	O
at	O
all	O
.	O
      
conversely	O
diethylpropion	B-Drug
may	O
interfere	O
with	O
antihypertensive	B-Group
drugs	I-Group
(	O
i.e.	O
guanethidine	B-Drug
a	B-Drug
-	O
methyldopa	I-Drug
)	O
.	O
      
Rifampicin	B-Drug
:	O
In	O
a	O
study	O
in	O
healthy	O
volunteers	O
a	O
six	O
-	O
day	O
course	O
of	O
rifampicin	B-Drug
at	O
9	O
mg	O
/	O
day	O
followed	O
by	O
a	O
single	O
9	O
mg	O
dose	O
of	O
isradipine	B-Drug
resulted	O
in	O
a	O
reduction	O
in	O
isradipine	B-Drug
levels	O
to	O
below	O
detectable	O
limits	O
.	O
      
The	O
use	O
of	O
NUROMAX	B-Brand
before	O
succinylcholine	B-Drug
to	O
attenuate	O
some	O
of	O
the	O
side	O
effects	O
of	O
succinylcholine	B-Drug
has	O
not	O
been	O
studied	O
.	O
      
Therefore	O
appropriate	O
dose	O
adjustments	O
may	O
be	O
necessary	O
for	O
these	O
drugs	O
.	O
      
The	O
average	O
infusion	O
rate	O
requirement	O
may	O
be	O
decreased	O
by	O
as	O
much	O
as	O
9	O
%	O
to	O
9	O
%	O
.	O
      
Rare	O
instances	O
of	O
dyspnea	O
palpitation	O
chest	O
pain	O
syncope	O
.	O
      
Cytotoxic	B-Group
Agents	I-Group
:	O
Enhanced	O
bone	O
marrow	O
suppression	O
by	O
cyclophosphamide	B-Drug
and	O
other	O
cytotoxic	B-Group
agents	I-Group
has	O
been	O
reported	O
among	O
patients	O
with	O
neoplastic	O
disease	O
except	O
leukemia	O
in	O
the	O
presence	O
of	O
allopurinol	B-Drug
.	O
      
A	O
total	O
of	O
9	O
clinical	O
drug	O
-	O
drug	O
interaction	O
studies	O
were	O
conducted	O
in	O
healthy	O
volunteers	O
to	O
evaluate	O
the	O
potential	O
for	O
interaction	O
between	O
MYCAMINE	B-Brand
and	O
mycophenolate	B-Drug
mofetil	I-Drug
cyclosporine	B-Drug
tacrolimus	B-Drug
prednisolone	B-Drug
sirolimus	B-Drug
nifedipine	B-Drug
fluconazole	B-Drug
ritonavir	B-Drug
and	O
rifampin	B-Drug
.	O
      
Drugs	O
Demonstrated	O
to	O
be	O
CYP	O
9A	O
Inhibitors	O
of	O
Possible	O
Clinical	O
Significance	O
on	O
the	O
Basis	O
of	O
Clinical	O
Studies	O
Involving	O
Alprazolam	B-Drug
(	O
caution	O
is	O
recommended	O
during	O
coadministration	O
with	O
alprazolam	B-Drug
)	O
:	O
Coadministration	O
of	O
fluoxetine	B-Drug
with	O
alprazolam	B-Drug
increased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	B-Drug
by	O
9	O
%	O
decreased	O
clearance	O
by	O
9	O
%	O
increased	O
half	O
-	O
life	O
by	O
9	O
%	O
and	O
decreased	O
measured	O
psychomotor	O
performance	O
.	O
      
In	O
general	O
most	O
patients	O
treated	O
with	O
dirithromycin	B-Drug
who	O
are	O
receiving	O
concomitant	O
theophylline	B-Drug
therapy	O
may	O
not	O
require	O
empiric	O
adjustment	O
of	O
theophylline	B-Drug
dosage	O
or	O
monitoring	O
of	O
theophylline	B-Drug
plasma	O
concentrations	O
.	O
      
There	O
have	O
been	O
reports	O
of	O
theophylline	B-Drug
-	O
related	O
side	O
effects	O
in	O
patients	O
on	O
concomitant	O
therapy	O
with	O
norfloxacin	B-Drug
and	O
theophylline	B-Drug
.	O
      
Ranitidine	B-Drug
also	O
has	O
no	O
effect	O
on	O
eprosartan	B-Drug
pharmacokinetics	O
.	O
      
anabolic	B-Group
steroids	I-Group
;	O
      
Enalapril	B-Drug
IV	O
has	O
been	O
used	O
concomitantly	O
with	O
digitalis	B-Group
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
reactions	O
.	O
      
Increases	O
in	O
INR	O
and	O
prothrombin	O
time	O
may	O
lead	O
to	O
abnormal	O
bleeding	O
and	O
even	O
death	O
.	O
      
These	O
agents	O
should	O
not	O
be	O
used	O
in	O
patients	O
treated	O
with	O
Itraconazole	B-Drug
.	O
      
CNS	B-Group
depressant	I-Group
medications	O
:	O
Concurrent	O
use	O
of	O
procaine	B-Drug
hydrochloride	I-Drug
and	O
CNS	B-Group
depressant	I-Group
medications	I-Group
may	O
result	O
in	O
additive	O
depressant	O
effects	O
.	O
      
Thus	O
concomitant	O
therapy	O
with	O
warfarin	B-Drug
and	O
Lodine	B-Brand
should	O
not	O
require	O
dosage	O
adjustment	O
of	O
either	O
drug	O
.	O
      
The	O
vasodilating	O
effects	O
of	O
nitroglycerin	B-Drug
may	O
be	O
additive	O
with	O
those	O
of	O
other	O
vasodilators	B-Group
.	O
      
Drugs	O
that	O
alter	O
the	O
gastrointestinal	O
flora	O
may	O
interact	O
with	O
Myfortic	B-Brand
by	O
disrupting	O
enterohepatic	O
recirculation	O
.	O
      
g	O
/	O
mL	O
;	O
      
Controlled	O
and	O
uncontrolled	O
domestic	O
studies	O
suggest	O
that	O
concomitant	O
use	O
of	O
diltiazem	B-Drug
hydrochloride	I-Drug
and	O
beta	B-Group
-	O
blockers	I-Group
is	O
usually	O
well	O
tolerated	O
but	O
available	O
data	O
are	O
not	O
sufficient	O
to	O
predict	O
the	O
effects	O
of	O
concomitant	O
treatment	O
in	O
patients	O
with	O
left	O
ventricular	O
dysfunction	O
or	O
cardiac	O
conduction	O
abnormalities	O
.	O
      
The	O
clinical	O
basis	O
of	O
this	O
drug	O
interaction	O
has	O
not	O
been	O
established	O
but	O
should	O
be	O
noted	O
when	O
allopurinol	B-Drug
is	O
given	O
to	O
patients	O
already	O
on	O
dicumarol	B-Drug
therapy	O
.	O
      
The	O
incidence	O
of	O
akathisia	O
in	O
clinical	O
trials	O
of	O
the	O
weekly	O
dosage	O
schedule	O
was	O
greater	O
(	O
9	O
%	O
9	O
/	O
9	O
patients	O
)	O
when	O
prochlorperazine	B-Drug
was	O
administered	O
on	O
the	O
same	O
day	O
as	O
CAMPTOSAR	B-Brand
than	O
when	O
these	O
drugs	O
were	O
given	O
on	O
separate	O
days	O
(	O
9	O
%	O
9	O
/	O
9	O
patients	O
)	O
.	O
      
The	O
concomitant	O
use	O
of	O
beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
with	O
digitalis	B-Group
and	O
calcium	B-Group
antagonists	I-Group
may	O
have	O
additive	O
effects	O
on	O
prolonging	O
atrioventricular	O
conduction	O
time	O
.	O
      
Chlorprothixene	B-Drug
may	O
increase	O
the	O
plasma	O
-	O
level	O
of	O
concomitantly	O
given	O
lithium	B-Drug
.	O
      
trimethoprim	B-Drug
/	O
sulfamethoxazole	B-Drug
;	O
      
9	O
.	O
      
Thyroid	O
hormonal	O
replacement	O
increases	O
metabolic	O
rate	O
which	O
requires	O
an	O
increase	O
in	O
digitalis	B-Group
dosage	O
.	O
      
In	O
vitro	O
studies	O
indicate	O
that	O
valdecoxib	B-Drug
is	O
a	O
moderate	O
inhibitor	O
of	O
CYP	O
9C9	O
(	O
IC9	O
=	O
9	O
g	O
/	O
mL	O
or	O
9	O
M	O
)	O
and	O
9C9	O
(	O
IC9	O
=	O
9	O
g	O
/	O
mL	O
or	O
9	O
M	O
)	O
and	O
a	O
weak	O
inhibitor	O
of	O
CYP	O
9D9	O
(	O
IC9	O
=	O
9	O
g	O
/	O
mL	O
or	O
9	O
M	O
)	O
and	O
9A9	O
(	O
IC9	O
=	O
9	O
g	O
/	O
mL	O
or	O
9	O
M	O
)	O
..	O
      
Other	O
substances	O
:	O
Grapefruit	O
juice	O
given	O
to	O
healthy	O
volunteers	O
increased	O
amiodarone	B-Drug
AUC	O
by	O
9	O
%	O
and	O
Cmax	O
by	O
9	O
%	O
resulting	O
in	O
increased	O
plasma	O
levels	O
of	O
amiodarone	B-Drug
.	O
      
When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
glipizide	B-Drug
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O
      
Concomitant	O
treatment	O
of	O
four	O
patients	O
in	O
the	O
United	O
Kingdom	O
with	O
FOSCAVIR	B-Brand
and	O
intravenous	O
pentamidine	B-Drug
may	O
have	O
caused	O
hypocalcemia	O
;	O
      
however	O
it	O
is	O
considered	O
to	O
be	O
unlikely	O
that	O
this	O
decrease	O
of	O
phosphorylated	O
lamivudine	B-Drug
concentration	O
is	O
of	O
clinical	O
significance	O
as	O
lamivudine	B-Drug
is	O
a	O
more	O
efficient	O
substrate	O
for	O
deoxycytidine	O
kinase	O
than	O
zalcitabine	B-Drug
.	O
      
Warfarin	B-Drug
:	O
The	O
coadministration	O
of	O
EVISTA	B-Brand
and	O
warfarin	B-Drug
has	O
not	O
been	O
assessed	O
under	O
chronic	O
conditions	O
.	O
      
Oral	O
Contraceptives	B-Group
:	O
Multiple	O
dose	O
administration	O
of	O
tiagabine	B-Drug
(	O
9	O
mg	O
/	O
day	O
monotherapy	O
)	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
oral	O
contraceptives	B-Group
in	O
healthy	O
women	O
of	O
childbearing	O
age	O
.	O
      
There	O
have	O
been	O
reports	O
of	O
increased	O
anticoagulant	O
effects	O
when	O
erythromycin	B-Drug
and	O
oral	O
anticoagulants	B-Group
were	O
used	O
concomitantly	O
.	O
      
Nitrofurantoin	B-Drug
interferes	O
with	O
the	O
therapeutic	O
action	O
of	O
nalidixic	B-Drug
acid	I-Drug
.	O
      
A	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
      
Auranofin	B-Drug
should	O
not	O
be	O
used	O
together	O
with	O
penicillamine	B-Drug
(	O
Depen	B-Brand
Cuprimine	B-Brand
)	O
another	O
arthritis	O
medication	O
.	O
      
Phenothiazines	B-Group
are	O
capable	O
of	O
potentiating	O
CNS	B-Group
depressants	I-Group
(	O
e.g.	O
barbiturates	B-Group
anesthetics	B-Group
opiates	B-Group
alcohol	B-Drug
etc	O
.	O
)	O
      
Microscopic	O
hematuria	O
(	O
9	O
/	O
9	O
)	O
and	O
gingival	O
bleeding	O
(	O
9	O
/	O
9	O
)	O
were	O
also	O
observed	O
.	O
      
Use	O
of	O
Cerubidine	B-Brand
in	O
a	O
patient	O
who	O
has	O
previously	O
received	O
doxorubicin	B-Drug
increases	O
the	O
risk	O
of	O
cardiotoxicity	O
.	O
      
Some	O
reports	O
have	O
shown	O
that	O
the	O
concomitant	O
administration	O
of	O
thiazides	B-Group
with	O
vitamin	B-Group
D	I-Group
causes	O
hypercalcemia	O
.	O
      
-	O
Hydroxychloroquine	B-Drug
(	O
e.g.	O
Plaquenil	B-Brand
)	O
or	O
      
Antiarrhythmics	B-Group
:	O
Amiodarone	B-Drug
bepridil	B-Drug
flecainide	B-Drug
propafenone	B-Drug
quinidine	B-Drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
.	O
      
Anticonvulsants	B-Group
(	O
Phenytoin	B-Drug
)	O
:	O
Steady	O
state	O
plasma	O
exposure	O
(	O
AUC	O
)	O
of	O
valdecoxib	B-Drug
(	O
9	O
mg	O
BID	O
for	O
9	O
days	O
)	O
was	O
decreased	O
by	O
9	O
%	O
when	O
co	O
-	O
administered	O
with	O
multiple	O
doses	O
(	O
9	O
mg	O
QD	O
for	O
9	O
days	O
)	O
of	O
phenytoin	B-Drug
(	O
a	O
CYP	O
9A9	O
inducer	O
)	O
.	O
      
Drugs	O
that	O
may	O
alter	O
imatinib	B-Drug
plasma	O
concentrations	O
Drugs	O
that	O
may	O
increase	O
imatinib	B-Drug
plasma	O
concentrations	O
:	O
Caution	O
is	O
recommended	O
when	O
administering	O
Gleevec	B-Brand
with	O
inhibitors	O
of	O
the	O
CYP9A9	O
family	O
(	O
e.g.	O
ketoconazole	B-Drug
itraconazole	B-Drug
erythromycin	B-Drug
clarithromycin	B-Drug
)	O
.	O
      
Influence	O
of	O
AED	B-Group
On	O
MHD	B-Drug_n
Concentration	O
(	O
Mean	O
change	O
9	O
%	O
Confidence	O
Interval	O
)	O
      
Therefore	O
it	O
should	O
be	O
recognized	O
that	O
a	O
positive	O
Coombs	O
test	O
could	O
be	O
due	O
to	O
the	O
drug	O
.	O
      
For	O
comprehensive	O
information	O
concerning	O
laboratory	O
test	O
alterations	O
associated	O
with	O
ritonavir	B-Drug
physicians	O
should	O
refer	O
to	O
the	O
complete	O
prescribing	O
information	O
for	O
NORVIR	B-Brand
(	O
ritonavir	B-Drug
)	O
.	O
      
Concurrent	O
use	O
with	O
probenecid	B-Drug
or	O
other	O
drugs	O
significantly	O
eliminated	O
by	O
active	O
renal	O
tubular	O
secretion	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
penciclovir	B-Drug
.	O
      
Free	O
hormone	O
concentrations	O
may	O
be	O
decreased	O
.	O
      
The	O
consumption	O
of	O
alcohol	B-Drug
during	O
treatment	O
with	O
WELLBUTRIN	B-Brand
should	O
be	O
minimized	O
or	O
avoided	O
(	O
also	O
see	O
a	O
href=	O
bupropz_od.htm	O
#	O
CI	O
CONTRAINDICATIONS	O
)	O
      
Metformin	B-Drug
:	O
When	O
Starlix	B-Brand
9	O
mg	O
three	O
times	O
daily	O
before	O
meals	O
was	O
administered	O
in	O
combination	O
with	O
metformin	B-Drug
9	O
mg	O
three	O
times	O
daily	O
to	O
patients	O
with	O
Type	O
9	O
diabetes	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O
      
Drug	O
interaction	O
studies	O
with	O
SUSTIVA	B-Brand
and	O
these	O
imidazole	B-Group
and	O
triazole	B-Group
antifungals	I-Group
have	O
not	O
been	O
conducted	O
.	O
      
Limited	O
evidence	O
suggests	O
that	O
ascorbic	B-Drug
acid	I-Drug
may	O
influence	O
the	O
intensity	O
and	O
duration	O
of	O
action	O
of	O
bishydroxycoumarin	B-Drug
.	O
      
increased	O
norepinephrine	O
-	O
induced	O
platel	O
et	O
aggregation	O
;	O
      
While	O
all	O
the	O
selective	O
serotonin	B-Group
reuptake	I-Group
inhibitors	I-Group
(	O
SSRIs	B-Group
)	O
e.g.	O
fluoxetine	B-Drug
sertraline	B-Drug
and	O
paroxetine	B-Drug
inhibit	O
P9	O
9D9	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O
      
(	O
See	O
<	O
a	O
href=	O
``	O
flucon_cp.htm	O
#	O
CP	O
''	O
>	O
CLINICAL	O
PHARMACOLOGY	O
:	O
Drug	O
Interaction	O
Studies	O
.	O
)	O
      
OTHER	O
CONCOMITANT	O
THERAPY	O
:	O
Although	O
specific	O
interaction	O
studies	O
were	O
not	O
performed	O
in	O
clinical	O
studies	O
cerivastatin	B-Drug
sodium	I-Drug
was	O
used	O
concomitantly	O
with	O
angiotensin	B-Group
-	O
converting	I-Group
enzyme	I-Group
ACE	I-Group
inhibitors	I-Group
betablockers	B-Group
calcium	B-Group
-	O
channel	I-Group
blockers	I-Group
diuretics	B-Group
and	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
(	O
NSAIDs	B-Group
)	O
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O
      
Phenobarbital	B-Drug
:	O
Amphetamines	B-Group
may	O
delay	O
intestinal	O
absorption	O
of	O
phenobarbital	B-Drug
;	O
      
Aspirin	B-Brand
:	O
CELEBREX	B-Brand
can	O
be	O
used	O
with	O
low	O
dose	O
aspirin	B-Brand
.	O
      
Naproxen	B-Drug
naproxen	B-Drug
sodium	I-Drug
and	O
other	O
NSAIDs	B-Group
have	O
been	O
reported	O
to	O
reduce	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B-Drug
in	O
an	O
animal	O
model	O
possibly	O
increasing	O
the	O
toxicity	O
of	O
methotrexate	B-Drug
.	O
      
Quinidine	B-Drug
:	O
Coadministration	O
of	O
a	O
9	O
-	O
mg	O
single	O
dose	O
of	O
aripiprazole	B-Drug
with	O
quinidine	B-Drug
(	O
9	O
mg	O
/	O
day	O
for	O
9	O
days	O
)	O
a	O
potent	O
inhibitor	O
of	O
CYP9D9	O
increased	O
the	O
AUC	O
of	O
aripiprazole	B-Drug
by	O
9	O
%	O
but	O
decreased	O
the	O
AUC	O
of	O
its	O
active	O
metabolite	O
dehydroaripiprazole	B-Drug_n
by	O
9	O
%	O
.	O
      
The	O
effects	O
of	O
anticholinergic	B-Group
drugs	I-Group
such	O
as	O
atropine	B-Drug
and	O
tricyclic	B-Group
antidepressants	I-Group
may	O
be	O
enhanced	O
by	O
the	O
concomitant	O
administration	O
of	O
triprolidine	B-Drug
.	O
      
The	O
effect	O
of	O
administering	O
different	O
botulinum	B-Group
neurotoxin	I-Group
serotypes	O
at	O
the	O
same	O
time	O
or	O
within	O
several	O
months	O
of	O
each	O
other	O
is	O
unknown	O
.	O
      
Antagonism	O
has	O
been	O
demonstrated	O
between	O
clindamycin	B-Drug
and	O
erythromycin	B-Drug
in	O
vitro	O
.	O
      
Drugs	O
Metabolized	O
by	O
P9	O
9D9	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	O
metabolizing	O
isozyme	O
cytochrome	O
P9	O
9D9	O
(	O
debrisoquin	O
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
caucasian	O
population	O
(	O
about	O
9	O
to	O
9	O
%	O
of	O
caucasians	O
are	O
so	O
called	O
poor	O
metabolizers	O
)	O
;	O
      
The	O
mechanism	O
and	O
long	O
-	O
term	O
consequences	O
of	O
these	O
events	O
are	O
currently	O
unknown	O
.	O
      
These	O
individuals	O
may	O
develop	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
clozapine	B-Drug
when	O
given	O
usual	O
doses	O
.	O
      
No	O
inhibition	O
of	O
deferasirox	B-Drug
metabolism	O
by	O
hydroxyurea	B-Drug
is	O
expected	O
based	O
on	O
the	O
results	O
of	O
an	O
in	O
vitro	O
study	O
.	O
      
Therefore	O
prothrombin	O
time	O
should	O
be	O
carefully	O
monitored	O
in	O
patients	O
receiving	O
Itraconazole	B-Drug
and	O
coumarin	B-Group
-	O
like	O
drugs	O
simultaneously	O
.	O
      
Concurrent	O
use	O
of	O
antibacterial	B-Group
drugs	I-Group
with	O
oral	O
contraceptives	B-Group
may	O
render	O
oral	O
contraceptives	B-Group
less	O
effective	O
.	O
      
Laboratory	O
Test	O
Interactions	O
      
miconazole	B-Drug
;	O
      
In	O
a	O
multiple	O
-	O
dose	O
study	O
enoxacin	B-Drug
caused	O
a	O
dose	O
-	O
related	O
increase	O
in	O
the	O
mean	O
elimination	O
half	O
-	O
life	O
of	O
caffeine	B-Drug
thereby	O
decreasing	O
the	O
clearance	O
of	O
caffeine	B-Drug
by	O
up	O
to	O
9	O
%	O
and	O
leading	O
to	O
a	O
five	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
and	O
the	O
half	O
-	O
life	O
of	O
caffeine	B-Drug
.	O
      
When	O
intravenous	O
morphine	B-Drug
and	O
BREVIBLOC	B-Brand
were	O
concomitantly	O
administered	O
in	O
normal	O
subjects	O
no	O
effect	O
on	O
morphine	B-Drug
blood	O
levels	O
was	O
seen	O
but	O
BREVIBLOC	B-Brand
steady	O
-	O
state	O
blood	O
levels	O
were	O
increased	O
by	O
9	O
%	O
in	O
the	O
presence	O
of	O
morphine	B-Drug
.	O
      
Cardiac	B-Group
Glycosides	I-Group
:	O
In	O
a	O
study	O
of	O
young	O
healthy	O
male	O
subjects	O
no	O
evidence	O
of	O
a	O
direct	O
pharmacokinetic	O
captopril	B-Drug
-	O
digoxin	B-Drug
interaction	O
could	O
be	O
found	O
.	O
      
When	O
combined	O
therapy	O
is	O
contemplated	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O
      
Steady	O
-	O
state	O
serum	O
concentrations	O
of	O
tricyclic	B-Group
antidepressants	I-Group
are	O
reported	O
to	O
fluctuate	O
significantly	O
when	O
cimetidine	B-Drug
is	O
either	O
added	O
or	O
deleted	O
from	O
the	O
drug	O
regimen	O
.	O
      
The	O
relevance	O
of	O
this	O
finding	O
to	O
humans	O
is	O
not	O
known	O
at	O
this	O
time	O
.	O
      
Co	O
-	O
administration	O
of	O
celecoxib	B-Drug
with	O
drugs	O
that	O
are	O
known	O
to	O
inhibit	O
9C9	O
should	O
be	O
done	O
with	O
caution	O
.	O
      
When	O
sympathomimetic	B-Group
drugs	I-Group
are	O
given	O
to	O
patients	O
receiving	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
hypertensive	O
reactions	O
including	O
hypertensive	O
crises	O
may	O
occur	O
.	O
      
.	O
      
Terfenadine	B-Drug
astemizole	B-Drug
and	O
cisapride	B-Drug
are	O
all	O
metabolized	O
by	O
the	O
cytochrome	O
P9IIIA9	O
isozyme	O
and	O
it	O
has	O
been	O
demonstrated	O
that	O
ketoconazole	B-Drug
a	O
potent	O
inhibitor	O
of	O
IIIA9	O
blocks	O
the	O
metabolism	O
of	O
these	O
drugs	O
resulting	O
in	O
increased	O
plasma	O
concentrations	O
of	O
parent	O
drug	O
.	O
      
Ethanol	B-Drug
decreases	O
the	O
elimination	O
of	O
abacavir	B-Drug
causing	O
an	O
increase	O
in	O
overall	O
exposure	O
.	O
The	O
addition	O
of	O
methadone	B-Drug
has	O
no	O
clinically	O
significant	O
effect	O
on	O
the	O
pharmacokinetic	O
properties	O
of	O
abacavir	B-Drug
.	O
      
Thus	O
patients	O
should	O
be	O
cautioned	O
about	O
the	O
use	O
of	O
such	O
drugs	O
concurrently	O
with	O
LEXAPRO	B-Brand
.	O
      
There	O
are	O
no	O
data	O
that	O
conclusively	O
establish	O
whether	O
the	O
concomitant	O
administration	O
of	O
Mefloquineuine	O
and	O
the	O
above	O
listed	O
agents	O
has	O
an	O
effect	O
on	O
cardiac	O
function	O
.	O
      
It	O
should	O
also	O
be	O
avoided	O
in	O
patients	O
with	O
blood	O
liver	O
or	O
kidney	O
diseases	O
recent	O
radiation	O
treatment	O
or	O
uncontrolled	O
diabetes	O
.	O
      
In	O
two	O
controlled	O
crossover	O
clinical	O
pharmacology	O
studies	O
in	O
healthy	O
male	O
(	O
n=9	O
in	O
each	O
study	O
)	O
a	O
nd	O
female	O
(	O
n=9	O
in	O
each	O
study	O
)	O
volunteers	O
desloratadine	B-Drug
9	O
mg	O
(	O
9	O
times	O
the	O
daily	O
dose	O
)	O
once	O
daily	O
was	O
coadministered	O
with	O
erythromycin	B-Drug
9	O
mg	O
every	O
9	O
hours	O
or	O
ketoconazole	B-Drug
9	O
mg	O
every	O
9	O
hours	O
for	O
9	O
days	O
.	O
      
Nifedipine	B-Drug
(	O
extended	O
-	O
release	O
tablets	O
)	O
:	O
In	O
9	O
normal	O
-	O
weight	O
subjects	O
receiving	O
XENICAL	B-Brand
9	O
mg	O
three	O
times	O
a	O
day	O
for	O
9	O
days	O
XENICAL	B-Brand
did	O
not	O
alter	O
the	O
bioavailability	O
of	O
nifedipine	B-Drug
(	O
extended	O
-	O
release	O
tablets	O
)	O
.	O
      
this	O
was	O
seen	O
in	O
studies	O
with	O
estazolam	B-Drug
.	O
      
Human	O
pharmacokinetics	O
data	O
indicate	O
that	O
oral	O
ketoconazole	B-Drug
potently	O
inhibits	O
the	O
metabolism	O
of	O
cisapride	B-Drug
resulting	O
in	O
a	O
mean	O
eight	O
-	O
fold	O
increase	O
in	O
AUC	O
of	O
cisapride	B-Drug
.	O
      
The	O
concomitant	O
use	O
of	O
sodium	B-Drug
cephalothin	I-Drug
and	O
Coly	B-Brand
-	O
Mycin	I-Brand
M	I-Brand
Parenteral	O
should	O
be	O
avoided	O
.	O
      
-	O
Plicamycin	B-Drug
(	O
e.g.	O
Mithracin	B-Brand
)	O
or	O
      
Rifabutin	B-Drug
      
Concomitant	O
administration	O
of	O
ketoconazole	B-Drug
and	O
terfenadine	B-Drug
is	O
contraindicated	O
.	O
      
Levodopa	B-Drug
and	O
Amantadine	B-Drug
:	O
Limited	O
clinical	O
data	O
suggest	O
a	O
higher	O
incidence	O
of	O
adverse	O
experiences	O
in	O
patients	O
receiving	O
bupropion	B-Drug
concurrently	O
with	O
either	O
levodopa	B-Drug
or	O
amantadine	B-Drug
.	O
      
Chlorpromazine	B-Drug
:	O
Chlorpromazine	B-Drug
blocks	O
dopamine	O
and	O
norepinephrine	O
reuptake	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	B-Group
and	O
can	O
be	O
used	O
to	O
treat	O
amphetamine	B-Group
poisoning	O
.	O
      
These	O
drugs	O
may	O
decrease	O
the	O
effects	O
of	O
mazindol	B-Drug
.	O
      
In	O
vitro	O
buspirone	B-Drug
may	O
displace	O
less	O
firmly	O
bound	O
drugs	O
like	O
digoxin	B-Drug
.	O
      
CHOLESTYRAMINE	B-Drug
:	O
The	O
influence	O
of	O
the	O
bile	O
-	O
acidsequestering	O
agent	O
cholestyramine	B-Drug
on	O
the	O
pharmacokinetits	O
of	O
cerivastatin	B-Drug
sodium	I-Drug
was	O
evaluated	O
in	O
9	O
healthy	O
males	O
in	O
9	O
separate	O
randomized	O
crossover	O
studies	O
.	O
      
.	O
      
When	O
estrogen	B-Group
therapy	O
is	O
initiated	O
a	O
reduction	O
in	O
corticosteroid	B-Group
dosage	O
may	O
be	O
required	O
and	O
increased	O
amounts	O
may	O
be	O
required	O
when	O
estrogen	B-Group
is	O
terminated	O
.	O
      
Changes	O
in	O
the	O
testes	O
and	O
epididymides	O
had	O
not	O
recovered	O
9	O
weeks	O
after	O
cessation	O
of	O
dosing	O
.	O
      
General	O
:	O
In	O
humans	O
valdecoxib	B-Drug
metabolism	O
is	O
predominantly	O
mediated	O
via	O
CYP	O
9A9	O
and	O
9C9	O
with	O
glucuronidation	O
being	O
a	O
further	O
(	O
9	O
%	O
)	O
route	O
of	O
metabolism	O
.	O
      
Buprenorphine	B-Drug
is	O
metabolized	O
to	O
norbuprenorphine	B-Drug_n
by	O
cytochrome	O
CYP	O
9A9	O
.	O
      
Concomitant	O
administration	O
of	O
FACTIVE	B-Brand
with	O
probenecid	B-Drug
resulted	O
in	O
a	O
9	O
%	O
increase	O
in	O
systemic	O
exposure	O
to	O
gemifloxacin	B-Drug
.	O
      
Ropivacaine	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
other	O
local	O
anesthetics	B-Group
or	O
agents	O
structurally	O
related	O
to	O
amide	B-Group
-	O
type	I-Group
local	I-Group
anesthetics	I-Group
since	O
the	O
toxic	O
effects	O
of	O
these	O
drugs	O
are	O
additive	O
.	O
      
Beta	B-Group
blockers	I-Group
may	O
exacerbate	O
the	O
hypertensive	O
response	O
seen	O
with	O
clonidine	B-Drug
withdrawl	O
.	O
      
However	O
theophylline	B-Drug
plasma	O
concentrations	O
should	O
be	O
monitored	O
with	O
dosage	O
adjustment	O
as	O
appropriate	O
in	O
patients	O
whose	O
pulmonary	O
disease	O
requires	O
maintaining	O
a	O
given	O
theophylline	B-Drug
plasma	O
concentration	O
for	O
optimal	O
pulmonary	O
function	O
or	O
in	O
patients	O
with	O
theophylline	B-Drug
concentrations	O
at	O
the	O
higher	O
end	O
of	O
the	O
therapeutic	O
range	O
.	O
      
It	O
is	O
not	O
known	O
whether	O
alosetron	B-Drug
might	O
induce	O
other	O
enzymes	O
.	O
      
John	O
Wort	O
and	O
certain	O
anticonvulsants	B-Group
(	O
phenytoin	B-Drug
phenobarbital	B-Drug
carbamazepine	B-Drug
)	O
may	O
induce	O
mifepristone	B-Drug
metabolism	O
(	O
lowering	O
serum	O
levels	O
of	O
mifepristone	B-Drug
)	O
.	O
      
Patients	O
receiving	O
beta	B-Group
-	O
blockers	I-Group
should	O
be	O
warned	O
of	O
this	O
potential	O
hazard	O
.	O
      
In	O
9	O
separate	O
studies	O
fexofenadine	B-Drug
hydrochloride	I-Drug
9	O
mg	O
twice	O
daily	O
(	O
9	O
mg	O
total	O
daily	O
dose	O
)	O
was	O
co	O
-	O
administered	O
with	O
either	O
erythromycin	B-Drug
9	O
mg	O
every	O
9	O
hours	O
or	O
ketoconazole	B-Drug
9	O
mg	O
once	O
daily	O
under	O
steady	O
-	O
state	O
conditions	O
to	O
healthy	O
volunteers	O
(	O
n=9	O
each	O
study	O
)	O
.	O
      
There	O
are	O
no	O
adequate	O
and	O
well	O
-	O
controlled	O
studies	O
of	O
PEGASYS	B-Brand
in	O
pregnant	O
women	O
.	O
      
Do	O
not	O
take	O
this	O
medicine	O
with	O
St.	O
Johns	O
Wort	O
because	O
of	O
the	O
additive	O
effects	O
of	O
sertonin	O
.	O
      
In	O
combination	O
with	O
other	O
central	B-Group
nervous	I-Group
system	I-Group
depressants	I-Group
heroin	B-Drug_n
may	O
still	O
kill	O
even	O
experienced	O
users	O
particularly	O
if	O
their	O
tolerance	O
to	O
the	O
drug	O
has	O
reduced	O
or	O
the	O
strength	O
of	O
their	O
usual	O
dose	O
has	O
increased	O
.	O
      
Antiarrhythmics	B-Group
      
Diflunisal	B-Drug
decreased	O
the	O
hyperuricemic	O
effect	O
of	O
furosemide	B-Drug
.	O
      
This	O
effect	O
of	O
aspirin	B-Brand
(	O
which	O
also	O
lowers	O
serum	O
concentrations	O
of	O
other	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
given	O
with	O
it	O
)	O
has	O
been	O
demonstrated	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
n=	O
9	O
)	O
as	O
well	O
as	O
normal	O
volunteers	O
(	O
n=	O
9	O
)	O
.	O
      
Naproxen	B-Drug
:	O
Coadministration	O
(	O
N=9	O
)	O
of	O
naproxen	B-Drug
sodium	I-Drug
capsules	O
(	O
9	O
mg	O
)	O
with	O
Neurontin	B-Brand
(	O
9	O
mg	O
)	O
appears	O
to	O
increase	O
the	O
amount	O
of	O
gabapentin	B-Drug
absorbed	O
by	O
9	O
%	O
to	O
9	O
%	O
.	O
      
Coadministration	O
of	O
efavirenz	B-Drug
with	O
drugs	O
primarily	O
metabolized	O
by	O
these	O
isozymes	O
may	O
result	O
in	O
altered	O
plasma	O
concentrations	O
of	O
the	O
coadministered	O
drug	O
.	O
      
unreliable	O
prothrombin	O
time	O
determinations	O
;	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
There	O
have	O
been	O
no	O
chemical	O
or	O
laboratory	O
test	O
interactions	O
with	O
ceftibuten	B-Drug
noted	O
to	O
date	O
.	O
      
Beta	B-Group
blockers	I-Group
may	O
exacerbate	O
the	O
rebound	O
hypertension	O
which	O
can	O
follow	O
the	O
withdrawal	O
of	O
clonidine	B-Drug
.	O
      
glucagon	B-Drug
;	O
      
Amiodarone	B-Drug
:	O
Amiodarone	B-Drug
therapy	O
alone	O
can	O
cause	O
hypothyroidism	O
or	O
hyperthyroidism	O
.	O
      
Concomitant	O
administration	O
of	O
erythromycin	B-Drug
and	O
digoxin	B-Drug
has	O
been	O
reported	O
to	O
result	O
in	O
elevated	O
digoxin	B-Drug
serum	O
levels	O
.	O
      
In	O
addition	O
to	O
bleeding	O
associated	O
with	O
heparin	B-Drug
and	O
vitamin	B-Group
K	I-Group
antagonists	I-Group
drugs	O
that	O
alter	O
platelet	O
function	O
(	O
such	O
as	O
acetylsalicylic	B-Drug
acid	I-Drug
dipyridamole	B-Drug
and	O
Abciximab	B-Drug
)	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
if	O
administered	O
prior	O
to	O
during	O
or	O
after	O
Activase	B-Brand
therapy	O
.	O
      
Clinical	O
studies	O
have	O
shown	O
that	O
INDOCIN	B-Brand
does	O
not	O
influence	O
the	O
hypoprothrombinemia	O
produced	O
by	O
anticoagulants	B-Group
.	O
      
The	O
action	O
of	O
nondepolarizing	O
relaxants	O
is	O
augmented	O
by	O
Enflurane	B-Drug
.	O
      
no	O
clear	O
-	O
cut	O
cause	O
and	O
effect	O
relationship	O
was	O
established	O
.	O
      
Therefore	O
based	O
on	O
these	O
in	O
vitro	O
data	O
estazolam	B-Drug
is	O
very	O
unlikely	O
to	O
inhibit	O
the	O
biotransformation	O
of	O
other	O
drugs	O
metabolized	O
by	O
these	O
CYP	O
isoforms	O
      
Most	O
of	O
the	O
above	O
effects	O
concerning	O
diuretics	B-Group
have	O
been	O
attributed	O
at	O
least	O
in	O
part	O
to	O
mechanisms	O
involving	O
inhibition	O
of	O
prostaglandin	O
synthesis	O
by	O
INDOCIN	B-Brand
.	O
      
No	O
differences	O
in	O
adverse	O
events	O
or	O
QTc	O
interval	O
were	O
observed	O
when	O
subjects	O
were	O
administered	O
fexofenadine	B-Drug
hydrochloride	I-Drug
alone	O
or	O
in	O
combination	O
with	O
either	O
erythromycin	B-Drug
or	O
ketoconazole	B-Drug
.	O
      
cardiovascular	O
effects	O
can	O
be	O
potentiated	O
.	O
      
Although	O
studies	O
designed	O
to	O
examine	O
drug	O
interactions	O
have	O
not	O
been	O
done	O
it	O
was	O
noted	O
that	O
corticosteroid	B-Group
or	O
ACTH	B-Drug
treatment	O
of	O
relapses	O
for	O
periods	O
of	O
up	O
to	O
9	O
days	O
has	O
been	O
administered	O
to	O
patients	O
(	O
N=9	O
)	O
receiving	O
Betaseron	B-Brand
.	O
      
Aminoglutethimide	B-Drug
diminishes	O
the	O
effect	O
of	O
coumarin	B-Group
and	O
warfarin	B-Drug
.	O
      
Given	O
the	O
possibility	O
of	O
extravasation	O
it	O
is	O
advisable	O
to	O
closely	O
monitor	O
the	O
infusion	O
site	O
for	O
possible	O
infiltration	O
during	O
drug	O
administration	O
.	O
      
Androgens	B-Group
may	O
increase	O
sensitivity	O
to	O
oral	O
anticoagulahts	O
.	O
      
Propranolol	B-Drug
:	O
In	O
normal	O
volunteers	O
there	O
was	O
no	O
clinically	O
significant	O
pharmacokinetic	O
or	O
pharmacodynamic	O
interaction	O
with	O
concomitant	O
administration	O
of	O
single	O
doses	O
of	O
lovastatin	B-Drug
and	O
propranolol	B-Drug
.	O
      
The	O
reported	O
dose	O
used	O
for	O
L	B-Drug
-	O
glutamine	I-Drug
was	O
9	O
grams	O
daily	O
taken	O
in	O
divided	O
doses	O
three	O
times	O
a	O
day	O
.	O
      
Other	O
drugs	O
have	O
not	O
been	O
studied	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
The	O
administration	O
of	O
cefepime	B-Drug
may	O
result	O
in	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
when	O
using	O
Clinitest	O
tablets	O
.	O
      
Other	O
Drugs	O
:	O
In	O
healthy	O
volunteers	O
amlodipine	B-Drug
phenytoin	B-Drug
glyburide	B-Drug
ranitidine	B-Drug
omeprazole	B-Drug
hormone	O
replacement	O
therapy	O
(	O
a	O
combination	O
of	O
conjugated	O
estrogens	B-Group
and	O
medroxyprogesterone	B-Drug
)	O
antacid	B-Group
(	O
aluminum	B-Drug
and	O
magnesium	B-Drug
hydroxides	I-Drug
)	O
and	O
theophylline	B-Drug
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
TIKOSYN	B-Brand
.	O
      
Magnesium	B-Drug
-	O
and	O
aluminum	B-Drug
-	O
containing	O
antacids	B-Group
administered	O
concomitantly	O
with	O
lomefloxacin	B-Drug
significantly	O
decreased	O
the	O
bioavailability	O
(	O
9	O
%	O
)	O
of	O
lomefloxacin	B-Drug
.	O
      
Clonidine	B-Drug
hydrochloride	I-Drug
may	O
enhance	O
the	O
CNS	O
-	O
depressive	O
effects	O
of	O
alcohol	B-Drug
barbiturates	B-Group
or	O
other	O
sedatives	B-Group
.	O
      
AMEVIVE	B-Brand
underwent	O
trans	O
-	O
placental	O
passage	O
and	O
produced	O
in	O
utero	O
exposure	O
in	O
the	O
developing	O
monkeys	O
.	O
      
Corticosteroids	B-Group
ACTH	B-Drug
:	O
intensified	O
electrolyte	O
depletion	O
particularly	O
hypokalemia	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
None	O
known	O
.	O
      
It	O
is	O
recommended	O
that	O
the	O
dose	O
of	O
rifabutin	B-Drug
be	O
reduced	O
to	O
one	O
-	O
half	O
the	O
usual	O
dose	O
when	O
administered	O
with	O
VIRACEPT	B-Brand
.	O
      
General	O
No	O
clinical	O
drug	O
interaction	O
studies	O
were	O
performed	O
.	O
      
Specific	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
ENBREL	B-Brand
.	O
      
Although	O
the	O
occurrence	O
has	O
not	O
been	O
reported	O
with	O
Cefizox	B-Brand
nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
other	O
cephalosporins	B-Group
and	O
aminoglycosides	B-Group
.	O
      
As	O
most	O
entacapone	B-Drug
excretion	O
is	O
via	O
the	O
bile	O
caution	O
should	O
be	O
exercised	O
when	O
drugs	O
known	O
to	O
interfere	O
with	O
biliary	O
excretion	O
glucuronidation	O
and	O
intestinal	O
beta	O
-	O
glucuronidase	O
are	O
given	O
concurrently	O
with	O
entacapone	B-Drug
.	O
      
There	O
are	O
few	O
clinical	O
situations	O
in	O
which	O
the	O
concurrent	O
use	O
of	O
''static	O
''	O
and	O
''cidal	O
''	O
antibiotics	B-Group
are	O
indicated	O
.	O
      
Ritalin	B-Brand
may	O
decrease	O
the	O
hypotensive	O
effect	O
of	O
guanethidine	B-Drug
.	O
      
Patients	O
who	O
are	O
treated	O
with	O
ZYVOX	B-Brand
and	O
concomitant	O
serotonergic	B-Group
agents	I-Group
should	O
be	O
closely	O
observed	O
for	O
signs	O
and	O
symptoms	O
of	O
serotonin	O
syndrome	O
(	O
e.g.	O
cognitive	O
dysfunction	O
hyperpyrexia	O
hyperreflexia	O
incoordination	O
)	O
.	O
      
Anti	B-Group
-	O
HIV	I-Group
Protease	I-Group
Inhibitors	I-Group
      
Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
has	O
been	O
demonstrated	O
to	O
interfere	O
with	O
the	O
elimination	O
of	O
other	O
quinolones	B-Group
.	O
      
The	O
risks	O
of	O
using	O
Clozapine	B-Drug
in	O
combination	O
with	O
other	O
drugs	O
have	O
not	O
been	O
systematically	O
evaluated	O
.	O
      
Dosage	O
of	O
the	O
drugs	O
mentioned	O
above	O
and	O
other	O
similarly	O
metabolized	O
drugs	O
particularly	O
those	O
of	O
low	O
therapeutic	O
ratio	O
or	O
in	O
patients	O
with	O
renal	O
and	O
/	O
or	O
hepatic	O
impairment	O
may	O
require	O
adjustment	O
when	O
starting	O
or	O
stopping	O
concomitantly	O
administered	O
Tagamet	B-Brand
to	O
maintain	O
optimum	O
therapeutic	O
blood	O
levels	O
.	O
      
Although	O
this	O
interaction	O
has	O
not	O
been	O
reported	O
with	O
cinoxacin	B-Drug
caution	O
should	O
be	O
exercised	O
when	O
cinoxacin	B-Drug
is	O
given	O
concomitantly	O
with	O
caffeine	B-Drug
-	O
containing	O
products	O
.	O
      
Carbamazepine	B-Drug
:	O
Steady	O
-	O
state	O
trough	O
plasma	O
carbamazepine	B-Drug
and	O
carbamazepine	B-Drug_n
9	I-Drug_n
9	I-Drug_n
epoxide	I-Drug_n
concentrations	O
were	O
not	O
affected	O
by	O
concomitant	O
gabapentin	B-Drug
(	O
9	O
mg	O
TID	O
;	O
      
In	O
general	O
any	O
added	O
antiarrhythmic	B-Drug
drug	I-Drug
should	O
be	O
initiated	O
at	O
a	O
lower	O
than	O
usual	O
dose	O
with	O
careful	O
monitoring	O
.	O
      
However	O
increased	O
prothrombin	O
time	O
and	O
bleeding	O
have	O
been	O
reported	O
in	O
patients	O
on	O
concomitant	O
TOLECTIN	B-Brand
and	O
warfarin	B-Drug
therapy	O
.	O
      
Rifampin	B-Drug
:	O
Following	O
concomitant	O
administration	O
of	O
a	O
single	O
dose	O
of	O
ARAVA	B-Brand
to	O
subjects	O
receiving	O
multiple	O
doses	O
of	O
rifampin	B-Drug
M9	O
peak	O
levels	O
were	O
increased	O
(	O
~9	O
%	O
)	O
over	O
those	O
seen	O
when	O
ARAVA	B-Brand
was	O
given	O
alone	O
.	O
      
Thyroid	B-Group
administration	O
to	O
a	O
digitalized	O
hypothyroid	O
patient	O
may	O
increase	O
the	O
dose	O
requirement	O
of	O
digoxin	B-Drug
.	O
      
It	O
is	O
recommended	O
that	O
plasma	O
lithium	B-Drug
levels	O
be	O
monitored	O
when	O
ketoprofen	B-Drug
is	O
coadministered	O
with	O
lithium	B-Drug
.	O
      
The	O
steady	O
-	O
state	O
Cmin	O
increased	O
to	O
9	O
9	O
micrograms	O
/	O
mL	O
when	O
9	O
mg	O
/	O
day	O
of	O
felbamate	B-Drug
was	O
coadministered	O
.	O
      
Acid	O
-	O
base	O
and	O
electrolyte	O
alterations	O
were	O
not	O
reported	O
in	O
the	O
clinical	O
trials	O
with	O
brinzolamide	B-Drug
.	O
      
When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
glipizide	B-Drug
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O
      
-	O
Drugs	O
with	O
nephrotoxic	O
potential	O
:	O
There	O
has	O
been	O
no	O
experience	O
on	O
the	O
concurrent	O
use	O
of	O
bumetanide	B-Drug
with	O
drugs	O
known	O
to	O
have	O
a	O
nephrotoxic	O
potential	O
.	O
      
One	O
death	O
has	O
also	O
been	O
reported	O
from	O
foreign	O
post	O
-	O
marketing	O
sources	O
.	O
      
Use	O
of	O
a	O
diuretic	B-Group
may	O
further	O
increase	O
the	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
Cevimeline	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
individuals	O
known	O
or	O
suspected	O
to	O
be	O
deficient	O
in	O
CYP9D9	O
activity	O
based	O
on	O
previous	O
experience	O
as	O
they	O
may	O
be	O
at	O
a	O
higher	O
risk	O
of	O
adverse	O
events	O
.	O
      
acidifying	O
drugs	O
or	O
foods	O
will	O
decrease	O
urinary	O
excretion	O
and	O
increase	O
plasma	O
levels	O
.	O
      
The	O
effect	O
of	O
clonazepam	B-Drug
on	O
the	O
metabolism	O
of	O
other	O
drugs	O
has	O
not	O
been	O
investigated	O
.	O
      
COPEGUS	B-Brand
therapy	O
is	O
contraindicated	O
in	O
women	O
who	O
are	O
pregnant	O
and	O
in	O
the	O
male	O
partners	O
of	O
women	O
who	O
are	O
pregnant	O
.	O
      
Cimetidine	B-Drug
:	O
Atorvastatin	B-Drug
plasma	O
concentrations	O
and	O
LDL	O
-	O
C	O
reduction	O
were	O
not	O
altered	O
by	O
coadministration	O
of	O
cimetidine	B-Drug
.	O
      
The	O
role	O
of	O
AMEVIVE	B-Brand
in	O
the	O
development	O
of	O
the	O
lymphoid	O
malignancy	O
and	O
the	O
hyperplasia	O
observed	O
in	O
non	O
-	O
human	O
primates	O
and	O
the	O
relevance	O
to	O
humans	O
is	O
unknown	O
.	O
      
In	O
an	O
in	O
vitro	O
study	O
in	O
human	O
liver	O
microsomes	O
inhibition	O
of	O
CYP9A9	O
hydroxylation	O
of	O
coumarin	B-Group
by	O
fondaparinux	B-Drug
(	O
9	O
m	O
m	O
M	O
i.e.	O
9	O
mg	O
/	O
L	O
)	O
was	O
9	O
-	O
9	O
%	O
.	O
      
The	O
extent	O
to	O
which	O
SSRI	B-Group
-	O
TCA	B-Group
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	B-Group
involved	O
.	O
      
Methenamine	B-Drug
      
Thioridazine	B-Drug
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
Sonata	B-Brand
9	O
mg	O
and	O
thioridazine	B-Drug
9	O
mg	O
produced	O
additive	O
effects	O
on	O
decreased	O
alertness	O
and	O
impaired	O
psychomotor	O
performance	O
for	O
9	O
to	O
9	O
hours	O
after	O
administration	O
.	O
      
Paliperidone	B-Drug
may	O
antagonize	O
the	O
effect	O
of	O
levodopa	B-Drug
and	O
other	O
dopamine	B-Group
agonists	I-Group
.	O
      
In	O
this	O
situation	O
special	O
patient	O
care	O
and	O
observation	O
are	O
appropriate	O
.	O
      
Therefore	O
when	O
MIDAMOR	B-Brand
and	O
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
are	O
used	O
concomitantly	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-Group
is	O
obtained	O
.	O
      
efavirenz	B-Drug
concentration	O
      
For	O
this	O
reason	O
the	O
dose	O
of	O
adrenaline	B-Drug
should	O
be	O
restricted	O
and	O
an	O
antiarrhythmic	B-Group
agent	I-Group
administered	O
as	O
appropriate	O
.	O
      
The	O
following	O
agents	O
may	O
increase	O
certain	O
actions	O
or	O
side	O
effects	O
of	O
anticholinergic	B-Group
drugs	I-Group
:	O
amantadine	B-Drug
antiarrhythmic	B-Group
agents	I-Group
of	I-Group
class	I-Group
I	I-Group
(	O
e.g.	O
quinidine	B-Drug
)	O
antihistamines	B-Group
antipsychotic	B-Group
agents	I-Group
(	O
e.g.	O
phenothiazines	B-Group
)	O
benzodiazepines	B-Group
MAO	B-Group
inhibitors	I-Group
narcotic	B-Group
analgesics	I-Group
(	O
e.g.	O
meperidine	B-Drug
)	O
nitrates	B-Group
and	O
nitrites	B-Group
sympathomimetic	B-Group
agents	I-Group
tricyclic	B-Group
antidepressants	I-Group
and	O
other	O
drugs	O
having	O
anticholinergic	O
activity	O
.	O
      
Sodium	B-Drug
Iodide	I-Drug
(	O
9I	O
and	O
9I	O
)	O
Sodium	B-Drug
Pertechnetate	I-Drug
Tc9m	I-Drug
:	O
Uptake	O
of	O
radiolabeled	O
ions	O
may	O
be	O
decreased	O
.	O
      
9	O
.	O
      
a	O
reduced	O
dose	O
of	O
theophylline	B-Drug
may	O
be	O
needed	O
.	O
      
Monitor	O
serum	O
potassium	O
levels	O
;	O
      
Concomitant	O
Drug	O
      
Cyclophosphamide	B-Drug
treatment	O
which	O
causes	O
a	O
marked	O
and	O
persistent	O
inhibition	O
of	O
cholinesterase	O
activity	O
potentiates	O
the	O
effect	O
of	O
succinylcholine	B-Drug
chloride	I-Drug
.	O
      
Although	O
a	O
9	O
-	O
day	O
regimen	O
of	O
Aprepitant	B-Drug
given	O
concomitantly	O
with	O
oral	O
contraceptives	B-Group
has	O
not	O
been	O
studied	O
alternative	O
or	O
back	O
-	O
up	O
methods	O
of	O
contraception	O
should	O
be	O
used	O
.	O
      
if	O
plasma	O
levels	O
are	O
being	O
monitored	O
they	O
should	O
be	O
reassessed	O
.	O
      
reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P9	O
9D9	O
isozyme	O
activity	O
among	O
Asian	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O
      
Since	O
the	O
effect	O
of	O
AMEVIVE	B-Brand
on	O
pregnancy	O
and	O
fetal	O
development	O
including	O
immune	O
system	O
development	O
is	O
not	O
known	O
health	O
care	O
providers	O
are	O
encouraged	O
to	O
enroll	O
patients	O
currently	O
taking	O
AMEVIVE	B-Brand
who	O
become	O
pregnant	O
into	O
the	O
Biogen	O
Pregnancy	O
Registry	O
by	O
calling	O
9	O
-	O
9	O
-	O
AMEVIVE	B-Brand
(	O
9	O
-	O
9	O
-	O
9	O
-	O
9	O
)	O
.	O
      
however	O
9	O
mg	O
of	O
ranitidine	B-Drug
q9h	O
for	O
9	O
days	O
increased	O
the	O
ceftibuten	B-Drug
C	O
max	O
by	O
9	O
%	O
and	O
ceftibuten	B-Drug
AUC	O
by	O
9	O
%	O
.	O
      
It	O
is	O
not	O
known	O
if	O
hormonal	B-Group
contraceptives	I-Group
differ	O
in	O
their	O
effectiveness	O
when	O
used	O
with	O
Accutane	B-Brand
.	O
      
Caverject	B-Brand
:	O
The	O
potential	O
for	O
pharmacokinetic	O
drug	O
-	O
drug	O
interactions	O
between	O
alprostadil	B-Drug
and	O
other	O
agents	O
has	O
not	O
been	O
formally	O
studied	O
.	O
      
The	O
mean	O
C	O
max	O
T	O
max	O
and	O
AUC	O
of	O
the	O
acid	O
metabolite	O
of	O
terfenadine	B-Drug
were	O
not	O
significantly	O
changed	O
.	O
      
-	O
Furazolidone	B-Drug
(	O
e.g.	O
Furoxone	B-Brand
)	O
or	O
      
sertraline	B-Drug
concentration	O
      
Itraconazole	B-Drug
plasma	O
concentrations	O
should	O
be	O
monitored	O
when	O
Itraconazole	B-Drug
and	O
isoniazid	B-Drug
are	O
coadministered	O
.	O
      
However	O
ketoconazole	B-Drug
a	O
potent	O
inhibitor	O
of	O
cytochrome	O
P9	O
9A9	O
may	O
increase	O
plasma	O
levels	O
of	O
mometasone	B-Drug
furoate	I-Drug
during	O
concomitant	O
dosing	O
.	O
      
Nabilone	B-Drug
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
who	O
are	O
taking	O
other	O
psychoactive	B-Group
drugs	I-Group
or	O
CNS	B-Group
depressants	I-Group
including	O
alcohol	B-Drug
barbiturates	B-Group
and	O
narcotic	B-Group
analgesics	I-Group
or	O
to	O
those	O
with	O
a	O
history	O
of	O
psychiatric	O
disorder	O
(	O
including	O
manic	O
-	O
depressive	O
illness	O
and	O
schizophrenia	O
)	O
.	O
      
Read	O
circulars	O
for	O
lithium	B-Drug
preparations	O
before	O
use	O
of	O
such	O
concomitant	O
therapy	O
.	O
      
Medications	O
that	O
interfere	O
with	O
your	O
bodys	O
ability	O
to	O
use	O
folate	O
may	O
also	O
increase	O
the	O
need	O
for	O
this	O
vitamin	B-Group
.	O
      
Isoflurane	B-Drug
enflurane	B-Drug
and	O
halothane	B-Drug
decrease	O
the	O
ED9	O
of	O
NUROMAX	B-Brand
by	O
9	O
%	O
to	O
9	O
%	O
.	O
      
The	O
AUC	O
and	O
Cmax	O
of	O
metoprolol	B-Drug
however	O
were	O
increased	O
approximately	O
9	O
and	O
9	O
%	O
respectively	O
.	O
      
Studies	O
have	O
shown	O
that	O
the	O
bioavailability	O
of	O
isoniazid	B-Drug
is	O
reduced	O
significantly	O
when	O
administered	O
with	O
food	O
.	O
      
Ritonavir	B-Drug
      
Serotonin	O
release	O
by	O
platelets	O
plays	O
an	O
important	O
role	O
in	O
hemostasis	O
.	O
      
Therefore	O
serum	O
levels	O
of	O
methotrexate	B-Drug
should	O
be	O
monitored	O
in	O
patients	O
to	O
avoid	O
drug	O
toxicity	O
.	O
      
Before	O
taking	O
this	O
medication	O
tell	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
a	O
tricyclic	B-Group
antidepressant	I-Group
such	O
as	O
amitriptyline	B-Drug
(	O
Elavil	B-Brand
)	O
amoxapine	B-Drug
(	O
Asendin	B-Brand
)	O
doxepin	B-Drug
(	O
Sinequan	B-Brand
)	O
nortriptyline	B-Drug
(	O
Pamelor	B-Brand
)	O
imipramine	B-Drug
(	O
Tofranil	B-Brand
)	O
clomipramine	B-Drug
(	O
Anafranil	B-Brand
)	O
protriptyline	B-Drug
(	O
Vivactil	B-Brand
)	O
or	O
desipramine	B-Drug
(	O
Norpramin	B-Brand
)	O
.	O
      
Indinavir	B-Drug
concentrations	O
may	O
be	O
decreased	O
in	O
the	O
presence	O
of	O
nevirapine	B-Drug
.	O
      
Oral	O
Anticoagulants	B-Group
:	O
In	O
some	O
normal	O
volunteers	O
the	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
warfarin	B-Drug
acenocoumarol	B-Drug
or	O
phenprocoumon	B-Drug
resulted	O
in	O
prolongation	O
of	O
prothrombin	O
time	O
.	O
      
Bosentan	B-Drug
had	O
no	O
relevant	O
inhibitory	O
effect	O
on	O
any	O
CYP	O
isoenzymes	O
tested	O
(	O
CYP9A9	O
CYP9C9	O
CYP9C9	O
CYP9D9	O
CYP9A9	O
)	O
.	O
      
Cmax	O
and	O
t9	O
/	O
9	O
were	O
increased	O
9	O
-	O
fold	O
and	O
9	O
-	O
fold	O
respectively	O
.	O
      
Anagrelide	B-Drug
is	O
an	O
inhibitor	O
of	O
cyclic	O
AMP	O
PDE	O
III	O
.	O
      
The	O
in	O
vitro	O
binding	O
of	O
warfarin	B-Drug
to	O
human	O
plasma	O
proteins	O
is	O
unaffected	O
by	O
tolmetin	B-Drug
and	O
tolmetin	B-Drug
does	O
not	O
alter	O
the	O
prothrombin	O
time	O
of	O
normal	O
volunteers	O
.	O
      
Methadonea	O
      
methylphenidate	B-Drug
;	O
      
Seizure	O
associated	O
with	O
increased	O
lidocaine	B-Drug
concentrations	O
has	O
been	O
reported	O
with	O
concomitant	O
administration	O
of	O
intravenous	O
amiodarone	B-Drug
.	O
      
Mean	O
T	O
max	O
and	O
mean	O
plasma	O
elimination	O
half	O
-	O
life	O
of	O
albendazole	B-Drug
sulfoxide	I-Drug
were	O
unchanged	O
.	O
      
These	O
drugs	O
should	O
be	O
coad	O
-	O
ministered	O
with	O
caution	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	B-Drug
levels	O
is	O
recommended	O
.	O
      
Drug	O
-	O
Laboratory	O
-	O
Test	O
Interactions	O
Interactions	O
between	O
tolterodine	B-Drug
and	O
laboratory	O
tests	O
have	O
not	O
been	O
studied	O
.	O
      
reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P9	O
9D9	O
isozyme	O
activity	O
among	O
Asian	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O
      
Drug	O
/	O
Laboratory	O
Tests	O
Interactions	O
Because	O
false	O
positive	O
readings	O
were	O
reported	O
with	O
the	O
Ames	O
N	O
-	O
Multistix	O
SG	O
dipstick	O
test	O
for	O
urinary	O
protein	O
when	O
gabapentin	B-Drug
was	O
added	O
to	O
other	O
antiepileptic	B-Group
drugs	I-Group
the	O
more	O
specific	O
sulfosalicylic	O
acid	O
precipitation	O
procedure	O
is	O
recommended	O
to	O
determine	O
the	O
presence	O
of	O
urine	O
protein	O
      
Oral	O
Contraceptives	B-Group
Multiple	O
doses	O
of	O
cefditoren	B-Drug
pivoxil	I-Drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
the	O
estrogenic	O
component	O
in	O
most	O
oral	O
contraceptives	B-Group
.	O
      
As	O
with	O
most	O
psychoactive	O
medications	O
patients	O
should	O
be	O
advised	O
to	O
avoid	O
alcohol	B-Drug
while	O
taking	O
ABILIFY	B-Brand
      
This	O
drug	O
may	O
interact	O
with	O
alcohol	B-Drug
or	O
other	O
CNS	B-Group
depressants	I-Group
(	O
may	O
potentiate	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	B-Group
)	O
anticholinergics	B-Group
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
(	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	B-Group
)	O
and	O
monoamine	B-Group
oxidase	I-Group
MAO	I-Group
inhibitors	I-Group
(	O
concurrent	O
use	O
with	O
antihistamines	B-Drug
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
and	O
CNS	O
depressant	O
effects	O
of	O
antihistamines	B-Drug
)	O
.	O
      
Mineral	B-Drug
oil	I-Drug
interferes	O
with	O
the	O
absorption	O
of	O
fat	B-Group
-	O
soluble	I-Group
vitamins	I-Group
including	O
vitamin	B-Group
D	I-Group
preparations	I-Group
.	O
      
cardiac	B-Group
glycosides	I-Group
;	O
      
C	O
max	O
AUC	O
9	O
-	O
9	O
hrs	O
C	O
max	O
AUC	O
9	O
-	O
9	O
hrs	O
      
-	O
Impaired	O
glucose	O
tolerance	O
      
Fluconazole	B-Drug
and	O
the	O
9	B-Group
-	O
HT9	I-Group
antiemetics	I-Group
ondansetron	B-Drug
(	O
Zofran	B-Brand
)	O
and	O
granisetron	B-Drug
(	O
Kytril	B-Brand
)	O
have	O
all	O
been	O
used	O
with	O
BUSULFEX	B-Brand
.	O
      
the	O
time	O
to	O
reach	O
maximum	O
concentration	O
was	O
delayed	O
approximately	O
9	O
minutes	O
.	O
      
Antacid	B-Group
:	O
The	O
effect	O
of	O
an	O
aluminum	B-Drug
hydroxide	I-Drug
-	O
and	O
magnesium	B-Drug
hydroxide	I-Drug
-	O
containing	O
antacid	B-Group
(	O
Maalox	B-Brand
)	O
*	O
on	O
the	O
pharmacokinetics	O
of	O
capecitabine	B-Drug
was	O
investigated	O
in	O
9	O
cancer	O
patients	O
.	O
      
Inhibition	O
of	O
CYP9A9	O
metabolic	O
reactions	O
was	O
not	O
detected	O
in	O
in	O
vitro	O
experiments	O
.	O
      
iii	O
.	O
      
Thus	O
no	O
dosing	O
adjustments	O
are	O
necessary	O
during	O
concomitant	O
use	O
with	O
these	O
agents	O
.	O
      
Antidiabetics	B-Group
:	O
Because	O
corticosteroids	B-Group
may	O
increase	O
blood	O
glucose	O
concentrations	O
dosage	O
adjustments	O
of	O
antidiabetic	B-Group
agents	I-Group
may	O
be	O
required	O
.	O
      
If	O
a	O
diuretic	B-Group
is	O
also	O
used	O
the	O
risk	O
of	O
lithium	O
toxicity	O
may	O
be	O
increased	O
.	O
      
.	O
      
however	O
in	O
a	O
study	O
of	O
9	O
normal	O
subjects	O
concurrent	O
administration	O
of	O
aspirin	B-Brand
decreased	O
ketoprofen	B-Drug
protein	O
binding	O
and	O
increased	O
ketoprofen	B-Drug
plasma	O
clearance	O
from	O
9	O
L	O
/	O
kg	O
/	O
h	O
without	O
aspirin	B-Brand
to	O
9	O
L	O
/	O
kg	O
/	O
h	O
with	O
aspirin	B-Brand
.	O
      
ISUPREL	B-Brand
should	O
be	O
used	O
with	O
caution	O
if	O
at	O
all	O
when	O
potent	O
inhalational	O
anesthetics	B-Group
such	O
as	O
halothane	B-Drug
are	O
employed	O
because	O
of	O
potential	O
to	O
sensitize	O
the	O
myocardium	O
to	O
effects	O
of	O
sympathomimetic	B-Group
amines	I-Group
.	O
      
.	O
      
The	O
appropriate	O
doses	O
for	O
this	O
combination	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
have	O
not	O
been	O
established	O
.	O
      
The	O
possibility	O
of	O
increased	O
interaction	O
should	O
be	O
kept	O
in	O
mind	O
when	O
Orudis	B-Brand
doses	O
greater	O
than	O
9	O
mg	O
as	O
a	O
single	O
dose	O
or	O
9	O
mg	O
of	O
ketoprofen	B-Drug
per	O
day	O
are	O
used	O
concomitantly	O
with	O
highly	O
bound	O
drugs	O
.	O
      
-	O
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
Thiazides	B-Group
should	O
be	O
discontinued	O
before	O
carrying	O
out	O
tests	O
for	O
parathyroid	O
function	O
.	O
      
Although	O
it	O
is	O
unknown	O
whether	O
this	O
could	O
result	O
in	O
clinically	O
significant	O
effects	O
caution	O
is	O
advised	O
when	O
administering	O
Cerebyx	B-Brand
with	O
other	O
drugs	O
that	O
significantly	O
bind	O
to	O
serum	O
albumin	O
.	O
      
This	O
antagonistic	O
effect	O
of	O
probenecid	B-Drug
on	O
bumetanide	B-Drug
natriuresis	O
is	O
not	O
due	O
to	O
a	O
direct	O
action	O
on	O
sodium	O
excretion	O
but	O
is	O
probably	O
secondary	O
to	O
its	O
inhibitory	O
effect	O
on	O
renal	O
tubular	O
secretion	O
of	O
bumetanide	B-Drug
.	O
      
Terbinafine	B-Drug
decreases	O
the	O
clearance	O
of	O
caffeine	B-Drug
by	O
9	O
%	O
.	O
      
In	O
renal	O
and	O
cardiac	O
transplant	O
recipients	O
a	O
reduction	O
of	O
cyclosporine	B-Drug
dose	O
ranging	O
from	O
9	O
%	O
to	O
9	O
%	O
was	O
necessary	O
to	O
maintain	O
cyclosporine	B-Drug
trough	O
concentrations	O
similar	O
to	O
those	O
seen	O
prior	O
to	O
the	O
addition	O
of	O
diltiazem	B-Drug
.	O
      
Theophylline	B-Drug
:	O
The	O
pharmacokinetics	O
of	O
theophylline	B-Drug
(	O
aminophylline	B-Drug
9	O
mg	O
/	O
kg	O
infused	O
over	O
9	O
minutes	O
)	O
were	O
unchanged	O
following	O
a	O
single	O
oral	O
dose	O
of	O
albendazole	B-Drug
(	O
9	O
mg	O
)	O
in	O
9	O
healthy	O
subjects	O
.	O
      
Drugs	O
Highly	O
Bound	O
to	O
Plasma	O
Protein	O
Zaleplon	B-Drug
is	O
not	O
highly	O
bound	O
to	O
plasma	O
proteins	O
(	O
fraction	O
bound	O
9	O
%	O
9	O
%	O
)	O
;	O
      
Exemestane	B-Drug
is	O
extensively	O
metabolized	O
by	O
CYP	O
9A9	O
but	O
coadministration	O
of	O
ketoconazole	B-Drug
a	O
potent	O
inhibitor	O
of	O
CYP	O
9A9	O
has	O
no	O
significant	O
effect	O
on	O
exemestane	B-Drug
pharmacokinetics	O
.	O
      
Antacids	B-Group
:	O
Enteric	O
Coated	O
Aspirin	B-Brand
should	O
not	O
be	O
given	O
concurrently	O
with	O
antacids	B-Group
since	O
an	O
increase	O
in	O
the	O
pH	O
of	O
the	O
stomach	O
may	O
effect	O
the	O
enteric	O
coating	O
of	O
the	O
tablets	O
.	O
      
however	O
an	O
increased	O
methadone	B-Drug
dose	O
may	O
be	O
required	O
in	O
a	O
small	O
number	O
of	O
patients	O
.	O
      
In	O
these	O
subjects	O
celecoxib	B-Drug
did	O
not	O
alter	O
the	O
anticoagulant	O
effect	O
of	O
warfarin	B-Drug
as	O
determined	O
by	O
prothrombin	O
time	O
.	O
      
Therefore	O
when	O
EDECRIN	B-Brand
and	O
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
are	O
used	O
concomitantly	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-Group
is	O
obtained	O
.	O
      
This	O
alteration	O
will	O
not	O
result	O
in	O
a	O
methadone	B-Drug
dose	O
modification	O
in	O
the	O
majority	O
of	O
patients	O
;	O
      
Rhabdomyolysis	O
has	O
been	O
observed	O
in	O
patients	O
receiving	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitors	I-Group
administered	O
alone	O
(	O
at	O
recommended	O
dosages	O
)	O
or	O
concomitantly	O
with	O
immunosuppressive	B-Group
drugs	I-Group
including	O
cyclosporine	B-Drug
.	O
      
tolbutamide	B-Drug
;	O
      
Co	O
-	O
administration	O
of	O
TIKOSYN	B-Brand
with	O
verapamil	B-Drug
resulted	O
in	O
increases	O
in	O
dofetilide	B-Drug
peak	O
plasma	O
levels	O
of	O
9	O
%	O
although	O
overall	O
exposure	O
to	O
dofetilide	B-Drug
was	O
not	O
significantly	O
increased	O
.	O
      
(	O
9	O
mg	O
Q9h	O
)	O
      
These	O
are	O
described	O
in	O
greater	O
detail	O
below	O
:	O
Oral	O
hypoglycemics	B-Group
Coumarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
Phenytoin	B-Drug
Cyclosporine	B-Drug
Rifampin	B-Drug
Theophylline	B-Drug
Terfenadine	B-Drug
Cisapride	B-Drug
Astemizole	B-Drug
Rifabutin	B-Drug
Tacrolimus	B-Drug
Short	B-Group
-	O
acting	I-Group
benzodiazepines	I-Group
Oral	O
hypoglycemics	B-Group
:	O
Clinically	O
significant	O
hypoglycemia	O
may	O
be	O
precipitated	O
by	O
the	O
use	O
of	O
DIFLUCAN	B-Brand
with	O
oral	O
hypoglycemic	B-Group
agents	I-Group
;	O
      
Fexofenadine	B-Drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
erythromycin	B-Drug
or	O
ketoconazole	B-Drug
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Acetaminophen	B-Drug
may	O
produce	O
false	O
-	O
positive	O
test	O
results	O
for	O
urinary	O
9	O
-	O
hydroxyindoleacetic	O
acid	O
.	O
      
Lithium	B-Drug
:	O
In	O
clinical	O
trials	O
NSAIDs	B-Group
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	B-Drug
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	B-Drug
clearance	O
.	O
      
However	O
on	O
a	O
body	O
surface	O
area	O
basis	O
this	O
dose	O
was	O
9	O
times	O
maximum	O
recommended	O
human	O
9	O
-	O
hour	O
dose	O
of	O
ribavirin	B-Drug
.	O
      
.	O
      
Other	O
kits	O
such	O
as	O
the	O
Coat	O
-	O
A	O
-	O
Count	O
RIA	O
Kit	O
may	O
be	O
used	O
.	O
      
Coadministration	O
of	O
Sanctura	B-Brand
with	O
drugs	O
that	O
are	O
eliminated	O
by	O
active	O
renal	O
tubular	O
secretion	O
may	O
increase	O
the	O
serum	O
concentration	O
of	O
Sanctura	B-Brand
and	O
/	O
or	O
the	O
coadministered	O
drug	O
due	O
to	O
competition	O
for	O
this	O
elimination	O
pathway	O
.	O
      
Drug	O
-	O
drug	O
interactions	O
have	O
not	O
been	O
observed	O
between	O
Argatroban	B-Drug
and	O
digoxin	B-Drug
or	O
erythromycin	B-Drug
.	O
      
Use	O
of	O
PRINIVIL	B-Brand
with	O
potassium	B-Group
-	O
sparing	I-Group
diuretics	I-Group
(	O
e.g.	O
spironolactone	B-Drug
triamterene	B-Drug
or	O
amiloride	B-Drug
)	O
potassium	B-Drug
supplements	O
or	O
potassium	O
-	O
containing	O
salt	O
substitutes	O
may	O
lead	O
to	O
significant	O
increases	O
in	O
serum	O
potassium	O
.	O
      
and	O
rarely	O
euphoria	O
excitement	O
depression	O
hallucinations	O
paresthesia	O
muscle	O
pain	O
tinnitus	O
slurred	O
speech	O
coordination	O
disorder	O
tremor	O
rigidity	O
dystonia	O
ataxia	O
blurred	O
vision	O
nystagmus	O
strabismus	O
miosis	O
mydriasis	O
diplopia	O
dysarthria	O
epileptic	O
seizure	O
.	O
      
In	O
oral	O
(	O
gavage	O
)	O
embryo	O
-	O
fetal	O
development	O
studies	O
of	O
ezetimibe	B-Drug
conducted	O
in	O
rats	O
and	O
rabbits	O
during	O
organogenesis	O
there	O
was	O
no	O
evidence	O
of	O
embryolethal	O
effects	O
at	O
the	O
doses	O
tested	O
(	O
9	O
9	O
9	O
mg	O
/	O
kg	O
/	O
day	O
)	O
.	O
      
Cefuroxime	B-Drug
does	O
not	O
interfere	O
with	O
the	O
assay	O
of	O
serum	O
and	O
urine	O
creatinine	O
by	O
the	O
alkaline	O
picrate	O
method	O
.	O
      
Digoxin	B-Drug
Methotrexate	B-Drug
Cyclosporine	B-Drug
:	O
Diclofenac	B-Drug
like	O
other	O
NSAIDs	B-Group
may	O
affect	O
renal	O
prostaglandins	O
and	O
increase	O
the	O
toxicity	O
of	O
certain	O
drugs	O
.	O
      
Thus	O
SYMLIN	B-Brand
and	O
insulin	B-Drug
should	O
not	O
be	O
mixed	O
and	O
must	O
be	O
administered	O
separately	O
.	O
      
Note	O
:	O
      
Coadministration	O
of	O
entecavir	B-Drug
with	O
lamivudine	B-Drug
adefovir	B-Drug
dipivoxil	I-Drug
or	O
tenofovir	B-Drug
disoproxil	I-Drug
fumarate	I-Drug
did	O
not	O
result	O
in	O
significant	O
drug	O
interactions	O
.	O
      
The	O
concomitant	O
administration	O
of	O
Exjade	B-Brand
and	O
aluminum	B-Drug
-	O
containing	O
antacid	B-Group
preparations	I-Group
has	O
not	O
been	O
formally	O
studied	O
.	O
      
The	O
concentration	O
of	O
AMICAR	B-Brand
necessary	O
to	O
maintain	O
inhibition	O
of	O
fibrinolysis	O
is	O
9	O
mMol	O
/	O
L	O
or	O
9	O
mg	O
/	O
mL	O
.	O
      
Carbamazepine	B-Drug
      
Aminoglutethimide	B-Drug
:	O
May	O
increase	O
CYP	O
metabolism	O
of	O
progestins	B-Group
leading	O
to	O
possible	O
decrease	O
in	O
contraceptive	O
effectiveness	O
.	O
      
Prothrombin	O
time	O
or	O
other	O
suitable	O
anticoagulation	O
test	O
should	O
be	O
monitored	O
if	O
tigecycline	B-Drug
is	O
administered	O
with	O
warfarin	B-Drug
.	O
      
Amiodarone	B-Drug
taken	O
concomitantly	O
with	O
procainamide	B-Drug
for	O
less	O
than	O
seven	O
days	O
increases	O
plasma	O
concentrations	O
of	O
procainamide	B-Drug
and	O
n	O
-	O
acetyl	O
procainamide	B-Drug
by	O
9	O
%	O
and	O
9	O
%	O
respectively	O
.	O
      
LABORATORY	O
TEST	O
FINDINGS	O
Asymptomatic	O
transitory	O
changes	O
in	O
serum	O
iron	O
have	O
been	O
observed	O
.	O
      
9	O
-	O
9	O
      
Although	O
specific	O
studies	O
have	O
not	O
been	O
performed	O
coadministration	O
with	O
drugs	O
that	O
are	O
mainly	O
metabolized	O
by	O
CYP9A9	O
(	O
eg	O
calcium	B-Group
channel	I-Group
blockers	I-Group
dapsone	B-Drug
disopyramide	B-Drug
quinine	B-Drug
amiodarone	B-Drug
quinidine	B-Drug
warfarin	B-Drug
tacrolimus	B-Drug
cyclosporine	B-Drug
ergot	B-Group
derivatives	I-Group
pimozide	B-Drug
carbamazepine	B-Drug
fentanyl	B-Drug
alfentanyl	B-Drug
alprazolam	B-Drug
and	O
triazolam	B-Drug
)	O
may	O
have	O
elevated	O
plasma	O
concentrations	O
when	O
coadministered	O
with	O
saquinavir	B-Drug
;	O
      
Tiagabine	B-Drug
has	O
shown	O
no	O
clinically	O
important	O
potentiation	O
of	O
the	O
pharmacodynamic	O
effects	O
of	O
triazo	O
lam	O
or	O
alcohol	B-Drug
.	O
      
Sucralfate	B-Drug
and	O
antacids	B-Group
:	O
Quinolones	B-Group
form	O
chelates	O
with	O
metal	O
cations	O
.	O
      
Because	O
of	O
possible	O
clinical	O
significance	O
these	O
two	O
drugs	O
should	O
not	O
be	O
administered	O
concurrently	O
.	O
      
*CBZ	O
epoxide	O
      
Oral	O
Hypoglycemic	B-Group
Agents	I-Group
:	O
In	O
pharmacokinetic	O
studies	O
of	O
MEVACOR	B-Brand
in	O
hypercholesterolemic	O
noninsulin	O
dependent	O
diabetic	O
patients	O
there	O
was	O
no	O
drug	O
interaction	O
with	O
glipizide	B-Drug
or	O
with	O
chlorpropamide	B-Drug
      
Therefore	O
inhibitors	O
of	O
these	O
enzymes	O
are	O
expected	O
to	O
reduce	O
vardenafil	B-Drug
clearance	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
False	O
elevations	O
of	O
urinary	O
catecholamine	O
levels	O
may	O
occur	O
due	O
to	O
interference	O
with	O
the	O
fluorescence	O
test	O
.	O
      
use	O
of	O
a	O
nonhormonal	B-Group
contraceptive	I-Group
product	I-Group
is	O
recommended	O
.	O
      
chloral	B-Drug
hydrate	I-Drug
*	O
;	O
      
Concomitant	O
use	O
of	O
tricyclic	B-Group
antidepressants	I-Group
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P9	O
9D9	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-Group
antidepressant	I-Group
or	O
the	O
other	O
drug	O
.	O
      
Estazolam	B-Drug
:	O
Interaction	O
with	O
Other	O
Drugs	O
that	O
are	O
Metabolized	O
by	O
Cytochrome	O
P9	O
(	O
CYP	O
)	O
:	O
At	O
clinically	O
relevant	O
concentrations	O
in	O
vitro	O
studies	O
indicate	O
that	O
estazolam	B-Drug
(	O
9	O
M	O
)	O
was	O
not	O
inhibitory	O
towards	O
the	O
major	O
cytochrome	O
P9	O
isoforms	O
CYP9A9	O
CYP9A9	O
CYP9C9	O
CYP9C9	O
CYP9D9	O
CYP9E9	O
and	O
CYP9A	O
.	O
      
In	O
a	O
study	O
of	O
9	O
male	O
subjects	O
(	O
ages	O
9	O
to	O
9	O
years	O
)	O
who	O
were	O
extensive	O
metabolizers	O
of	O
the	O
CYP9D9	O
isoenzyme	O
daily	O
doses	O
of	O
bupropion	B-Drug
given	O
as	O
9	O
mg	O
twice	O
daily	O
followed	O
by	O
a	O
single	O
dose	O
of	O
9	O
mg	O
desipramine	B-Drug
increased	O
the	O
Cmax	O
AUC	O
and	O
t9	O
/	O
9	O
of	O
desipramine	B-Drug
by	O
an	O
average	O
of	O
approximately	O
9	O
-	O
9	O
-	O
and	O
9	O
-	O
fold	O
respectively	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Blood	O
Glucose	O
Blood	O
glucose	O
measurement	O
must	O
be	O
done	O
with	O
a	O
glucose	O
-	O
specific	O
method	O
to	O
prevent	O
maltose	O
interference	O
with	O
test	O
results	O
.	O
      
Antacids	B-Group
or	O
H	B-Group
9	I-Group
receptor	I-Group
antagonists	I-Group
:	O
When	O
dirithromycin	B-Drug
is	O
administered	O
immediately	O
following	O
antacids	B-Group
or	O
H	B-Group
9	I-Group
-	O
receptor	I-Group
antagonists	I-Group
the	O
absorption	O
of	O
dirithromycin	B-Drug
is	O
slightly	O
enhanced	O
.	O
      
Monoamine	O
Oxidase	O
Inhibition	O
:	O
Linezolid	B-Drug
is	O
a	O
reversible	O
nonselective	O
inhibitor	O
of	O
monoamine	O
oxidase	O
.	O
      
Until	O
further	O
data	O
are	O
available	O
regarding	O
the	O
potential	O
interaction	O
of	O
dirithromycin	B-Drug
with	O
these	O
compounds	O
caution	O
should	O
be	O
used	O
during	O
coadministration	O
.	O
      
The	O
hypoglycemic	O
action	O
of	O
sulfonylurea	B-Group
may	O
be	O
potentiated	O
by	O
certain	O
drugs	O
including	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
and	O
other	O
drugs	O
that	O
are	O
highly	O
protein	O
bound	O
salicylates	B-Group
sulfonamides	B-Group
chloramphenicol	B-Drug
probenecid	B-Drug
coumarins	B-Group
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
and	O
beta	B-Group
adrenergic	I-Group
blocking	I-Group
agents	I-Group
.	O
      
this	O
effect	O
is	O
at	O
least	O
balanced	O
by	O
decreased	O
metabolism	O
of	O
corticosteroids	B-Group
.	O
      
use	O
of	O
a	O
nonhormonal	B-Group
contraceptive	I-Group
product	I-Group
is	O
recommended	O
.	O
      
Furthermore	O
whenever	O
one	O
of	O
these	O
drugs	O
is	O
withdrawn	O
from	O
co	O
-	O
therapy	O
an	O
increased	O
dose	O
of	O
tricyclic	B-Group
antidepressant	I-Group
agent	I-Group
may	O
be	O
required	O
.	O
      
Antidiabetic	B-Group
drugs	I-Group
:	O
(	O
oral	O
agents	O
and	O
insulin	B-Drug
)	O
-	O
dosage	O
adjustment	O
of	O
the	O
antidiabetic	B-Group
drug	I-Group
may	O
be	O
required	O
.	O
      
Changes	O
in	O
hepatic	O
function	O
induced	O
by	O
concomitant	O
therapies	O
may	O
affect	O
epirubicin	B-Drug
metabolism	O
pharmacokinetics	O
therapeutic	O
efficacy	O
and	O
/	O
or	O
toxicity	O
.	O
      
Considerable	O
caution	O
should	O
be	O
exercised	O
if	O
PEGANONE	B-Brand
is	O
administered	O
concurrently	O
with	O
Phenurone	B-Brand
(	O
phenacemide	B-Drug
)	O
since	O
paranoid	O
symptoms	O
have	O
been	O
reported	O
during	O
therapy	O
with	O
this	O
combination	O
.	O
      
Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-Drug
used	O
to	O
treat	O
allergic	O
reaction	O
.	O
      
Literature	O
reports	O
indicate	O
that	O
coadministration	O
of	O
indomethacin	B-Drug
may	O
reduce	O
the	O
natriuretic	O
and	O
antihypertensive	O
effects	O
of	O
furosemide	B-Drug
in	O
some	O
patients	O
by	O
inhibiting	O
prostaglandin	O
synthesis	O
.	O
      
Pregnancy	O
Pregnancy	O
Category	O
D	O
:	O
.	O
      
The	O
effects	O
celecoxib	B-Drug
on	O
the	O
pharmacokinetics	O
and	O
/	O
or	O
pharmacodynamics	O
of	O
glyburide	B-Drug
ketoconazole	B-Drug
methotrexate	B-Drug
phenytoin	B-Drug
tolbutamide	B-Drug
and	O
warfarin	B-Drug
have	O
been	O
studied	O
in	O
vivo	O
and	O
clinically	O
important	O
interactions	O
have	O
not	O
been	O
found	O
.	O
      
Warfarin	B-Drug
      
Potential	O
drug	O
interactions	O
between	O
Mentax	B-Brand
(	O
butenafine	B-Drug
HCl	I-Drug
cream	O
)	O
Cream	O
9	O
%	O
and	O
other	O
drugs	O
have	O
not	O
been	O
systematically	O
evaluated	O
.	O
      
these	O
drugs	O
were	O
not	O
tested	O
to	O
determine	O
the	O
effect	O
of	O
administration	O
one	O
hour	O
before	O
colestipol	B-Drug
hydrochloride	I-Drug
.	O
      
Pharmacokinetic	O
studies	O
indicate	O
that	O
administration	O
of	O
disulfiram	B-Drug
or	O
diazepam	B-Drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
acamprosate	B-Drug
.	O
      
Antacids	B-Group
:	O
In	O
a	O
clinical	O
pharmacology	O
study	O
coadministration	O
of	O
an	O
antacid	B-Group
(	O
aluminum	B-Drug
hydroxide	I-Drug
magnesium	B-Drug
hydroxide	I-Drug
and	O
simethicone	B-Drug
)	O
with	O
fosinopril	B-Drug
reduced	O
serum	O
levels	O
and	O
urinary	O
excretion	O
of	O
fosinoprilat	B-Drug_n
as	O
compared	O
with	O
fosinopril	B-Drug
administered	O
alone	O
suggesting	O
that	O
antacids	B-Group
may	O
impair	O
absorption	O
of	O
fosinopril	B-Drug
.	O
      
salicylates	B-Group
;	O
sulfinpyrazone	B-Drug
;	O
      
However	O
iloprost	B-Drug
has	O
the	O
potential	O
to	O
increase	O
the	O
hypotensive	O
effect	O
of	O
vasodilators	B-Group
and	O
antihypertensive	B-Group
agents	I-Group
.	O
      
Anticholinergic	B-Group
drugs	I-Group
may	O
antagonize	O
the	O
effects	O
of	O
the	O
drugs	O
that	O
alter	O
gastrointestinal	O
motility	O
such	O
as	O
metoclopramide	B-Drug
.	O
      
-	O
Nitrofurantoin	B-Drug
(	O
e.g.	O
Furadantin	B-Brand
)	O
or	O
      
Caffeine	B-Drug
-	O
related	O
adverse	O
effects	O
have	O
occurred	O
in	O
patients	O
consuming	O
caffeine	B-Drug
while	O
on	O
therapy	O
with	O
enoxacin	B-Drug
.	O
      
Grapefruit	O
juice	O
Co	O
-	O
administration	O
of	O
felodipine	B-Drug
with	O
grapefruit	O
juice	O
resulted	O
in	O
more	O
than	O
9	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
and	O
Cmax	O
but	O
no	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
felodipine	B-Drug
.	O
      
Lithium	B-Drug
salts	O
      
The	O
pressor	O
effects	O
of	O
diethylpropion	B-Drug
and	O
those	O
of	O
other	O
drugs	O
may	O
be	O
additive	O
when	O
the	O
drugs	O
are	O
used	O
concomitantly	O
;	O
      
these	O
agents	O
may	O
diminish	O
the	O
effectiveness	O
of	O
Permax	B-Brand
.	O
      
Usually	O
severe	O
abdominal	O
symptoms	O
appear	O
before	O
there	O
is	O
such	O
a	O
fall	O
in	O
the	O
blood	O
pressure	O
.	O
      
In	O
evaluating	O
the	O
potential	O
for	O
interactions	O
among	O
co	O
-	O
administered	O
antiepilepsy	O
drugs	O
(	O
AEDs	B-Group
)	O
whether	O
or	O
not	O
an	O
AED	B-Group
induces	O
or	O
does	O
not	O
induce	O
metabolic	O
enzymes	O
is	O
an	O
important	O
consideration	O
.	O
      
-	O
Drugs	O
that	O
may	O
decrease	O
plasma	O
phenytoin	B-Drug
concentrations	O
include	O
:	O
carbamazepine	B-Drug
chronic	O
alcohol	B-Drug
abuse	O
reserpine	B-Drug
      
Patients	O
on	O
lithium	B-Drug
treatment	O
should	O
be	O
closely	O
monitored	O
when	O
MOBIC	B-Brand
is	O
introduced	O
or	O
withdrawn	O
.	O
      
Methadone	B-Drug
      
Lodine	B-Brand
treatment	O
is	O
associated	O
with	O
a	O
small	O
decrease	O
in	O
serum	O
uric	O
acid	O
levels	O
.	O
      
Digoxin	B-Drug
did	O
not	O
affect	O
BREVIBLOC	B-Brand
pharmacokinetics	O
.	O
      
Another	O
investigator	O
found	O
no	O
increase	O
in	O
digoxin	B-Drug
levels	O
in	O
9	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O
      
(	O
Effects	O
may	O
be	O
potentiated	O
when	O
used	O
concurrently	O
with	O
thiazide	B-Group
diuretics	I-Group
;	O
      
Paricalcitol	B-Drug_n
is	O
not	O
expected	O
to	O
inhibit	O
the	O
clearance	O
of	O
drugs	O
metabolized	O
by	O
cytochrome	O
P9	O
enzymes	O
CYP9A9	O
CYP9A9	O
CYP9B9	O
CYP9C9	O
CYP9C9	O
CYP9C9	O
CYP9D9	O
CYP9E9	O
or	O
CYP9A	O
nor	O
induce	O
the	O
clearance	O
of	O
drugs	O
metabolized	O
by	O
CYP9B9	O
CYP9C9	O
or	O
CYP9A	O
.	O
      
-	O
Lithium	B-Drug
:	O
Lithium	B-Drug
should	O
generally	O
not	O
be	O
given	O
with	O
diuretics	B-Group
(	O
such	O
as	O
bumetanide	B-Drug
)	O
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
In	O
the	O
treatment	O
of	O
acute	O
MI	O
aspirin	B-Brand
when	O
not	O
otherwise	O
contraindicated	O
should	O
be	O
administered	O
with	O
Streptokinase	B-Drug
(	O
see	O
below	O
)	O
.	O
      
Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
a	O
known	O
inhibitor	O
of	O
renal	O
tubular	O
secretion	O
of	O
organic	O
bases	O
via	O
the	O
cationic	O
transport	O
system	O
caused	O
a	O
9	O
%	O
increase	O
in	O
pramipexole	B-Drug
AUC	O
and	O
a	O
9	O
%	O
increase	O
in	O
half	O
-	O
life	O
(	O
N=	O
9	O
)	O
.	O
      
There	O
are	O
no	O
clinical	O
data	O
on	O
the	O
use	O
of	O
MIVACRON	B-Brand
with	O
other	O
nondepolarizing	B-Group
neuromuscular	I-Group
blocking	I-Group
agents	I-Group
.	O
      
Warfarin	B-Drug
:	O
Increased	O
INR	O
(	O
International	O
Normalized	O
Ratio	O
)	O
when	O
ARAVA	B-Brand
and	O
warfarin	B-Drug
were	O
co	O
-	O
administered	O
has	O
been	O
rarely	O
reported	O
.	O
      
A	O
similar	O
association	O
though	O
less	O
marked	O
has	O
been	O
suggested	O
with	O
barbiturates	B-Group
phenyl	O
-	O
butazone	O
phenytoin	B-Drug
sodium	I-Drug
carbamazepine	B-Drug
and	O
possibly	O
with	O
griseofulvin	B-Drug
ampicillin	B-Drug
and	O
tetracyclines	B-Group
(	O
9	O
)	O
      
The	O
concomitant	O
use	O
of	O
vasopressors	B-Group
vasoconstricting	O
agents	O
(	O
such	O
as	O
ergonovine	B-Drug
)	O
and	O
some	O
oxytocic	B-Group
drugs	I-Group
may	O
result	O
in	O
severe	O
hypertension	O
.	O
      
Latent	O
LCV	O
infection	O
is	O
generally	O
asymptomatic	O
but	O
can	O
lead	O
to	O
B	O
-	O
cell	O
lymphomas	O
when	O
animals	O
are	O
immune	O
suppressed	O
.	O
      
This	O
medication	O
should	O
not	O
be	O
taken	O
with	O
MAO	B-Group
inhibitors	I-Group
.	O
      
Patients	O
receiving	O
hydantoins	B-Group
sulfonamides	B-Group
or	O
sulfonylureas	B-Group
should	O
be	O
observed	O
for	O
increased	O
activity	O
of	O
these	O
drugs	O
and	O
therefore	O
signs	O
of	O
toxicity	O
from	O
these	O
drugs	O
.	O
      
Risk	O
of	O
anaphylactic	O
reaction	O
:	O
While	O
taking	O
beta	B-Group
blockers	I-Group
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
either	O
accidental	O
diagnostic	O
or	O
therapeutic	O
.	O
      
antihistamines	B-Group
;	O
      
Potassium	O
sparing	O
agents	O
should	O
generally	O
not	O
be	O
used	O
in	O
patients	O
with	O
heart	O
failure	O
receiving	O
enalapril	B-Drug
.	O
      
Nevertheless	O
clinical	O
studies	O
as	O
well	O
as	O
postmarketing	O
observations	O
have	O
shown	O
that	O
Lodine	B-Brand
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
and	O
thiazides	B-Group
in	O
some	O
patients	O
.	O
      
Theophylline	B-Drug
:	O
In	O
three	O
pharmacokinetic	O
studies	O
including	O
9	O
normal	O
healthy	O
subjects	O
theophylline	B-Drug
clearance	O
and	O
concentration	O
were	O
not	O
significantly	O
altered	O
by	O
the	O
addition	O
of	O
lomefloxacin	B-Drug
.	O
      
Methylprednisolone	B-Drug
may	O
increase	O
the	O
clearance	O
of	O
chronic	O
high	O
dose	O
aspirin	B-Brand
.	O
      
The	O
effects	O
of	O
adenosine	B-Drug
are	O
antagonized	O
by	O
methylxanthines	B-Group
such	O
as	O
caffeine	B-Drug
and	O
theophylline	B-Drug
.	O
      
Need	O
for	O
more	O
inhalations	O
than	O
usual	O
of	O
short	B-Group
-	O
acting	I-Group
inhaled	I-Group
beta9	I-Group
-	O
agonists	I-Group
.	O
      
Mutual	O
inhibition	O
of	O
metabolism	O
occurs	O
with	O
concurrent	O
use	O
of	O
cyclosporin	B-Drug
and	O
methylprednisolone	B-Drug
;	O
      
Chloral	B-Drug
hydrate	I-Drug
may	O
cause	O
an	O
increased	O
prothrombin	O
response	O
by	O
displacing	O
the	O
anticoagulant	B-Group
from	O
protein	O
binding	O
sites	O
or	O
a	O
diminished	O
prothrombin	O
response	O
through	O
increased	O
metabolism	O
of	O
the	O
unbound	O
drug	O
by	O
hepatic	O
enzyme	O
induction	O
thus	O
leading	O
to	O
inter	O
-	O
patient	O
variation	O
in	O
ultimate	O
prothrombin	O
effect	O
.	O
      
adjust	O
dosage	O
of	O
antidiabetic	B-Group
drug	I-Group
upward	O
if	O
necessary	O
.	O
      
No	O
dose	O
adjustment	O
is	O
necessary	O
.	O
      
Gemfibrozil	B-Drug
Other	O
fibrates	B-Group
Niacin	B-Drug
(	O
nicotinic	B-Drug
acid	I-Drug
)	O
(	O
=9	O
g	O
/	O
day	O
)	O
      
Although	O
trough	O
citalopram	B-Drug
plasma	O
levels	O
were	O
unaffected	O
given	O
the	O
enzyme	O
-	O
inducing	O
properties	O
of	O
carbamazepine	B-Drug
the	O
possibility	O
that	O
carbamazepine	B-Drug
might	O
increase	O
the	O
clearance	O
of	O
escitalopram	B-Drug
should	O
be	O
considered	O
if	O
the	O
two	O
drugs	O
are	O
coadministered	O
.	O
      
Adrenergic	B-Group
blockers	I-Group
:	O
Adrenergic	B-Group
blockers	I-Group
are	O
inhibited	O
by	O
amphetamines	B-Group
.	O
      
The	O
effects	O
of	O
nonbenzodiazepine	O
agonists	O
at	O
benzodiazepine	O
receptors	O
such	O
as	O
zopiclone	B-Drug
triazolopyridazines	O
and	O
others	O
are	O
also	O
blocked	O
by	O
ROMAZICON	B-Brand
.	O
      
Probenecid	B-Drug
:	O
As	O
with	O
other	O
b	B-Group
-	O
lactam	I-Group
antibiotics	I-Group
co	O
-	O
administration	O
of	O
probenecid	B-Drug
with	O
cefditoren	B-Drug
pivoxil	I-Drug
resulted	O
in	O
an	O
increase	O
in	O
the	O
plasma	O
exposure	O
of	O
cefditoren	B-Drug
with	O
a	O
9	O
%	O
increase	O
in	O
mean	O
Cmax	O
a	O
9	O
%	O
increase	O
in	O
mean	O
AUC	O
and	O
a	O
9	O
%	O
increase	O
in	O
half	O
-	O
life	O
.	O
      
Co	O
-	O
administration	O
with	O
other	O
drugs	O
that	O
are	O
metabolized	O
by	O
CYP	O
9A9	O
(	O
e.g.	O
indinavir	B-Drug
erythromycin	B-Drug
)	O
may	O
increase	O
their	O
clearance	O
resulting	O
in	O
decreased	O
plasma	O
concentration	O
.	O
      
When	O
administered	O
concomitantly	O
with	O
ProAmatine	B-Brand
cardiac	B-Group
glycosides	I-Group
may	O
enhance	O
or	O
precipitate	O
bradycardia	O
A.V	O
.	O
      
If	O
rifampicin	B-Drug
therapy	O
is	O
required	O
isradipine	B-Drug
concentrations	O
and	O
therapeutic	O
effects	O
are	O
likely	O
to	O
be	O
markedly	O
reduced	O
or	O
abolished	O
as	O
a	O
consequence	O
of	O
increased	O
metabolism	O
and	O
higher	O
clearance	O
of	O
isradipine	B-Drug
.	O
      
Methenamine	B-Drug
:	O
Efficacy	O
may	O
be	O
decreased	O
due	O
to	O
urinary	O
alkalizing	O
effect	O
of	O
metolazone	B-Drug
.	O
      
In	O
rheumatoid	O
arthritis	O
concomitant	O
medications	O
besides	O
MTX	B-Drug
were	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
folic	B-Drug
acid	I-Drug
corticosteroids	B-Group
and	O
/	O
or	O
narcotics	B-Group
.	O
      
If	O
hypotension	O
does	O
occur	O
during	O
anesthesia	O
it	O
usually	O
can	O
be	O
controlled	O
by	O
vasopressors	B-Group
.	O
      
Heparin	B-Drug
Sodium	I-Drug
Injection	O
should	O
not	O
be	O
mixed	O
with	O
doxorubicin	B-Drug
droperidol	B-Drug
ciprofloxacin	B-Drug
or	O
mitoxantrone	B-Drug
since	O
it	O
has	O
been	O
reported	O
that	O
these	O
drugs	O
are	O
incompatible	O
with	O
heparin	B-Drug
and	O
a	O
precipitate	O
may	O
form	O
.	O
      
Abciximab	B-Drug
has	O
been	O
administered	O
to	O
patients	O
with	O
ischemic	O
heart	O
disease	O
treated	O
concomitantly	O
with	O
a	O
broad	O
range	O
of	O
medications	O
used	O
in	O
the	O
treatment	O
of	O
angina	O
myocardial	O
infarction	O
and	O
hypertension	O
.	O
      
This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	B-Group
concomitantly	O
with	O
ACE	B-Group
-	O
inhibitors	I-Group
.	O
      
therefore	O
concomitant	O
administration	O
of	O
Itraconazole	B-Drug
with	O
cisapride	B-Drug
is	O
contraindicated	O
.	O
      
Small	O
decreases	O
in	O
blood	O
pressure	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
TRENTAL	B-Brand
;	O
      
None	O
Reported	O
      
Therefore	O
paliperidone	B-Drug
is	O
not	O
expected	O
to	O
inhibit	O
clearance	O
of	O
drugs	O
that	O
are	O
metabolized	O
by	O
these	O
metabolic	O
pathways	O
in	O
a	O
clinically	O
relevant	O
manner	O
.	O
      
SUSTIVAhas	O
the	O
potential	O
to	O
decrease	O
serum	O
concentrations	O
of	O
amprenavir	B-Drug
.	O
      
St	O
.	O
John	O
wort	O
(	O
Hypericum	O
perforatum	O
)	O
      
These	O
fulvestrant	B-Drug
doses	O
correspond	O
to	O
approximately	O
9	O
-	O
9	O
-	O
and	O
9	O
-	O
fold	O
the	O
systemic	O
exposure	O
[	O
AUC9	O
-	O
9	O
days	O
]	O
achieved	O
in	O
women	O
.	O
      
The	O
occurrence	O
of	O
stupor	O
muscular	O
rigidity	O
severe	O
agitation	O
and	O
elevated	O
temperature	O
has	O
been	O
reported	O
in	O
some	O
patients	O
receiving	O
the	O
combination	O
of	O
selegiline	B-Drug
and	O
meperidine	B-Drug
.	O
      
ETHANOL	B-Drug
/	O
NUTRITION	O
/	O
HERB	O
INTERACTIONS	O
:	O
Food	O
:	O
CNS	O
effects	O
of	O
caffeine	B-Drug
may	O
be	O
enhanced	O
if	O
combination	B-Group
hormonal	I-Group
contraceptives	I-Group
are	O
used	O
concurrently	O
with	O
caffeine	B-Drug
.	O
      
Even	O
when	O
an	O
aminoglycoside	B-Group
and	O
a	O
penicillin	B-Group
-	O
type	O
drug	O
are	O
administered	O
separately	O
by	O
different	O
routes	O
a	O
reduction	O
in	O
aminoglycoside	B-Group
serum	O
half	O
-	O
life	O
or	O
serum	O
levels	O
has	O
been	O
reported	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
and	O
in	O
some	O
patients	O
with	O
normal	O
renal	O
function	O
.	O
      
Also	O
flucytosine	B-Drug
.	O
      
Chlorthalidone	B-Drug
may	O
add	O
to	O
or	O
potentiate	O
the	O
action	O
of	O
other	O
antihypertensive	B-Group
drugs	I-Group
.	O
      
However	O
in	O
vitro	O
studies	O
have	O
shown	O
that	O
at	O
high	O
concentrations	O
(	O
9	O
mMol	O
/	O
L	O
or	O
9	O
mg	O
/	O
mL	O
and	O
greater	O
)	O
EACA	B-Drug
inhibits	O
ADP	O
and	O
collagen	O
-	O
induced	O
platelet	O
aggregation	O
the	O
release	O
of	O
ATP	O
and	O
serotonin	O
and	O
the	O
binding	O
of	O
fibrinogen	O
to	O
the	O
platelets	O
in	O
a	O
concentration	O
-	O
response	O
manner	O
.	O
      
Convulsions	O
have	O
been	O
reported	O
with	O
this	O
concurrent	O
use	O
.	O
      
The	O
presence	O
of	O
sulfamethoxazole	B-Drug
may	O
interfere	O
with	O
the	O
Jaff	O
alkaline	O
picrate	O
reaction	O
assay	O
for	O
creatinine	O
resulting	O
in	O
overestimations	O
of	O
about	O
9	O
%	O
in	O
the	O
range	O
of	O
normal	O
values	O
.	O
      
Recent	O
better	O
designed	O
studies	O
have	O
not	O
reported	O
these	O
adverse	O
effects	O
.	O
      
laryngeal	O
edema	O
      
Women	O
should	O
practice	O
additional	O
methods	O
of	O
contraception	O
and	O
not	O
rely	O
on	O
hormonal	O
contraception	O
alone	O
when	O
taking	O
TRACLEER	B-Brand
.	O
      
No	O
specific	O
information	O
available	O
      
Anakinra	B-Drug
:	O
Concurrent	O
administration	O
of	O
anakinra	B-Drug
(	O
an	O
interleukin	B-Group
-	O
9	I-Group
antagonist	I-Group
)	O
and	O
another	O
TNF	B-Group
-	O
blocking	I-Group
agent	I-Group
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	O
an	O
increased	O
risk	O
of	O
neutropenia	O
and	O
no	O
additional	O
benefit	O
compared	O
to	O
these	O
medicinal	O
products	O
alone	O
.	O
      
The	O
appropriate	O
doses	O
for	O
this	O
combination	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
have	O
not	O
been	O
established	O
.	O
      
Concomitant	O
treatment	O
with	O
coumarin	B-Group
derivatives	I-Group
(	O
vitamin	B-Group
K	I-Group
antagonists	I-Group
)	O
and	O
drugs	O
that	O
affect	O
platelet	O
function	O
may	O
also	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O
      
The	O
mean	O
minimum	O
lithium	B-Drug
concentration	O
increased	O
9	O
%	O
and	O
the	O
renal	O
clearance	O
was	O
decreased	O
by	O
approximately	O
9	O
%	O
.	O
      
Warfarin	B-Drug
-	O
Administration	O
of	O
9	O
mg	O
/	O
day	O
racemic	O
citalopram	B-Drug
for	O
9	O
days	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
warfarin	B-Drug
a	O
CYP9A9	O
substrate	O
.	O
      
There	O
are	O
case	O
reports	O
of	O
patients	O
who	O
developed	O
increased	O
BUN	O
serum	O
creatinine	O
and	O
serum	O
potassium	O
levels	O
and	O
weight	O
gain	O
when	O
furosemide	B-Drug
was	O
used	O
in	O
conjunction	O
with	O
NSAIDs	B-Group
.	O
      
Patients	O
in	O
clinical	O
studies	O
were	O
prohibited	O
from	O
receiving	O
growth	O
factor	O
treatment	O
for	O
9	O
weeks	O
prior	O
to	O
the	O
ZEVALIN	B-Brand
therapeutic	O
regimen	O
as	O
well	O
as	O
for	O
9	O
weeks	O
following	O
completion	O
of	O
the	O
regimen	O
.	O
      
Because	O
prostaglandina	O
play	O
an	O
important	O
role	O
in	O
hemostasis	O
and	O
ketoprofen	B-Drug
has	O
an	O
effect	O
on	O
platelet	O
function	O
as	O
well	O
concurent	O
therapy	O
with	O
ketoprofen	B-Drug
and	O
warfarin	B-Drug
requires	O
close	O
monitoring	O
of	O
patients	O
on	O
both	O
drugs	O
.	O
      
Phenytoin	B-Drug
/	O
Phenobarbital	B-Drug
:	O
The	O
coadministration	O
of	O
phenytoin	B-Drug
or	O
phenobarbital	B-Drug
will	O
not	O
affect	O
plasma	O
concentrations	O
of	O
vitamin	B-Group
D	I-Group
but	O
may	O
reduce	O
endogenous	O
plasma	O
levels	O
of	O
calcitriol	B-Drug
/	O
ergocalcitriol	O
by	O
accelerating	O
metabolism	O
.	O
      
The	O
possibility	O
of	O
reduced	O
statin	B-Group
efficacy	O
should	O
be	O
considered	O
.	O
      
Hydrocodone	B-Drug
:	O
Coadministration	O
of	O
Neurontin	B-Brand
(	O
9	O
to	O
9	O
mg	O
;	O
      
T9	O
resin	O
uptake	O
is	O
decreased	O
reflecting	O
the	O
elevated	O
TBG	O
.	O
      
Serum	O
transaminase	O
levels	O
should	O
be	O
obtained	O
before	O
starting	O
treatment	O
with	O
Plenaxis	B-Brand
and	O
periodically	O
during	O
treatment	O
.	O
      
The	O
concomitant	O
use	O
of	O
oxybutynin	B-Drug
with	O
other	O
anticholinergic	B-Group
drugs	I-Group
or	O
with	O
other	O
agents	O
which	O
produce	O
dry	O
mouth	O
constipation	O
somnolence	O
(	O
drowsiness	O
)	O
and	O
/	O
or	O
other	O
anticholinergic	O
-	O
like	O
effects	O
may	O
increase	O
the	O
frequency	O
and	O
/	O
or	O
severity	O
of	O
such	O
effects	O
.	O
      
Concomitant	O
administration	O
of	O
an	O
aluminum	B-Drug
-	O
containing	O
antacid	B-Group
had	O
no	O
significant	O
effect	O
in	O
the	O
bioavailability	O
of	O
9MNA	B-Drug_n
.	O
      
Although	O
it	O
has	O
not	O
been	O
definitively	O
demonstrated	O
that	O
fluvoxamine	B-Drug
is	O
a	O
potent	O
IIIA9	O
inhibitor	O
it	O
is	O
likely	O
to	O
be	O
given	O
the	O
substantial	O
interaction	O
of	O
fluvoxamine	B-Drug
with	O
alprazolam	B-Drug
.	O
      
Human	O
pharmacokinetic	O
data	O
indicate	O
that	O
oral	O
ketoconazole	B-Drug
markedly	O
inhibits	O
the	O
metabolism	O
of	O
cisapride	B-Drug
resulting	O
in	O
a	O
mean	O
eight	O
-	O
fold	O
increase	O
in	O
AUC	O
of	O
cisapride	B-Drug
.	O
      
Therefore	O
when	O
using	O
these	O
blocking	O
agents	O
to	O
treat	O
hypertension	O
patients	O
should	O
be	O
observed	O
carefully	O
in	O
order	O
to	O
confirm	O
that	O
the	O
desired	O
therapeutic	O
effect	O
has	O
been	O
obtained	O
.	O
      
Effect	O
of	O
other	O
agents	O
on	O
the	O
pharmacokinefics	O
of	O
aprepitant	B-Drug
      
N=9	O
)	O
administration	O
.	O
      
Diazoxide	B-Drug
Hypotension	O
      
Since	O
higher	O
doses	O
of	O
ketoconazole	B-Drug
(	O
9	O
mg	O
daily	O
)	O
may	O
result	O
in	O
higher	O
increases	O
in	O
Cmax	O
and	O
AUC	O
a	O
single	O
9	O
mg	O
dose	O
of	O
Vardenafil	B-Drug
should	O
not	O
be	O
exceeded	O
in	O
a	O
9	O
-	O
hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
ketoconazole	B-Drug
9	O
mg	O
daily	O
.	O
      
Concomitant	O
administration	O
of	O
rifampin	B-Drug
with	O
ketoconazole	B-Drug
tablets	O
reduces	O
the	O
blood	O
levels	O
of	O
the	O
latter	O
.	O
      
Oral	O
anticoagulant	B-Group
agents	I-Group
:	O
Pharmacokinetic	O
drug	O
-	O
drug	O
interactions	O
between	O
Argatroban	B-Drug
and	O
warfarin	B-Drug
(	O
9	O
mg	O
single	O
oral	O
dose	O
)	O
have	O
not	O
been	O
demonstrated	O
.	O
      
Coadministration	O
of	O
CRIXIVAN	B-Brand
and	O
drugs	O
primarily	O
metabolized	O
by	O
CYP9A9	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
the	O
other	O
drug	O
which	O
could	O
increase	O
or	O
prolong	O
its	O
therapeutic	O
and	O
adverse	O
effects	O
.	O
      
Lincomycin	B-Drug
has	O
been	O
shown	O
to	O
have	O
neuromuscular	O
blocking	O
properties	O
that	O
may	O
enhance	O
the	O
action	O
of	O
other	O
neuromuscular	B-Group
blocking	I-Group
agents	I-Group
.	O
      
antacids	B-Group
;	O
      
Adrenocorticoids	O
:	O
Metabolic	O
clearance	O
of	O
adrenocorticoids	O
is	O
decreased	O
in	O
hypothyroid	O
patients	O
and	O
increased	O
in	O
hyperthyroid	O
patients	O
and	O
may	O
therefore	O
change	O
with	O
changing	O
thyroid	O
status	O
.	O
      
Patients	O
response	O
to	O
oral	O
anticoagulants	B-Group
may	O
be	O
affected	O
by	O
his	O
/	O
her	O
thyroid	O
and	O
metabolic	O
status	O
.	O
      
Caffeine	B-Drug
:	O
Two	O
hundred	O
mg	O
of	O
caffeine	B-Drug
(	O
equivalent	O
to	O
9	O
to	O
9	O
cups	O
of	O
American	O
coffee	O
)	O
was	O
administered	O
to	O
9	O
normal	O
healthy	O
volunteers	O
who	O
had	O
achieved	O
steady	O
-	O
state	O
blood	O
concentrations	O
of	O
lomefloxacin	B-Drug
after	O
being	O
dosed	O
at	O
9	O
mg	O
qd	O
.	O
      
Labor	O
and	O
Delivery	O
The	O
effects	O
of	O
ZETIA	B-Brand
on	O
labor	O
and	O
delivery	O
in	O
pregnant	O
women	O
are	O
unknown	O
.	O
      
Although	O
the	O
clinical	O
significance	O
is	O
not	O
known	O
it	O
is	O
not	O
recommended	O
that	O
cefditoren	B-Drug
pivoxil	I-Drug
be	O
taken	O
concomitantly	O
with	O
antacids	B-Group
.	O
      
increased	O
norepinephrine	O
-	O
induced	O
platelet	O
aggregability	O
      
A	O
chemically	O
similar	O
drug	O
in	O
this	O
class	O
produced	O
optic	O
nerve	O
degeneration	O
(	O
Wallerian	O
degeneration	O
of	O
retinogeniculate	O
fibers	O
)	O
in	O
clinically	O
normal	O
dogs	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
at	O
a	O
dose	O
that	O
produced	O
plasma	O
drug	O
levels	O
about	O
9	O
times	O
higher	O
than	O
the	O
mean	O
drug	O
level	O
in	O
humans	O
taking	O
the	O
highest	O
recommended	O
dose	O
.	O
      
Caution	O
should	O
be	O
exercised	O
if	O
an	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitor	I-Group
is	O
administered	O
concomitantly	O
with	O
drugs	O
that	O
may	O
decrease	O
the	O
levels	O
or	O
activity	O
of	O
endogenous	O
steroid	O
hormones	O
such	O
as	O
ketoconazole	B-Drug
spironolactone	B-Drug
and	O
cimetidine	B-Drug
.	O
      
Some	O
quinolones	B-Group
have	O
also	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B-Drug
.	O
      
Therefore	O
hormonal	B-Group
contraceptives	I-Group
including	O
oral	O
injectable	O
transdermal	O
and	O
implantable	O
forms	O
may	O
not	O
be	O
reliable	O
when	O
TRACLEER	B-Brand
is	O
co	O
-	O
administered	O
.	O
      
No	O
teratogenic	O
effects	O
were	O
seen	O
in	O
the	O
offspring	O
delivered	O
at	O
term	O
.	O
      
Combined	O
effects	O
may	O
induce	O
serious	O
cardiac	O
arrhythmias	O
.	O
      
This	O
is	O
especially	O
important	O
for	O
drugs	O
associated	O
with	O
serious	O
toxicity	O
such	O
as	O
other	O
antiarrhythmics	B-Group
.	O
      
A	O
9	O
(	O
9	O
)	O
%	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
AUC	O
of	O
ganciclovir	B-Drug
was	O
observed	O
when	O
VIDEX	B-Brand
was	O
administered	O
9	O
hours	O
prior	O
to	O
ganciclovir	B-Drug
but	O
not	O
when	O
the	O
two	O
drugs	O
were	O
administered	O
simultaneously	O
(	O
n	O
=	O
9	O
)	O
.	O
      
Diuretic	B-Group
agents	I-Group
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	B-Drug
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
There	O
is	O
one	O
reported	O
case	O
of	O
a	O
patient	O
with	O
acute	O
delirium	O
associated	O
with	O
the	O
simultaneous	O
use	O
of	O
fluphenazine	B-Drug
and	O
oral	O
clonidine	B-Drug
.	O
      
Studies	O
to	O
evaluate	O
potential	O
interactions	O
of	O
terfenadine	B-Drug
with	O
azithromycin	B-Drug
are	O
in	O
progress	O
.	O
      
Testicular	O
atrophy	O
was	O
seen	O
with	O
dexrazoxane	B-Drug
administration	O
at	O
doses	O
as	O
low	O
as	O
9	O
mg	O
/	O
kg	O
weekly	O
for	O
9	O
weeks	O
in	O
rats	O
(	O
9	O
/	O
9	O
the	O
human	O
dose	O
on	O
a	O
mg	O
/	O
m	O
9	O
basis	O
)	O
and	O
as	O
low	O
as	O
9	O
mg	O
/	O
kg	O
weekly	O
for	O
9	O
weeks	O
in	O
dogs	O
(	O
approximately	O
equal	O
to	O
the	O
human	O
dose	O
on	O
a	O
mg	O
/	O
m	O
9	O
basis	O
)	O
.	O
      
Drugs	O
Metabolized	O
by	O
P9	O
9D9	O
:	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	O
metabolizing	O
isozyme	O
cytochrome	O
P9	O
9D9	O
(	O
debrisoquin	O
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
Caucasian	O
population	O
(	O
about	O
9	O
-	O
9	O
%	O
of	O
Caucasians	O
are	O
so	O
-	O
called	O
poor	O
metabolizers	O
)	O
;	O
      
Drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
TRACRIUM	B-Brand
include	O
:	O
enflurane	B-Drug
;	O
isoflurane	B-Drug
;	O
halothane	B-Drug
;	O
certain	O
antibiotics	B-Group
especially	O
the	O
aminoglycosides	B-Group
and	O
polymyxins	B-Group
;	O
lithium	B-Drug
;	O
magnesium	B-Drug
salts	O
;	O
procainamide	B-Drug
;	O
and	O
quinidine	B-Drug
.	O
      
(	O
SGOT	O
)	O
ALT	O
(	O
SGPT	O
)	O
      
Examples	O
of	O
Drugs	O
in	O
Which	O
Plasma	O
Concentrations	O
May	O
Be	O
Decreased	O
By	O
Co	O
-	O
administration	O
With	O
Nevirapine	B-Drug
      
Dosages	O
of	O
concomitantly	O
administered	O
opioids	B-Group
should	O
be	O
reduced	O
by	O
approximately	O
half	O
because	O
levomepromazine	B-Drug
amplifies	O
the	O
therapeutic	O
actions	O
and	O
side	O
-	O
effects	O
of	O
opioids	B-Group
.	O
      
Certain	O
antibiotic	B-Group
cisplatin	B-Drug
cyclosporine	B-Drug
diuretic	B-Group
foscarnet	B-Drug
and	O
vaccines	B-Group
.	O
      
Unfortunately	O
folic	B-Drug
acid	I-Drug
will	O
not	O
correct	O
changes	O
in	O
the	O
nervous	O
system	O
that	O
result	O
from	O
vitamin	O
B9	O
deficiency	O
.	O
      
the	O
disulfiram	B-Drug
should	O
be	O
discontinued	O
if	O
such	O
signs	O
appear	O
.	O
      
Exert	O
particular	O
caution	O
in	O
combining	O
chlorprothixene	B-Drug
with	O
other	O
anticholinergic	B-Group
drugs	I-Group
(	O
tricyclic	B-Group
antidepressants	I-Group
and	O
antiparkinsonian	B-Group
agents	I-Group
)	O
:	O
Particularly	O
the	O
elderly	O
may	O
develop	O
delirium	O
high	O
fever	O
severe	O
obstipation	O
even	O
ileus	O
and	O
glaucoma	O
.	O
      
Read	O
circulars	O
for	O
lithium	B-Drug
preparations	O
before	O
use	O
of	O
such	O
concomitant	O
therapy	O
.	O
      
antacids	B-Group
after	O
meals	O
.	O
      
Because	O
Nalfon	B-Brand
has	O
not	O
been	O
shown	O
to	O
produce	O
any	O
additional	O
effect	O
beyond	O
that	O
obtained	O
with	O
aspirin	B-Brand
alone	O
and	O
because	O
aspirin	B-Brand
increases	O
the	O
rate	O
of	O
excretion	O
of	O
Nalfon	B-Brand
the	O
concomitant	O
use	O
of	O
Nalfon	B-Brand
and	O
salicylates	B-Group
is	O
not	O
recommended	O
.	O
      
Concomitant	O
administration	O
of	O
Norpace	B-Brand
and	O
quinidine	B-Drug
resulted	O
in	O
slight	O
increases	O
in	O
plasma	O
disopyramide	B-Drug
levels	O
and	O
slight	O
decreases	O
in	O
plasma	O
quinidine	B-Drug
levels	O
.	O
      
-	O
Increased	O
serum	O
triglyceride	O
and	O
phospholipid	O
concentration	O
.	O
      
9	O
.	O
      
Nine	O
additional	O
patients	O
who	O
had	O
initial	O
positive	O
tests	O
were	O
negative	O
on	O
repeat	O
testing	O
.	O
      
Restoration	O
of	O
female	O
fertility	O
to	O
values	O
similar	O
to	O
controls	O
was	O
evident	O
following	O
a	O
9	O
-	O
day	O
withdrawal	O
period	O
after	O
dosing	O
at	O
9	O
mg	O
/	O
kg	O
/	O
day	O
(	O
twice	O
the	O
human	O
dose	O
based	O
on	O
BSA	O
)	O
.	O
      
however	O
as	O
with	O
other	O
NSAIDs	B-Group
concomitant	O
administration	O
of	O
Lodine	B-Brand
and	O
aspirin	B-Brand
is	O
not	O
generally	O
recommended	O
because	O
of	O
the	O
potential	O
of	O
increased	O
adverse	O
effects	O
.	O
      
one	O
-	O
half	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
when	O
administered	O
during	O
the	O
period	O
of	O
organogenesis	O
.	O
      
In	O
a	O
ten	O
-	O
subject	O
study	O
coadministration	O
of	O
diltiazem	B-Drug
(	O
9	O
mg	O
bid	O
)	O
with	O
lovastatin	B-Drug
resulted	O
in	O
a	O
9	O
-	O
9	O
times	O
increase	O
in	O
mean	O
lovastatin	B-Drug
AUC	O
and	O
Cmax	O
vs.	O
lovastatin	B-Drug
alone	O
;	O
      
Both	O
digoxin	B-Drug
and	O
COREG	B-Brand
slow	O
AV	O
conduction	O
.	O
      
this	O
did	O
not	O
interfere	O
with	O
its	O
effect	O
.	O
      
Administration	O
of	O
ELLENCE	B-Brand
after	O
previous	O
radiation	O
therapy	O
may	O
induce	O
an	O
inflammatory	O
recall	O
reaction	O
at	O
the	O
site	O
of	O
the	O
irradiation	O
.	O
      
Itraconazole	B-Drug
:	O
Torsades	O
de	O
pointes	O
and	O
elevated	O
parent	O
terfenadine	B-Drug
levels	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
terfenadine	B-Drug
and	O
itraconazole	B-Drug
in	O
clinical	O
trials	O
of	O
itraconazole	B-Drug
and	O
from	O
foreign	O
post	O
-	O
marketing	O
sources	O
.	O
      
Fenofibrate	B-Drug
:	O
In	O
a	O
pharmacokinetic	O
study	O
concomitant	O
fenofibrate	B-Drug
administration	O
increased	O
total	O
ezetimibe	B-Drug
concentrations	O
approximately	O
9	O
-	O
fold	O
.	O
      
Fluoxetine	B-Drug
      
The	O
effectiveness	O
of	O
progestin	B-Group
-	O
only	O
pills	O
is	O
reduced	O
by	O
hepatic	O
enzyme	O
-	O
inducing	O
drugs	O
such	O
as	O
the	O
anticonvulsants	B-Group
phenytoin	B-Drug
carbamazepine	B-Drug
and	O
barbiturates	B-Group
and	O
the	O
antituberculosis	B-Group
drug	I-Group
rifampin	B-Drug
.	O
      
Laboratory	O
Tests	O
The	O
pathologist	O
should	O
be	O
advised	O
of	O
progestin	O
therapy	O
when	O
relevant	O
specimens	O
are	O
submitted	O
.	O
      
It	O
is	O
recommended	O
that	O
Myfortic	B-Drug
and	O
antacids	B-Group
not	O
be	O
administered	O
simultaneously	O
.	O
      
Drugs	O
That	O
Induce	O
CYP9A9	O
Rifampin	B-Drug
:	O
CYP9A9	O
is	O
ordinarily	O
a	O
minor	O
metabolizing	O
enzyme	O
of	O
zaleplon	B-Drug
.	O
      
-	O
Androgens	B-Group
(	O
male	O
hormones	O
)	O
or	O
      
Warfarin	B-Drug
Digoxin	B-Drug
Salicylate	B-Group
and	O
Heparin	B-Drug
The	O
in	O
vitro	O
binding	O
of	O
warfarin	B-Drug
to	O
plasma	O
proteins	O
is	O
only	O
slightly	O
reduced	O
by	O
ketorolac	B-Drug
tromethamine	I-Drug
(	O
9	O
%	O
control	O
vs	O
9	O
%	O
)	O
when	O
ketorolac	B-Drug
plasma	O
concentrations	O
reach	O
9	O
to9	O
m	O
g	O
/	O
mL	O
.	O
      
Clinically	O
significant	O
effects	O
have	O
been	O
reported	O
with	O
the	O
tricyclic	B-Drug
antidepressants	I-Drug
when	O
used	O
concomitantly	O
with	O
cimetidine	B-Drug
.	O
      
Rifampin	B-Drug
:	O
Rifampin	B-Drug
enhances	O
the	O
metabolism	O
of	O
concurrently	O
administered	O
DIFLUCAN	B-Brand
.	O
      
Phenobarbital	B-Drug
:	O
It	O
appears	O
that	O
phenobarbital	B-Drug
may	O
reduce	O
plasma	O
felbamate	B-Drug
concentrations	O
.	O
      
DEA	O
concentrations	O
were	O
not	O
affected	O
.	O
      
The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
.	O
      
If	O
the	O
TARCEVA	B-Brand
dose	O
is	O
adjusted	O
upward	O
the	O
dose	O
will	O
need	O
to	O
be	O
reduced	O
upon	O
discontinuation	O
of	O
rifampicin	B-Drug
or	O
other	O
inducers	O
.	O
      
Carcinogenesis	O
Mutagenesis	O
Impairment	O
of	O
Fertility	O
A	O
9	O
-	O
week	O
dietary	O
carcinogenicity	O
study	O
with	O
ezetimibe	B-Drug
was	O
conducted	O
in	O
rats	O
at	O
doses	O
up	O
to	O
9	O
mg	O
/	O
kg	O
/	O
day	O
(	O
males	O
)	O
and	O
9	O
mg	O
/	O
kg	O
/	O
day	O
(	O
females	O
)	O
(	O
~9	O
times	O
the	O
human	O
exposure	O
at	O
9	O
mg	O
daily	O
based	O
on	O
AUC9	O
-	O
9hr	O
for	O
total	O
ezetimibe	B-Drug
)	O
.	O
      
It	O
is	O
recommended	O
that	O
serum	O
lithium	B-Drug
levels	O
be	O
monitored	O
frequently	O
if	O
PRINIVIL	B-Brand
is	O
administered	O
concomitantly	O
with	O
lithium	B-Drug
.	O
      
RESPIRATORY	O
DEPRESSION	O
HYPOTENSION	O
AND	O
PROFOUND	O
SEDATION	O
OR	O
COMA	O
MAY	O
RESULT	O
.	O
      
prolonged	O
hot	O
weather	O
;	O
      
The	O
appropriate	O
interval	O
between	O
administration	O
of	O
these	O
agents	O
and	O
dexfenfluramine	B-Drug
has	O
not	O
been	O
established	O
.	O
      
Caution	O
should	O
be	O
exercised	O
when	O
INDOCIN	B-Brand
and	O
anticoagulants	B-Group
are	O
administered	O
concomitantly	O
.	O
      
Also	O
the	O
potential	O
for	O
hepatic	O
injury	O
should	O
be	O
considered	O
when	O
Rebif	B-Brand
is	O
used	O
in	O
combination	O
with	O
other	O
products	O
associated	O
with	O
hepatic	O
injury	O
or	O
when	O
new	O
agents	O
are	O
added	O
to	O
the	O
regimen	O
of	O
patients	O
already	O
on	O
Rebif	B-Brand
.	O
      
FORADIL	B-Brand
should	O
not	O
be	O
used	O
as	O
a	O
substitute	O
for	O
oral	O
or	O
inhaled	O
corticosteroids	B-Group
.	O
      
.	O
      
metronidazole	B-Drug
;	O
      
Preliminary	O
animal	O
and	O
human	O
studies	O
have	O
shown	O
that	O
small	O
quantities	O
of	O
systemically	O
administered	O
leucovorin	B-Drug
enter	O
the	O
CSF	O
primarily	O
as	O
9	O
-	O
methyltetrahydro	O
-	O
folate	O
and	O
in	O
humans	O
remain	O
9	O
to	O
9	O
orders	O
of	O
magnitude	O
lower	O
than	O
the	O
usual	O
methotrexate	B-Drug
concentrations	O
following	O
intrathecal	O
administration	O
.	O
      
These	O
individuals	O
may	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B-Group
antidepressants	I-Group
when	O
given	O
usual	O
doses	O
.	O
      
reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P9	O
9D9	O
isozyme	O
activity	O
among	O
Asian	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O
      
Absorption	O
of	O
tetracyclines	B-Group
is	O
impaired	O
by	O
antacids	B-Group
containing	O
aluminum	B-Drug
calcium	B-Drug
or	O
magnesium	B-Drug
and	O
iron	B-Drug
-	O
containing	O
preparations	O
.	O
      
Aprepitant	B-Drug
is	O
unlikely	O
to	O
interact	O
with	O
drugs	O
that	O
are	O
substrates	O
for	O
the	O
P	O
-	O
glycoprotein	O
transporter	O
as	O
demonstrated	O
by	O
the	O
lack	O
of	O
interaction	O
of	O
Aprepitant	B-Drug
with	O
digoxin	B-Drug
in	O
a	O
clinical	O
drug	O
interaction	O
study	O
.	O
      
The	O
concurrent	O
use	O
of	O
TORADOL	B-Brand
with	O
muscle	B-Group
relaxants	I-Group
has	O
not	O
been	O
formally	O
studied	O
.	O
      
Other	O
short	B-Group
-	O
acting	I-Group
beta	I-Group
adrenergic	I-Group
aerosol	I-Group
bronchodilators	I-Group
should	O
not	O
be	O
used	O
concomitantly	O
with	O
MAXAIR	B-Brand
AUTOHALER	I-Brand
because	O
they	O
may	O
have	O
additive	O
effects	O
.	O
      
Concomitant	O
administration	O
of	O
itraconazole	B-Drug
and	O
terfenadine	B-Drug
is	O
contraindicated	O
.	O
      
These	O
drugs	O
should	O
not	O
be	O
given	O
concomitantly	O
.	O
      
NOTE	O
:	O
Do	O
not	O
use	O
the	O
injection	O
if	O
it	O
contains	O
precipitate	O
.	O
      
Theophylline	B-Drug
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	B-Drug
(	O
9	O
mg	O
/	O
day	O
for	O
9	O
days	O
)	O
and	O
the	O
CYP9A9	O
substrate	O
theophylline	B-Drug
(	O
single	O
dose	O
of	O
9	O
mg	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
theophylline	B-Drug
.	O
      
Although	O
erythromycin	O
measurably	O
decreases	O
the	O
clearance	O
of	O
the	O
terfenadine	B-Drug
acid	O
metabolite	O
its	O
influence	O
on	O
terfenadine	O
plasma	O
levels	O
is	O
still	O
under	O
investigation	O
.	O
      
The	O
clinical	O
significance	O
if	O
any	O
of	O
these	O
observations	O
is	O
unknown	O
.	O
      
Drugs	O
Metabolized	O
by	O
P9	O
9D9	O
:	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	O
metabolizing	O
isozyme	O
cytochrome	O
P9	O
9D9	O
(	O
debrisoquin	O
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
caucasian	O
population	O
(	O
about	O
9	O
to	O
9	O
%	O
of	O
caucasians	O
are	O
so	O
called	O
poor	O
metabolizers	O
)	O
;	O
      
Ibuprofen	B-Drug
-	O
L	B-Drug
-	O
arginine	I-Drug
may	O
increase	O
the	O
absorption	O
of	O
ibuprofen	B-Drug
if	O
taken	O
concomitantly	O
.	O
      
Other	O
binding	O
proteins	O
may	O
be	O
elevated	O
in	O
serum	O
(	O
i.e.	O
corticosteroid	O
binding	O
globulin	O
(	O
CBG	O
)	O
sex	O
hormone	O
binding	O
globulin	O
(	O
SHBG	O
)	O
)	O
leading	O
to	O
increased	O
total	O
circulating	O
corticosteroids	B-Group
and	O
sex	B-Group
steroids	I-Group
respectively	O
.	O
      
Drugs	O
that	O
raise	O
the	O
gastrointestinal	O
pH	O
may	O
lead	O
to	O
an	O
earlier	O
release	O
of	O
duloxetine	B-Drug
.	O
      
Mixing	O
of	O
Insulins	B-Group
      
FLUOTHANE	B-Brand
may	O
augment	O
the	O
hypotension	O
caused	O
by	O
the	O
ganglionic	O
-	O
blocking	O
effect	O
of	O
tubocurarine	B-Drug
.	O
      
Therefore	O
precaution	O
should	O
be	O
taken	O
when	O
coadministration	O
is	O
necessary	O
.	O
      
Cimetidine	B-Drug
-	O
In	O
subjects	O
who	O
had	O
received	O
9	O
days	O
of	O
9	O
mg	O
/	O
day	O
racemic	O
citalopram	B-Drug
combined	O
administration	O
of	O
9	O
mg	O
/	O
day	O
cimetidine	B-Drug
for	O
9	O
days	O
resulted	O
in	O
an	O
increase	O
in	O
citalopram	B-Drug
AUC	O
and	O
Cmax	O
of	O
9	O
%	O
and	O
9	O
%	O
respectively	O
.	O
      
Each	O
month	O
of	O
therapy	O
the	O
patient	O
must	O
have	O
a	O
negative	O
result	O
from	O
a	O
urine	O
or	O
serum	O
pregnancy	O
test	O
.	O
      
Other	O
serious	O
reactions	O
(	O
including	O
severe	O
agitation	O
hallucinations	O
and	O
death	O
)	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
this	O
combination	O
.	O
      
This	O
may	O
adversely	O
affect	O
blood	O
pressure	O
control	O
in	O
patients	O
treated	O
with	O
methyldopa	B-Drug
.	O
      
Dasatinib	B-Drug
and	O
its	O
metabolites	O
are	O
minimally	O
excreted	O
via	O
the	O
kidney	O
.	O
      
The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
;	O
      
No	O
inhibition	O
of	O
any	O
of	O
the	O
other	O
isoforms	O
tested	O
was	O
observed	O
at	O
gabapentin	B-Drug
concentrations	O
up	O
to	O
9	O
mg	O
/	O
mL	O
(	O
approximately	O
9	O
times	O
the	O
Cmax	O
at	O
9	O
mg	O
/	O
day	O
)	O
.	O
      
ACE	B-Group
-	O
inhibitors	I-Group
:	O
Reports	O
suggest	O
that	O
NSAIDs	B-Group
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	B-Group
-	O
inhibitors	I-Group
.	O
      
In	O
clinical	O
trials	O
in	O
patients	O
undergoing	O
PTCA	O
/	O
PCI	O
co	O
-	O
administration	O
of	O
Angiomax	B-Brand
with	O
heparin	B-Drug
warfarin	B-Drug
thrombolytics	B-Group
or	O
glycoprotein	O
IIb	O
/	O
IIIa	O
inhibitors	O
was	O
associated	O
with	O
increased	O
risks	O
of	O
major	O
bleeding	O
events	O
compared	O
to	O
patients	O
not	O
receiving	O
these	O
concomitant	O
medications	O
.	O
      
In	O
addition	O
there	O
was	O
no	O
evidence	O
of	O
genotoxicity	O
in	O
the	O
in	O
vivo	O
mouse	O
micronucleus	O
test	O
.	O
      
If	O
a	O
patient	O
has	O
been	O
treated	O
with	O
cyclophosphamide	B-Drug
within	O
9	O
days	O
of	O
general	O
anesthesia	O
the	O
anesthesiologist	O
should	O
be	O
alerted	O
.	O
      
However	O
it	O
was	O
observed	O
that	O
the	O
pharmacokinetics	O
of	O
ENBREL	B-Brand
was	O
unaltered	O
by	O
concomitant	O
methotrexate	B-Drug
in	O
rheumatoid	O
arthritis	O
patients	O
.	O
      
In	O
addition	O
to	O
established	O
drug	O
interactions	O
there	O
may	O
be	O
potential	O
pharmacokinetic	O
interactions	O
between	O
nevirapine	B-Drug
and	O
other	O
drug	O
classes	O
that	O
are	O
metabolized	O
by	O
the	O
cytochrome	O
P9	O
system	O
.	O
      
If	O
short	B-Group
-	O
acting	I-Group
benzodiazepines	I-Group
which	O
are	O
metabolized	O
by	O
the	O
cytochrome	O
P9	O
system	O
are	O
concomitantly	O
administered	O
with	O
fluconazole	B-Drug
consideration	O
should	O
be	O
given	O
to	O
decreasing	O
the	O
benzodiazepine	B-Group
dosage	O
and	O
the	O
patients	O
should	O
be	O
appropriately	O
monitored	O
.	O
      
Ritonavir	B-Drug
(	O
9	O
mg	O
b.i.d	O
.	O
)	O
co	O
-	O
administered	O
with	O
Vardenafil	B-Drug
9	O
mg	O
resulted	O
in	O
a	O
9	O
-	O
fold	O
increase	O
in	O
vardenafil	B-Drug
AUC	O
and	O
a	O
9	O
-	O
fold	O
increase	O
in	O
vardenafil	B-Drug
Cmax	O
.	O
      
Beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
:	O
concurrent	O
use	O
may	O
blunt	O
the	O
response	O
to	O
arbutamine	B-Drug
.	O
      
Concomitant	O
administration	O
of	O
Targretin	B-Brand
capsules	O
and	O
gemfibrozil	B-Drug
resulted	O
in	O
substantial	O
increases	O
in	O
plasma	O
concentrations	O
of	O
bexarotene	B-Drug
probably	O
at	O
least	O
partially	O
related	O
to	O
cytochrome	O
P9	O
9A9	O
inhibition	O
by	O
gemfibrozil	B-Drug
.	O
      
Histamine	B-Group
H9	I-Group
-	O
receptor	I-Group
antagonists	I-Group
:	O
Histamine	B-Group
H9	I-Group
-	O
receptor	I-Group
antagonists	I-Group
appear	O
to	O
have	O
no	O
significant	O
effect	O
on	O
the	O
bioavailability	O
of	O
ciprofloxacin	B-Drug
.	O
      
Patients	O
receiving	O
these	O
drugs	O
who	O
are	O
given	O
Lodine	B-Brand
or	O
any	O
other	O
NSAID	B-Group
and	O
particularly	O
those	O
patients	O
with	O
altered	O
renal	O
function	O
should	O
be	O
observed	O
for	O
the	O
development	O
of	O
the	O
specific	O
toxicities	O
of	O
these	O
drugs	O
.	O
      
The	O
principal	O
drugs	O
given	O
(	O
number	O
of	O
patients	O
in	O
parentheses	O
)	O
were	O
:	O
cardiac	B-Group
glycosides	I-Group
(	O
9	O
)	O
sedatives	B-Group
and	O
hypnotics	B-Group
(	O
9	O
)	O
coronary	B-Group
vasodilators	I-Group
(	O
9	O
)	O
oral	O
hypoglycemics	B-Group
(	O
9	O
)	O
cough	O
and	O
cold	O
preparations	O
(	O
9	O
)	O
NSAIDs	B-Group
(	O
9	O
)	O
antihyperlipidemics	B-Group
(	O
9	O
)	O
antigout	B-Group
drugs	I-Group
(	O
9	O
)	O
oral	O
contraceptives	B-Group
(	O
9	O
)	O
bronchodilators	B-Group
(	O
9	O
)	O
insulin	B-Drug
(	O
9	O
)	O
and	O
beta	B-Group
blockers	I-Group
(	O
9	O
)	O
.	O
      
Finasteride	B-Drug
does	O
not	O
appear	O
to	O
affect	O
the	O
cytochrome	O
P9	O
-	O
linked	O
drug	O
-	O
metabolizing	O
enzyme	O
system	O
.	O
      
Coadministration	O
of	O
VIRACEPT	B-Brand
and	O
drugs	O
that	O
inhibit	O
CYP9A	O
may	O
increase	O
nelfinavir	B-Drug
plasma	O
concentrations	O
.	O
      
Influence	O
of	O
Trileptal	B-Brand
on	O
AED	B-Group
Concentration	O
(	O
Mean	O
change	O
9	O
%	O
Confidence	O
Interval	O
)	O
      
Other	O
binding	O
proteins	O
may	O
be	O
elevated	O
in	O
serum	O
i.e.	O
corticosteroid	O
binding	O
globulin	O
(	O
CBG	O
)	O
sex	O
hormone	O
-	O
binding	O
globulin	O
(	O
SHBG	O
)	O
leading	O
to	O
increased	O
total	O
circulating	O
corticosteroids	B-Group
and	O
sex	B-Group
steroids	I-Group
respectively	O
.	O
      
Ketoconazole	B-Drug
(	O
9	O
mg	O
once	O
daily	O
)	O
      
Patients	O
on	O
warfarin	B-Group
-	O
type	I-Group
anticoagulant	I-Group
therapy	O
may	O
require	O
dosage	O
adjustment	O
of	O
the	O
anticoagulant	O
during	O
and	O
after	O
griseofulvin	B-Drug
therapy	O
.	O
      
cardiovascular	O
effects	O
can	O
be	O
potentiated	O
.	O
      
Ketoconazole	B-Drug
:	O
When	O
a	O
single	O
9	O
-	O
mg	O
dose	O
of	O
Aprepitant	B-Drug
was	O
administered	O
on	O
Day9	O
of	O
a	O
9	O
-	O
day	O
regimen	O
of	O
9	O
mg	O
/	O
day	O
of	O
ketoconazole	B-Drug
a	O
strong	O
CYP9A9	O
inhibitor	O
the	O
AUC	O
of	O
aprepitant	B-Drug
increased	O
approximately	O
9	O
-	O
fold	O
and	O
the	O
mean	O
terminal	O
half	O
-	O
life	O
of	O
aprepitant	B-Drug
increased	O
approximately	O
9	O
-	O
fold	O
.	O
      
Warfarin	B-Drug
:	O
The	O
effects	O
of	O
warfarin	B-Drug
and	O
NSAIDs	B-Group
on	O
GI	O
bleeding	O
are	O
synergistic	O
such	O
that	O
users	O
of	O
both	O
drugs	O
together	O
have	O
a	O
risk	O
of	O
serious	O
GI	O
bleeding	O
higher	O
than	O
that	O
of	O
users	O
of	O
either	O
drug	O
alone	O
.	O
      
Furosemide	B-Drug
:	O
Clinical	O
studies	O
as	O
well	O
as	O
post	O
-	O
marketing	O
observations	O
have	O
shown	O
that	O
NSAIDs	B-Group
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
and	O
thiazides	B-Group
in	O
some	O
patients	O
.	O
      
Similarly	O
patients	O
receiving	O
the	O
drug	O
and	O
a	O
hydantoin	B-Group
sulfonamide	B-Group
or	O
sulfonylurea	B-Group
should	O
be	O
observed	O
for	O
signs	O
of	O
toxicity	O
to	O
these	O
drugs	O
.	O
      
Drug	O
/	O
Laboratory	O
Interactions	O
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
with	O
Campath	B-Brand
.	O
      
Monitor	O
cardiovascular	O
status	O
.	O
      
Pimozide	B-Drug
and	O
Celexa	B-Brand
-	O
In	O
a	O
controlled	O
study	O
a	O
single	O
dose	O
of	O
pimozide	B-Drug
9	O
mg	O
co	O
-	O
administered	O
with	O
racemic	O
citalopram	B-Drug
9	O
mg	O
given	O
once	O
daily	O
for	O
9	O
days	O
was	O
associated	O
with	O
a	O
mean	O
increase	O
in	O
QTc	O
values	O
of	O
approximately	O
9	O
msec	O
compared	O
to	O
pimozide	B-Drug
given	O
alone	O
.	O
      
Epidural	O
clonidine	B-Drug
may	O
prolong	O
the	O
duration	O
of	O
pharmacologic	O
effects	O
of	O
epidural	O
local	O
anesthetics	B-Group
including	O
both	O
sensory	O
and	O
motor	O
blockade	O
.	O
      
Short	B-Group
-	O
acting	I-Group
Benzodiazepines	I-Group
:	O
Following	O
oral	O
administration	O
of	O
midazolam	B-Drug
fluconazole	B-Drug
resulted	O
in	O
substantial	O
increases	O
in	O
midazolam	B-Drug
concentrations	O
and	O
psychomotor	O
effects	O
.	O
      
increased	O
levels	O
of	O
fibrinogen	B-Drug
and	O
fibrinogen	B-Drug
activity	O
;	O
      
The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
increase	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
and	O
susceptibility	O
to	O
hypoglycemia	O
:	O
oral	O
antidiabetes	O
products	O
ACE	B-Group
inhibitors	I-Group
disopyramide	B-Drug
fibrates	B-Group
fluoxetine	B-Drug
MAO	B-Group
inhibitors	I-Group
propoxyphene	B-Drug
salicylates	B-Group
somatostatin	B-Group
analog	I-Group
(	O
e.g.	O
octreotide	B-Drug
)	O
sulfonamide	B-Group
antibiotics	I-Group
.	O
      
Extended	O
Release	O
Tablets	O
:	O
Administration	O
of	O
nifedipine	B-Drug
with	O
digoxin	B-Drug
increased	O
digoxin	B-Drug
levels	O
in	O
9	O
of	O
9	O
normal	O
volunteers	O
.	O
      
When	O
carbamazepine	B-Drug
is	O
withdrawn	O
from	O
the	O
combination	O
therapy	O
aripiprazole	B-Drug
dose	O
should	O
then	O
be	O
reduced	O
.	O
      
Nephrotoxic	O
agents	O
:	O
Concomitant	O
administration	O
of	O
VISTIDE	B-Brand
and	O
agents	O
with	O
nephrotoxic	O
potential	O
[	O
e.g.	O
intravenous	O
aminoglycosides	B-Group
(	O
e.g.	O
tobramycin	B-Drug
gentamicin	B-Drug
and	O
amikacin	B-Drug
)	O
amphotericin	B-Drug
B	I-Drug
foscarnet	B-Drug
intravenous	O
pentamidine	B-Drug
vancomycin	B-Drug
and	O
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
]	O
is	O
contraindicated	O
.	O
      
propranolol	B-Drug
to	O
healthy	O
volunteers	O
under	O
steady	O
-	O
state	O
conditions	O
had	O
no	O
relevant	O
effect	O
on	O
either	O
drug	O
bioavailability	O
AUC	O
and	O
Cmax	O
differences	O
were	O
9	O
%	O
between	O
isradipine	B-Drug
given	O
singly	O
and	O
in	O
combination	O
with	O
propranolol	B-Drug
and	O
between	O
propranolol	B-Drug
given	O
singly	O
and	O
in	O
combination	O
with	O
isradipine	B-Drug
.	O
      
Cross	O
-	O
reactions	O
with	O
non	O
-	O
Aspergillus	O
polysaccharides	O
and	O
polyfuranoses	O
with	O
the	O
Bio	O
-	O
Rad	O
Laboratories	O
Platelia	O
Aspergillus	O
EIA	O
test	O
have	O
been	O
reported	O
.	O
      
However	O
since	O
aspirin	B-Brand
NSAIDs	B-Group
and	O
bisphosphonates	B-Group
are	O
all	O
associated	O
with	O
gastrointestinal	O
irritation	O
caution	O
should	O
be	O
exercised	O
in	O
the	O
concomitant	O
use	O
of	O
aspirin	B-Brand
or	O
NSAIDs	B-Group
with	O
Ibandronate	B-Drug
.	O
      
**No	O
significant	O
effect	O
.	O
      
Monitoring	O
of	O
cyclosporine	B-Drug
levels	O
and	O
possible	O
adjustment	O
of	O
cyclosporine	B-Drug
dosage	O
should	O
be	O
considered	O
when	O
these	O
drugs	O
are	O
co	O
-	O
administered	O
.	O
      
Dexamethasone	O
suppression	O
test	O
(	O
DST	O
)	O
:	O
False	O
-	O
negative	O
results	O
in	O
the	O
dexamethasone	O
suppression	O
test	O
(	O
DST	O
)	O
in	O
patients	O
being	O
treated	O
with	O
indomethacin	B-Drug
have	O
been	O
reported	O
.	O
      
Exert	O
particular	O
caution	O
in	O
combining	O
levomepromazine	B-Drug
with	O
other	O
anticholinergic	B-Group
drugs	I-Group
(	O
tricyclic	B-Group
antidepressants	I-Group
and	O
antiparkinsonian	B-Group
-	O
agents	I-Group
)	O
:	O
Particularly	O
the	O
elderly	O
may	O
develop	O
delirium	O
high	O
fever	O
severe	O
obstipation	O
even	O
ileus	O
and	O
glaucoma	O
.	O
      
When	O
such	O
combined	O
therapy	O
is	O
contemplated	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O
      
TAMBOCOR	B-Brand
has	O
been	O
used	O
in	O
a	O
large	O
number	O
of	O
patients	O
receiving	O
diuretics	B-Group
without	O
apparent	O
interaction	O
.	O
      
Antacids	B-Group
:	O
Nonclinical	O
data	O
demonstrate	O
that	O
the	O
solubility	O
of	O
dasatinib	B-Drug
is	O
pH	O
dependent	O
.	O
      
A	O
reduced	O
Clozapine	B-Drug
dose	O
should	O
be	O
considered	O
.	O
      
Due	O
to	O
the	O
frequent	O
occurrence	O
of	O
severe	O
and	O
prolonged	O
thrombocytopenia	O
the	O
potential	O
benefits	O
of	O
medications	O
which	O
interfere	O
with	O
platelet	O
function	O
and	O
/	O
or	O
anticoagulation	O
should	O
be	O
weighed	O
against	O
the	O
potential	O
increased	O
risks	O
of	O
bleeding	O
and	O
hemorrhage	O
.	O
      
The	O
absorption	O
of	O
tetracycline	B-Drug
furosemide	B-Drug
penicillin	B-Drug
G	I-Drug
hydrochlorothiazide	B-Drug
and	O
gemfibrozil	B-Drug
was	O
significantly	O
decreased	O
when	O
given	O
simultaneously	O
with	O
colestipol	B-Drug
hydrochloride	I-Drug
;	O
      
Caution	O
should	O
be	O
exercised	O
when	O
administering	O
ETOPOPHOS	B-Brand
with	O
drugs	O
that	O
are	O
known	O
to	O
inhibit	O
phosphatase	O
activities	O
(	O
e.g.	O
levamisole	B-Drug
hydrochloride	I-Drug
)	O
.	O
      
A	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
with	O
copper	O
reduction	O
tests	O
(	O
Benedicts	O
or	O
Fehlings	O
solution	O
or	O
with	O
CLINITEST	O
tablets	O
)	O
but	O
not	O
with	O
enzyme	O
-	O
based	O
tests	O
for	O
glycosuria	O
(	O
e.g.	O
CLINISTIX	O
TES	O
-	O
TAPE	O
)	O
.	O
      
An	O
initial	O
dose	O
of	O
9	O
mg	O
should	O
be	O
given	O
to	O
patients	O
who	O
are	O
concomitantly	O
being	O
treated	O
with	O
cimetidine	B-Drug
.	O
      
Caution	O
however	O
is	O
advised	O
in	O
patients	O
taking	O
tricyclic	B-Group
antidepressants	I-Group
which	O
can	O
affect	O
the	O
metabolism	O
and	O
uptake	O
of	O
circulating	O
amines	O
.	O
      
Pretreatment	O
and	O
follow	O
-	O
up	O
measurements	O
should	O
be	O
obtained	O
under	O
fasting	O
conditions	O
.	O
      
Phenobarbital	B-Drug
:	O
Estimates	O
of	O
steady	O
-	O
state	O
pharmacokinetic	O
parameters	O
for	O
phenobarbital	B-Drug
or	O
gabapentin	B-Drug
(	O
9	O
mg	O
TID	O
;	O
      
Coadministration	O
of	O
glyburide	B-Drug
with	O
doses	O
higher	O
than	O
9	O
mg	O
valdecoxib	B-Drug
(	O
e.g.	O
9	O
mg	O
BID	O
)	O
have	O
not	O
been	O
studied	O
.	O
      
When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
DIABINESE	B-Brand
the	O
patient	O
should	O
be	O
closely	O
observed	O
for	O
loss	O
of	O
control	O
.	O
      
Potassium	B-Group
-	O
sparing	I-Group
diuretics	I-Group
(	O
spironolactone	B-Drug
amiloride	B-Drug
triamterene	B-Drug
and	O
others	O
)	O
or	O
potassium	B-Drug
supplements	O
can	O
increase	O
the	O
risk	O
of	O
hyperkalemia	O
.	O
      
clarithromycin	B-Drug
concentration	O
indinavir	B-Drug
concentration	O
      
Coadministration	O
of	O
thioridazine	B-Drug
has	O
been	O
reported	O
to	O
worsen	O
the	O
tremor	O
in	O
elderly	O
patients	O
with	O
Parkinsons	O
disease	O
;	O
      
Labetalol	B-Drug
HCl	I-Drug
has	O
also	O
been	O
reported	O
to	O
produce	O
a	O
false	O
positive	O
test	O
for	O
amphetamine	B-Drug
when	O
screening	O
urine	O
for	O
the	O
presence	O
of	O
drugs	O
using	O
the	O
commercially	O
available	O
assay	O
methods	O
Toxi	O
-	O
Lab	O
A	O
(	O
thin	O
-	O
layer	O
chromatographic	O
assay	O
)	O
and	O
Emit	O
-	O
d.a.u	O
.	O
(	O
radioenzymatic	O
assay	O
)	O
.	O
      
Verapamil	B-Drug
produced	O
a	O
decrease	O
of	O
9	O
%	O
[	O
9	O
%	O
CI	O
:	O
9	O
-	O
9	O
]	O
of	O
the	O
plasma	O
levels	O
of	O
MHD	B-Drug_n
.	O
      
It	O
is	O
not	O
known	O
if	O
REGRANEX	B-Brand
Gel	O
interacts	O
with	O
other	O
topical	O
medications	O
applied	O
to	O
the	O
ulcer	O
site	O
.	O
      
Because	O
the	O
small	O
magnitude	O
and	O
the	O
direction	O
of	O
the	O
effect	O
on	O
theophylline	B-Drug
clearance	O
this	O
interaction	O
is	O
unlikely	O
to	O
be	O
clinical	O
concern	O
.	O
      
The	O
following	O
drug	O
interactions	O
were	O
observed	O
in	O
some	O
patients	O
undergoing	O
treatment	O
with	O
oral	O
allopurinol	B-Drug
.	O
      
The	O
concurrent	O
use	O
of	O
intravenously	O
or	O
orally	O
administered	O
methylxanthines	B-Group
(	O
e.g.	O
aminophylline	B-Drug
theophylline	B-Drug
)	O
by	O
patients	O
receiving	O
BROVANA	B-Brand
has	O
not	O
been	O
completely	O
evaluated	O
.	O
      
Plasma	O
valproate	B-Drug
concentration	O
should	O
be	O
monitored	O
when	O
isoniazid	B-Drug
and	O
valproate	B-Drug
are	O
co	O
administered	O
and	O
appropriate	O
dosage	O
adjustments	O
of	O
valproate	B-Drug
should	O
be	O
made	O
.	O
      
Aprepitant	B-Drug
is	O
a	O
substrate	O
a	O
moderate	O
inhibitor	O
and	O
an	O
inducer	O
of	O
CYP9A9	O
.	O
      
Steroids	B-Group
enhance	O
the	O
renal	O
toxicity	O
of	O
edetate	B-Drug
calcium	I-Drug
disodium	I-Drug
in	O
animals	O
.	O
9	O
Edetate	B-Drug
calcium	I-Drug
disodium	I-Drug
interferes	O
with	O
the	O
action	O
of	O
zinc	B-Drug
insulin	I-Drug
preparations	O
by	O
chelating	O
the	O
zinc	B-Drug
.	O
9	O
      
When	O
methyldopa	B-Drug
is	O
used	O
with	O
other	O
antihypertensive	B-Group
drugs	I-Group
potentiation	O
of	O
antihypertensive	O
effect	O
may	O
occur	O
.	O
      
The	O
effect	O
of	O
digoxin	B-Drug
on	O
Exjade	B-Brand
pharmacokinetics	O
has	O
not	O
been	O
studied	O
.	O
      
Avoid	O
saw	O
palmetto	O
red	O
clover	O
ginseng	O
.	O
      
Thalidomide	B-Drug
:	O
Co	O
-	O
administration	O
with	O
thalidomide	B-Drug
should	O
be	O
employed	O
cautiously	O
as	O
toxic	O
epidermal	O
necrolysis	O
has	O
been	O
reported	O
with	O
concomitant	O
use	O
.	O
      
one	O
patient	O
died	O
with	O
severe	O
hypocalcemia	O
.	O
      
Prothrombin	O
time	O
was	O
increased	O
by	O
9	O
%	O
the	O
clinical	O
significance	O
of	O
which	O
is	O
unknown	O
.	O
      
Interaction	O
with	O
Other	O
Central	B-Group
Nervous	I-Group
System	I-Group
Depressants	I-Group
:	O
MEPERIDINE	B-Drug
SHOULD	O
BE	O
USED	O
WITH	O
GREAT	O
CAUTION	O
AND	O
IN	O
REDUCED	O
DOSAGE	O
IN	O
PATIENTS	O
WHO	O
ARE	O
CONCURRENTLY	O
RECEIVING	O
OTHER	O
NARCOTIC	B-Group
ANALGESICS	I-Group
GENERAL	O
ANESTHETICS	B-Group
PHENOTHIAZINES	B-Group
OTHER	O
TRANQUILIZERS	B-Group
SEDATIVE	B-Group
-	O
HYPNOTICS	I-Group
(	O
INCLUDING	O
BARBITURATES	B-Group
)	O
TRICYCLIC	B-Group
ANTIDEPRESSANTS	I-Group
AND	O
OTHER	O
CNS	B-Group
DEPRESSANTS	I-Group
(	O
INCLUDING	O
ALCOHOL	B-Drug
)	O
.	O
      
Reduced	O
response	O
to	O
metyrapone	O
test	O
.	O
      
Methscopolamine	B-Drug
may	O
interact	O
with	O
antidepressants	B-Group
(	O
tricyclic	B-Group
type	O
)	O
MAO	B-Group
inhibitors	I-Group
(	O
e.g.	O
phenelzine	B-Drug
linezolid	B-Drug
tranylcypromine	B-Drug
isocarboxazid	B-Drug
selegiline	B-Drug
furazolidone	B-Drug
)	O
quinidine	B-Drug
amantadine	B-Drug
antihistamines	B-Group
(	O
e.g.	O
diphenhydramine	B-Drug
)	O
other	O
anticholinergics	B-Group
potassium	B-Drug
chloride	I-Drug
supplements	O
antacids	B-Group
absorbent	B-Group
-	O
type	I-Group
anti	I-Group
-	O
diarrhea	I-Group
medicines	I-Group
(	O
e.g.	O
kaolin	B-Drug
-	O
pectin	B-Drug
)	O
phenothiazines	B-Group
(	O
e.g.	O
chlorpromazine	B-Drug
promethazine	B-Drug
)	O
.	O
      
The	O
elevation	O
of	O
prothrombin	O
time	O
induced	O
by	O
warfarin	B-Drug
is	O
not	O
affected	O
by	O
administration	O
of	O
Exelon	B-Brand
.	O
      
.	O
      
An	O
interval	O
of	O
at	O
least	O
two	O
hours	O
between	O
intake	O
of	O
this	O
agent	O
and	O
chloroquine	B-Drug
should	O
be	O
observed	O
.	O
      
The	O
effect	O
of	O
gabapentin	B-Drug
on	O
cimetidine	B-Drug
was	O
not	O
evaluated	O
.	O
      
*Increased	O
and	O
decreased	O
prothrombin	O
time	O
responses	O
have	O
been	O
reported	O
.	O
      
Marked	O
symptomatic	O
orthostatic	O
hypotension	O
has	O
been	O
reported	O
when	O
calcium	B-Group
channel	I-Group
blockers	I-Group
and	O
organic	B-Group
nitrates	I-Group
were	O
used	O
in	O
combination	O
.	O
      
Tissue	O
culture	O
and	O
animal	O
studies	O
indicate	O
that	O
ELSPAR	B-Brand
can	O
diminish	O
or	O
abolish	O
the	O
effect	O
of	O
methotrexate	B-Drug
on	O
malignant	O
cells.9	O
This	O
effect	O
on	O
methotrexate	B-Drug
activity	O
persists	O
as	O
long	O
as	O
plasma	O
asparagine	O
levels	O
are	O
suppressed	O
.	O
      
Such	O
interactions	O
might	O
be	O
manifested	O
by	O
increased	O
susceptibility	O
to	O
bruising	O
nosebleeds	O
hemoptysis	O
hematemesis	O
hematuria	O
and	O
blood	O
in	O
the	O
stool	O
.	O
      
in	O
9	O
out	O
of	O
9	O
patients	O
methadone	B-Drug
AUC	O
doubled	O
.	O
      
There	O
have	O
been	O
reports	O
of	O
interactions	O
of	O
erythromycin	B-Drug
with	O
carbamazepine	B-Drug
cyclosporine	B-Drug
tacrolimus	B-Drug
hexobarbital	B-Drug
phenytoin	B-Drug
alfentanil	B-Drug
cisapride	B-Drug
disopyramide	B-Drug
lovastatin	B-Drug
bromocriptine	B-Drug
valproate	B-Drug
terfenadine	B-Drug
and	O
astemizole	B-Drug
.	O
      
Patients	O
receiving	O
both	O
drugs	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
diuretic	O
and	O
/	O
or	O
antihypertensive	O
effect	O
of	O
furosemide	B-Drug
is	O
achieved	O
.	O
      
The	O
pharmacokinetics	O
of	O
ethanol	B-Drug
were	O
not	O
affected	O
by	O
multiple	O
-	O
dose	O
administration	O
of	O
tiagabine	B-Drug
.	O
      
Caution	O
should	O
also	O
be	O
applied	O
for	O
other	O
sympathomimetics	B-Group
and	O
for	O
aminophylline	B-Drug
and	O
theophylline	B-Drug
and	O
tricyclic	B-Group
antidepressants	I-Group
which	O
may	O
also	O
precipitate	O
arrhythmias	O
.	O
      
Antacids	B-Group
increase	O
the	O
rate	O
of	O
absorption	O
of	O
pseudoephedrine	B-Drug
while	O
kaolin	B-Drug
decreases	O
it	O
.	O
      
If	O
possible	O
anticholinesterase	B-Group
agents	I-Group
should	O
be	O
withdrawn	O
at	O
least	O
9	O
hours	O
before	O
initiating	O
corticosteroid	B-Group
therapy	O
.	O
      
Fluconazole	B-Drug
and	O
Ketoconazole	B-Drug
:	O
Ketoconazole	B-Drug
and	O
fluconazole	B-Drug
are	O
predominantly	O
CYP	O
9A9	O
and	O
9C9	O
inhibitors	O
respectively	O
.	O
      
Potentiation	O
occurs	O
with	O
ganglionic	B-Group
peripheral	I-Group
adrenergic	I-Group
blocking	I-Group
drugs	I-Group
.	O
      
(	O
Concurrent	O
use	O
with	O
thiazide	B-Group
diuretics	I-Group
is	O
not	O
recommended	O
as	O
they	O
may	O
provoke	O
lithium	B-Drug
toxicity	O
because	O
of	O
reduced	O
renal	O
clearance	O
.	O
)	O
      
Care	O
should	O
be	O
taken	O
if	O
labetalol	B-Drug
is	O
used	O
concomitantly	O
with	O
calcium	B-Group
antagonists	I-Group
of	O
the	O
verapamil	B-Drug
type	O
.	O
      
thyroid	O
function	O
and	O
basal	O
metabolism	O
are	O
unaffected	O
.	O
      
Digoxin	B-Drug
and	O
verapamil	B-Drug
use	O
may	O
be	O
rarely	O
associated	O
with	O
ventricular	O
fibrillation	O
when	O
combined	O
with	O
Adenocard	B-Brand
.	O
      
Additive	O
depressant	O
effect	O
when	O
used	O
with	O
general	O
anesthetics	B-Group
sedatives	B-Group
antianxiety	B-Group
drugs	I-Group
hypnotics	B-Group
alcohol	B-Drug
and	O
other	O
opiate	B-Group
analgesics	I-Group
.	O
      
In	O
adjuvant	O
trials	O
of	O
epirubicin	B-Drug
-	O
containing	O
CEF	O
-	O
9	O
or	O
FEC	O
-	O
9	O
chemotherapies	O
breast	O
irradiation	O
was	O
delayed	O
until	O
after	O
chemotherapy	O
was	O
completed	O
.	O
      
9	O
.	O
      
Although	O
not	O
studied	O
with	O
alosetron	B-Drug
inhibition	O
of	O
N	O
-	O
acetyltransferase	O
may	O
have	O
clinically	O
relevant	O
consequences	O
for	O
drugs	O
such	O
as	O
isoniazid	B-Drug
procainamide	B-Drug
and	O
hydralazine	B-Drug
.	O
      
CANCIDAS	B-Brand
reduced	O
the	O
blood	O
AUC9	O
-	O
9	O
of	O
tacrolimus	B-Drug
by	O
approximately	O
9	O
%	O
peak	O
blood	O
concentration	O
(	O
Cmax	O
)	O
by	O
9	O
%	O
and	O
9	O
-	O
hour	O
blood	O
concentration	O
(	O
C9hr	O
)	O
by	O
9	O
%	O
in	O
healthy	O
subjects	O
when	O
tacrolimus	B-Drug
(	O
9	O
doses	O
of	O
9	O
mg	O
/	O
kg	O
9	O
hours	O
apart	O
)	O
was	O
administered	O
on	O
the	O
9th	O
day	O
of	O
CANCIDAS	B-Brand
9	O
mg	O
daily	O
as	O
compared	O
to	O
results	O
from	O
a	O
control	O
period	O
in	O
which	O
tacrolimus	B-Drug
was	O
administered	O
alone	O
.	O
      
Geriatric	O
Use	O
Of	O
the	O
patients	O
who	O
received	O
ZETIA	B-Brand
in	O
clinical	O
studies	O
9	O
were	O
9	O
and	O
older	O
(	O
this	O
included	O
9	O
who	O
were	O
9	O
and	O
older	O
)	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
Measurement	O
of	O
serum	O
creatinine	O
levels	O
should	O
be	O
determined	O
by	O
the	O
Jaffe	O
reaction	O
since	O
Ancobon	B-Brand
does	O
not	O
interfere	O
with	O
the	O
determination	O
of	O
creatinine	O
values	O
by	O
this	O
method	O
.	O
      
Gentamicin	B-Drug
-	O
Methionine	B-Drug
may	O
protect	O
against	O
the	O
ototoxic	O
effects	O
of	O
gentamicin	B-Drug
.	O
      
Due	O
to	O
high	O
inter	O
-	O
patient	O
variability	O
and	O
limited	O
sampling	O
the	O
extent	O
of	O
the	O
increase	O
in	O
SN9	B-Drug_n
levels	O
in	O
patients	O
receiving	O
concurrent	O
irinotecan	B-Drug
and	O
AVASTIN	B-Brand
is	O
uncertain	O
.	O
      
Patients	O
taking	O
diuretics	B-Group
are	O
at	O
a	O
greater	O
risk	O
of	O
developing	O
renal	O
failure	O
secondary	O
to	O
a	O
decrease	O
in	O
renal	O
blood	O
flow	O
caused	O
by	O
prostaglandin	O
inhibition	O
.	O
      
No	O
formal	O
clinical	O
studies	O
have	O
been	O
conducted	O
to	O
assess	O
if	O
there	O
is	O
an	O
interactive	O
effect	O
on	O
bone	O
loss	O
between	O
phenytoin	B-Drug
and	O
Accutane	B-Brand
.	O
      
The	O
therapeutic	O
efficacy	O
of	O
tricyclic	B-Group
antidepressants	I-Group
may	O
be	O
compromised	O
in	O
these	O
patients	O
when	O
cimetidine	B-Drug
is	O
discontinued	O
.	O
      
Rifabutin	B-Drug
:	O
Coadministration	O
of	O
rifabutin	B-Drug
and	O
VIRACEPT	B-Brand
resulted	O
in	O
a	O
9	O
%	O
decrease	O
in	O
nelfinavir	B-Drug
plasma	O
AUC	O
and	O
a	O
9	O
%	O
increase	O
in	O
rifabutin	B-Drug
plasma	O
A.C	O
.	O
      
Intravenous	O
infusion	O
of	O
iloprost	B-Drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
.	O
      
In	O
a	O
study	O
of	O
schizophrenic	O
patients	O
who	O
received	O
clozapine	B-Drug
under	O
steady	O
state	O
conditions	O
fluvoxamine	B-Drug
or	O
paroxetine	B-Drug
was	O
added	O
in	O
9	O
and	O
9	O
patients	O
respectively	O
.	O
      
phophatase	O
      
The	O
effect	O
of	O
Keppra	B-Brand
on	O
probenecid	B-Drug
was	O
not	O
studied	O
.	O
      
This	O
allows	O
bitolterol	B-Drug
to	O
open	O
air	O
passages	O
increasing	O
the	O
effectiveness	O
of	O
the	O
steroid	B-Group
.	O
      
Interations	O
      
*	O
No	O
longer	O
marketed	O
in	O
the	O
US	O
.	O
      
If	O
you	O
think	O
you	O
are	O
taking	O
an	O
MAO	B-Group
inhibitor	I-Group
talk	O
to	O
your	O
doctor	O
or	O
pharmacist	O
.	O
      
9	O
.	O
      
pentoxifylline	B-Drug
;	O
      
Expected	O
to	O
substantially	O
decrease	O
plasma	O
levels	O
of	O
efavirenz	B-Drug
;	O
has	O
not	O
been	O
studied	O
in	O
combination	O
with	O
SUSTIVA	B-Brand
.	O
      
In	O
a	O
single	O
-	O
dose	O
crossover	O
study	O
examining	O
lansoprazole	B-Drug
9	O
mg	O
and	O
omeprazole	B-Drug
9	O
mg	O
each	O
administered	O
alone	O
and	O
concomitantly	O
with	O
sucralfate	B-Drug
9	O
gram	O
absorption	O
of	O
the	O
proton	B-Group
pump	I-Group
inhibitors	I-Group
was	O
delayed	O
and	O
their	O
bioavailability	O
was	O
reduced	O
by	O
9	O
%	O
and	O
9	O
%	O
respectively	O
when	O
administered	O
concomitantly	O
with	O
sucralfate	B-Drug
.	O
      
The	O
steady	O
-	O
state	O
Cmin	O
increased	O
to	O
9	O
9	O
micrograms	O
/	O
mL	O
when	O
9	O
mg	O
/	O
day	O
of	O
felbamate	B-Drug
was	O
coadministered	O
.	O
      
This	O
may	O
be	O
avoided	O
by	O
using	O
the	O
lowest	O
dose	O
possible	O
with	O
the	O
substances	O
in	O
question	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interaction	O
Fosinopril	B-Drug
may	O
cause	O
a	O
false	O
low	O
measurement	O
of	O
serum	O
digoxin	B-Drug
levels	O
with	O
the	O
Digi	O
-	O
Tab	O
RIA	O
Kit	O
for	O
Digoxin	B-Drug
.	O
      
Patients	O
on	O
thyroid	O
replacement	O
therapy	O
may	O
require	O
higher	O
doses	O
of	O
thyroid	B-Group
hormone	I-Group
.	O
      
Dolasetron	B-Drug
has	O
been	O
safely	O
coadministered	O
with	O
drugs	O
used	O
in	O
chemotherapy	O
and	O
surgery	O
.	O
      
Use	O
cautiously	O
with	O
pressor	O
agents	O
.	O
      
Antimyasthenics	O
Concurrent	O
use	O
of	O
procaine	B-Drug
hydrochloride	I-Drug
and	O
antimyasthenics	O
may	O
result	O
in	O
loss	O
of	O
control	O
of	O
symptoms	O
of	O
myasthenia	O
gravis	O
due	O
to	O
antagonism	O
of	O
the	O
effects	O
of	O
antimyasthenics	O
on	O
skeletal	O
muscle	O
.	O
      
Naproxen	B-Drug
had	O
no	O
effect	O
on	O
plasma	O
levels	O
of	O
diflunisal	B-Drug
.	O
      
There	O
is	O
no	O
evidence	O
that	O
EPA	B-Drug
supplements	O
have	O
detrimental	O
effects	O
on	O
glucose	O
tolerance	O
insulin	O
secretion	O
or	O
insulin	O
resistance	O
in	O
non	O
-	O
diabetic	O
subjects	O
.	O
      
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulceration	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms	O
physicians	O
should	O
follow	O
chronically	O
treated	O
patients	O
for	O
the	O
signs	O
and	O
symptoms	O
of	O
ulceration	O
and	O
bleeding	O
and	O
should	O
inform	O
them	O
of	O
the	O
importance	O
of	O
this	O
follow	O
-	O
up	O
.	O
      
Therefore	O
a	O
starting	O
daily	O
dose	O
of	O
9	O
mg	O
of	O
VIOXX	B-Brand
should	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
osteoarthritis	O
when	O
VIOXX	B-Brand
is	O
co	O
-	O
administered	O
with	O
potent	O
inducers	O
of	O
hepatic	O
metabolism	O
.	O
      
These	O
drugs	O
include	O
the	O
thiazides	B-Group
and	O
other	O
diuretics	B-Group
corticosteroids	B-Group
phe	O
-	O
nothiazines	O
thyroid	B-Group
products	I-Group
estrogens	B-Group
oral	O
contraceptives	B-Group
phenytoin	B-Drug
nicotinic	B-Drug
acid	I-Drug
sympathomimet	O
-	O
ics	O
calcium	B-Group
channel	I-Group
blocking	I-Group
drugs	I-Group
and	O
isoniazid	B-Drug
.	O
      
TABLE	O
9	O
Effects	O
on	O
Plasma	O
Concentrations	O
(	O
AUC	O
9	O
-	O
9	O
hrs	O
)	O
of	O
Loratadine	B-Drug
and	O
Descarboethoxyloratadine	B-Drug
After	O
9	O
Days	O
of	O
Coadministration	O
(	O
Loratadine	B-Drug
9	O
mg	O
)	O
in	O
Normal	O
Volunteers	O
      
When	O
daily	O
doses	O
of	O
sulfasalazine	B-Drug
9	O
g	O
and	O
weekly	O
doses	O
of	O
methotrexate	B-Drug
9	O
mg	O
were	O
coadministered	O
to	O
9	O
rheumatoid	O
arthritis	O
patients	O
in	O
a	O
drug	O
-	O
drug	O
interaction	O
study	O
the	O
pharmacokinetic	O
disposition	O
of	O
the	O
drugs	O
was	O
not	O
altered	O
.	O
      
Phenytoin	B-Drug
decreases	O
serum	O
amiodarone	O
levels	O
.	O
      
Ethosuximide	B-Drug
:	O
Amphetamines	B-Group
may	O
delay	O
intestinal	O
absorption	O
of	O
ethosuximide	B-Drug
.	O
      
Aspirin	B-Brand
:	O
Concomitant	O
administration	O
of	O
aspirin	B-Brand
with	O
valdecoxib	B-Drug
may	O
result	O
in	O
an	O
increased	O
risk	O
of	O
GI	O
ulceration	O
and	O
complications	O
compared	O
to	O
valdecoxib	B-Drug
alone	O
.	O
      
.	O
      
Paroxetine	B-Drug
produced	O
only	O
minor	O
changes	O
in	O
the	O
levels	O
of	O
clozapine	B-Drug
and	O
its	O
metabolites	O
.	O
      
Coadministration	O
of	O
phenytoin	B-Drug
with	O
9	O
mg	O
SULAR	B-Brand
tablets	O
in	O
epileptic	O
patients	O
lowered	O
the	O
nisoldipine	B-Drug
plasma	O
concentrations	O
to	O
undetectable	O
levels	O
.	O
      
While	O
only	O
a	O
limited	O
number	O
of	O
in	O
vivo	O
drug	O
-	O
drug	O
interactions	O
with	O
amiodarone	B-Drug
have	O
been	O
reported	O
chiefly	O
with	O
the	O
oral	O
formulation	O
the	O
potential	O
for	O
other	O
interactions	O
should	O
be	O
anticipated	O
.	O
      
Methyldopa	B-Drug
does	O
not	O
interfere	O
with	O
measurement	O
of	O
VMA	B-Drug_n
(	O
vanillylmandelic	B-Drug_n
acid	I-Drug_n
)	O
a	O
test	O
for	O
pheochromocytoma	O
by	O
those	O
methods	O
which	O
convert	O
VMA	B-Drug_n
to	O
vanillin	B-Drug_n
.	O
      
Anastrozole	B-Drug
did	O
not	O
inhibit	O
P9	O
9A9	O
or	O
the	O
polymorphic	O
P9	O
9D9	O
in	O
human	O
liver	O
microsomes	O
.	O
      
.	O
      
Antidiabetic	B-Group
drugs	I-Group
(	O
oral	O
agents	O
and	O
insulin	B-Drug
)	O
diminished	O
antidiabetic	O
effect	O
.	O
      
Gastrointestinal	O
:	O
Nausea	O
(	O
9	O
-	O
9	O
%	O
)	O
constipation	O
(	O
9	O
-	O
9	O
%	O
)	O
;	O
      
when	O
the	O
drugs	O
were	O
administered	O
together	O
the	O
effects	O
were	O
additive	O
.	O
      
Due	O
to	O
the	O
chemical	O
similarity	O
of	O
other	O
azole	B-Group
-	O
type	I-Group
antifungal	I-Group
agents	I-Group
(	O
including	O
fluconazole	B-Drug
metronidazole	B-Drug
and	O
miconazole	B-Drug
)	O
to	O
ketoconazole	B-Drug
and	O
itraconazole	B-Drug
concomitant	O
use	O
of	O
these	O
products	O
with	O
terfenadine	B-Drug
is	O
not	O
recommended	O
pending	O
full	O
examination	O
of	O
potential	O
interactions	O
.	O
      
tricyclic	B-Group
antidepressants	I-Group
.	O
      
This	O
has	O
been	O
observed	O
with	O
CLINITEST	O
reagent	O
tablets	O
      
Coadministration	O
of	O
single	O
oral	O
doses	O
of	O
zaleplon	B-Drug
with	O
erythromycin	B-Drug
(	O
9	O
mg	O
and	O
9	O
mg	O
respectively	O
)	O
a	O
strong	O
selective	O
CYP9A9	O
inhibitor	O
produced	O
a	O
9	O
%	O
increase	O
in	O
zaleplons	B-Drug
maximal	O
plasma	O
concentrations	O
and	O
a	O
9	O
%	O
increase	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
.	O
      
Exposure	O
from	O
the	O
proposed	O
topical	O
dose	O
is	O
about	O
9	O
%	O
of	O
that	O
from	O
the	O
9	O
mg	O
oral	O
dose	O
even	O
when	O
co	O
-	O
administered	O
with	O
TMP	B-Drug
/	O
SMX	B-Drug
.	O
      
Therefore	O
the	O
potential	O
for	O
such	O
drug	O
interactions	O
should	O
be	O
considered	O
in	O
patients	O
receiving	O
dorzolamide	B-Drug
.	O
      
Co	O
-	O
administration	O
of	O
bosentan	B-Drug
decreased	O
the	O
plasma	O
concentrations	O
of	O
glyburide	B-Drug
by	O
approximately	O
9	O
%	O
.	O
      
In	O
vivo	O
interaction	O
studies	O
in	O
humans	O
have	O
demonstrated	O
that	O
digoxin	B-Drug
and	O
warfarin	B-Drug
do	O
not	O
affect	O
the	O
PK	O
properties	O
of	O
anagrelide	B-Drug
nor	O
does	O
anagrelide	B-Drug
affect	O
the	O
PK	O
properties	O
of	O
digoxin	B-Drug
or	O
warfarin	B-Drug
.	O
      
Inducers	O
of	O
CYP9A9	O
      
Blood	O
glucose	O
concentrations	O
should	O
be	O
carefully	O
monitored	O
when	O
Itraconazole	B-Drug
and	O
oral	O
hypoglycemic	B-Group
agents	I-Group
are	O
coadministered	O
.	O
      
Quinidine	B-Drug
and	O
procainamide	O
doses	O
should	O
be	O
reduced	O
by	O
one	O
-	O
third	O
when	O
either	O
is	O
administered	O
with	O
amiodarone	B-Drug
.	O
      
The	O
amount	O
of	O
metformin	B-Drug
absorbed	O
while	O
taking	O
Acarbose	B-Drug
was	O
bioequivalent	O
to	O
the	O
amount	O
absorbed	O
when	O
taking	O
placebo	O
as	O
indicated	O
by	O
the	O
plasma	O
AUC	O
values	O
.	O
      
SYMLIN	B-Brand
has	O
the	O
potential	O
to	O
delay	O
the	O
absorption	O
of	O
concomitantly	O
administered	O
oral	O
medications	O
.	O
      
Permanent	O
nerve	O
damage	O
could	O
theoretically	O
occur	O
if	O
vitamin	O
B9	O
deficiency	O
is	O
not	O
treated	O
.	O
      
Probenecid	B-Drug
:	O
As	O
with	O
other	O
b	B-Group
-	O
lactam	I-Group
antibiotics	I-Group
renal	O
excretion	O
of	O
loracarbef	B-Drug
is	O
inhibited	O
by	O
probenecid	B-Drug
and	O
resulted	O
in	O
an	O
approximate	O
9	O
%	O
increase	O
in	O
the	O
AUC	O
for	O
loracarbef	B-Drug
.	O
      
May	O
interact	O
with	O
the	O
following	O
:	O
beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
(	O
these	O
medicines	O
may	O
make	O
your	O
condition	O
worse	O
and	O
prevent	O
the	O
adrenergic	B-Group
bronchodilators	I-Group
from	O
working	O
properly	O
)	O
and	O
disopyramide	B-Drug
quinidine	B-Drug
phenothiazines	B-Group
and	O
procainamide	B-Drug
(	O
these	O
medicines	O
may	O
increase	O
the	O
risk	O
of	O
heart	O
problems	O
)	O
.	O
      
sulfonamides	B-Group
long	O
acting	O
;	O
      
Antacid	B-Group
(	O
Maalox	B-Brand
)	O
:	O
Maalox	B-Brand
reduced	O
the	O
bioavailability	O
of	O
gabapentin	B-Drug
(	O
N=9	O
)	O
by	O
about	O
9	O
%	O
.	O
      
In	O
addition	O
certain	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isoenzyme	O
including	O
many	O
antidepressants	B-Group
(	O
tricyclic	B-Group
antidepressants	I-Group
selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
and	O
others	O
)	O
may	O
inhibit	O
the	O
activity	O
of	O
this	O
isoenzyme	O
and	O
thus	O
may	O
make	O
normal	O
metab	O
-	O
olizers	O
resemble	O
poor	O
metabolizers	O
with	O
regard	O
to	O
concomitant	O
therapy	O
with	O
other	O
drugs	O
metabolized	O
by	O
this	O
enzyme	O
system	O
leading	O
to	O
drug	O
interactions	O
.	O
      
This	O
oxidation	O
which	O
is	O
catalyzed	O
by	O
xanthine	O
oxidase	O
inactivates	O
mercaptopurine	B-Drug
.	O
      
Clonidine	B-Drug
:	O
Concomitant	O
administration	O
of	O
clonidine	B-Drug
with	O
agents	B-Group
with	I-Group
b	I-Group
-	O
blocking	I-Group
properties	I-Group
may	O
potentiate	O
blood	O
-	O
pressure	O
-	O
and	O
heart	O
-	O
rate	O
-	O
lowering	O
effects	O
.	O
      
CANCIDAS	B-Brand
did	O
not	O
increase	O
the	O
plasma	O
levels	O
of	O
cyclosporine	B-Drug
.	O
      
antibiotics	B-Group
;	O
      
CIMETlDINE	B-Drug
:	O
Cerivastatin	B-Drug
plasma	O
concentrations	O
were	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
cimetidine	B-Drug
.	O
      
Other	O
depressasnts	O
such	O
as	O
alcohol	B-Drug
barbiturates	B-Group
and	O
MAOIs	B-Group
may	O
enhance	O
CNS	O
depression	O
when	O
administered	O
with	O
ethchlorvynol	B-Drug
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
Amphetamines	B-Group
can	O
cause	O
a	O
significant	O
elevation	O
in	O
plasma	O
corticosteroid	B-Group
levels	O
.	O
      
No	O
evaluation	O
of	O
EXTRANEALs	B-Brand
effects	O
on	O
the	O
cytochrome	O
P9	O
system	O
was	O
conducted	O
.	O
      
The	O
elimination	O
half	O
life	O
of	O
midazolam	B-Drug
and	O
triazolam	B-Drug
also	O
increased	O
(	O
9	O
-	O
9	O
fold	O
)	O
during	O
coadministration	O
with	O
diltiazem	B-Drug
.	O
      
Ketoconazole	B-Drug
(	O
9	O
mg	O
q9h	O
)	O
9	O
%	O
9%	O
      
Coadministration	O
of	O
rifampin	B-Drug
with	O
diltiazem	B-Drug
lowered	O
the	O
diltiazem	B-Drug
plasma	O
concentrations	O
to	O
undetectable	O
levels	O
.	O
      
-	O
Mephenytoin	B-Drug
(	O
e.g.	O
Mesantoin	B-Brand
)	O
Use	O
of	O
sulfapyridine	B-Drug
with	O
these	O
medicines	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
of	O
these	O
medicines	O
      
If	O
additional	O
adrenergic	B-Group
drugs	I-Group
are	O
to	O
be	O
administered	O
by	O
any	O
route	O
they	O
should	O
be	O
used	O
with	O
caution	O
because	O
the	O
pharmacologically	O
predictable	O
sympathetic	O
effects	O
of	O
BROVANA	B-Brand
may	O
be	O
potentiated	O
.	O
      
Drugs	O
Prolonging	O
the	O
QT	O
/	O
QTc	O
Interval	O
Caution	O
should	O
be	O
exercised	O
when	O
prescribing	O
apomorphine	B-Drug
concomitantly	O
with	O
drugs	O
that	O
prolong	O
the	O
QT	O
/	O
QTc	O
interval	O
.	O
      
Each	O
volunteer	O
was	O
administered	O
one	O
9	O
-	O
mg	O
ceftibuten	B-Drug
capsule	O
.	O
      
The	O
findings	O
of	O
these	O
studies	O
are	O
summarized	O
in	O
the	O
following	O
table	O
:	O
Effects	O
on	O
steady	O
-	O
state	O
fexofenadine	B-Drug
pharmacokinetics	O
after	O
9	O
days	O
of	O
co	O
-	O
administration	O
with	O
fexofenadine	B-Drug
hydrochloride	I-Drug
9	O
mg	O
every	O
9	O
hours	O
(	O
two	O
times	O
the	O
recommended	O
twice	O
daily	O
dose	O
)	O
in	O
healthy	O
volunteers	O
(	O
n=9	O
)	O
      
Probenecid	B-Drug
-	O
concurrent	O
use	O
decreases	O
gastrointestinal	O
absorption	O
of	O
riboflavin	B-Drug
;	O
      
Interconversion	O
between	O
caffeine	B-Drug
and	O
theophylline	B-Drug
has	O
been	O
reported	O
in	O
preterm	O
neonates	O
.	O
      
Anticholinergic	B-Group
drugs	I-Group
in	O
the	O
presence	O
of	O
increased	O
intraocular	O
pressure	O
may	O
be	O
hazardous	O
when	O
taken	O
concurrently	O
with	O
agents	O
such	O
as	O
corticosteroids	B-Group
.	O
      
Alcohol	B-Drug
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
aripiprazole	B-Drug
coadministered	O
with	O
ethanol	B-Drug
and	O
placebo	O
coadministered	O
with	O
ethanol	B-Drug
on	O
performance	O
of	O
gross	O
motor	O
skills	O
or	O
stimulus	O
response	O
in	O
healthy	O
subjects	O
.	O
      
Careful	O
monitoring	O
of	O
serum	O
theophylline	B-Drug
concentrations	O
in	O
patients	O
receiving	O
DIFLUCAN	B-Brand
and	O
theophylline	B-Drug
is	O
recommended	O
.	O
      
Increased	O
anticoagulation	O
effects	O
due	O
to	O
interactions	O
of	O
erythromycin	B-Drug
with	O
various	O
oral	O
anticoagulents	O
may	O
be	O
more	O
pronounced	O
in	O
the	O
elderly	O
.	O
      
Diltiazem	B-Drug
plasma	O
levels	O
were	O
not	O
significantly	O
affected	O
by	O
lovastatin	B-Drug
or	O
pravastatin	B-Drug
.	O
      
Diuretic	B-Group
:	O
Hydrochlorothiazide	B-Drug
given	O
concomitantly	O
with	O
ketoprofen	B-Drug
produces	O
a	O
reduction	O
in	O
urinary	O
potassium	O
and	O
chloride	O
excretion	O
compared	O
to	O
hydrochlorothiazide	B-Drug
alone	O
.	O
      
Tell	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
following	O
drugs	O
:	O
blood	B-Group
thinners	I-Group
(	O
Coumadin	B-Brand
)	O
other	O
antidepressants	B-Group
metoprolol	B-Drug
antihistamines	B-Group
carbamazepine	B-Drug
(	O
Tegretol	B-Brand
)	O
cimetidine	B-Drug
(	O
Tagamet	B-Brand
)	O
estrogens	B-Group
fluoxetine	B-Drug
(	O
Prozac	B-Brand
)	O
intraconazole	O
(	O
Sporanox	B-Brand
)	O
ketoconazole	B-Drug
(	O
Nizoral	B-Brand
)	O
levodopa	B-Drug
lithium	B-Drug
muscle	B-Group
relaxants	I-Group
birth	O
control	O
pills	O
sleeping	O
pills	O
thyroid	O
medications	O
      
in	O
vitro	O
Gleevec	B-Brand
inhibits	O
the	O
cytochrome	O
P9	O
isoenzyme	O
CYP9D9	O
activity	O
at	O
similar	O
concentrations	O
that	O
affect	O
CYP9A9	O
activity	O
.	O
      
In	O
several	O
well	O
-	O
controlled	O
studies	O
guanfacine	B-Drug
was	O
administered	O
together	O
with	O
diuretics	B-Group
with	O
no	O
drug	O
interactions	O
reported	O
.	O
      
.	O
      
Vecuronium	B-Drug
:	O
When	O
used	O
in	O
the	O
perioperative	O
period	O
piperacillin	B-Drug
has	O
been	O
implicated	O
in	O
the	O
prolongation	O
of	O
the	O
neuromuscular	O
blockade	O
of	O
vecuronium	B-Drug
.	O
      
These	O
doses	O
correspond	O
to	O
approximately	O
9	O
-	O
9	O
-	O
and	O
9	O
-	O
fold	O
(	O
in	O
females	O
)	O
and	O
9	O
-	O
9	O
-	O
and	O
9	O
-	O
fold	O
(	O
in	O
males	O
)	O
the	O
systemic	O
exposure	O
[	O
AUC9	O
-	O
9	O
days	O
]	O
]	O
achieved	O
in	O
women	O
receiving	O
the	O
recommended	O
dose	O
of	O
9	O
mg	O
/	O
month	O
.	O
      
The	O
utilization	O
of	O
digitoxin	B-Drug
for	O
such	O
patients	O
may	O
be	O
considered	O
as	O
an	O
alternative	O
.	O
      
Potential	O
for	O
reduction	O
in	O
anticonvulsant	B-Group
and	O
/	O
or	O
efavirenz	B-Drug
plasma	O
levels	O
;	O
      
Since	O
bacteriostatic	O
drugs	O
may	O
interfere	O
with	O
the	O
bactericidal	O
action	O
of	O
penicillin	B-Drug
it	O
is	O
advisable	O
to	O
avoid	O
giving	O
tetracyclines	B-Group
in	O
conjunction	O
with	O
penicillin	B-Group
.	O
      
Carbamazepine	B-Drug
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	B-Drug
(	O
9	O
mg	O
/	O
day	O
for	O
9	O
days	O
)	O
and	O
carbamazepine	B-Drug
(	O
titrated	O
to	O
9	O
mg	O
/	O
day	O
for	O
9	O
days	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
carbamazepine	B-Drug
a	O
CYP9A9	O
substrate	O
.	O
      
On	O
the	O
average	O
for	O
the	O
group	O
the	O
dose	O
of	O
cyclosporine	B-Drug
was	O
reduced	O
about	O
9	O
%	O
in	O
these	O
patients	O
.	O
      
Other	O
inhibitors	O
of	O
the	O
cytochrome	O
P9	O
9A9	O
enzyme	O
system	O
such	O
as	O
antimycotic	B-Group
agents	I-Group
(	O
e.g.	O
itraconazole	B-Drug
and	O
miconazole	B-Drug
)	O
or	O
macrolide	B-Group
antibiotics	I-Group
(	O
e.g.	O
erythromycin	B-Drug
and	O
clarithromycin	B-Drug
)	O
may	O
alter	O
oxybutynin	B-Drug
mean	O
pharmacokinetic	O
parameters	O
(	O
i.e.	O
Cmax	O
and	O
AUC	O
)	O
.	O
      
There	O
was	O
no	O
evidence	O
of	O
drug	O
interactions	O
in	O
clinical	O
studies	O
in	O
which	O
dobutamine	B-Drug
was	O
administered	O
concurrently	O
with	O
other	O
drugs	O
including	O
digitalis	B-Group
preparations	I-Group
furosemide	B-Drug
spironolactone	B-Drug
lidocaine	B-Drug
glyceryl	B-Drug
trinitrate	I-Drug
isosorbide	B-Drug
dinitrate	I-Drug
morphine	B-Drug
atropine	B-Drug
heparin	B-Drug
protamine	B-Drug
potassium	B-Drug
chloride	I-Drug
folic	B-Drug
acid	I-Drug
and	O
acetaminophen	B-Drug
.	O
      
Effects	O
of	O
Erythromycin	B-Drug
on	O
Felbatol	B-Brand
The	O
coadministration	O
of	O
erythromycin	B-Drug
(	O
9	O
mg	O
/	O
day	O
)	O
for	O
9	O
days	O
did	O
not	O
alter	O
the	O
pharmacokinetic	O
parameters	O
of	O
Cmax	O
Cmin	O
AUC	O
CI	O
/	O
kg	O
or	O
tmax	O
at	O
felbamate	B-Drug
daily	O
doses	O
of	O
9	O
or	O
9	O
mg	O
/	O
day	O
in	O
9	O
otherwise	O
healthy	O
subjects	O
with	O
epilepsy	O
.	O
      
May	O
interact	O
with	O
addictive	O
medications	O
especially	O
central	B-Group
nervous	I-Group
system	I-Group
CNS	I-Group
depressants	I-Group
with	O
habituating	O
potential	O
(	O
prolonged	O
concurrent	O
use	O
may	O
increase	O
the	O
risk	O
of	O
habituation	O
)	O
alcohol	B-Drug
or	O
CNS	O
depression	O
producing	O
medications	O
(	O
concurrent	O
use	O
may	O
increase	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
ethinamate	B-Drug
)	O
.	O
      
Sildenafil	B-Drug
citrate	I-Drug
-	O
Theoretically	O
L	B-Drug
-	O
arginine	I-Drug
supplements	O
taken	O
concomitantly	O
with	O
sildenafil	B-Drug
citrate	I-Drug
may	O
potentiate	O
the	O
effects	O
of	O
the	O
drug	O
.	O
      
A	O
study	O
of	O
interaction	O
between	O
BREVIBLOC	B-Brand
and	O
warfarin	B-Drug
showed	O
that	O
concomitant	O
administration	O
of	O
BREVIBLOC	B-Brand
and	O
warfarin	B-Drug
does	O
not	O
alter	O
warfarin	B-Drug
plasma	O
levels	O
.	O
      
Among	O
9	O
subjects	O
who	O
received	O
Angiomax	B-Brand
in	O
clinical	O
trials	O
and	O
were	O
tested	O
for	O
antibodies	O
9	O
subjects	O
had	O
treatment	O
-	O
emergent	O
positive	O
bivalirudin	B-Drug
antibody	O
tests	O
.	O
      
Steady	O
-	O
state	O
bosentan	B-Drug
plasma	O
concentrations	O
were	O
9	O
-	O
to	O
9	O
-	O
fold	O
higher	O
than	O
in	O
the	O
absence	O
of	O
cyclosporine	B-Drug
A	I-Drug
.	O
      
Patients	O
in	O
a	O
clinical	O
study	O
who	O
were	O
on	O
established	O
therapy	O
with	O
sulfasalazine	B-Drug
to	O
which	O
ENBREL	B-Brand
was	O
added	O
were	O
noted	O
to	O
develop	O
a	O
mild	O
decrease	O
in	O
mean	O
neutrophil	O
counts	O
in	O
comparison	O
to	O
groups	O
treated	O
with	O
either	O
ENBREL	B-Brand
CI	O
or	O
sulfasalazine	B-Drug
alone	O
.	O
      
Alternatives	O
to	O
clarithromycin	B-Drug
such	O
as	O
azithromycin	B-Drug
should	O
be	O
considered	O
.	O
      
Because	O
of	O
its	O
potential	O
for	O
inducing	O
orthostatic	O
hypotension	O
an	O
additive	O
effect	O
may	O
be	O
observed	O
when	O
INVEGA	B-Brand
is	O
administered	O
with	O
other	O
therapeutic	O
agents	O
that	O
have	O
this	O
potential	O
.	O
      
No	O
dose	O
adjustment	O
of	O
bosentan	B-Drug
is	O
necessary	O
but	O
increased	O
effects	O
of	O
bosentan	B-Drug
should	O
be	O
considered	O
.	O
      
Both	O
itraconazole	B-Drug
and	O
its	O
major	O
metabolite	O
hydroxyitraconazole	B-Drug_n
are	O
inhibitors	O
of	O
the	O
cytochrome	O
P9	O
9A9	O
enzyme	O
system	O
.	O
      
Further	O
in	O
rabbits	O
dosed	O
at	O
9	O
mg	O
/	O
kg	O
/	O
day	O
(	O
about	O
one	O
-	O
half	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
increases	O
in	O
placental	O
weight	O
and	O
post	O
-	O
implantation	O
loss	O
were	O
observed	O
but	O
there	O
were	O
no	O
observed	O
effects	O
on	O
fetal	O
development	O
.	O
      
Drug	O
and	O
Laboratory	O
Test	O
Interactions	O
9	O
.	O
      
fenoprofen	B-Drug
;	O
      
Data	O
from	O
in	O
vitro	O
studies	O
of	O
benzodiazepines	B-Group
other	O
than	O
alprazolam	B-Drug
suggest	O
a	O
possible	O
drug	O
interaction	O
for	O
the	O
following	O
:	O
ergotamine	B-Drug
cyclosporine	B-Drug
amiodarone	B-Drug
nicardipine	B-Drug
and	O
nifedipine	B-Drug
.	O
      
Nicotine	B-Drug
Transdermal	O
System	O
:	O
.	O
      
The	O
safety	O
of	O
such	O
concomitant	O
use	O
with	O
Activase	B-Brand
for	O
the	O
management	O
of	O
acute	O
ischemic	O
stroke	O
is	O
unknown	O
.	O
      
In	O
a	O
similar	O
study	O
with	O
tamsulosin	B-Drug
in	O
healthy	O
volunteers	O
9	O
of	O
9	O
subjects	O
dosed	O
with	O
Vardenafil	B-Drug
9	O
mg	O
and	O
tamsulosin	B-Drug
9	O
mg	O
separated	O
by	O
9	O
hours	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
below	O
9	O
mm	O
Hg	O
.	O
      
Other	O
strong	O
inhibitors	O
of	O
CYP9A9	O
(	O
itraconazole	B-Drug
)	O
would	O
be	O
expected	O
to	O
have	O
similar	O
effects	O
and	O
need	O
similar	O
dose	O
reductions	O
;	O
      
Carbamazepine	B-Drug
(	O
CBZ	B-Drug
)	O
      
Since	O
colestipol	B-Drug
hydrochloride	I-Drug
is	O
an	O
anion	B-Group
exchange	I-Group
resin	I-Group
it	O
may	O
have	O
a	O
strong	O
affinity	O
for	O
anions	O
other	O
than	O
the	O
bile	O
acids	O
.	O
      
Delavirdine	B-Drug
      
See	O
      
Ketoconazole	B-Drug
:	O
Potential	O
interaction	O
of	O
Ketoconazole	B-Drug
and	O
Isoniazid	B-Drug
may	O
exist	O
.	O
      
The	O
administration	O
of	O
epinephrine	B-Drug
should	O
be	O
avoided	O
in	O
the	O
treatment	O
of	O
drug	O
induced	O
hypotension	O
because	O
of	O
a	O
possible	O
reverse	O
epinephrine	B-Drug
effect	O
.	O
      
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
with	O
Cetrotide	B-Brand
.	O
      
Drugs	O
such	O
as	O
troleandomycin	B-Drug
and	O
ketoconazole	B-Drug
may	O
inhibit	O
the	O
metabolism	O
of	O
corticosteroids	B-Group
and	O
thus	O
decrease	O
their	O
clearance	O
.	O
      
In	O
vitro	O
perfusion	O
of	O
isolated	O
rat	O
liver	O
has	O
shown	O
that	O
cimetidine	B-Drug
caused	O
a	O
significant	O
reduction	O
in	O
trimetrexate	B-Drug
metabolism	O
and	O
that	O
acetaminophen	B-Drug
altered	O
the	O
relative	O
concentration	O
of	O
trimetrexate	O
metabolites	O
possibly	O
by	O
competing	O
for	O
sulfate	O
metabolites	O
.	O
      
There	O
have	O
been	O
no	O
formal	O
drug	O
interaction	O
studies	O
performed	O
with	O
HERCEPTIN	B-Brand
in	O
humans	O
.	O
      
Azathioprine	B-Drug
/	O
Mycophenolate	B-Drug
Mofetil	I-Drug
:	O
Given	O
that	O
azathioprine	B-Drug
and	O
mycophenolate	B-Drug
mofetil	I-Drug
inhibit	O
purine	O
metabolism	O
it	O
is	O
recommended	O
that	O
Myfortic	B-Brand
not	O
be	O
administered	O
concomitantly	O
with	O
azathioprine	B-Drug
or	O
mycophenolate	B-Drug
mofetil	I-Drug
.	O
      
Pediatric	O
Use	O
      
In	O
vivo	O
the	O
plasma	O
clearance	O
of	O
ropivacaine	B-Drug
was	O
reduced	O
by	O
9	O
%	O
during	O
coadministration	O
of	O
fluvoxamine	B-Drug
(	O
9	O
mg	O
bid	O
for	O
9	O
days	O
)	O
a	O
selective	O
and	O
potent	O
CYP9A9	O
inhibitor	O
.	O
      
The	O
atorvastatin	B-Drug
Cmax	O
values	O
were	O
not	O
significantly	O
affected	O
by	O
fenofibrate	B-Drug
.	O
      
Concomitant	O
use	O
of	O
calcium	B-Drug
supplements	O
and	O
L	B-Drug
-	O
lysine	I-Drug
may	O
increase	O
calcium	B-Drug
absorption	O
      
Indomethacin	B-Drug
may	O
also	O
affect	O
plasma	O
renin	O
levels	O
aldosterone	O
excretion	O
and	O
renin	O
profile	O
evaluation	O
.	O
      
Clinically	O
significant	O
effects	O
have	O
been	O
reported	O
with	O
the	O
warfarin	B-Group
anticoagulants	I-Group
;	O
      
In	O
order	O
to	O
avoid	O
the	O
occurrence	O
of	O
severe	O
hypersensitivity	O
reactions	O
all	O
patients	O
treated	O
with	O
TAXOL	B-Brand
should	O
be	O
premedicated	O
with	O
corticosteroids	B-Group
(	O
such	O
as	O
dexamethasone	B-Drug
)	O
diphen	O
-	O
hydramine	O
and	O
H9	B-Group
antagonists	I-Group
(	O
such	O
as	O
cimetidine	B-Drug
or	O
ranitidine	B-Drug
)	O
.	O
      
In	O
vitro	O
data	O
indicate	O
that	O
the	O
phosphorylation	O
of	O
stavudine	B-Drug
is	O
also	O
inhibited	O
at	O
relevant	O
concentrations	O
by	O
doxorubicin	B-Drug
and	O
ribavirin	B-Drug
.	O
      
Some	O
quinolone	B-Group
antibiotics	I-Group
would	O
be	O
expected	O
to	O
have	O
similar	O
effects	O
and	O
these	O
combinations	O
should	O
be	O
avoided	O
.	O
      
.	O
      
A	O
further	O
phenomenon	O
of	O
toxicity	O
common	O
to	O
many	O
hydrazine	B-Group
derivatives	I-Group
is	O
hemolysis	O
and	O
the	O
appearance	O
of	O
Heinz	O
-	O
Ehrlich	O
inclusion	O
bodies	O
in	O
erythrocytes	O
.	O
      
Depending	O
on	O
the	O
fraction	O
of	O
drug	O
metabolized	O
by	O
P9	O
9D9	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
or	O
quite	O
large	O
(	O
9	O
-	O
fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	B-Group
)	O
.	O
      
The	O
possibility	O
of	O
worsened	O
glucose	O
control	O
in	O
patients	O
using	O
these	O
agents	O
should	O
be	O
considered	O
.	O
      
Ketoconazole	B-Drug
      
MAO	B-Group
inhibitors	I-Group
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
effects	O
of	O
antihistamines	B-Group
.	O
      
Caution	O
is	O
advised	O
when	O
TRISENOX	B-Brand
is	O
coadministered	O
with	O
other	O
medications	O
that	O
can	O
prolong	O
the	O
QT	O
interval	O
(	O
e.g	O
.	O
certain	O
antiarrhythmics	B-Group
or	O
thioridazine	B-Drug
)	O
or	O
lead	O
to	O
electrolyte	O
abnormalities	O
(	O
such	O
as	O
diuretics	B-Group
or	O
amphotericin	B-Drug
B	I-Drug
)	O
.	O
      
H	O
-	O
9	O
Antagonists	O
:	O
In	O
studies	O
with	O
human	O
volunteers	O
co	O
-	O
administration	O
of	O
cimetidine	B-Drug
or	O
ranitidine	B-Drug
with	O
ibuprofen	B-Drug
had	O
no	O
substantive	O
effect	O
on	O
ibuprofen	B-Drug
serum	O
concentrations	O
.	O
      
therefore	O
administration	O
of	O
EQUETROTM	B-Brand
to	O
a	O
patient	O
taking	O
another	O
drug	O
that	O
is	O
highly	O
protein	O
bound	O
should	O
not	O
cause	O
increased	O
free	O
concentrations	O
of	O
the	O
other	O
drug	O
.	O
      
Videx	B-Brand
(	O
Didanosine	B-Drug
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
or	O
within	O
9	O
hours	O
of	O
the	O
administration	O
of	O
norfloxacin	B-Drug
because	O
these	O
products	O
may	O
interfere	O
with	O
absorption	O
resulting	O
in	O
lower	O
serum	O
and	O
urine	O
levels	O
of	O
norfloxacin	B-Drug
.	O
      
The	O
magnitude	O
and	O
relative	O
importance	O
of	O
the	O
effects	O
noted	O
below	O
are	O
likely	O
to	O
be	O
patient	O
specific	O
and	O
may	O
vary	O
by	O
such	O
factors	O
as	O
age	O
gender	O
race	O
intercurrent	O
illnesses	O
dose	O
of	O
either	O
agent	O
additional	O
concomitant	O
medications	O
and	O
timing	O
of	O
drug	O
administration	O
.	O
      
Among	O
aspirin	B-Brand
or	O
NSAID	B-Group
users	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
events	O
in	O
patients	O
treated	O
with	O
ibandronate	B-Drug
9	O
mg	O
daily	O
(	O
9	O
%	O
)	O
was	O
similar	O
to	O
that	O
in	O
placebo	O
-	O
treated	O
patients	O
(	O
9	O
%	O
)	O
.	O
      
Netilmicin	B-Drug
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
potent	O
loop	B-Group
diuretics	I-Group
such	O
as	O
furosemide	B-Drug
and	O
ethacrynic	B-Drug
acid	I-Drug
as	O
the	O
potential	O
for	O
ototoxicity	O
is	O
enhanced	O
by	O
the	O
combination	O
.	O
      
Elevated	O
serum	O
levels	O
of	O
cyclosporine	B-Drug
have	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
some	O
quinolones	B-Group
and	O
cyclosporine	B-Drug
.	O
      
monitor	O
closely	O
for	O
evidence	O
of	O
hypotension	O
and	O
/	O
or	O
excessive	O
bradycardia	O
(	O
e.g.	O
vertigo	O
syncope	O
postural	O
hypotension	O
)	O
.	O
      
Alternate	O
or	O
additional	O
contraceptive	O
measures	O
should	O
be	O
used	O
during	O
therapy	O
with	O
VIRACEPT	B-Brand
      
Compounds	O
that	O
have	O
been	O
tested	O
in	O
man	O
include	O
antipyrine	B-Drug
digoxin	B-Drug
propranolol	B-Drug
theophylline	B-Drug
and	O
warfarin	B-Drug
and	O
no	O
clinically	O
meaningful	O
interactions	O
were	O
found	O
.	O
      
Because	O
of	O
the	O
small	O
effect	O
on	O
half	O
-	O
life	O
the	O
coadministration	O
with	O
probenecid	B-Drug
to	O
extend	O
the	O
half	O
-	O
life	O
of	O
ertapenem	B-Drug
is	O
not	O
recommended	O
.	O
      
certain	O
antipsychotic	B-Group
medications	I-Group
(	O
such	O
as	O
sertindole	B-Drug
)	O
;	O
      
Observations	O
from	O
drug	O
interaction	O
studies	O
with	O
FORTOVASE	B-Brand
may	O
not	O
be	O
predictive	O
for	O
INVIRASE	B-Brand
.	O
      
Pregnancy	O
Pregnancy	O
Category	O
:	O
C	O
There	O
are	O
no	O
adequate	O
and	O
well	O
-	O
controlled	O
studies	O
of	O
ezetimibe	B-Drug
in	O
pregnant	O
women	O
.	O
      
Therefore	O
the	O
dose	O
of	O
corticosteroid	B-Group
should	O
be	O
titrated	O
to	O
avoid	O
steroid	O
toxicity	O
.	O
      
Dexbrompheniramine	B-Drug
can	O
interact	O
with	O
alcohol	B-Drug
or	O
other	O
CNS	B-Group
depressants	I-Group
(	O
may	O
potentiate	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	B-Group
)	O
anticholinergics	B-Group
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
(	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	B-Group
)	O
and	O
monoamine	B-Group
oxidase	I-Group
MAO	I-Group
inhibitors	I-Group
(	O
concurrent	O
use	O
with	O
antihistamines	B-Group
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
and	O
CNS	O
depressant	O
effects	O
of	O
antihistamines	B-Group
)	O
.	O
      
No	O
effects	O
on	O
plasma	O
concentrations	O
of	O
cimetidine	B-Drug
or	O
ketoconazole	B-Drug
were	O
observed	O
.	O
      
When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
patients	O
receiving	O
Acarbose	B-Drug
in	O
combination	O
with	O
sulfonylureas	B-Group
or	O
insulin	B-Drug
patients	O
should	O
be	O
observed	O
closely	O
for	O
any	O
evidence	O
of	O
hypoglycemia	O
.	O
      
Pregnancy	O
(	O
Category	O
B	O
)	O
      
fluoxetine	B-Drug
fluvoxamine	B-Drug
paroxetine	B-Drug
sertraline	B-Drug
)	O
.	O
      
Drug	O
interactions	O
with	O
SUSTIVA	B-Brand
are	O
summarized	O
in	O
Table	O
9	O
.	O
      
Patients	O
receiving	O
SUTENT	B-Brand
should	O
not	O
take	O
St	O
.	O
      
In	O
vitro	O
studies	O
have	O
shown	O
that	O
because	O
of	O
its	O
affinity	O
for	O
protein	O
9MNA	B-Drug_n
may	O
displace	O
other	O
protein	O
-	O
bound	O
drugs	O
from	O
their	O
binding	O
site	O
.	O
      
Medications	O
can	O
interfere	O
with	O
folate	O
utilization	O
including	O
:	O
anticonvulsant	B-Group
medications	I-Group
(	O
such	O
as	O
phenytoin	B-Drug
and	O
primidone	B-Drug
)	O
metformin	B-Drug
(	O
sometimes	O
prescribed	O
to	O
control	O
blood	O
sugar	O
in	O
type	O
9	O
diabetes	O
)	O
sulfasalazine	B-Drug
(	O
used	O
to	O
control	O
inflammation	O
associated	O
with	O
Crohns	O
disease	O
and	O
ulcerative	O
colitis	O
)	O
triamterene	B-Drug
(	O
a	O
diuretic	B-Group
)	O
Methotrexate	B-Drug
There	O
has	O
been	O
concern	O
about	O
the	O
interaction	O
between	O
vitamin	B-Drug
B9	I-Drug
and	O
folic	B-Drug
acid	I-Drug
.	O
      
While	O
all	O
the	O
selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
(	O
SSRIs	B-Group
)	O
e.	O
g.	O
fluoxetine	B-Drug
sertraline	B-Drug
and	O
paroxetine	B-Drug
inhibit	O
P9	O
9D9	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O
      
Reproductive	O
toxicology	O
studies	O
have	O
been	O
performed	O
in	O
cynomolgus	O
monkeys	O
at	O
doses	O
up	O
to	O
9	O
mg	O
/	O
kg	O
/	O
week	O
(	O
about	O
9	O
times	O
the	O
human	O
dose	O
based	O
on	O
body	O
weight	O
)	O
and	O
have	O
revealed	O
no	O
evidence	O
of	O
impaired	O
fertility	O
or	O
harm	O
to	O
the	O
fetus	O
due	O
to	O
AMEVIVE	B-Brand
.	O
      
e.g.	O
other	O
belladonna	B-Group
alkaloids	I-Group
antihistamines	B-Group
(	O
including	O
meclizine	B-Drug
)	O
tricyclic	B-Group
antidepressants	I-Group
and	O
muscle	B-Group
relaxants	I-Group
.	O
      
Because	O
antacids	B-Group
may	O
interfere	O
with	O
the	O
absorption	O
of	O
anticholinergic	B-Group
agents	I-Group
simultaneous	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O
      
CNS	O
-	O
Active	O
Drugs	O
Ethanol	B-Drug
An	O
additive	O
effect	O
on	O
psychomotor	O
performance	O
was	O
seen	O
with	O
coadministration	O
of	O
eszopiclone	B-Drug
and	O
ethanol	B-Drug
9	O
g	O
/	O
kg	O
for	O
up	O
to	O
9	O
hours	O
after	O
ethanol	B-Drug
administration	O
.	O
      
Because	O
warfarin	B-Drug
is	O
metabolized	O
by	O
CYP9C9	O
and	O
CYP9A9	O
patients	O
who	O
require	O
anticoagulation	O
should	O
receive	O
low	O
-	O
molecular	O
weight	O
or	O
standard	O
heparin	B-Drug
.	O
      
Laboratory	O
Tests	O
Response	O
to	O
Plenaxis	B-Brand
should	O
be	O
monitored	O
by	O
measuring	O
serum	O
total	O
testosterone	B-Drug
concentrations	O
just	O
prior	O
to	O
administration	O
on	O
Day	O
9	O
and	O
every	O
9	O
weeks	O
thereafter	O
.	O
      
Administration	O
of	O
phenytoin	B-Drug
to	O
patients	O
receiving	O
dopamine	B-Drug
HCl	I-Drug
has	O
been	O
reported	O
to	O
lead	O
to	O
hypotension	O
and	O
bradycardia	O
.	O
      
Drugs	O
That	O
Inhibit	O
Alprazolam	B-Drug
Metabolism	O
Via	O
Cytochrome	O
P9	O
9A	O
:	O
The	O
initial	O
step	O
in	O
alprazolam	B-Drug
metabolism	O
is	O
hydroxylation	O
catalyzed	O
by	O
cytochrome	O
P9	O
9A	O
(	O
CYP	O
9A	O
)	O
.	O
      
indinavir	B-Drug
concentration	O
      
The	O
drug	O
interaction	O
data	O
described	O
in	O
this	O
section	O
were	O
obtained	O
from	O
studies	O
involving	O
healthy	O
adults	O
and	O
adult	O
patients	O
with	O
epilepsy	O
.	O
      
The	O
pharmacodynamic	O
effects	O
can	O
be	O
explained	O
by	O
a	O
combination	O
of	O
the	O
increase	O
in	O
dofetilide	B-Drug
exposure	O
and	O
the	O
reductions	O
in	O
serum	O
potassium	O
.	O
      
During	O
co	O
-	O
administration	O
systemic	O
levels	O
of	O
TMP	B-Drug
and	O
SMX	B-Drug
were	O
essentially	O
unchanged	O
.	O
      
They	O
are	O
weak	O
inhibitors	O
of	O
CYP9C9	O
and	O
CYP9A9	O
and	O
mild	O
-	O
to	O
-	O
moderate	O
inhibitors	O
of	O
CYP9C9	O
at	O
therapeutic	O
concentrations	O
.	O
      
Clinical	O
interaction	O
studies	O
with	O
cimetidine	B-Drug
and	O
warfarin	B-Drug
indicated	O
that	O
the	O
coadministration	O
of	O
Femara	B-Brand
with	O
these	O
drugs	O
does	O
not	O
result	O
in	O
clinically	O
-	O
significant	O
drug	O
interactions	O
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
of	O
Aranesp	B-Brand
have	O
been	O
performed	O
.	O
      
Also	O
concomitant	O
administration	O
of	O
quinolones	B-Group
with	O
products	O
containing	O
iron	B-Drug
multivitamins	B-Group
containing	O
zinc	B-Drug
or	O
Videx	B-Brand
(	O
didanosine	B-Drug
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
may	O
result	O
in	O
low	O
urine	O
levels	O
.	O
      
(	O
Indomethacin	B-Drug
)	O
diuretics	B-Group
are	O
used	O
concomitantly	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-Group
is	O
obtained	O
.	O
      
There	O
is	O
no	O
information	O
available	O
from	O
adequate	O
drug	O
-	O
drug	O
interaction	O
studies	O
with	O
the	O
following	O
classes	O
of	O
drugs	O
:	O
oral	O
contraceptives	B-Group
hormone	O
replacement	O
therapies	O
hypoglycemics	B-Group
theophyllines	B-Drug
phenytoins	B-Drug
thiazide	B-Group
diuretics	I-Group
beta	B-Group
blockers	I-Group
and	O
calcium	B-Group
channel	I-Group
blockers	I-Group
.	O
      
There	O
have	O
been	O
rare	O
reports	O
of	O
reddish	O
stools	O
in	O
patients	O
who	O
have	O
received	O
cefdinir	B-Drug
in	O
Japan	O
.	O
      
Antacids	B-Group
:	O
Administration	O
of	O
flurbiprofen	B-Drug
to	O
volunteers	O
under	O
fasting	O
conditions	O
or	O
with	O
antacid	B-Group
suspension	O
yielded	O
similar	O
serum	O
flurbiprofen	B-Drug
time	O
profiles	O
in	O
young	O
subjects	O
(	O
n=9	O
)	O
.	O
      
Although	O
clinical	O
studies	O
have	O
not	O
been	O
performed	O
based	O
on	O
the	O
involvement	O
of	O
the	O
cytochrome	O
P	O
-	O
9	O
9A	O
family	O
in	O
clonazepam	B-Drug
metabolism	O
inhibitors	O
of	O
this	O
enzyme	O
system	O
notably	O
oral	O
antifungal	B-Group
agents	I-Group
should	O
be	O
used	O
cautiously	O
in	O
patients	O
receiving	O
clonazepam	B-Drug
.	O
      
Indinavir	B-Drug
steady	O
-	O
state	O
Cmax	O
A.C.	O
and	O
Cmin	O
were	O
decreased	O
by	O
9	O
%	O
9	O
%	O
and	O
9	O
%	O
respectively	O
by	O
concomitant	O
amprenavir	B-Drug
.	O
      
angioedema	O
      
Other	O
Antihypertensives	B-Group
:	O
When	O
MYKROX	B-Brand
Tablets	O
are	O
used	O
with	O
other	O
antihypertensive	B-Group
drugs	I-Group
care	O
must	O
be	O
taken	O
especially	O
during	O
initial	O
therapy	O
.	O
      
Grapefruit	O
may	O
also	O
increase	O
plasma	O
concentrations	O
of	O
SUTENT	B-Brand
.	O
      
Although	O
not	O
observed	O
in	O
this	O
study	O
adverse	O
effects	O
could	O
potentially	O
arise	O
from	O
co	O
-	O
administration	O
of	O
cephalexin	B-Drug
and	O
metformin	B-Drug
by	O
inhibition	O
of	O
tubular	O
secretion	O
via	O
organic	O
cationic	O
transporter	O
systems	O
.	O
      
Therefore	O
concurrent	O
use	O
of	O
aspirin	B-Brand
and	O
ketoprofen	B-Drug
is	O
not	O
recommended	O
.	O
      
increased	O
alkaline	O
      
Carbamazepine	B-Drug
:	O
Felbatol	B-Brand
causes	O
a	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
carbamazepine	B-Drug
plasma	O
concentrations	O
and	O
an	O
increase	O
in	O
the	O
steady	O
-	O
state	O
carbamazepine	B-Drug_n
epoxide	I-Drug_n
plasma	O
concentration	O
.	O
      
Since	O
there	O
is	O
a	O
high	O
degree	O
of	O
variability	O
in	O
the	O
bioavailability	O
of	O
verapamil	B-Drug
the	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unclear	O
.	O
      
In	O
addition	O
there	O
have	O
been	O
cases	O
reported	O
in	O
which	O
concomitant	O
use	O
of	O
amphotericin	B-Drug
B	I-Drug
and	O
hydrocortisone	B-Drug
was	O
followed	O
by	O
cardiac	O
enlargement	O
and	O
congestive	O
heart	O
failure	O
.	O
      
In	O
patients	O
receiving	O
coumarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
the	O
addition	O
of	O
Nalfon	B-Brand
to	O
therapy	O
could	O
prolong	O
the	O
prothrombin	O
time	O
.	O
      
With	O
oral	O
dapsone	B-Drug
treatment	O
folic	B-Group
acid	I-Group
antagonists	I-Group
such	O
as	O
pyrimethamine	B-Drug
have	O
been	O
noted	O
to	O
possibly	O
increase	O
the	O
likelihood	O
of	O
hematologic	O
reactions	O
      
Cardiac	O
effects	O
of	O
dopamine	B-Drug
are	O
antagonized	O
by	O
beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
such	O
as	O
propranolol	B-Drug
and	O
metoprolol	B-Drug
.	O
      
Renal	O
Impairment	O
There	O
are	O
currently	O
no	O
clinical	O
studies	O
with	O
SPRYCEL	B-Brand
in	O
patients	O
with	O
impaired	O
renal	O
function	O
(	O
clinical	O
studies	O
have	O
excluded	O
patients	O
with	O
serum	O
creatinine	O
concentration	O
9	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
)	O
.	O
      
Therefore	O
the	O
dose	O
of	O
methylprednisolone	B-Drug
should	O
be	O
titrated	O
to	O
avoid	O
steroid	O
toxicity	O
.	O
      
Concomitant	O
use	O
of	O
these	O
substances	O
should	O
be	O
avoided	O
.	O
      
Thiabendazole	B-Drug
may	O
compete	O
with	O
other	O
drugs	O
such	O
as	O
theophylline	B-Drug
for	O
sites	O
of	O
metabolism	O
in	O
the	O
liver	O
thus	O
elevating	O
the	O
serum	O
levels	O
of	O
such	O
compounds	O
to	O
potentially	O
toxic	O
levels	O
.	O
      
Methadone	B-Drug
levels	O
may	O
be	O
decreased	O
;	O
increased	O
dosages	O
may	O
be	O
required	O
to	O
prevent	O
symptoms	O
of	O
opiate	B-Group
withdrawal	O
.	O
Methadone	B-Drug
maintained	O
patients	O
beginning	O
nevirapine	B-Drug
therapy	O
should	O
be	O
monitored	O
forevidence	O
of	O
withdrawal	O
and	O
methadone	B-Drug
dose	O
should	O
be	O
adjusted	O
accordingly	O
.	O
      
Acetazolamide	B-Drug
and	O
sodium	B-Drug
bicarbonate	I-Drug
used	O
concurrently	O
increases	O
the	O
risk	O
of	O
renal	O
calculus	O
formation	O
.	O
      
However	O
this	O
sample	O
size	O
is	O
too	O
small	O
to	O
allow	O
for	O
any	O
conclusions	O
to	O
be	O
drawn	O
regarding	O
the	O
risk	O
of	O
rashes	O
with	O
concomitant	O
AUGMENTIN	B-Brand
XR	I-Brand
and	O
allopurinol	B-Drug
use	O
.	O
      
If	O
combination	O
therapy	O
is	O
needed	O
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
all	O
agents	O
to	O
be	O
used	O
.	O
      
Compounds	O
tested	O
in	O
man	O
include	O
warfarin	B-Drug
theophylline	B-Drug
phenytoin	B-Drug
diazepam	B-Drug
aminopyrine	B-Drug
and	O
antipyrine	B-Drug
.	O
      
When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
glipizide	B-Drug
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
loss	O
of	O
control	O
.	O
      
Approximately	O
9	O
/	O
9	O
of	O
the	O
patients	O
in	O
the	O
Phase	O
9	O
study	O
received	O
either	O
prophylactic	O
low	O
dose	O
heparin	B-Drug
(	O
unfractionated	B-Drug
heparin	I-Drug
up	O
to	O
9	O
9	O
units	O
/	O
day	O
)	O
or	O
prophylactic	O
doses	O
of	O
low	B-Group
molecular	I-Group
weight	I-Group
heparins	I-Group
as	O
indicated	O
in	O
the	O
prescribing	O
information	O
for	O
the	O
specific	O
products	O
.	O
      
Although	O
there	O
is	O
little	O
risk	O
for	O
loss	O
of	O
contraceptive	O
efficacy	O
the	O
clinical	O
significance	O
of	O
these	O
increased	O
exposures	O
in	O
terms	O
of	O
safety	O
is	O
not	O
known	O
.	O
      
.	O
      
Concomitant	O
use	O
of	O
SPRYCEL	B-Brand
and	O
drugs	O
that	O
inhibit	O
CYP9A9	O
(	O
eg	O
ketoconazole	B-Drug
itraconazole	B-Drug
erythromycin	B-Drug
clarithromycin	B-Drug
ritonavir	B-Drug
atazanavir	B-Drug
indinavir	B-Drug
nefazodone	B-Drug
nelfinavir	B-Drug
saquinavir	B-Drug
telithromycin	B-Drug
)	O
may	O
increase	O
exposure	O
to	O
dasatinib	B-Drug
and	O
should	O
be	O
avoided	O
.	O
      
The	O
concomitant	O
use	O
of	O
nitrofurantoin	B-Drug
is	O
not	O
recommended	O
since	O
nitrofurantoin	B-Drug
may	O
antagonize	O
the	O
antibacterial	O
effect	O
of	O
Norfloxacin	B-Drug
in	O
the	O
urinary	O
tract	O
.	O
      
Products	O
containing	O
calcium	B-Drug
and	O
other	O
multivalent	B-Drug
cations	I-Drug
likely	O
will	O
interfere	O
with	O
absorption	O
of	O
alendronate	B-Drug
.	O
      
Studies	O
showed	O
that	O
diltiazem	B-Drug
increased	O
the	O
AUC	O
of	O
midazolam	B-Drug
and	O
triazolam	B-Drug
by	O
9	O
-	O
9	O
fold	O
and	O
the	O
Cmax	O
by	O
9	O
-	O
fold	O
compared	O
to	O
placebo	O
.	O
      
No	O
clinically	O
relevant	O
interactions	O
with	O
drugs	O
metabolized	O
by	O
these	O
CYP	O
enzymes	O
would	O
be	O
expected	O
.	O
      
The	O
pharmacokinetic	O
interactions	O
listed	O
below	O
are	O
potentially	O
clinically	O
important	O
.	O
      
Digoxin	B-Drug
:	O
In	O
controlled	O
studies	O
in	O
healthy	O
volunteers	O
bepridil	B-Drug
hydrochloride	I-Drug
either	O
had	O
no	O
effect	O
(	O
one	O
study	O
)	O
or	O
was	O
associated	O
with	O
modest	O
increases	O
about	O
9	O
%	O
(	O
two	O
studies	O
)	O
in	O
steady	O
-	O
state	O
serum	O
digoxin	B-Drug
concentrations	O
.	O
      
Concomitant	O
treatment	O
with	O
NEXAVAR	B-Brand
resulted	O
in	O
a	O
9	O
%	O
increase	O
in	O
the	O
AUC	O
of	O
doxorubicin	B-Drug
.	O
      
Although	O
a	O
dose	O
adjustment	O
of	O
azithromycin	B-Drug
is	O
not	O
recommended	O
when	O
administered	O
in	O
combination	O
with	O
nelfinavir	B-Drug
close	O
monitoring	O
for	O
known	O
side	O
effects	O
of	O
azithromycin	B-Drug
such	O
as	O
liver	O
enzyme	O
abnormalities	O
and	O
hearing	O
impairment	O
is	O
warranted	O
.	O
      
Concomitant	O
treatment	O
with	O
thrombolytics	B-Group
(	O
eg	O
rt	O
-	O
PA	O
or	O
streptokinase	B-Drug
)	O
may	O
:	O
-	O
increase	O
the	O
risk	O
of	O
bleeding	O
complications	O
-	O
considerably	O
enhance	O
the	O
effect	O
of	O
REFLUDAN	B-Brand
on	O
aPTT	O
prolongation	O
      
In	O
these	O
studies	O
no	O
interaction	O
that	O
altered	O
the	O
pharmacokinetics	O
of	O
micafungin	B-Drug
was	O
observed	O
.	O
      
Warfarin	B-Drug
:	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
R	B-Drug
-	O
warfarin	I-Drug
or	O
S	B-Drug
-	O
warfarin	I-Drug
with	O
the	O
addition	O
of	O
tiagabine	B-Drug
given	O
as	O
a	O
single	O
dose	O
.	O
      
Concomitant	O
use	O
of	O
Isocarboxazid	B-Drug
and	O
other	O
psychotropic	B-Group
agents	I-Group
is	O
generally	O
not	O
recommended	O
because	O
of	O
possible	O
potentiating	O
effects	O
.	O
      
This	O
has	O
been	O
demonstrated	O
in	O
view	O
however	O
the	O
clinical	O
significance	O
of	O
this	O
interaction	O
is	O
not	O
well	O
documented	O
.	O
      
When	O
a	O
single	O
9	O
mg	O
dose	O
of	O
rimantadine	B-Drug
HCl	I-Drug
was	O
administered	O
one	O
hour	O
after	O
the	O
initiation	O
of	O
Cimetidine	B-Drug
(	O
9	O
mg	O
four	O
times	O
a	O
day	O
)	O
the	O
apparent	O
total	O
rimantadine	B-Drug
clearance	O
of	O
this	O
single	O
dose	O
in	O
normal	O
healthy	O
adults	O
was	O
reduced	O
by	O
9	O
%	O
(	O
compared	O
to	O
the	O
apparent	O
total	O
rimantadine	B-Drug
clearance	O
in	O
the	O
same	O
subjects	O
in	O
the	O
absence	O
of	O
cimetidine	B-Drug
)	O
.	O
      
In	O
situations	O
when	O
concurrent	O
therapy	O
is	O
necessary	O
careful	O
patient	O
monitoring	O
is	O
essential	O
.	O
      
These	O
agents	O
may	O
also	O
prolong	O
the	O
clinically	O
effective	O
duration	O
of	O
action	O
by	O
up	O
to	O
9	O
%	O
.	O
      
H9	B-Group
-	O
Receptor	I-Group
Antagonists	I-Group
:	O
Co	O
-	O
administration	O
of	O
a	O
single	O
dose	O
of	O
intravenously	O
administered	O
famotidine	B-Drug
(	O
9	O
mg	O
)	O
reduced	O
the	O
oral	O
absorption	O
of	O
a	O
single	O
9	O
mg	O
dose	O
of	O
cefditoren	B-Drug
pivoxil	I-Drug
administered	O
following	O
a	O
meal	O
as	O
evidenced	O
by	O
a	O
9	O
%	O
decrease	O
in	O
mean	O
Cmax	O
and	O
a	O
9	O
%	O
decrease	O
in	O
mean	O
AUC	O
.	O
      
A	O
possible	O
interaction	O
has	O
been	O
suggested	O
with	O
hormonal	B-Group
contraceptives	I-Group
and	O
the	O
herbal	O
supplement	O
St.	O
Johns	O
Wort	O
based	O
on	O
some	O
reports	O
of	O
oral	O
contraceptive	B-Group
users	O
experiencing	O
breakthrough	O
bleeding	O
shortly	O
after	O
starting	O
St.	O
Johns	O
Wort	O
.	O
      
Do	O
not	O
start	O
or	O
stop	O
any	O
medicine	O
without	O
doctor	O
or	O
pharmacist	O
approval	O
.	O
      
While	O
mean	O
INR	O
values	O
were	O
only	O
slightly	O
increased	O
with	O
coadministration	O
of	O
valdecoxib	B-Drug
the	O
day	O
-	O
to	O
-	O
day	O
variability	O
in	O
individual	O
INR	O
values	O
was	O
increased	O
.	O
      
Therefore	O
OMNICEF	B-Brand
for	O
Oral	O
Suspension	O
can	O
be	O
administered	O
with	O
iron	B-Drug_n
-	O
fortified	O
infant	O
formula	O
.	O
      
block	O
or	O
arrhythmia	O
.	O
      
The	O
effect	O
of	O
corticosteroids	B-Group
on	O
oral	O
anticoagulants	B-Group
is	O
variable	O
.	O
      
-	O
Anticoagulants	B-Group
:	O
Interaction	O
studies	O
in	O
humans	O
have	O
shown	O
bumetanide	B-Drug
to	O
have	O
no	O
effect	O
on	O
warfarin	B-Drug
metabolism	O
or	O
on	O
plasma	O
prothrombin	O
activity	O
.	O
      
.	O
      
Nevertheless	O
the	O
effects	O
of	O
Mefloquine	B-Drug
on	O
travelers	O
receiving	O
comedication	O
particularly	O
diabetics	O
or	O
patients	O
using	O
anticoagulants	B-Group
should	O
be	O
checked	O
before	O
departure	O
.	O
      
Since	O
entecavir	B-Drug
is	O
primarily	O
eliminated	O
by	O
the	O
kidneys	O
coadministration	O
of	O
BARACLUDE	B-Brand
with	O
drugs	O
that	O
reduce	O
renal	O
function	O
or	O
compete	O
for	O
active	O
tubular	O
secretion	O
may	O
increase	O
serum	O
concentrations	O
of	O
either	O
entecavir	B-Drug
or	O
the	O
coadministered	O
drug	O
.	O
      
If	O
concomitant	O
treatment	O
with	O
naratriptan	B-Drug
and	O
an	O
SSRI	B-Group
is	O
clinically	O
warranted	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O
      
Antihistamines	B-Group
may	O
partially	O
counteract	O
the	O
anticoagulation	O
effects	O
of	O
heparin	B-Drug
or	O
warfarin	B-Drug
.	O
      
Limited	O
published	O
data	O
indicate	O
that	O
GH	B-Drug
treatment	O
increases	O
cytochrome	O
P9	O
(	O
CP9	O
)	O
mediated	O
antipyrine	B-Drug
clearance	O
in	O
man	O
.	O
      
therefore	O
the	O
disposition	O
of	O
eszopiclone	B-Drug
is	O
not	O
expected	O
to	O
be	O
sensitive	O
to	O
alterations	O
in	O
protein	O
binding	O
.	O
      
Drugs	O
such	O
as	O
troleandomycin	B-Drug
and	O
ketoconazole	B-Drug
may	O
inhibit	O
the	O
metabolism	O
of	O
methylprednisolone	B-Drug
and	O
thus	O
decrease	O
its	O
clearance	O
.	O
      
Of	O
particular	O
importance	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	B-Drug
given	O
the	O
long	O
half	O
-	O
life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
9	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O
      
Patients	O
medicated	O
with	O
these	O
drugs	O
and	O
trimetrexate	B-Drug
should	O
be	O
carefully	O
monitored	O
.	O
      
aBased	O
on	O
reports	O
of	O
narcotic	O
withdrawal	O
syndrome	O
in	O
patients	O
treated	O
with	O
nevirapine	B-Drug
and	O
methadone	B-Drug
concurrently	O
and	O
evidence	O
of	O
decreased	O
plasma	O
concentrations	O
of	O
methadone	B-Drug
.	O
      
Other	O
interactions	O
:	O
Vardenafil	B-Drug
had	O
no	O
effect	O
on	O
the	O
pharmacodynamics	O
of	O
glyburide	B-Drug
(	O
glucose	O
and	O
insulin	O
concentrations	O
)	O
and	O
warfarin	B-Drug
(	O
prothrombin	O
time	O
or	O
other	O
pharmacodynamic	O
parameters	O
)	O
.	O
      
Special	O
consideration	O
should	O
be	O
given	O
to	O
the	O
administration	O
of	O
ETHYOL	B-Brand
in	O
patients	O
receiving	O
antihypertensive	B-Group
medications	I-Group
or	O
other	O
drugs	O
that	O
could	O
cause	O
or	O
potentiate	O
hypotension	O
.	O
      
Once	O
a	O
stable	O
prothrombin	O
time	O
has	O
been	O
documented	O
prothrombin	O
times	O
can	O
be	O
monitored	O
at	O
the	O
intervals	O
usually	O
recommended	O
for	O
patients	O
on	O
coumarin	B-Group
anticoagulants	I-Group
.	O
      
A	O
greater	O
potentiation	O
of	O
the	O
neuromuscular	O
blocking	O
effects	O
of	O
MIVACRON	B-Brand
may	O
be	O
expected	O
with	O
higher	O
concentrations	O
of	O
enflurane	B-Drug
or	O
isoflurane	B-Drug
.	O
      
Based	O
on	O
an	O
in	O
vitro	O
rat	O
liver	O
model	O
nitrogen	O
substituted	O
imidazole	B-Group
drugs	I-Group
(	O
clotrimazole	B-Drug
ketoconazole	B-Drug
miconazole	B-Drug
)	O
were	O
potent	O
non	O
-	O
competitive	O
inhibitors	O
of	O
trimetrexate	B-Drug
metabolism	O
.	O
      
.	O
      
Multivalent	O
Cation	O
-	O
Containing	O
Products	O
:	O
Concurrent	O
administration	O
of	O
a	O
quinolone	B-Group
including	O
ciprofloxacin	B-Drug
with	O
multivalent	O
cation	O
-	O
containing	O
products	O
such	O
as	O
magnesium	B-Drug
or	O
aluminum	B-Drug
antacids	B-Group
sucralfate	B-Drug
VIDEX	B-Brand
chewable	O
/	O
buffered	O
tablets	O
or	O
pediatric	O
powder	O
or	O
products	O
containing	O
calcium	B-Drug
iron	B-Drug
or	O
zinc	B-Drug
may	O
substantially	O
decrease	O
the	O
absorption	O
of	O
ciprofloxacin	B-Drug
resulting	O
in	O
serum	O
and	O
urine	O
levels	O
considerably	O
lower	O
than	O
desired	O
.	O
      
If	O
the	O
treatment	O
is	O
continued	O
these	O
patients	O
should	O
be	O
particularly	O
carefully	O
monitored	O
for	O
adverse	O
effects	O
especially	O
conduction	O
disturbances	O
and	O
exacerbation	O
of	O
tachyarrhythmias	O
as	O
amiodarone	B-Drug
is	O
continued	O
.	O
      
.	O
      
Neither	O
subject	O
demonstrated	O
clinical	O
evidence	O
of	O
allergic	O
or	O
anaphylactic	O
reactions	O
and	O
repeat	O
testing	O
was	O
not	O
performed	O
.	O
      
Oral	O
neomycin	B-Drug
sulfate	I-Drug
may	O
enhance	O
the	O
effect	O
of	O
coumarin	B-Group
in	O
anticoagulants	B-Group
by	O
decreasing	O
vitamin	O
K	O
availability	O
.	O
      
Thus	O
the	O
interaction	O
observed	O
between	O
erythromycin	B-Drug
and	O
terfenadine	B-Drug
is	O
not	O
expected	O
for	O
dirithromycin	B-Drug
.	O
      
For	O
patients	O
receiving	O
ketoconazole	B-Drug
or	O
other	O
potent	O
CYP9A9	O
inhibitors	O
such	O
as	O
other	O
azole	B-Group
antifungals	I-Group
(	O
eg	O
itraconazole	B-Drug
miconazole	B-Drug
)	O
or	O
macrolide	B-Group
antibiotics	I-Group
(	O
eg	O
erythromycin	B-Drug
clarithromycin	B-Drug
)	O
or	O
cyclosporine	B-Drug
or	O
vinblastine	B-Drug
the	O
recommended	O
dose	O
of	O
DETROL	B-Brand
LA	I-Brand
is	O
9	O
mg	O
daily	O
.	O
      
In	O
one	O
controlled	O
clinical	O
study	O
the	O
ureidopenicillins	O
including	O
piperacillin	B-Drug
were	O
reported	O
to	O
prolong	O
the	O
action	O
of	O
vecuronium	B-Drug
.	O
      
In	O
five	O
men	O
terfenadine	B-Drug
levels	O
were	O
undetectable	O
(	O
9	O
ng	O
/	O
mL	O
)	O
throughout	O
the	O
study	O
;	O
      
Avoid	O
the	O
use	O
of	O
preparations	O
such	O
as	O
decongestants	B-Group
and	O
local	O
anesthetics	B-Group
which	O
contain	O
any	O
sympathomimetic	B-Group
amine	I-Group
(	O
e.g.	O
epinephrine	B-Drug
norepinephrine	B-Drug
)	O
since	O
it	O
has	O
been	O
reported	O
that	O
tricyclic	B-Group
antidepressants	I-Group
can	O
potentiate	O
the	O
effects	O
of	O
catecholamines	O
.	O
      
Concurrent	O
use	O
of	O
phenothiazines	B-Group
may	O
antagonize	O
the	O
anorectic	O
effect	O
of	O
diethylpropion	B-Drug
.	O
      
In	O
the	O
absence	O
of	O
definitive	O
information	O
caution	O
should	O
be	O
used	O
when	O
coadministering	O
fluconazole	B-Drug
.	O
      
Therefore	O
precaution	O
should	O
be	O
taken	O
when	O
coadministration	O
is	O
necessary	O
.	O
      
Leucovorin	B-Drug
:	O
The	O
concentration	O
of	O
9	B-Drug
-	O
fluorouracil	I-Drug
is	O
increased	O
and	O
its	O
toxicity	O
may	O
be	O
enhanced	O
by	O
leucovorin	B-Drug
.	O
      
When	O
carbamazepine	B-Drug
is	O
added	O
to	O
aripiprazole	B-Drug
therapy	O
aripiprazole	B-Drug
dose	O
should	O
be	O
doubled	O
.	O
      
administration	O
9	O
hour	O
before	O
or	O
9	O
hours	O
after	O
colestipol	B-Drug
is	O
recommended	O
.	O
)	O
      
=	O
increase	O
;	O
      
Since	O
animal	O
studies	O
suggest	O
that	O
the	O
action	O
of	O
barbiturates	B-Group
may	O
be	O
prolonged	O
by	O
therapy	O
with	O
chlorpropamide	B-Drug
barbiturates	B-Group
should	O
be	O
employed	O
with	O
caution	O
.	O
      
The	O
potential	O
for	O
drug	O
-	O
drug	O
interaction	O
with	O
drugs	O
affected	O
by	O
cytochrome	O
P9	O
enzymes	O
may	O
not	O
be	O
ruled	O
out	O
.	O
      
therefore	O
the	O
disposition	O
of	O
zaleplon	B-Drug
is	O
not	O
expected	O
to	O
be	O
sensitive	O
to	O
alterations	O
in	O
protein	O
binding	O
.	O
      
In	O
addition	O
based	O
on	O
the	O
population	O
pharmacokinetics	O
analysis	O
of	O
the	O
combined	O
data	O
from	O
grapefruit	O
and	O
orange	O
juices	O
studies	O
with	O
the	O
data	O
from	O
a	O
bioequivalence	O
study	O
the	O
bioavailability	O
of	O
fexofenadine	B-Drug
was	O
reduced	O
by	O
9	O
%	O
.	O
      
Elevated	O
cyclosporine	B-Drug
serum	O
levels	O
have	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
quinolones	B-Group
and	O
cyclosporine	B-Drug
.	O
      
However	O
there	O
were	O
9	O
%	O
and	O
9	O
%	O
increases	O
in	O
the	O
AUC	O
and	O
Cmax	O
respectively	O
of	O
the	O
combined	O
moieties	O
of	O
threohydrobupropion	B-Drug_n
and	O
erythrohydrobupropion	B-Drug_n
.	O
      
The	O
effect	O
of	O
clofarabine	B-Drug
on	O
the	O
metabolism	O
of	O
cytochrome	O
p9	O
substrates	O
has	O
not	O
been	O
studied	O
.	O
      
Hypotension	O
Patients	O
on	O
Diuretic	B-Group
Therapy	O
:	O
Patients	O
on	O
diuretics	B-Group
and	O
especially	O
those	O
in	O
whom	O
diuretic	B-Group
therapy	O
was	O
recently	O
instituted	O
as	O
well	O
as	O
those	O
on	O
severe	O
dietary	O
salt	O
restriction	O
or	O
dialysis	O
may	O
occasionally	O
experience	O
a	O
precipitous	O
reduction	O
of	O
blood	O
pressure	O
usually	O
within	O
the	O
first	O
hour	O
after	O
receiving	O
the	O
initial	O
dose	O
of	O
captopril	B-Drug
.	O
      
Therefore	O
the	O
potential	O
exists	O
for	O
a	O
drug	O
interaction	O
between	O
WELLBUTRIN	B-Brand
and	O
drugs	O
that	O
affect	O
the	O
CYP9B9	O
isoenzyme	O
(	O
e.g.	O
orphenadrine	B-Drug
and	O
cyclophosphamide	B-Drug
)	O
.	O
      
The	O
concentrations	O
of	O
SN9	B-Drug_n
the	O
active	O
metabolite	O
of	O
irinotecan	B-Drug
were	O
on	O
average	O
9	O
%	O
higher	O
in	O
patients	O
receiving	O
bolus	O
-	O
IFL	O
in	O
combination	O
with	O
AVASTIN	B-Brand
when	O
compared	O
with	O
bolus	O
-	O
IFL	O
alone	O
.	O
      
Although	O
such	O
a	O
reaction	O
has	O
not	O
been	O
demonstrated	O
with	O
roxithromycin	B-Drug
concomitant	O
administration	O
of	O
roxithromycin	B-Drug
with	O
terfenadine	B-Drug
or	O
astemizole	B-Drug
is	O
not	O
recommended	O
.	O
      
9	O
%	O
      
Rare	O
cases	O
of	O
a	O
disulfiram	O
-	O
like	O
reaction	O
to	O
alcohol	B-Drug
have	O
been	O
reported	O
.	O
      
plasma	O
levels	O
of	O
several	O
closely	O
related	O
tricyclic	B-Group
antidepressants	I-Group
have	O
been	O
reported	O
to	O
be	O
increased	O
by	O
the	O
concomitant	O
administration	O
of	O
methylphenidate	B-Drug
or	O
hepatic	O
enzyme	O
inhibitors	O
(	O
e.g.	O
cimetidine	B-Drug
fluoxetine	B-Drug
)	O
and	O
decreased	O
by	O
the	O
concomitant	O
administration	O
of	O
hepatic	O
enzyme	O
inducers	O
(	O
e.g.	O
barbiturates	B-Group
phenytoin	B-Drug
)	O
and	O
such	O
an	O
effect	O
may	O
be	O
anticipated	O
with	O
CMI	B-Drug
as	O
well	O
.	O
      
Terfenadine	B-Drug
:	O
In	O
a	O
prospective	O
study	O
involving	O
six	O
-	O
healthy	O
-	O
male	O
volunteers	O
dirithromycin	B-Drug
did	O
not	O
affect	O
the	O
metabolism	O
of	O
terfenadine	B-Drug
.	O
      
The	O
AUC	O
of	O
ciprofloxacin	B-Drug
was	O
decreased	O
an	O
average	O
of	O
9	O
-	O
fold	O
in	O
9	O
healthy	O
subjects	O
given	O
ciprofloxacin	B-Drug
and	O
didanosine	B-Drug
-	O
placebo	O
tablets	O
concurrently	O
.	O
      
Antiarrhythmics	B-Group
:	O
amiodarone	B-Drug
      
Prednisone	B-Drug
/	O
prednisolone	B-Drug
:	O
Rofecoxib	B-Drug
did	O
not	O
have	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
prednisolone	B-Drug
or	O
prednisone	B-Drug
.	O
      
In	O
addition	O
a	O
decrease	O
in	O
PBI	O
and	O
radioactive	O
iodine	O
uptake	O
may	O
occur	O
.	O
      
Hypersensitivity	O
reactions	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
combination	O
regimens	O
containing	O
sequential	O
high	O
dose	O
PROLEUKIN	B-Brand
and	O
antineoplastic	B-Group
agents	I-Group
specifically	O
dacarbazine	B-Drug
cis	B-Drug
-	O
platinum	I-Drug
tamoxifen	B-Drug
and	O
interferon	B-Drug
-	O
alfa	I-Drug
.	O
      
Anastrozole	B-Drug
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
antipyrine	B-Drug
.	O
      
Fluvoxamine	B-Drug
increased	O
mean	O
alosetron	B-Drug
plasma	O
concentrations	O
(	O
AUC	O
)	O
approximately	O
9	O
-	O
fold	O
and	O
prolonged	O
the	O
half	O
-	O
life	O
by	O
approximately	O
9	O
-	O
fold	O
.	O
      
Therefore	O
concurrent	O
use	O
of	O
Trileptal	B-Brand
with	O
hormonal	B-Group
contraceptives	I-Group
may	O
render	O
these	O
contraceptives	B-Group
less	O
effective	O
.	O
      
Quinolone	B-Group
Antibiotics	I-Group
:	O
VIDEX	B-Brand
should	O
be	O
administered	O
at	O
least	O
9	O
hours	O
after	O
or	O
9	O
hours	O
before	O
dosing	O
with	O
ciprofloxacin	B-Drug
because	O
plasma	O
concentrations	O
of	O
ciprofloxacin	B-Drug
are	O
decreased	O
when	O
administered	O
with	O
antacids	B-Group
containing	O
magnesium	B-Drug
calcium	B-Drug
or	O
aluminum	B-Drug
.	O
      
These	O
are	O
described	O
in	O
greater	O
detail	O
below	O
:	O
DIFLUCAN	B-Brand
and	O
the	O
following	O
agents	O
/	O
classes	O
have	O
been	O
observed	O
.	O
      
Ritonavir	B-Drug
-	O
Combined	O
administration	O
of	O
a	O
single	O
dose	O
of	O
ritonavir	B-Drug
(	O
9	O
mg	O
)	O
both	O
a	O
CYP9A9	O
substrate	O
and	O
a	O
potent	O
inhibitor	O
of	O
CYP9A9	O
and	O
escitalopram	B-Drug
(	O
9	O
mg	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
ritonavir	B-Drug
or	O
escitalopram	B-Drug
.	O
      
Amprenavir	B-Drug
      
When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
MICRONASE	B-Brand
the	O
patient	O
should	O
be	O
closely	O
observed	O
for	O
loss	O
of	O
control	O
.	O
      
The	O
second	O
pregnancy	O
test	O
(	O
a	O
confirmation	O
test	O
)	O
should	O
be	O
done	O
during	O
the	O
first	O
9	O
days	O
of	O
the	O
menstrual	O
period	O
immediately	O
preceding	O
the	O
beginning	O
of	O
Accutane	B-Brand
therapy	O
.	O
      
Because	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
oral	O
miconazole	B-Drug
(	O
an	O
imidazole	B-Group
)	O
and	O
oral	O
hypoglycemic	B-Group
agents	I-Group
such	O
a	O
potential	O
interaction	O
involving	O
the	O
latter	O
agents	O
when	O
used	O
concomitantly	O
with	O
ketoconazole	B-Drug
tablets	O
(	O
an	O
imidazole	B-Group
)	O
can	O
not	O
be	O
ruled	O
out	O
.	O
      
Itraconazole	B-Drug
      
Concomitant	O
Crohn	O
disease	O
medications	O
were	O
antibiotics	B-Group
antivirals	B-Group
corticosteroids	B-Group
9	B-Drug
-	O
MP	I-Drug
/	O
AZA	B-Drug
and	O
aminosalicylates	O
.	O
      
Fluvoxamine	B-Drug
has	O
also	O
been	O
shown	O
to	O
inhibit	O
P9	O
9A9	O
an	O
isoform	O
also	O
involved	O
in	O
TCA	B-Group
metabolism	O
.	O
      
Acute	O
symptoms	O
should	O
be	O
treated	O
with	O
a	O
short	O
-	O
acting	O
inhaled	O
beta9	B-Group
-	O
agonist	I-Group
such	O
as	O
salbutamol	B-Drug
(	O
the	O
physician	O
should	O
provide	O
the	O
patient	O
with	O
such	O
medication	O
and	O
instruct	O
the	O
patient	O
in	O
how	O
it	O
should	O
be	O
used	O
)	O
.	O
      
.	O
      
The	O
mean	O
minimum	O
lithium	B-Drug
concentration	O
increased	O
9	O
%	O
and	O
the	O
renal	O
clearance	O
of	O
lithium	B-Drug
was	O
decreased	O
by	O
9	O
%	O
during	O
this	O
period	O
of	O
concomitant	O
drug	O
administration	O
.	O
      
Erythromycin	B-Drug
has	O
been	O
reported	O
to	O
decrease	O
the	O
clearance	O
of	O
triazolam	B-Drug
and	O
midazolam	B-Drug
and	O
thus	O
may	O
increase	O
the	O
pharmacologic	O
effect	O
of	O
these	O
benzodiazepines	B-Group
.	O
      
Usually	O
this	O
has	O
been	O
observed	O
in	O
patients	O
with	O
a	O
history	O
of	O
diabetes	O
mellitus	O
or	O
evidence	O
of	O
glucose	O
intolerance	O
prior	O
to	O
administration	O
of	O
CAMPTOSAR	B-Brand
.	O
      
Acetaminophen	B-Drug
and	O
methotrexate	B-Drug
-	O
L	B-Drug
-	O
methionine	I-Drug
may	O
decrease	O
hepatic	O
toxicity	O
in	O
those	O
with	O
acetaminophen	B-Drug
overdosage	O
or	O
in	O
those	O
taking	O
methotrexate	B-Drug
.	O
      
In	O
vitro	O
studies	O
have	O
shown	O
succimer	B-Drug
to	O
cause	O
false	O
positive	O
results	O
for	O
ketones	O
in	O
urine	O
using	O
nitroprusside	O
reagents	O
such	O
as	O
Ketostix	O
and	O
falsely	O
decreased	O
measurements	O
of	O
serum	O
uric	O
acid	O
and	O
CPK	O
.	O
      
Caution	O
is	O
advised	O
if	O
patients	O
receive	O
large	O
doses	O
of	O
ethchlorvynol	B-Drug
concurrently	O
.	O
      
The	O
plasma	O
concentration	O
of	O
imipramine	B-Drug
may	O
increase	O
when	O
the	O
drug	O
is	O
given	O
concomitantly	O
with	O
hepatic	O
enzyme	O
inhibitors	O
(	O
e.g.	O
cimetidine	B-Drug
fluoxetine	B-Drug
)	O
and	O
decrease	O
by	O
concomitant	O
administration	O
of	O
hepatic	O
enzyme	O
inducers	O
(	O
e.g.	O
barbiturates	B-Group
phenytoin	B-Drug
)	O
and	O
adjustment	O
of	O
the	O
dosage	O
of	O
imipramine	B-Drug
may	O
therefore	O
be	O
necessary	O
.	O
      
The	O
clinical	O
significance	O
of	O
these	O
findings	O
is	O
unknown	O
.	O
      
In	O
some	O
patients	O
the	O
combined	O
use	O
of	O
indomethacin	B-Drug
and	O
diflunisal	B-Drug
has	O
been	O
associated	O
with	O
fatal	O
gastrointestinal	O
hemorrhage	O
.	O
      
Antimycobacterial	B-Group
:	O
rifampin	B-Drug
      
In	O
a	O
pharmacokinetic	O
study	O
9	O
healthy	O
female	O
subjects	O
received	O
ketoconazole	B-Drug
9	O
mg	O
twice	O
daily	O
for	O
9	O
days	O
with	O
coadministration	O
of	O
alosetron	B-Drug
9	O
mg	O
on	O
the	O
last	O
day	O
.	O
      
The	O
magnitude	O
of	O
interaction	O
within	O
the	O
recommended	O
dose	O
ranges	O
of	O
either	O
drug	O
is	O
not	O
known	O
.	O
      
In	O
the	O
case	O
that	O
you	O
are	O
taking	O
digoxin	B-Drug
while	O
taking	O
aminosalicylic	B-Drug
acid	I-Drug
higher	O
doses	O
of	O
digoxin	B-Drug
may	O
be	O
needed	O
.	O
      
Anti	B-Group
-	O
arrhythmics	I-Group
and	O
tricyclic	B-Group
anti	I-Group
-	O
depressants	I-Group
could	O
exaggerate	O
the	O
prolongation	O
of	O
the	O
QT	O
interval	O
observed	O
with	O
bepridil	B-Drug
hydrochloride	I-Drug
.	O
      
The	O
rate	O
and	O
extent	O
of	O
perindopril	B-Drug
absorption	O
and	O
elimination	O
are	O
not	O
affected	O
by	O
concomitant	O
diuretics	B-Group
.	O
      
Caution	O
should	O
be	O
exercised	O
when	O
imipramine	B-Drug
hydrochloride	I-Drug
is	O
used	O
with	O
agents	O
that	O
lower	O
blood	O
pressure	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Cephalosporins	B-Group
are	O
known	O
to	O
occasionally	O
induce	O
a	O
positive	O
direct	O
Coombs	O
test	O
.	O
      
Cerubidine	B-Brand
should	O
not	O
be	O
used	O
in	O
patients	O
who	O
have	O
previously	O
received	O
the	O
recommended	O
maximum	O
cumulative	O
doses	O
of	O
doxorubicin	B-Drug
or	O
Cerubidine	B-Brand
.	O
      
Acetazolamide	B-Drug
:	O
Concurrent	O
use	O
of	O
acetazolamide	B-Drug
and	O
procaine	B-Drug
hydrochloride	I-Drug
may	O
extend	O
the	O
plasma	O
half	O
-	O
life	O
of	O
procaine	B-Drug
.	O
      
urticaria	O
      
Other	O
nephrotoxic	O
medications	O
:	O
agents	O
such	O
as	O
aminoglycosides	B-Group
cyclosporine	B-Drug
and	O
pentamidine	B-Drug
may	O
enhance	O
the	O
potential	O
for	O
drug	O
-	O
induced	O
renal	O
toxicity	O
and	O
should	O
be	O
used	O
concomitantly	O
only	O
with	O
great	O
caution	O
.	O
      
In	O
vitro	O
studies	O
with	O
human	O
liver	O
microsomes	O
showed	O
that	O
terbinafine	B-Drug
does	O
not	O
inhibit	O
the	O
metabolism	O
of	O
tolbutamide	B-Drug
ethinylestradiol	B-Drug
ethoxycoumarin	B-Drug_n
and	O
cyclosporine	B-Drug
.	O
      
Patients	O
treated	O
with	O
Nalfon	B-Brand
may	O
be	O
resistant	O
to	O
the	O
effects	O
of	O
loop	B-Group
diuretics	I-Group
.	O
      
Inhibition	O
of	O
metabolism	O
may	O
produce	O
significant	O
increases	O
in	O
circulating	O
phenytoin	B-Drug
concentrations	O
and	O
enhance	O
the	O
risk	O
of	O
drug	O
toxicity	O
.	O
      
Systemic	O
clonidine	B-Drug
may	O
inhibit	O
the	O
production	O
of	O
catecholamines	O
in	O
response	O
to	O
insulin	O
-	O
induced	O
hypoglycemia	O
and	O
mask	O
the	O
signs	O
and	O
symptoms	O
of	O
hypoglycemia	O
.	O
      
-	O
did	O
not	O
change	O
the	O
plasma	O
concentration	O
profile	O
of	O
terfenadine	B-Drug
(	O
a	O
substrate	O
of	O
cytochrome	O
P9	O
9A9	O
)	O
or	O
fexofenadine	B-Drug
its	O
carboxylated	O
metabolite	O
and	O
did	O
not	O
prolong	O
the	O
QTc	O
interval	O
following	O
co	O
-	O
administration	O
with	O
terfenadine	B-Drug
9	O
mg	O
twice	O
daily	O
.	O
      
The	O
onset	O
of	O
neuromuscular	O
blockade	O
by	O
succinylcholine	B-Drug
was	O
unaffected	O
by	O
BREVIBLOC	B-Brand
but	O
the	O
duration	O
of	O
neuromuscular	O
blockade	O
was	O
prolonged	O
from	O
9	O
minutes	O
to	O
9	O
minutes	O
.	O
      
Drugs	O
that	O
induce	O
hepatic	O
enzymes	O
such	O
as	O
phenobarbital	B-Drug
phenytoin	B-Drug
and	O
rifampin	B-Drug
may	O
increase	O
the	O
clearance	O
of	O
corticosteroids	B-Group
and	O
may	O
require	O
increases	O
in	O
corticosteroid	B-Group
dose	O
to	O
achieve	O
the	O
desired	O
response	O
.	O
      
Agents	O
with	O
Increased	O
Levels	O
in	O
the	O
Presence	O
of	O
Carbamazepine	B-Drug
:	O
EQUETROTM	B-Brand
increases	O
the	O
plasma	O
levels	O
of	O
the	O
following	O
agents	O
:	O
Clomipramine	B-Drug
HCl	I-Drug
Phenytoin	B-Drug
(	O
9	O
)	O
and	O
primidone	B-Drug
Thus	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
one	O
of	O
the	O
agents	O
in	O
this	O
category	O
and	O
then	O
begins	O
a	O
course	O
of	O
the	O
treatment	O
with	O
EQUETROTM	B-Brand
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
decrease	O
for	O
the	O
concomitant	O
agent	O
may	O
be	O
necessary	O
.	O
      
Fenbufen	B-Drug
is	O
not	O
approved	O
in	O
the	O
United	O
States	O
at	O
this	O
time	O
.	O
      
Drugs	O
that	O
may	O
decrease	O
dasatinib	B-Drug
plasma	O
concentrations	O
CYP9A9	O
Inducers	O
:	O
Drugs	O
that	O
induce	O
CYP9A9	O
activity	O
may	O
decrease	O
dasatinib	B-Drug
plasma	O
concentrations	O
.	O
      
Therefore	O
it	O
is	O
recommended	O
that	O
oral	O
contraceptives	B-Group
are	O
co	O
-	O
administered	O
with	O
Myfortic	B-Brand
with	O
caution	O
and	O
additional	O
birth	O
control	O
methods	O
be	O
considered	O
.	O
      
Disulfiram	B-Drug
appears	O
to	O
decrease	O
the	O
rate	O
at	O
which	O
certain	O
drugs	O
are	O
metabolized	O
and	O
therefore	O
may	O
increase	O
the	O
blood	O
levels	O
and	O
the	O
possibility	O
of	O
clinical	O
toxicity	O
of	O
drugs	O
given	O
concomitantly	O
.	O
      
As	O
with	O
other	O
drugs	O
that	O
block	O
angiotensin	O
II	O
or	O
its	O
effects	O
concomitant	O
use	O
of	O
potassium	B-Group
-	O
sparing	I-Group
diuretics	I-Group
(	O
e.g.	O
spironolactone	B-Drug
triamterene	B-Drug
amiloride	B-Drug
)	O
potassium	B-Drug
supplements	O
or	O
salt	O
substitutes	O
containing	O
potassium	O
may	O
lead	O
to	O
increases	O
in	O
serum	O
potassium	O
.	O
      
When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
DIABINESE	B-Brand
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O
      
Therefore	O
co	O
-	O
administration	O
of	O
clozapine	B-Drug
with	O
other	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isozyme	O
including	O
antidepressants	B-Group
phenothiazines	B-Group
carbamazepine	B-Drug
and	O
Type	B-Group
9C	I-Group
antiarrhythmics	I-Group
(	O
e.g.	O
propafenone	B-Drug
flecainide	B-Drug
and	O
encainide	B-Drug
)	O
or	O
that	O
inhibit	O
this	O
enzyme	O
(	O
e.g.	O
quinidine	B-Drug
)	O
should	O
be	O
approached	O
with	O
caution	O
.	O
      
ARAMINE	B-Brand
should	O
be	O
used	O
with	O
caution	O
in	O
digitalized	O
patients	O
since	O
the	O
combination	O
of	O
digitalis	B-Group
and	O
sympathomimetic	B-Group
amines	I-Group
may	O
cause	O
ectopic	O
arrhythmias	O
.	O
      
Downward	O
dosage	O
adjustments	O
of	O
these	O
drugs	O
may	O
be	O
required	O
when	O
given	O
concomitantly	O
with	O
Ritalin	B-Brand
.	O
      
As	O
with	O
other	O
drugs	O
the	O
potential	O
for	O
interaction	O
by	O
a	O
variety	O
of	O
mechanisms	O
(	O
e.g.	O
pharmacodynamic	O
pharmacokinetic	O
inhibition	O
or	O
enhancement	O
etc	O
.	O
)	O
      
this	O
phenomenon	O
was	O
not	O
observed	O
in	O
North	O
American	O
clinical	O
trials	O
.	O
      
9HT9	B-Group
Antagonists	I-Group
:	O
Based	O
on	O
reports	O
of	O
profound	O
hypotension	O
and	O
loss	O
of	O
consciousness	O
when	O
apomorphine	B-Drug
was	O
administered	O
with	O
ondansetron	B-Drug
the	O
concomitant	O
use	O
of	O
apomorphine	B-Drug
with	O
drugs	O
of	O
the	O
9HT9	B-Group
antagonist	I-Group
class	I-Group
(	O
including	O
for	O
example	O
ondansetron	B-Drug
granisetron	B-Drug
dolasetron	B-Drug
palonosetron	B-Drug
and	O
alosetron	B-Drug
)	O
is	O
contraindicated	O
.	O
      
The	O
effects	O
of	O
coadministration	O
of	O
BARACLUDE	B-Brand
with	O
other	O
drugs	O
that	O
are	O
renally	O
eliminated	O
or	O
are	O
known	O
to	O
affect	O
renal	O
function	O
have	O
not	O
been	O
evaluated	O
and	O
patients	O
should	O
be	O
monitored	O
closely	O
for	O
adverse	O
events	O
when	O
BARACLUDE	B-Brand
is	O
coadministered	O
with	O
such	O
drugs	O
.	O
      
However	O
current	O
evidence	O
suggests	O
that	O
isoniazid	B-Drug
does	O
induce	O
P	O
-	O
9IIE9	O
a	O
mixed	O
-	O
function	O
oxidase	O
enzyme	O
that	O
appears	O
to	O
generate	O
the	O
toxic	O
metabolites	O
in	O
the	O
liver	O
.	O
      
Benzthiazide	B-Drug
may	O
interact	O
with	O
alcohol	B-Drug
blood	B-Group
thinners	I-Group
decongestant	B-Group
drugs	I-Group
(	O
allergy	O
cold	O
and	O
sinus	O
medicines	O
)	O
diabetic	O
drugs	O
lithium	B-Drug
norepinephrine	B-Drug
NSAIDs	B-Group
like	O
Aleve	B-Brand
or	O
Ibuprofen	B-Drug
and	O
high	O
blood	O
pressure	O
medications	O
.	O
      
cimetidine	B-Drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P9	O
9D9	O
(	O
many	O
other	O
antidepressants	B-Group
phenothiazines	B-Group
and	O
the	O
Type	B-Group
9C	I-Group
antiarrhythmics	I-Group
propafenone	B-Drug
and	O
flecainide	B-Drug
)	O
.	O
      
Increases	O
in	O
plasma	O
levels	O
of	O
tricyclic	B-Drug
antidepressants	I-Drug
and	O
in	O
the	O
frequency	O
and	O
severity	O
of	O
side	O
effects	O
particularly	O
anticholinergic	B-Drug
have	O
been	O
reported	O
when	O
cimetidine	B-Drug
was	O
added	O
to	O
the	O
drug	B-Drug
regimen	O
.	O
      
Phenytoin	B-Drug
phenobarbital	B-Drug
and	O
carbamazepine	B-Drug
are	O
ge	O
nerally	O
classified	O
as	O
enzyme	O
inducers	O
;	O
      
Tetracyclines	B-Group
:	O
Since	O
both	O
acitretin	B-Drug
and	O
tetracyclines	B-Group
can	O
cause	O
increased	O
intracranial	O
pressure	O
their	O
combined	O
use	O
is	O
contraindicated	O
.	O
      
When	O
DIFLUCAN	B-Brand
is	O
used	O
concomitantly	O
with	O
these	O
or	O
other	O
sulfonylurea	B-Group
oral	I-Group
hypoglycemic	I-Group
agents	I-Group
blood	O
glucose	O
concentrations	O
should	O
be	O
carefully	O
monitored	O
and	O
the	O
dose	O
of	O
the	O
sulfonylurea	B-Group
should	O
be	O
adjusted	O
as	O
necessary	O
.	O
      
ranitidine	B-Drug
*	O
;	O
      
Zidovudine	B-Drug
:	O
There	O
is	O
no	O
significant	O
pharmacokinetic	O
interaction	O
between	O
ZDV	B-Drug
and	O
zalcitabine	B-Drug
which	O
has	O
been	O
confirmed	O
clinically	O
.	O
      
In	O
a	O
pharmacokinetic	O
study	O
9	O
healthy	O
female	O
subjects	O
received	O
fluvoxamine	B-Drug
in	O
escalating	O
doses	O
from	O
9	O
to	O
9	O
mg	O
per	O
day	O
for	O
9	O
days	O
with	O
coadministration	O
of	O
alosetron	B-Drug
9	O
mg	O
on	O
the	O
last	O
day	O
.	O
      
Beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
may	O
also	O
interact	O
with	O
sympathomimetics	B-Group
.	O
      
Results	O
demonstrate	O
that	O
oxcarbazepine	B-Drug
and	O
its	O
pharmacologically	O
active	O
9	O
-	O
monohydroxy	O
metabolite	O
(	O
MHD	B-Drug_n
)	O
have	O
little	O
or	O
no	O
capacity	O
to	O
function	O
as	O
inhibitors	O
for	O
most	O
of	O
the	O
human	O
cytochrome	O
P9	O
enzymes	O
evaluated	O
(	O
CYP9A9	O
CYP9A9	O
CYP9C9	O
CYP9D9	O
CYP9E9	O
CYP9A9	O
and	O
CYP9A9	O
)	O
with	O
the	O
exception	O
of	O
CYP9C9	O
and	O
CYP9A9	O
/	O
9	O
.	O
      
9	O
.	O
      
Both	O
groups	O
of	O
agents	O
increase	O
blood	O
levels	O
and	O
therefore	O
potentiate	O
the	O
actions	O
of	O
amphetamines	B-Group
.	O
      
Fluconazole	B-Drug
      
(	O
See	O
CLINICAL	O
PHARMACOLOGY	O
)	O
Coadministration	O
of	O
Femara	B-Brand
and	O
tamoxifen	B-Drug
9	O
mg	O
daily	O
resulted	O
in	O
a	O
reduction	O
of	O
letrozole	B-Drug
plasma	O
levels	O
by	O
9	O
%	O
on	O
average	O
.	O
      
The	O
carcinogenic	O
potential	O
of	O
ribavirin	B-Drug
has	O
not	O
been	O
fully	O
determined	O
.	O
      
Anticoagulants	B-Group
:	O
There	O
have	O
been	O
reports	O
of	O
increased	O
anticoagulant	O
effects	O
when	O
erythromycin	B-Drug
and	O
oral	O
anticoagulants	B-Group
were	O
used	O
concomitantly	O
.	O
      
The	O
mean	O
minimum	O
lithium	B-Drug
concentration	O
increased	O
9	O
%	O
and	O
the	O
renal	O
clearance	O
was	O
decreased	O
by	O
approximately	O
9	O
%	O
.	O
      
Although	O
this	O
has	O
not	O
occurred	O
in	O
in	O
vitro	O
studies	O
with	O
coumarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
interactions	O
with	O
coumarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
have	O
been	O
reported	O
with	O
FELDENE	B-Brand
since	O
marketing	O
therefore	O
physicians	O
should	O
closely	O
monitor	O
patients	O
for	O
a	O
change	O
in	O
dosage	O
requirements	O
when	O
administering	O
FELDENE	B-Brand
to	O
patients	O
on	O
coumarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
and	O
other	O
highly	O
protein	O
-	O
bound	O
drugs	O
.	O
      
The	O
risk	O
of	O
hypoglycemia	O
secondary	O
to	O
this	O
mechanism	O
may	O
be	O
increased	O
if	O
allopurinol	B-Drug
and	O
chlorpropamide	B-Drug
are	O
given	O
concomitantly	O
in	O
the	O
presence	O
of	O
renal	O
insufficiency	O
.	O
      
Amphetamines	B-Group
may	O
enhance	O
the	O
effects	O
of	O
tricyclic	B-Group
antidepressants	I-Group
.	O
      
Drug	O
Name	O
      
Ingestion	O
of	O
diclofenac	B-Drug
may	O
increase	O
serum	O
concentrations	O
of	O
digoxin	B-Drug
and	O
methotrexate	B-Drug
and	O
increase	O
cyclosporine	B-Drug
nephrotoxicity	O
.	O
      
Such	O
agents	O
must	O
be	O
discontinued	O
at	O
least	O
seven	O
days	O
prior	O
to	O
starting	O
therapy	O
with	O
VISTIDE	B-Brand
.	O
      
In	O
addition	O
certain	O
drugs	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
.	O
      
-	O
Vitamin	B-Group
K	I-Group
(	O
e.g.	O
AquaMEPHYTON	B-Brand
Synkayvite	B-Brand
)	O
Use	O
of	O
sulfapyridine	B-Drug
with	O
these	O
medicines	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
blood	O
      
Streptozocin	B-Drug
has	O
been	O
reported	O
to	O
prolong	O
the	O
elimination	O
half	O
-	O
life	O
of	O
doxorubicin	B-Drug
and	O
may	O
lead	O
to	O
severe	O
bone	O
marrow	O
suppression	O
;	O
      
In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
suggest	O
that	O
decitabine	B-Drug
is	O
unlikely	O
to	O
inhibit	O
or	O
induce	O
cytochrome	O
P9	O
enzymes	O
.	O
      
Lovastatin	B-Drug
therapy	O
has	O
not	O
been	O
associated	O
with	O
bleeding	O
or	O
with	O
changes	O
in	O
prothrombin	O
time	O
in	O
patients	O
not	O
taking	O
anticoagulants	B-Group
.	O
      
-	O
The	O
action	O
of	O
sulphonylureas	B-Group
and	O
insulin	B-Drug
may	O
be	O
enhanced	O
by	O
Bezalip	B-Brand
or	O
Bezalip	B-Brand
retard	I-Brand
.	O
      
Concurrent	O
administration	O
of	O
cimetidine	B-Drug
and	O
Mexitil	B-Brand
has	O
been	O
reported	O
to	O
increase	O
decrease	O
or	O
leave	O
unchanged	O
Mexitil	B-Brand
plasma	O
levels	O
;	O
      
When	O
indinavir	B-Drug
at	O
an	O
increased	O
dose	O
(	O
9	O
mg	O
every	O
9	O
hours	O
)	O
was	O
given	O
with	O
SUSTIVA	B-Brand
(	O
9	O
mg	O
once	O
daily	O
)	O
the	O
indinavir	B-Drug
AUC	O
and	O
Cmin	O
were	O
decreased	O
on	O
average	O
by	O
9	O
-	O
9	O
%	O
and	O
9	O
-	O
9	O
%	O
respectively	O
compared	O
to	O
when	O
indinavir	B-Drug
(	O
9	O
mg	O
every	O
9	O
hours	O
)	O
was	O
given	O
alone	O
.	O
      
Concomitant	O
use	O
of	O
HIVID	B-Drug
with	O
didanosine	B-Drug
is	O
not	O
recommended	O
.	O
      
Other	O
quinolones	B-Group
have	O
demonstrated	O
moderate	O
to	O
marked	O
interference	O
with	O
the	O
metabolism	O
of	O
caffeine	B-Drug
resulting	O
in	O
a	O
reduced	O
clearance	O
a	O
prolongation	O
of	O
plasma	O
half	O
-	O
life	O
and	O
an	O
increase	O
in	O
symptoms	O
that	O
accompany	O
high	O
levels	O
of	O
caffeine	B-Drug
.	O
      
Drug	O
-	O
Laboratory	O
-	O
Test	O
Interactions	O
Interactions	O
between	O
Sanctura	B-Brand
and	O
laboratory	O
tests	O
have	O
not	O
been	O
studied	O
.	O
      
Phospholine	B-Drug
Iodide	I-Drug
potentiates	O
other	O
cholinesterase	B-Group
inhibitors	I-Group
such	O
as	O
succinylcholine	B-Drug
or	O
organophosphate	B-Drug_n
and	O
carbamate	B-Drug_n
insecticide	I-Drug_n
.	O
      
Ketoconazole	B-Drug
:	O
Spontaneous	O
adverse	O
reaction	O
reports	O
of	O
patients	O
taking	O
concomitant	O
ketoconazole	B-Drug
with	O
recommended	O
doses	O
of	O
terfenadine	B-Drug
demonstrate	O
QT	O
interval	O
prolongation	O
and	O
rare	O
serious	O
cardiac	O
events	O
e.g	O
.	O
      
There	O
have	O
been	O
no	O
formal	O
studies	O
of	O
the	O
interaction	O
of	O
LEVULAN	B-Brand
KERASTICK	I-Brand
for	O
Topical	O
Solution	O
with	O
any	O
other	O
drugs	O
and	O
no	O
drug	O
-	O
specific	O
interactions	O
were	O
noted	O
during	O
any	O
of	O
the	O
controlled	O
clinical	O
trials	O
.	O
      
Corticosteroids	B-Group
or	O
ACTH	B-Drug
:	O
May	O
increase	O
the	O
risk	O
of	O
hypokalemia	O
and	O
increase	O
salt	O
and	O
water	O
retention	O
.	O
      
-	O
Although	O
not	O
a	O
true	O
drug	O
interaction	O
tricyclic	B-Group
antidepressants	I-Group
may	O
precipitate	O
seizures	O
in	O
susceptible	O
patients	O
and	O
Cerebyx	B-Brand
dosage	O
may	O
need	O
to	O
be	O
adjusted	O
      
Certain	O
concomitant	O
medications	O
(	O
such	O
as	O
rifampin	B-Drug
anticonvulsants	B-Group
St	O
.	O
      
Aminophylline	B-Drug
Etomidate	B-Drug
antagonism	O
      
In	O
uninfected	O
volunteers	O
9	O
%	O
developed	O
rash	O
while	O
receiving	O
SUSTIVA	B-Brand
and	O
clarithromycin	B-Drug
.	O
      
Edema	O
has	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
Itraconazole	B-Drug
and	O
dihydropyridine	B-Group
calcium	I-Group
channel	I-Group
blockers	I-Group
.	O
      
Pharmacokinetic	O
-	O
related	O
Interactions	O
:	O
Clozapine	B-Drug
is	O
a	O
substrate	O
for	O
many	O
CYP	O
9	O
isozymes	O
in	O
particular	O
9A9	O
9D9	O
and	O
9A9	O
.	O
      
Cardiovascular	O
:	O
Hypotension	O
(	O
9	O
-	O
9	O
%	O
)	O
.	O
      
Concurrent	O
use	O
of	O
butorphanol	B-Drug
with	O
central	B-Group
nervous	I-Group
system	I-Group
depressants	I-Group
(	O
e.g.	O
alcohol	B-Drug
barbiturates	B-Group
tranquilizers	B-Group
and	O
antihistamines	B-Group
)	O
may	O
result	O
in	O
increased	O
central	B-Group
nervous	I-Group
system	I-Group
depressant	I-Group
effects	O
.	O
      
Of	O
particular	O
importance	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	B-Group
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	B-Drug
given	O
the	O
long	O
half	O
-	O
life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
9	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O
      
Inhibition	O
of	O
the	O
other	O
isozymes	O
evaluated	O
(	O
CYPs	O
9A9	O
9C9	O
9C9	O
9D9	O
9A9	O
and	O
9E9	O
)	O
was	O
9	O
-	O
9	O
%	O
.	O
      
Warfarin	B-Drug
:	O
Co	O
-	O
administration	O
of	O
bosentan	B-Drug
9	O
mg	O
b.i.d	O
.	O
for	O
9	O
days	O
decreased	O
the	O
plasma	O
concentrations	O
of	O
both	O
S	B-Drug
-	O
warfarin	I-Drug
(	O
a	O
CYP9C9	O
substrate	O
)	O
and	O
R	B-Drug
-	O
warfarin	I-Drug
(	O
a	O
CYP9A9	O
substrate	O
)	O
by	O
9	O
and	O
9	O
%	O
respectively	O
.	O
      
Neither	O
racemic	O
warfarin	B-Drug
nor	O
isradipine	B-Drug
binding	O
to	O
plasma	O
proteins	O
in	O
vitro	O
was	O
altered	O
by	O
the	O
addition	O
of	O
the	O
other	O
drug	O
.	O
      
Concomitant	O
administration	O
of	O
ketoconazole	B-Drug
tablets	O
with	O
phenytoin	B-Drug
may	O
alter	O
the	O
metabolism	O
of	O
one	O
or	O
both	O
of	O
the	O
drugs	O
.	O
      
Concurrent	O
use	O
of	O
rifampin	B-Drug
increases	O
the	O
metabolic	O
clearance	O
of	O
ZEBETA	B-Brand
resulting	O
in	O
a	O
shortened	O
elimination	O
half	O
-	O
life	O
of	O
ZEBETA	B-Brand
.	O
      
Calcium	B-Group
channel	I-Group
blocking	I-Group
agents	I-Group
:	O
Coadministration	O
of	O
calcium	B-Group
channel	I-Group
blockers	I-Group
did	O
not	O
have	O
any	O
effect	O
on	O
either	O
the	O
safety	O
or	O
efficacy	O
of	O
ibutilide	B-Drug
in	O
the	O
clinical	O
trials	O
.	O
      
Antacids	B-Group
kaolin	B-Drug
-	O
pectin	O
sulfasalazine	B-Drug
neomycin	B-Drug
cholestyramine	B-Drug
certain	O
anticancer	O
drugs	O
and	O
metoclopramide	B-Drug
may	O
interfere	O
with	O
intestinal	O
digoxin	B-Drug
absorption	O
resulting	O
in	O
unexpectedly	O
low	O
serum	O
concentrations	O
.	O
      
A	O
study	O
in	O
eight	O
healthy	O
volunteers	O
has	O
shown	O
a	O
9	O
%	O
increase	O
in	O
mean	O
peak	O
nimodipine	B-Drug
plasma	O
concentrations	O
and	O
a	O
9	O
%	O
increase	O
in	O
mean	O
area	O
under	O
the	O
curve	O
after	O
a	O
one	O
week	O
course	O
of	O
cimetidine	B-Drug
at	O
9	O
9	O
mg	O
/	O
day	O
and	O
nimodipine	B-Drug
at	O
9	O
mg	O
/	O
day	O
.	O
      
Amphetamines	B-Group
may	O
interfere	O
with	O
urinary	O
steroid	O
determinations	O
.	O
      
The	O
anticoagulant	O
effect	O
of	O
heparin	B-Drug
is	O
enhanced	O
by	O
concurrent	O
treatment	O
with	O
antithrombin	B-Drug
III	I-Drug
(	O
human	O
)	O
in	O
patients	O
with	O
hereditary	O
antithrombin	O
III	O
deficiency	O
.	O
      
Hypokalemia	O
may	O
develop	O
during	O
concomitant	O
use	O
of	O
steroids	B-Group
or	O
ACTH	B-Drug
.	O
      
Vitamin	B-Group
A	I-Group
and	O
oral	O
retinoids	B-Group
:	O
Concomitant	O
administration	O
of	O
vitamin	B-Group
A	I-Group
and	O
/	O
or	O
other	O
oral	O
retinoids	B-Group
with	O
acitretin	B-Drug
must	O
be	O
avoided	O
because	O
of	O
the	O
risk	O
of	O
hypervitaminosis	O
A	O
.	O
      
Use	O
with	O
caution	O
and	O
be	O
prepared	O
to	O
treat	O
hypertension	O
if	O
necessary	O
.	O
      
It	O
is	O
not	O
clear	O
whether	O
this	O
was	O
due	O
to	O
the	O
combination	O
of	O
therapy	O
.	O
      
Neuromuscular	B-Group
blocking	I-Group
agents	I-Group
(	O
such	O
as	O
suxamethonium	B-Drug
chloride	I-Drug
)	O
:	O
Concurrent	O
use	O
of	O
procaine	B-Drug
hydrochloride	I-Drug
and	O
neuromuscular	B-Group
blocking	I-Group
agents	I-Group
may	O
result	O
in	O
prolongation	O
or	O
enhancement	O
of	O
the	O
neuromuscular	O
blockade	O
.	O
      
The	O
following	O
drug	O
interactions	O
were	O
studied	O
with	O
ketoprofen	B-Drug
doses	O
of	O
9	O
mg	O
/	O
day	O
.	O
      
When	O
concomitant	O
treatment	O
with	O
agents	B-Group
with	I-Group
b	I-Group
-	O
blocking	I-Group
properties	I-Group
and	O
clonidine	B-Drug
is	O
to	O
be	O
terminated	O
the	O
b	B-Group
-	O
blocking	I-Group
agent	I-Group
should	O
be	O
discontinued	O
first	O
.	O
      
The	O
effect	O
of	O
orally	O
ingested	O
peginterferon	B-Drug
or	O
ribavirin	B-Drug
from	O
breast	O
milk	O
on	O
the	O
nursing	O
infant	O
has	O
not	O
been	O
evaluated	O
.	O
      
Nephrotoxicity	O
associated	O
with	O
cyclosporine	B-Drug
may	O
also	O
be	O
enhanced	O
.	O
      
It	O
is	O
reasonable	O
to	O
employ	O
appropriate	O
clinical	O
monitoring	O
when	O
potent	O
cytochrome	O
P9	O
enzyme	O
inducers	O
such	O
as	O
phenobarbital	B-Drug
or	O
rifampin	B-Drug
are	O
co	O
-	O
administered	O
with	O
montelukast	B-Drug
.	O
      
Effects	O
of	O
GABITRIL	B-Brand
on	O
other	O
Antiepilepsy	O
Drugs	O
(	O
AEDs	B-Group
)	O
:	O
Phenytoin	B-Drug
:	O
Tiagabine	B-Drug
had	O
no	O
effect	O
on	O
the	O
steady	O
-	O
state	O
plasma	O
concentrations	O
of	O
phenytoin	B-Drug
in	O
patients	O
with	O
epilepsy	O
.	O
      
Patients	O
with	O
Congenital	O
or	O
Acquired	O
QT	O
Prolongation	O
In	O
a	O
study	O
of	O
the	O
effect	O
of	O
solifenacin	B-Drug
on	O
the	O
QT	O
interval	O
in	O
9	O
healthy	O
women	O
the	O
QT	O
prolonging	O
effect	O
appeared	O
less	O
with	O
solifenacin	B-Drug
9	O
mg	O
than	O
with	O
9	O
mg	O
(	O
three	O
times	O
the	O
maximum	O
recommended	O
dose	O
)	O
and	O
the	O
effect	O
of	O
solifenacin	B-Drug
9	O
mg	O
did	O
not	O
appear	O
as	O
large	O
as	O
that	O
of	O
the	O
positive	O
control	O
moxifloxacin	B-Drug
at	O
its	O
therapeutic	O
dose	O
.	O
      
Do	O
not	O
take	O
this	O
medicine	O
with	O
thioridizine	O
or	O
within	O
9	O
weeks	O
of	O
taking	O
fluoxetine	B-Drug
.	O
      
.	O
      
ondansetron	B-Drug
did	O
not	O
increase	O
blood	O
levels	O
of	O
high	O
-	O
dose	O
methotrexate	B-Drug
.	O
      
.	O
      
Insulin	B-Drug
or	O
Oral	O
Hypoglycemics	B-Group
:	O
Initiating	O
thyroid	O
replacement	O
therapy	O
may	O
cause	O
increases	O
in	O
insulin	B-Drug
or	O
oral	O
hypoglycemic	B-Group
requirements	O
.	O
      
CYP9A9	O
inducers	O
:	O
CYP9A9	O
inducers	O
may	O
decrease	O
the	O
levels	O
/	O
effects	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
.	O
      
Drug	O
-	O
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
known	O
interactions	O
between	O
CAMPTOSAR	B-Brand
and	O
laboratory	O
tests	O
.	O
      
Ergotamine	B-Drug
or	O
dihydroergotamine	B-Drug
acute	O
ergot	O
toxicity	O
characterized	O
by	O
severe	O
peripheral	O
vasospasm	O
and	O
dysesthesia	O
.	O
      
This	O
treatment	O
arm	O
was	O
discontinued	O
from	O
the	O
trial	O
.	O
      
Also	O
antimyasthenics	O
may	O
have	O
anticholinesterase	O
activity	O
.	O
      
Thus	O
when	O
NSAIDs	B-Group
and	O
lithium	B-Drug
are	O
administered	O
concurrently	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
No	O
pharmacokinetic	O
interactions	O
between	O
dexmedetomidine	B-Drug
and	O
isoflurane	B-Drug
propofol	B-Drug
alfentanil	B-Drug
and	O
midazolam	B-Drug
have	O
been	O
demonstrated	O
.	O
      
Warfarin	B-Drug
:	O
A	O
single	O
9	O
-	O
mg	O
dose	O
of	O
Aprepitant	B-Drug
was	O
administered	O
on	O
Day	O
9	O
and	O
9	O
mg	O
/	O
day	O
on	O
Days	O
9	O
and	O
9	O
to	O
healthy	O
subjects	O
who	O
were	O
stabilized	O
on	O
chronic	O
warfarin	B-Drug
therapy	O
.	O
      
9	O
.	O
      
An	O
inhibitor	O
of	O
CYP9C9	O
(	O
such	O
as	O
gemfibrozil	B-Drug
)	O
may	O
increase	O
the	O
AUC	O
of	O
rosiglitazone	B-Drug
and	O
an	O
inducer	O
of	O
CYP9C9	O
(	O
such	O
as	O
rifampin	B-Drug
)	O
may	O
decrease	O
the	O
AUC	O
of	O
rosiglitazone	B-Drug
.	O
      
Vardenafil	B-Drug
      
Mean	O
oxybutynin	B-Drug
chloride	I-Drug
plasma	O
concentrations	O
were	O
approximately	O
9	O
fold	O
higher	O
when	O
DITROPAN	B-Brand
XL	I-Brand
was	O
administered	O
with	O
ketoconazole	B-Drug
a	O
potent	O
CYP9A9	O
inhibitor	O
.	O
      
Patients	O
may	O
require	O
reduced	O
doses	O
of	O
anesthetics	B-Group
when	O
on	O
methyldopa	B-Drug
.	O
      
Beta	B-Group
Blockers	I-Group
      
Therefore	O
if	O
concomitant	O
use	O
of	O
such	O
agents	O
is	O
indicated	O
they	O
should	O
be	O
given	O
with	O
caution	O
and	O
the	O
patients	O
serum	O
potassium	O
should	O
be	O
monitored	O
frequently	O
.	O
      
Patients	O
taking	O
both	O
flurbiprofen	B-Drug
and	O
a	O
beta	B-Group
-	O
blocker	I-Group
should	O
be	O
monitored	O
to	O
ensure	O
that	O
a	O
satisfactory	O
hypotensive	O
effect	O
is	O
achieved	O
.	O
      
Antiacid	O
clarithromycin	B-Drug
Didanosine	B-Drug
Fluconazole	B-Drug
Fluoxetine	B-Drug
Indanavir	O
Ketoconazole	B-Drug
Phenytoin	B-Drug
Phenobarbitol	O
carbamazepine	B-Drug
Rifabutin	B-Drug
Rifampin	B-Drug
Ritanovir	O
Saquinavir	B-Drug
.	O
      
The	O
following	O
drugs	O
have	O
been	O
coadministered	O
with	O
Kerlone	B-Brand
and	O
have	O
not	O
altered	O
its	O
pharmacokinetics	O
:	O
cimetidine	B-Drug
nifedipine	B-Drug
chlorthalidone	B-Drug
and	O
hydrochlorothiazide	B-Drug
.	O
      
THE	O
DOSAGE	O
OF	O
THE	O
ANTICOAGULANTS	B-Group
SHOULD	O
BE	O
REDUCED	O
TO	O
MAINTAIN	O
THE	O
PROTHROMBIN	O
TIME	O
/	O
INR	O
AT	O
THE	O
DESIRED	O
LEVEL	O
TO	O
PREVENT	O
BLEEDING	O
COMPLICATIONS	O
.	O
      
In	O
clinical	O
studies	O
propofol	B-Drug
had	O
no	O
effect	O
on	O
the	O
duration	O
of	O
action	O
or	O
dosing	O
requirements	O
for	O
NIMBEX	B-Brand
.	O
      
If	O
such	O
drugs	O
are	O
needed	O
their	O
dose	O
should	O
be	O
reassessed	O
and	O
where	O
appropriate	O
plasma	O
concentration	O
measured	O
.	O
      
Micafungin	B-Drug
is	O
not	O
an	O
inhibitor	O
of	O
P	O
-	O
glycoprotein	O
and	O
therefore	O
would	O
not	O
be	O
expected	O
to	O
alter	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
drug	O
transport	O
activity	O
.	O
      
Refer	O
to	O
the	O
package	O
insert	O
for	O
lithium	B-Drug
preparations	O
before	O
use	O
of	O
such	O
preparations	O
with	O
Hydrochlorothiazide	B-Drug
.	O
      
PEGASYS	B-Brand
and	O
COPEGUS	B-Brand
are	O
excreted	O
by	O
the	O
kidney	O
and	O
the	O
risk	O
of	O
toxic	O
reactions	O
to	O
this	O
therapy	O
may	O
be	O
greater	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
.	O
      
Orthostatic	O
hypotension	O
in	O
patients	O
taking	O
clozapine	B-Drug
can	O
in	O
rare	O
cases	O
(	O
approximately	O
9	O
case	O
per	O
9	O
9	O
patients	O
)	O
be	O
accompanied	O
by	O
profound	O
collapse	O
and	O
respiratory	O
and	O
/	O
or	O
cardiac	O
arrest	O
.	O
      
There	O
have	O
been	O
spontaneous	O
reports	O
of	O
increase	O
or	O
decrease	O
in	O
prothrombin	O
times	O
in	O
patients	O
concomitantly	O
taking	O
oral	O
terbinafine	B-Drug
and	O
warfarin	B-Drug
however	O
a	O
causal	O
relationship	O
between	O
LAMISIL	B-Brand
Tablets	O
and	O
these	O
changes	O
has	O
not	O
been	O
established	O
.	O
      
In	O
common	O
with	O
other	O
broad	B-Group
-	O
spectrum	I-Group
antibiotics	I-Group
AUGMENTIN	B-Brand
XR	I-Brand
may	O
reduce	O
the	O
efficacy	O
of	O
oral	O
contraceptives	B-Group
      
Ergotamine	B-Drug
:	O
Concurrent	O
use	O
of	O
erythromycin	B-Drug
and	O
ergotamine	B-Drug
or	O
dihydroergotamine	B-Drug
has	O
been	O
associated	O
in	O
some	O
patients	O
with	O
acute	O
ergot	O
toxicity	O
characterized	O
by	O
severe	O
peripheral	O
vasospasm	O
and	O
dysesthesia	O
.	O
      
and	O
rarely	O
enuresis	O
urinary	O
retention	O
dysuria	O
impotence	O
inability	O
to	O
ejaculate	O
nocturia	O
hematuria	O
.	O
      
Ampicillin	B-Drug
:	O
In	O
a	O
study	O
of	O
healthy	O
volunteers	O
chloroquine	B-Drug
significantly	O
reduced	O
the	O
bioavailability	O
of	O
ampicillin	B-Drug
.	O
      
Lamivudine	B-Drug
is	O
predominantly	O
eliminated	O
in	O
the	O
urine	O
by	O
active	O
organic	O
cationic	O
secretion	O
.	O
      
Coadministration	O
of	O
terfenadine	B-Drug
with	O
Itraconazole	B-Drug
has	O
led	O
to	O
elevated	O
plasma	O
concentrations	O
of	O
terfenadine	B-Drug
resulting	O
in	O
rare	O
instances	O
of	O
life	O
-	O
threatening	O
cardiac	O
dysrhythmias	O
and	O
one	O
death	O
.	O
      
No	O
volunteer	O
showed	O
hormonal	O
evidence	O
of	O
ovulation	O
but	O
one	O
volunteer	O
reported	O
intermenstrual	O
bleeding	O
during	O
felbamate	B-Drug
treatment	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
Amphetamines	B-Group
can	O
cause	O
a	O
significant	O
elevation	O
in	O
plasma	O
corticosteroid	O
levels	O
.	O
      
Dosage	O
adjustment	O
of	O
STRATTERA	B-Brand
may	O
be	O
necessary	O
when	O
coadministered	O
with	O
CYP9D9	O
inhibitors	O
e.g.	O
paroxetine	B-Drug
fluoxetine	B-Drug
and	O
quinidine	B-Drug
.	O
      
diflunisal	B-Drug
;	O
      
Other	O
common	O
adverse	O
reactions	O
are	O
dizziness	O
(	O
9	O
-	O
9	O
%	O
)	O
weakness	O
(	O
9	O
-	O
9	O
%	O
)	O
and	O
fatigue	O
(	O
9	O
-	O
9	O
%	O
)	O
.	O
      
In	O
a	O
9	O
-	O
month	O
controlled	O
trial	O
that	O
included	O
a	O
9	O
mcg	O
once	O
daily	O
BROVANA	B-Brand
dose	O
9	O
of	O
the	O
9	O
BROVANA	B-Brand
-	O
treated	O
subjects	O
received	O
concomitant	O
theophylline	B-Drug
at	O
study	O
entry	O
.	O
      
.	O
      
Potential	O
for	O
Other	O
Drugs	O
to	O
Affect	O
ABILIFY	B-Brand
Aripiprazole	B-Brand
is	O
not	O
a	O
substrate	O
of	O
CYP9A9	O
CYP9A9	O
CYP9A9	O
CYP9B9	O
CYP9C9	O
CYP9C9	O
CYP9C9	O
or	O
CYP9E9	O
enzymes	O
.	O
      
Heparin	B-Drug
:	O
Since	O
heparin	B-Drug
is	O
contraindicated	O
in	O
patients	O
with	O
heparin	B-Drug
-	O
induced	O
thrombocytopenia	O
the	O
co	O
-	O
administration	O
of	O
Argatroban	B-Drug
and	O
heparin	B-Drug
is	O
unlikely	O
for	O
this	O
indication	O
.	O
      
Caution	O
is	O
warranted	O
and	O
clinical	O
monitoring	O
of	O
patients	O
is	O
recommended	O
.	O
      
Similarly	O
in	O
the	O
9	O
-	O
year	O
monthly	O
comparison	O
study	O
aspirin	B-Brand
and	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
were	O
taken	O
by	O
9	O
%	O
of	O
the	O
9	O
patients	O
.	O
      
-	O
Quinine	B-Drug
(	O
e.g.	O
Quinamm	B-Brand
)	O
or	O
      
Cholestyramine	B-Drug
-	O
Concomitant	O
intake	O
of	O
cholestyramine	B-Drug
and	O
vitamin	B-Group
K	I-Group
may	O
reduce	O
the	O
absorption	O
of	O
vitamin	B-Group
K	I-Group
.	O
      
Drugs	O
Metabolized	O
by	O
P9	O
9D9	O
-	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	O
metabolizing	O
isozyme	O
cytochrome	O
P9	O
9D9	O
(	O
debrisoquin	O
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
caucasian	O
population	O
(	O
about	O
9	O
-	O
9	O
%	O
of	O
caucasians	O
are	O
so	O
called	O
poor	O
metabolizers	O
)	O
;	O
      
Hepatotoxic	O
medications	O
such	O
as	O
high	O
-	O
dose	O
methotrexate	B-Drug
may	O
impair	O
liver	O
function	O
and	O
increase	O
the	O
risk	O
of	O
toxicity	O
.	O
      
When	O
these	O
products	O
are	O
administered	O
concomitantly	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
test	O
should	O
be	O
closely	O
monitored	O
.	O
      
Nevertheless	O
the	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
test	O
should	O
be	O
monitored	O
when	O
warfarin	B-Drug
or	O
its	O
derivatives	O
and	O
enoxacin	B-Drug
are	O
given	O
concomitantly	O
.	O
      
It	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	O
glucose	O
oxidase	O
reactions	O
be	O
used	O
.	O
      
Fluoxetine	B-Drug
and	O
its	O
active	O
metabolite	O
norfluoxe	O
-	O
tine	O
have	O
long	O
half	O
-	O
lives	O
(	O
9	O
to	O
9	O
days	O
for	O
norfluoxetine	B-Drug_n
)	O
that	O
may	O
affect	O
strategies	O
during	O
conversion	O
from	O
one	O
drug	O
to	O
the	O
other	O
.	O
      
Patients	O
taking	O
these	O
drugs	O
with	O
LODOSYN	B-Brand
and	O
levodopa	B-Drug
or	O
carbidopa	B-Drug
-	O
levodopa	B-Drug
combination	O
products	O
should	O
be	O
carefully	O
observed	O
for	O
loss	O
of	O
therapeutic	O
response	O
.	O
      
However	O
the	O
plasma	O
clearance	O
of	O
methotrexate	B-Drug
was	O
slightly	O
increased	O
.	O
      
The	O
addition	O
of	O
aspirin	B-Brand
to	O
Streptokinase	B-Drug
causes	O
a	O
minimal	O
increase	O
in	O
the	O
risk	O
of	O
minor	O
bleeding	O
(	O
9	O
%	O
vs.	O
9	O
%	O
)	O
but	O
does	O
not	O
appear	O
to	O
increase	O
the	O
incidence	O
of	O
major	O
bleeding	O
(	O
see	O
      
Potential	O
interactions	O
between	O
TAXOL	B-Brand
a	O
substrate	O
of	O
CYP9A9	O
and	O
protease	B-Group
inhibitors	I-Group
(	O
ritonavir	B-Drug
saquinavir	B-Drug
indinavir	B-Drug
and	O
nelfinavir	B-Drug
)	O
which	O
are	O
substrates	O
and	O
/	O
or	O
inhibitors	O
of	O
CYP9A9	O
have	O
not	O
been	O
evaluated	O
in	O
clinical	O
trials	O
.	O
      
Salicylates	B-Group
given	O
concomitantly	O
with	O
anticoagulant	B-Group
drugs	I-Group
may	O
predispose	O
to	O
systemic	O
bleeding	O
.	O
      
Nursing	O
Mothers	O
      
indinavir	B-Drug
concentration	O
      
isoflurane	B-Drug
;	O
      
Warfarin	B-Drug
:	O
When	O
healthy	O
subjects	O
were	O
administered	O
Starlix	B-Brand
9	O
mg	O
three	O
times	O
daily	O
before	O
meals	O
for	O
four	O
days	O
in	O
combination	O
with	O
a	O
single	O
dose	O
of	O
warfarin	B-Drug
9	O
mg	O
on	O
day	O
9	O
there	O
were	O
no	O
alterations	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O
      
This	O
is	O
also	O
to	O
be	O
considered	O
when	O
leflunomide	B-Drug
treatment	O
is	O
followed	O
by	O
such	O
drugs	O
without	O
a	O
drug	O
elimination	O
procedure	O
.	O
      
Bosentan	B-Drug
is	O
also	O
expected	O
to	O
reduce	O
plasma	O
concentrations	O
of	O
other	O
oral	O
hypoglycemic	B-Group
agents	I-Group
that	O
are	O
predominantly	O
metabolized	O
by	O
CYP9C9	O
or	O
CYP9A9	O
.	O
      
However	O
LDL	O
-	O
C	O
reduction	O
was	O
greater	O
when	O
atorvastatin	B-Drug
and	O
colestipol	B-Drug
were	O
coadministered	O
than	O
when	O
either	O
drug	O
was	O
given	O
alone	O
.	O
      
In	O
vitro	O
studies	O
:	O
Vardenafil	B-Drug
and	O
its	O
metabolites	O
had	O
no	O
effect	O
on	O
CYP9A9	O
9A9	O
and	O
9E9	O
(	O
Ki	O
9uM	O
)	O
.	O
      
Ketoconazole	B-Drug
:	O
Ketoconazole	B-Drug
may	O
inhibit	O
both	O
synthetic	O
and	O
catabolic	O
enzymes	O
of	O
vitamin	B-Group
D	I-Group
.	O
      
If	O
midazolam	B-Drug
is	O
administered	O
parenterally	O
special	O
precaution	O
is	O
required	O
since	O
the	O
sedative	O
effect	O
may	O
be	O
prolonged	O
.	O
      
Other	O
beta	B-Group
adrenergic	I-Group
aerosol	I-Group
bronchodilators	I-Group
should	O
not	O
be	O
used	O
concomitantly	O
with	O
Alupent	B-Brand
(	O
metaproterenol	B-Drug
sulfate	I-Drug
USP	O
)	O
because	O
they	O
may	O
have	O
additive	O
effects	O
.	O
      
These	O
facts	O
should	O
be	O
considered	O
when	O
evaluating	O
plasma	O
renin	O
activity	O
in	O
hypertensive	O
patients	O
.	O
      
(	O
d	O
)	O
T9	O
-	O
uptake	O
values	O
may	O
decrease	O
.	O
      
T9	O
resin	O
uptake	O
is	O
decreased	O
reflecting	O
the	O
elevated	O
TBG	O
.	O
      
Concurrent	O
administration	O
of	O
vasopressor	B-Group
drugs	I-Group
and	O
of	O
ergot	B-Group
-	O
type	I-Group
oxytocic	I-Group
drugs	I-Group
may	O
cause	O
severe	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O
      
9%	O
9%	O
9%	O
9%	O
      
Laboratory	O
Tests	O
:	O
The	O
combination	O
of	O
Amprenavir	B-Drug
and	O
low	O
-	O
dose	O
ritonavir	B-Drug
has	O
been	O
associated	O
with	O
elevations	O
of	O
cholesterol	O
and	O
triglycerides	O
SGOT	O
(	O
AST	O
)	O
and	O
SGPT	O
(	O
ALT	O
)	O
in	O
some	O
patients	O
.	O
      
If	O
they	O
do	O
occur	O
the	O
EPA	B-Drug
dose	O
should	O
be	O
lowered	O
or	O
discontinued	O
.	O
      
Tricyclic	B-Group
antidepressants	I-Group
have	O
been	O
reported	O
to	O
blunt	O
the	O
hypotensive	O
effect	O
of	O
systemic	O
clonidine	B-Drug
.	O
      
Use	O
With	O
Ribavirin	B-Drug
Ribavirin	B-Drug
is	O
genotoxic	O
and	O
mutagenic	O
.	O
      
There	O
is	O
little	O
if	O
any	O
clinically	O
significant	O
interaction	O
between	O
Acarbose	B-Drug
and	O
metformin	B-Drug
.	O
      
.	O
      
zaleplon	B-Drug
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
ethanol	B-Drug
.	O
      
The	O
use	O
of	O
drugs	O
that	O
stimulate	O
alpha	O
-	O
adrenergic	O
receptors	O
(	O
e.g.	O
phenylephrine	B-Drug
pseudoephedrine	B-Drug
ephedrine	B-Drug
phenylpropanolamine	B-Drug
or	O
dihydroergotamine	B-Drug
)	O
may	O
enhance	O
or	O
potentiate	O
the	O
pressor	O
effects	O
of	O
ProAmatine	B-Brand
.	O
Therefore	O
caution	O
should	O
be	O
used	O
when	O
ProAmatine	B-Brand
is	O
administered	O
concomitantly	O
with	O
agents	O
that	O
cause	O
vasoconstriction	O
.	O
      
Sinus	O
bradycardia	O
has	O
been	O
reported	O
with	O
oral	O
amiodarone	B-Drug
in	O
combination	O
with	O
lidocaine	B-Drug
(	O
CYP9A9	B-Drug
substrate	O
)	O
given	O
for	O
local	O
anesthesia	B-Drug
.	O
      
If	O
indicated	O
dosage	O
of	O
the	O
antihypertensive	B-Group
agents	I-Group
should	O
be	O
reduced	O
.	O
      
Acarbose	B-Drug
may	O
affect	O
digoxin	B-Drug
bioavailabillty	O
and	O
may	O
require	O
dose	O
adjustment	O
of	O
digoxin	B-Drug
by	O
9	O
%	O
(	O
9	O
%	O
confidence	O
interval	O
:	O
9	O
-	O
9	O
%	O
)	O
decrease	O
mean	O
C	O
max	O
digoxin	B-Drug
by	O
9	O
%	O
(	O
9	O
%	O
confidence	O
interval	O
:	O
9	O
-	O
9	O
%	O
)	O
and	O
decrease	O
mean	O
trough	O
concentrations	O
of	O
digoxin	B-Drug
by	O
9	O
%	O
(	O
9	O
%	O
confidence	O
limit	O
:	O
9	O
%	O
decrease	O
to	O
9	O
%	O
increase	O
)	O
.	O
      
Antidepressants	B-Group
(	O
tricyclic	B-Group
)	O
atropine	B-Drug
or	O
other	O
anticholinergic	B-Group
agents	I-Group
or	O
digitalis	B-Group
glycosides	I-Group
:	O
concurrent	O
use	O
with	O
arbutamine	B-Drug
may	O
produce	O
additive	O
inotropic	O
and	O
/	O
or	O
chronotropic	O
effects	O
.	O
      
Plasma	O
levels	O
of	O
flecainide	B-Drug
have	O
been	O
reported	O
to	O
increase	O
in	O
the	O
presence	O
of	O
oral	O
amiodarone	B-Drug
;	O
      
Concomitant	O
use	O
of	O
bromocriptine	B-Drug
mesylate	I-Drug
with	O
other	O
ergot	B-Group
alkaloids	I-Group
is	O
not	O
recommended	O
.	O
      
Careful	O
supervision	O
of	O
diabetic	O
patients	O
under	O
treatment	O
with	O
Soriatane	B-Brand
is	O
recommended	O
.	O
      
Tablets	O
Injection	O
and	O
Oral	O
Solution	O
One	O
study	O
in	O
six	O
subjects	O
demonstrated	O
that	O
the	O
combination	O
of	O
furosemide	B-Drug
and	O
acetylsalicylic	B-Drug
acid	I-Drug
temporarily	O
reduced	O
creatinine	O
clearance	O
in	O
patients	O
with	O
chronic	O
renal	O
insufficiency	O
.	O
      
The	O
pharmacokinetics	O
of	O
a	O
9	O
-	O
mg	O
dose	O
of	O
butorphanol	B-Drug
administered	O
as	O
STADOL	B-Brand
NS	I-Brand
were	O
not	O
affected	O
by	O
the	O
coadministration	O
of	O
cimetidine	B-Drug
(	O
9	O
mg	O
QID	O
)	O
.	O
      
The	O
adverse	O
effects	O
of	O
CAMPTOSAR	B-Brand
such	O
as	O
myelosuppression	O
and	O
diarrhea	O
would	O
be	O
expected	O
to	O
be	O
exacerbated	O
by	O
other	O
antineoplastic	B-Group
agents	I-Group
having	O
similar	O
adverse	O
effects	O
.	O
      
In	O
clinical	O
studies	O
of	O
TOBI	B-Brand
patients	O
taking	O
TOBI	B-Brand
concomitantly	O
with	O
dornase	B-Drug
alfa	I-Drug
(	O
PULMOZYME	B-Brand
Genentech	O
)	O
beta	B-Group
-	O
agonists	I-Group
inhaled	O
corticosteroids	B-Group
other	O
anti	B-Group
-	O
pseudomonal	I-Group
antibiotics	I-Group
or	O
parenteral	O
aminoglycosides	B-Group
demonstrated	O
adverse	O
experience	O
profiles	O
similar	O
to	O
the	O
study	O
population	O
as	O
a	O
whole	O
.	O
      
The	O
syndrome	O
requires	O
immediate	O
medical	O
attention	O
and	O
may	O
include	O
one	O
or	O
more	O
of	O
the	O
following	O
symptoms	O
:	O
excitement	O
hypomania	O
restlessness	O
loss	O
of	O
consciousness	O
confusion	O
disorientation	O
anxiety	O
agitation	O
motor	O
weakness	O
myoclonus	O
tremor	O
hemiballismus	O
hyperreflexia	O
ataxia	O
dysarthria	O
incoordination	O
hyperthermia	O
shivering	O
pupillary	O
dilation	O
diaphoresis	O
emesis	O
and	O
tachycardia	O
.	O
      
The	O
in	O
vitro	O
interaction	O
between	O
nevirapine	B-Drug
and	O
the	O
antithrombotic	B-Group
agent	I-Group
warfarin	B-Drug
is	O
complex	O
.	O
      
This	O
will	O
interfere	O
with	O
the	O
diagnosis	O
of	O
pheochromocytoma	O
.	O
      
The	O
elevated	O
plasma	O
alprazolam	B-Drug
concentrations	O
resulted	O
in	O
decreased	O
psychomotor	O
performance	O
and	O
memory	O
.	O
      
There	O
is	O
a	O
single	O
case	O
report	O
which	O
suggests	O
that	O
sucralfate	B-Drug
may	O
interfere	O
with	O
anagrelide	B-Drug
absorption	O
.	O
      
Salicylate	B-Group
levels	O
have	O
been	O
found	O
to	O
be	O
falsely	O
elevated	O
with	O
some	O
assay	O
methods	O
.	O
      
No	O
information	O
provided	O
      
In	O
addition	O
to	O
bleeding	O
associated	O
with	O
heparin	B-Drug
and	O
vitamin	B-Group
K	I-Group
antagonists	I-Group
drugs	O
that	O
alter	O
platelet	O
function	O
(	O
such	O
as	O
aspirin	B-Brand
dipyridamole	B-Drug
and	O
abciximab	B-Drug
)	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
if	O
administered	O
prior	O
to	O
or	O
after	O
Retavase	B-Brand
therapy	O
.	O
      
.	O
      
When	O
digoxin	B-Drug
and	O
BREVIBLOC	B-Brand
were	O
concomitantly	O
administered	O
intravenously	O
to	O
normal	O
volunteers	O
there	O
was	O
a	O
9	O
-	O
9	O
%	O
increase	O
in	O
digoxin	B-Drug
blood	O
levels	O
at	O
some	O
time	O
points	O
.	O
      
Although	O
there	O
was	O
no	O
clinical	O
evidence	O
in	O
the	O
vehicle	O
-	O
controlled	O
studies	O
of	O
drug	O
interactions	O
with	O
systemic	O
antiretroviral	B-Group
agents	I-Group
including	O
protease	B-Group
inhibitors	I-Group
macrolide	B-Group
antibiotics	I-Group
and	O
azole	B-Group
antifungals	I-Group
the	O
effect	O
of	O
Panretin	B-Brand
gel	O
on	O
the	O
steady	O
-	O
state	O
concentrations	O
of	O
these	O
drugs	O
is	O
not	O
known	O
.	O
      
Theoretically	O
fenoprofen	B-Drug
could	O
likewise	O
be	O
displaced	O
.	O
      
No	O
information	O
available	O
.	O
      
Drugs	O
that	O
inhibit	O
cytochrome	O
P9IID9	O
such	O
as	O
quinidine	B-Drug
might	O
increase	O
the	O
plasma	O
concentrations	O
of	O
flecainide	B-Drug
in	O
patients	O
that	O
are	O
on	O
chronic	O
flecainide	B-Drug
therapy	O
;	O
      
Calcium	B-Group
Channel	I-Group
Blockers	I-Group
:	O
Isolated	O
cases	O
of	O
conduction	O
disturbance	O
(	O
rarely	O
with	O
hemodynamic	O
compromise	O
)	O
have	O
been	O
observed	O
when	O
COREG	B-Brand
is	O
co	O
-	O
administered	O
with	O
diltiazem	B-Drug
.	O
      
MAO	B-Group
inhibitors	I-Group
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
(	O
drying	O
)	O
effects	O
of	O
antihistamines	B-Group
.	O
      
Tinnitus	O
and	O
decreased	O
hearing	O
have	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
Itraconazole	B-Drug
and	O
quinidine	B-Drug
.	O
      
a	O
reduction	O
of	O
the	O
doxorubicin	B-Drug
dosage	O
should	O
be	O
considered	O
in	O
patients	O
receiving	O
ZANOSAR	B-Brand
concurrently	O
.	O
      
PEGASYS	B-Brand
is	O
recommended	O
for	O
use	O
in	O
women	O
of	O
childbearing	O
potential	O
only	O
when	O
they	O
are	O
using	O
effective	O
contraception	O
during	O
therapy	O
.	O
      
Antacids	B-Group
and	O
kaolin	B-Drug
:	O
Antacids	B-Group
and	O
kaolin	B-Drug
can	O
reduce	O
absorption	O
of	O
chloroquine	B-Drug
;	O
      
When	O
other	O
potent	O
parental	O
antihypertensive	B-Group
drugs	I-Group
such	O
as	O
diazoxide	B-Drug
are	O
used	O
in	O
combination	O
with	O
hydralazine	B-Drug
patients	O
should	O
be	O
continuously	O
observed	O
for	O
several	O
hours	O
for	O
any	O
excessive	O
fall	O
in	O
blood	O
pressure	O
.	O
      
A	O
dose	O
increase	O
of	O
lopinavir	B-Drug
/	O
ritonavir	B-Drug
to	O
9	O
/	O
9	O
mg	O
twice	O
daily	O
with	O
food	O
isrecommended	O
in	O
combination	O
with	O
nevirapine	B-Drug
.	O
      
Posicor	B-Brand
inhibits	O
some	O
of	O
the	O
liver	O
's	O
ability	O
to	O
metabolize	O
some	O
other	O
drugs	O
-	O
terfenadine	B-Drug
astemizole	B-Drug
cisapride	B-Drug
cyclosporine	B-Drug
and	O
tricyclic	B-Group
antidepressants	I-Group
.	O
      
Therefore	O
when	O
INDOCIN	B-Brand
and	O
digoxin	B-Drug
are	O
used	O
concomitantly	O
serum	O
digoxin	B-Drug
levels	O
should	O
be	O
closely	O
monitored	O
.	O
      
Erythromycin	B-Drug
(	O
9	O
mg	O
q9h	O
)	O
+	O
9	O
%	O
9%	O
      
There	O
is	O
limited	O
experience	O
with	O
concomitant	O
antihypertensive	B-Group
agents	I-Group
such	O
as	O
alpha	B-Group
-	O
blockers	I-Group
calcium	B-Group
channel	I-Group
-	O
blockers	I-Group
ACE	B-Group
inhibitors	I-Group
and	O
diuretics	B-Group
(	O
both	O
thiazide	B-Group
-	O
like	O
and	O
loop	O
)	O
.	O
      
If	O
used	O
concomitantly	O
closely	O
monitor	O
serum	O
electrolytes	O
and	O
cardiac	O
function	O
.	O
      
Acetazolamide	B-Drug
may	O
prevent	O
the	O
urinary	O
antiseptic	O
effect	O
of	O
methenamine	B-Drug
.	O
      
Bentiromide	B-Drug
may	O
interact	O
with	O
acetaminophen	B-Drug
(	O
e.g.	O
Tylenol	B-Brand
)	O
chloramphenicol	B-Drug
(	O
e.g.	O
Chloromycetin	B-Brand
)	O
local	O
anesthetics	B-Group
(	O
e.g.	O
benzocaine	B-Drug
and	O
lidocaine	B-Drug
)	O
para	B-Drug_n
-	O
aminobenzoic	I-Drug_n
acid	I-Drug_n
(	O
PABA	B-Drug_n
)	O
-	O
containing	O
preparations	O
(	O
e.g.	O
sunscreens	O
and	O
some	O
multivitamins	B-Group
)	O
procainamide	B-Drug
(	O
e.g.	O
Pronestyl	B-Brand
)	O
sulfonamides	B-Group
(	O
sulfa	O
medicines	O
)	O
thiazide	B-Group
diuretics	I-Group
(	O
use	O
of	O
these	O
medicines	O
during	O
the	O
test	O
period	O
will	O
affect	O
the	O
test	O
results	O
)	O
and	O
pancreatic	O
supplements	O
(	O
use	O
of	O
pancreatic	O
supplements	O
may	O
give	O
false	O
test	O
results	O
)	O
.	O
      
Valdecoxib	B-Drug
did	O
not	O
have	O
a	O
statistically	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
phenytoin	B-Drug
(	O
a	O
CYP	O
9C9	O
and	O
CYP	O
9C9	O
substrate	O
)	O
.	O
      
Aspirin	B-Brand
:	O
As	O
with	O
other	O
NSAIDs	B-Group
concomitant	O
administration	O
of	O
Ponstel	B-Brand
and	O
aspirin	B-Brand
is	O
not	O
generally	O
recommended	O
because	O
of	O
the	O
potential	O
of	O
increased	O
adverse	O
effects	O
.	O
      
Drugs	O
that	O
may	O
have	O
their	O
plasma	O
concentration	O
altered	O
by	O
dasatinib	B-Drug
CYP9A9	O
Substrates	O
:	O
Dasatinib	B-Drug
is	O
a	O
time	O
-	O
dependent	O
inhibitor	O
of	O
CYP9A9	O
.	O
      
There	O
are	O
no	O
significant	O
effects	O
on	O
cefdinir	B-Drug
pharmacokinetics	O
if	O
the	O
antacid	B-Group
is	O
administered	O
9	O
hours	O
before	O
or	O
9	O
hours	O
after	O
cefdinir	B-Drug
.	O
      
Nonsteroidal	B-Group
Anti	I-Group
-	O
Inflammatory	I-Group
Drugs	I-Group
:	O
The	O
administration	O
of	O
diflunisal	B-Drug
to	O
normal	O
volunteers	O
receiving	O
indomethacin	B-Drug
decreased	O
the	O
renal	O
clearance	O
and	O
significantly	O
increased	O
the	O
plasma	O
levels	O
of	O
indomethacin	B-Drug
.	O
      
The	O
clinical	O
effects	O
of	O
this	O
combination	O
have	O
not	O
been	O
studied	O
.	O
      
Drugs	O
Highly	O
Bound	O
To	O
Plasma	O
Protein	O
Eszopiclone	B-Drug
is	O
not	O
highly	O
bound	O
to	O
plasma	O
proteins	O
(	O
9	O
-	O
9	O
%	O
bound	O
)	O
;	O
      
When	O
methyldopa	B-Drug
and	O
lithium	B-Drug
are	O
given	O
concomitantly	O
the	O
patient	O
should	O
be	O
carefully	O
monitored	O
for	O
symptoms	O
of	O
lithium	B-Drug
toxicity	O
.	O
      
In	O
separate	O
studies	O
of	O
patients	O
receiving	O
maintenance	O
doses	O
of	O
warfarin	B-Drug
hydrochlorothiazide	B-Drug
or	O
digoxin	B-Drug
irbesartan	B-Drug
administration	O
for	O
9	O
days	O
had	O
no	O
effect	O
on	O
the	O
pharmacodynamics	O
of	O
warfarin	B-Drug
(	O
prothrombin	O
time	O
)	O
or	O
pharmacokinetics	O
of	O
digoxin	B-Drug
.	O
      
However	O
prudent	O
evaluation	O
of	O
individual	O
cases	O
is	O
warranted	O
in	O
the	O
clinical	O
setting	O
.	O
      
The	O
magnitude	O
of	O
interaction	O
with	O
multiple	O
doses	O
of	O
erythromycin	B-Drug
is	O
unknown	O
.	O
      
Cimetidine	B-Drug
(	O
9	O
mg	O
qid	O
)	O
9	O
%	O
+	O
9	O
%	O
      
This	O
may	O
be	O
of	O
clinical	O
relevance	O
for	O
compounds	O
predominantly	O
metabolized	O
by	O
this	O
enzyme	O
such	O
as	O
tricyclic	B-Group
antidepressants	I-Group
-	O
blockers	O
selective	B-Group
serotonin	I-Group
reuptake	I-Group
inhibitors	I-Group
(	O
SSRIs	B-Group
)	O
and	O
monoamine	B-Group
oxidase	I-Group
inhibitors	I-Group
MAO	I-Group
-	O
Is	I-Group
Type	I-Group
B	I-Group
if	O
they	O
have	O
a	O
narrow	O
therapeutic	O
window	O
.	O
      
CNS	O
depression	O
producing	O
medications	O
-	O
concurrent	O
use	O
may	O
potentiate	O
the	O
effects	O
of	O
either	O
these	O
medications	O
or	O
diphenidol	B-Drug
;	O
      
The	O
vasodilating	O
effects	O
of	O
isosorbide	B-Drug
mononitrate	I-Drug
may	O
be	O
additive	O
with	O
those	O
of	O
other	O
vasodilators	B-Group
.	O
      
Patients	O
receiving	O
antibiotics	B-Group
and	O
sulfonamides	B-Group
generally	O
should	O
not	O
be	O
treated	O
with	O
ganglion	B-Group
blockers	I-Group
.	O
      
Anagrelide	B-Drug
demonstrates	O
some	O
limited	O
inhibitory	O
activity	O
towards	O
CYP9A9	O
which	O
may	O
present	O
a	O
theoretical	O
potential	O
for	O
interaction	O
with	O
other	O
coadministered	O
medicinal	O
products	O
sharing	O
that	O
clearance	O
mechanism	O
e.g	O
.	O
theophylline	B-Drug
.	O
      
In	O
some	O
patients	O
the	O
administration	O
of	O
INDOCIN	B-Brand
can	O
reduce	O
the	O
diuretic	O
natriuretic	O
and	O
antihypertensive	O
effects	O
of	O
loop	B-Group
potassium	B-Group
-	O
sparing	I-Group
and	O
thiazide	B-Group
diuretics	I-Group
.	O
      
Prior	O
administration	O
of	O
succinylcholine	B-Drug
had	O
no	O
effect	O
on	O
the	O
duration	O
of	O
neuromuscular	O
block	O
following	O
initial	O
or	O
maintenance	O
bolus	O
doses	O
of	O
NIMBEX	B-Brand
.	O
      
Pharmacokinetics	O
of	O
levetiracetam	B-Drug
were	O
also	O
not	O
affected	O
by	O
phenytoin	B-Drug
.	O
      
Phenytoin	B-Drug
nicotine	B-Drug
and	O
rifampin	B-Drug
may	O
decrease	O
Clozapine	B-Drug
plasma	O
levels	O
resulting	O
in	O
a	O
decrease	O
in	O
effectiveness	O
of	O
a	O
previously	O
effective	O
Clozapine	B-Drug
dose	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
The	O
following	O
drugs	O
or	O
moieties	O
are	O
known	O
to	O
interfere	O
with	O
laboratory	O
tests	O
performed	O
in	O
patients	O
on	O
thyroid	B-Group
hormone	I-Group
therapy	O
:	O
androgens	B-Group
corticosteroids	B-Group
estrogens	B-Group
oral	O
contraceptives	B-Group
containing	O
estrogens	B-Group
iodine	B-Group
-	O
containing	O
preparations	O
and	O
the	O
numerous	O
preparations	O
containing	O
salicylates	B-Group
.	O
      
Less	O
potent	O
inhibitors	O
include	O
saquinavir	B-Drug
nefazodone	B-Drug
fluconazole	B-Drug
grapefruit	O
juice	O
fluoxetine	B-Drug
fluvoxamine	B-Drug
zileuton	B-Drug
and	O
clotrimazole	B-Drug
.	O
      
Based	O
on	O
known	O
metabolic	O
profiles	O
clinically	O
significant	O
drug	O
interactions	O
are	O
not	O
expected	O
between	O
VIRACEPT	B-Brand
and	O
dapsone	B-Drug
trimethoprim	B-Drug
/	O
sulfamethoxazole	B-Drug
clarithromycin	B-Drug
erythromycin	B-Drug
itraconazole	B-Drug
or	O
fluconazole	B-Drug
.	O
      
-	O
Methyldopa	B-Drug
(	O
e.g.	O
Aldomet	B-Brand
)	O
Use	O
of	O
methyldopa	B-Drug
with	O
sulfapyridine	B-Drug
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
and	O
/	O
or	O
the	O
blood	O
      
reduced	O
serum	O
folate	O
concentration	O
;	O
      
Concurrent	O
administration	O
of	O
bacteriostatic	B-Group
antibiotics	I-Group
(	O
e.g.	O
erythromycin	B-Drug
tetracycline	B-Drug
)	O
may	O
diminish	O
the	O
bactericidal	O
effects	O
of	O
penicillins	B-Group
by	O
slowing	O
the	O
rate	O
of	O
bacterial	O
growth	O
.	O
      
Alteration	O
of	O
pH	O
may	O
affect	O
absorption	O
of	O
certain	O
drugs	O
(	O
e.g.	O
ketoconazole	B-Drug
)	O
.	O
      
Peak	O
plasma	O
concentrations	O
and	O
AUC	O
of	O
rimantadine	B-Drug
were	O
reduced	O
approximately	O
9	O
%	O
in	O
the	O
presence	O
of	O
aspirin	B-Brand
.	O
      
Carbidopa	B-Drug
/	O
Levodopa	B-Drug
:	O
Carbidopa	B-Drug
/	O
Levodopa	B-Drug
does	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
pramipexole	B-Drug
in	O
healthy	O
volunteers	O
(	O
N=	O
9	O
)	O
.	O
      
Antacids	B-Group
:	O
Concomitant	O
administration	O
of	O
aluminum	B-Drug
and	O
magnesium	B-Drug
hydroxides	I-Drug
does	O
not	O
interfere	O
with	O
absorption	O
of	O
meclofenamate	B-Drug
sodium	I-Drug
.	O
      
Concomitant	O
administration	O
of	O
substances	O
that	O
are	O
also	O
tubularly	O
secreted	O
(	O
e.g.	O
probenecid	B-Drug
)	O
could	O
potentially	O
result	O
in	O
delayed	O
clearance	O
of	O
ALIMTA	B-Brand
.	O
      
.	O
      
Antihypertensives	B-Group
:	O
Amphetamines	B-Group
may	O
antagonize	O
the	O
hypotensive	O
effects	O
of	O
antihypertensives	B-Group
.	O
      
In	O
vitro	O
buspirone	B-Drug
does	O
not	O
displace	O
tightly	O
bound	O
drugs	O
like	O
phenytoin	B-Drug
propranolol	B-Drug
and	O
warfarin	B-Drug
from	O
serum	O
proteins	O
.	O
      
Prescribers	O
are	O
advised	O
to	O
consult	O
the	O
package	O
insert	O
of	O
medication	O
administered	O
concomitantly	O
with	O
hormonal	B-Group
contraceptives	I-Group
since	O
some	O
medications	O
may	O
decrease	O
the	O
effectiveness	O
of	O
these	O
birth	O
control	O
products	O
.	O
      
Aspirin	B-Brand
/	O
Acetaminophen	B-Drug
:	O
Pharmacokinetic	O
or	O
pharmacodynamic	O
drug	O
-	O
drug	O
interactions	O
have	O
not	O
been	O
demonstrated	O
between	O
Argatroban	B-Drug
and	O
concomitantly	O
administered	O
aspirin	B-Brand
(	O
9	O
mg	O
orally	O
given	O
9	O
and	O
9	O
hours	O
prior	O
to	O
initiation	O
of	O
Argatroban	B-Drug
9	O
g	O
/	O
kg	O
/	O
min	O
.	O
over	O
9	O
hours	O
)	O
or	O
acetaminophen	B-Drug
(	O
9	O
mg	O
orally	O
given	O
9	O
9	O
and	O
9	O
hours	O
prior	O
to	O
and	O
9	O
and	O
9	O
hours	O
subsequent	O
to	O
initiation	O
of	O
Argatroban	B-Drug
9	O
g	O
/	O
kg	O
/	O
min	O
.	O
over	O
9	O
hours	O
)	O
.	O
      
Oral	O
Contraceptives	B-Group
:	O
Valdecoxib	B-Drug
(	O
9	O
mg	O
BID	O
)	O
did	O
not	O
induce	O
the	O
metabolism	O
of	O
the	O
combination	O
oral	O
contraceptive	B-Group
norethindrone	B-Drug
/	O
ethinyl	B-Drug
estradiol	I-Drug
(	O
9	O
mg	O
/	O
9	O
mcg	O
combination	O
Ortho	B-Brand
-	O
Novum	I-Brand
9	O
/	O
9	O
)	O
.	O
      
Serum	O
theophylline	B-Drug
concentrations	O
increase	O
when	O
grepafloxacin	B-Drug
is	O
initiated	O
in	O
a	O
patient	O
maintained	O
on	O
theophylline	B-Drug
.	O
      
These	O
effects	O
are	O
usually	O
reversible	O
.	O
      
The	O
effect	O
of	O
BREVIBLOC	B-Drug
on	O
the	O
duration	O
of	O
succinylcholine	B-Drug
-	O
induced	O
neuromuscular	O
blockade	O
was	O
studied	O
in	O
patients	O
undergoing	O
surgery	O
.	O
      
These	O
drugs	O
should	O
be	O
coadministered	O
with	O
caution	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	B-Drug
levels	O
is	O
recommended	O
.	O
      
therefore	O
patients	O
should	O
be	O
followed	O
carefully	O
during	O
concurrent	O
therapy	O
.	O
      
No	O
formal	O
drug	O
-	O
interaction	O
studies	O
have	O
been	O
performed	O
and	O
a	O
clinically	O
significant	O
interaction	O
with	O
other	O
medications	O
used	O
in	O
the	O
treatment	O
of	O
hypoxic	O
respiratory	O
failure	O
can	O
not	O
be	O
excluded	O
based	O
on	O
the	O
available	O
data	O
.	O
      
Warfarin	B-Drug
:	O
Meclofenamate	B-Drug
sodium	I-Drug
enhances	O
the	O
effect	O
of	O
warfarin	B-Drug
.	O
      
in	O
vitro	O
data	O
on	O
metabolic	O
interactions	O
indicate	O
that	O
Keppra	B-Brand
is	O
unlikely	O
to	O
produce	O
or	O
be	O
subject	O
to	O
pharmacokinetic	O
interactions	O
.	O
      
There	O
are	O
other	O
agents	O
that	O
may	O
result	O
in	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
drug	O
interactions	O
.	O
      
No	O
drug	O
interactions	O
of	O
clinical	O
importance	O
have	O
been	O
identified	O
.	O
      
Lithium	B-Drug
:	O
Diclofenac	B-Drug
decreases	O
lithium	B-Drug
renal	O
clearance	O
and	O
increases	O
lithium	B-Drug
plasma	O
levels	O
.	O
      
Anticoagulants	B-Group
:	O
Ten	O
patients	O
who	O
were	O
stabilized	O
on	O
oral	O
anticoagulants	B-Group
were	O
given	O
guanfacine	B-Drug
9	O
-	O
9	O
mg	O
/	O
day	O
for	O
9	O
weeks	O
.	O
      
Particular	O
caution	O
should	O
be	O
observed	O
with	O
digitalis	B-Group
preparations	I-Group
since	O
there	O
are	O
conflicting	O
results	O
for	O
the	O
effect	O
of	O
colestipol	B-Drug
hydrochloride	I-Drug
on	O
the	O
availability	O
of	O
digoxin	B-Drug
and	O
digitoxin	B-Drug
.	O
      
May	O
interact	O
with	O
thyroid	O
medication	O
(	O
e.g.	O
levothyroxine	B-Drug
)	O
iodine	B-Drug
-	O
containing	O
products	O
antacids	B-Group
H9	B-Group
-	O
antagonists	I-Group
(	O
e.g.	O
famotidine	B-Drug
ranitidine	B-Drug
)	O
and	O
proton	B-Group
pump	I-Group
inhibitors	I-Group
(	O
e.g.	O
lansoprazole	B-Drug
omeprazole	B-Drug
)	O
.	O
      
As	O
with	O
some	O
other	O
nondepolarizing	B-Group
neuromuscular	I-Group
blocking	I-Group
agents	I-Group
the	O
time	O
of	O
onset	O
of	O
neuromuscular	O
block	O
induced	O
by	O
NUROMAX	B-Brand
is	O
lengthened	O
and	O
the	O
duration	O
of	O
block	O
is	O
shortened	O
in	O
patients	O
receiving	O
phenytoin	B-Drug
or	O
carbamazepine	B-Drug
.	O
      
Care	O
should	O
be	O
taken	O
when	O
using	O
immunoanalytical	O
methods	O
to	O
measure	O
plasma	O
phenytoin	B-Drug
concentrations	O
following	O
Cerebyx	B-Brand
administration	O
.	O
      
Anesthetics	B-Group
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
During	O
TNKase	B-Brand
therapy	O
results	O
of	O
coagulation	O
tests	O
and	O
/	O
or	O
measures	O
of	O
fibrinolytic	O
activity	O
may	O
be	O
unreliable	O
unless	O
specific	O
precautions	O
are	O
taken	O
to	O
prevent	O
in	O
vitro	O
artifacts	O
.	O
      
Drug	O
Interaction	O
with	O
Fluoxetine	B-Drug
:	O
A	O
multiple	O
-	O
dose	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
effect	O
of	O
fluoxetine	B-Drug
9	O
mg	O
BID	O
on	O
the	O
pharmacokinetics	O
of	O
estazolam	B-Drug
9	O
mg	O
QHS	O
after	O
seven	O
days	O
.	O
      
Concomitant	O
oral	O
administration	O
of	O
ketoconazole	B-Drug
(	O
a	O
known	O
inhibitor	O
of	O
CYP9A9	O
activity	O
in	O
the	O
liver	O
and	O
in	O
the	O
intestinal	O
mucosa	O
)	O
caused	O
an	O
eight	O
-	O
fold	O
increase	O
of	O
the	O
systemic	O
exposure	O
to	O
oral	O
budesonide	B-Drug
.	O
      
Although	O
bupropion	B-Drug
is	O
not	O
metabolized	O
by	O
this	O
isoenzyme	O
bupropion	B-Drug
and	O
hydroxybupropion	B-Drug_n
are	O
inhibitors	O
of	O
the	O
CYP9D9	O
isoenzyme	O
in	O
vitro	O
.	O
      
DIFLUCAN	B-Brand
reduces	O
the	O
metabolism	O
of	O
tolbutamide	B-Drug
glyburide	B-Drug
and	O
glipizide	B-Drug
and	O
increases	O
the	O
plasma	O
concentration	O
of	O
these	O
agents	O
.	O
      
Periodic	O
measurement	O
of	O
serum	O
PSA	O
levels	O
may	O
also	O
be	O
considered	O
.	O
      
Concomitant	O
administration	O
of	O
CHEMET	B-Brand
with	O
other	O
chelation	O
therapy	O
such	O
as	O
CaNa	B-Drug
9	I-Drug
EDTA	I-Drug
is	O
not	O
recommended	O
.	O
      
These	O
medications	O
have	O
included	O
heparin	B-Drug
warfarin	B-Drug
beta	B-Group
-	O
adrenergic	I-Group
receptor	I-Group
blockers	I-Group
calcium	B-Group
channel	I-Group
antagonists	I-Group
angiotensin	B-Group
converting	I-Group
enzyme	I-Group
inhibitors	I-Group
intravenous	O
and	O
oral	O
nitrates	B-Group
ticlopidine	B-Drug
and	O
aspirin	B-Brand
.	O
      
Coadministration	O
of	O
NIZORAL	B-Brand
Tablets	O
with	O
midazolam	B-Drug
or	O
triazolam	B-Drug
has	O
resulted	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
latter	O
two	O
drugs	O
.	O
      
A	O
drug	O
-	O
drug	O
interaction	O
study	O
with	O
rifampin	B-Drug
in	O
healthy	O
volunteers	O
has	O
shown	O
a	O
9	O
%	O
decrease	O
in	O
caspofungin	B-Drug
trough	O
concentrations	O
.	O
      
9	O
.	O
      
Haloperidol	B-Drug
:	O
Haloperidol	B-Drug
blocks	O
dopamine	O
receptors	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	B-Group
.	O
      
Indinavir	B-Drug
and	O
didanosine	B-Drug
formulations	O
containing	O
buffer	O
should	O
be	O
administered	O
at	O
least	O
one	O
hour	O
apart	O
on	O
an	O
empty	O
stomach	O
.	O
      
The	O
benzodiazepines	B-Group
including	O
alprazolam	B-Drug
produce	O
additive	O
CNS	O
depressant	O
effects	O
when	O
co	O
-	O
administered	O
with	O
other	O
psychotropic	B-Group
medications	I-Group
anticonvulsants	B-Group
antihistaminics	B-Group
ethanol	B-Drug
and	O
other	O
drugs	O
which	O
themselves	O
produce	O
CNS	O
depression	O
.	O
      
The	O
effect	O
of	O
these	O
interactions	O
on	O
mean	O
AUCs	O
and	O
Cmin	O
are	O
summarized	O
in	O
Table	O
9	O
:	O
Table	O
9	O
:	O
Summary	O
of	O
AED	O
interactions	O
with	O
Trileptal	B-Brand
      
Reported	O
examples	O
of	O
this	O
interaction	O
include	O
the	O
following	O
:	O
Immunosuppressives	B-Drug
:	O
Cyclosporine	B-Drug
(	O
CYP9A9	B-Drug
substrate	O
)	O
administered	O
in	O
combination	O
with	O
oral	O
amiodarone	B-Drug
has	O
been	O
reported	O
to	O
produce	O
persistently	O
elevated	O
plasma	O
concentrations	O
of	O
cyclosporine	B-Drug
resulting	O
in	O
elevated	O
creatinine	O
despite	O
reduction	O
in	O
dose	O
of	O
cyclosporine	B-Drug
.	O
      
In	O
a	O
study	O
in	O
which	O
patients	O
with	O
active	O
RA	O
were	O
treated	O
for	O
up	O
to	O
9	O
weeks	O
with	O
concurrent	O
ENBREL	B-Brand
and	O
anakinra	B-Drug
therapy	O
a	O
9	O
%	O
rate	O
of	O
serious	O
infections	O
was	O
observed	O
which	O
was	O
higher	O
than	O
that	O
observed	O
with	O
ENBREL	B-Brand
alone	O
(	O
9	O
%	O
)	O
.	O
      
Hypokalemia	O
may	O
increase	O
susceptibility	O
to	O
cardiac	O
arrhythmias	O
in	O
patients	O
treated	O
with	O
digitalis	B-Group
.	O
      
however	O
patients	O
should	O
be	O
monitored	O
for	O
the	O
signs	O
and	O
symptoms	O
of	O
increased	O
narcotic	O
effect	O
.	O
      
Because	O
many	O
drugs	O
are	O
excreted	O
in	O
human	O
milk	O
and	O
because	O
there	O
exists	O
the	O
potential	O
for	O
serious	O
adverse	O
reactions	O
in	O
nursing	O
infants	O
from	O
AMEVIVE	B-Brand
a	O
decision	O
should	O
be	O
made	O
whether	O
to	O
discontinue	O
nursing	O
while	O
taking	O
the	O
drug	O
or	O
to	O
discontinue	O
the	O
use	O
of	O
the	O
drug	O
taking	O
into	O
account	O
the	O
importance	O
of	O
the	O
drug	O
to	O
the	O
mother	O
.	O
      
Examples	O
of	O
some	O
of	O
the	O
more	O
potent	O
CYP	O
9A9	O
inhibitors	O
include	O
macrolide	B-Group
antibiotics	I-Group
(	O
e.g.	O
erythromycin	B-Drug
troleandomycin	B-Drug
clarithromycin	B-Drug
)	O
HIV	B-Group
protease	I-Group
or	O
reverse	B-Group
transcriptase	I-Group
inhibitors	I-Group
(	O
e.g.	O
ritonavir	B-Drug
indinavir	B-Drug
nelfinavir	B-Drug
delavirdine	B-Drug
)	O
or	O
azole	B-Group
antifungals	I-Group
(	O
e.g.	O
ketoconazole	B-Drug
itraconazole	B-Drug
voriconazole	B-Drug
)	O
.	O
      
Upon	O
administration	O
of	O
9	O
mg	O
of	O
Vardenafil	B-Drug
with	O
9	O
mg	O
TID	O
indinavir	B-Drug
the	O
Cmax	O
and	O
AUC	O
of	O
indinavir	B-Drug
were	O
reduced	O
by	O
9	O
%	O
and	O
9	O
%	O
respectively	O
.	O
      
Higher	O
dosage	O
of	O
oral	O
hypoglycemic	B-Group
agents	I-Group
may	O
be	O
required	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interferences	O
:	O
Dicumarol	B-Drug
and	O
indanedione	B-Group
anticoagulants	I-Group
including	O
anisindione	B-Drug
or	O
their	O
metabolites	O
may	O
color	O
alkaline	O
urine	O
red	O
-	O
orange	O
which	O
may	O
interfere	O
with	O
spectrophotometrically	O
determined	O
urinary	O
laboratory	O
tests	O
.	O
      
Warfarin	B-Drug
:	O
Quinolones	B-Group
including	O
enoxacin	B-Drug
decrease	O
the	O
clearance	O
of	O
R	B-Drug
-	O
warfarin	I-Drug
the	O
less	O
active	O
isomer	O
of	O
racemic	O
warfarin	B-Drug
.	O
      
Insulin	B-Drug
or	O
Oral	O
Hypoglycemics	B-Group
:	O
Agents	B-Group
with	I-Group
b	I-Group
-	O
blocking	I-Group
properties	I-Group
may	O
enhance	O
the	O
blood	O
-	O
sugar	O
-	O
reducing	O
effect	O
of	O
insulin	B-Drug
and	O
oral	O
hypoglycemics	B-Group
.	O
      
Pyrazolone	B-Group
Derivatives	I-Group
(	O
phenylbutazone	B-Drug
oxyphenbutazone	B-Drug
and	O
possibly	O
dipyrone	B-Drug
)	O
:	O
Concomitant	O
administration	O
with	O
aspirin	B-Drug
may	O
increase	O
the	O
risk	O
of	O
gastrointestinal	O
ulceration	O
.	O
      
Based	O
on	O
the	O
chemical	O
resemblance	O
of	O
itraconazole	B-Drug
and	O
ketoconazole	B-Drug
coadministration	O
of	O
astemizole	B-Drug
with	O
itraconazole	B-Drug
is	O
contraindicated	O
.	O
      
Tizoxanide	B-Drug
is	O
highly	O
bound	O
to	O
plasma	O
protein	O
(	O
9	O
%	O
)	O
.	O
      
clinical	O
implications	O
are	O
unclear	O
.	O
      
In	O
some	O
patients	O
the	O
administration	O
of	O
a	O
non	B-Group
-	O
steroidal	I-Group
antiinflammatory	I-Group
agent	I-Group
can	O
reduce	O
the	O
diuretic	O
natriuretic	O
and	O
antihypertensive	O
effects	O
of	O
loop	B-Group
potassium	B-Group
-	O
sparing	I-Group
and	O
thiazide	B-Group
diuretics	I-Group
.	O
      
Both	O
CRIXIVAN	B-Brand
and	O
atazanavir	B-Drug
are	O
associated	O
with	O
indirect	O
(	O
unconjugated	O
)	O
hyperbilirubinemia	O
.	O
      
These	O
reactions	O
have	O
also	O
been	O
reported	O
in	O
patients	O
who	O
have	O
discontinued	O
that	O
drug	O
and	O
have	O
been	O
started	O
on	O
a	O
MAOI	B-Group
.	O
      
vii	O
.	O
      
Administer	O
LEVSIN	B-Brand
before	O
meals	O
;	O
      
Drugs	O
With	O
A	O
Narrow	O
Therapeutic	O
Index	O
Digoxin	B-Drug
A	O
single	O
dose	O
of	O
eszopiclone	B-Drug
9	O
mg	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
measured	O
at	O
steady	O
state	O
following	O
dosing	O
of	O
9	O
mg	O
twice	O
daily	O
for	O
one	O
day	O
and	O
9	O
mg	O
daily	O
for	O
the	O
next	O
9	O
days	O
.	O
      
General	O
:	O
Significant	O
interactions	O
may	O
occur	O
when	O
celecoxib	B-Drug
is	O
administered	O
together	O
with	O
drugs	O
that	O
inhibit	O
P9	O
9C9	O
.	O
      
Cholestyramine	B-Drug
:	O
Pretreatment	O
for	O
four	O
days	O
with	O
cholestyramine	B-Drug
significantly	O
increased	O
the	O
clearance	O
of	O
meloxicam	B-Drug
by	O
9	O
%	O
.	O
      
Although	O
undercarboxylated	O
osteocalcin	O
a	O
marker	O
of	O
vitamin	O
K	O
nutritional	O
status	O
was	O
unaltered	O
with	O
XENICAL	B-Brand
administration	O
vitamin	O
K	O
levels	O
tended	O
to	O
decline	O
in	O
subjects	O
taking	O
XENICAL	B-Brand
.	O
      
Ritonavir	B-Drug
and	O
indinavir	B-Drug
:	O
Upon	O
concomitant	O
administration	O
of	O
9	O
mg	O
of	O
Vardenafil	B-Drug
with	O
9	O
mg	O
BID	O
ritonavir	B-Drug
the	O
Cmax	O
and	O
AUC	O
of	O
ritonavir	B-Drug
were	O
reduced	O
by	O
approximately	O
9	O
%	O
.	O
      
Sucralfate	B-Drug
should	O
not	O
be	O
taken	O
within	O
9	O
hours	O
of	O
FACTIVE	B-Brand
.	O
      
Trough	O
plasma	O
enoxacin	B-Drug
levels	O
were	O
also	O
9	O
%	O
higher	O
when	O
caffeine	B-Drug
and	O
enoxacin	B-Drug
were	O
administered	O
concomitantly	O
.	O
      
ANTACID	B-Group
(	O
Magnesium	B-Drug
-	O
Aluminum	I-Drug
Hydroxide	I-Drug
)	O
:	O
Cerivastatin	B-Drug
plasma	O
concentrations	O
were	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
antacid	B-Group
.	O
      
Drugs	O
that	O
impair	O
intestinal	O
absorption	O
of	O
fat	B-Group
-	O
soluble	I-Group
vitamins	I-Group
such	O
as	O
cholestyramine	B-Drug
may	O
interfere	O
with	O
the	O
absorption	O
of	O
Zemplar	B-Brand
Capsules	O
.	O
      
Carbamazepine	B-Drug
:	O
In	O
healthy	O
subjects	O
receiving	O
the	O
CYP9A9	O
inducer	O
carbamazepine	B-Drug
at	O
9	O
mg	O
twice	O
daily	O
for	O
9	O
days	O
and	O
9	O
mg	O
twice	O
daily	O
for	O
9	O
days	O
systemic	O
exposure	O
(	O
AUC	O
)	O
to	O
lapatinib	B-Drug
was	O
decreased	O
approximately	O
9	O
%	O
.	O
      
Although	O
the	O
specific	O
drug	O
interaction	O
was	O
not	O
studied	O
in	O
a	O
clinical	O
trial	O
there	O
have	O
been	O
more	O
than	O
9	O
episodes	O
of	O
concomitant	O
use	O
of	O
antifibrinolytic	O
therapies	O
(	O
i.e.	O
tranexamic	B-Drug
acid	I-Drug
aminocaproic	B-Drug
acid	I-Drug
)	O
and	O
NovoSeven	B-Brand
.	O
      
The	O
drug	O
interaction	O
studies	O
with	O
valdecoxib	B-Drug
were	O
performed	O
both	O
with	O
valdecoxib	B-Drug
and	O
a	O
rapidly	O
hydrolyzed	O
intravenous	O
prodrug	O
form	O
.	O
      
9	O
.	O
      
The	O
effect	O
of	O
cyclosporine	B-Drug
on	O
diltiazem	B-Drug
plasma	O
concentrations	O
has	O
not	O
been	O
evaluated	O
.	O
      
Serious	O
adverse	O
events	O
have	O
been	O
reported	O
in	O
concomitant	O
use	O
with	O
clonidine	B-Drug
although	O
no	O
causality	O
for	O
the	O
combination	O
has	O
been	O
established	O
.	O
      
The	O
concomitant	O
use	O
of	O
alcohol	B-Drug
or	O
other	O
central	B-Group
nervous	I-Group
system	I-Group
depressants	I-Group
may	O
have	O
an	O
additive	O
effect	O
.	O
      
Although	O
MIVACRON	B-Brand
(	O
a	O
mixture	O
of	O
three	O
stereoisomers	O
)	O
has	O
been	O
administered	O
safely	O
following	O
succinylcholine	O
-	O
facilitated	O
tracheal	O
intubation	O
the	O
interaction	O
between	O
MIVACRON	B-Brand
and	O
succinylcholine	B-Drug
has	O
not	O
been	O
systematically	O
studied	O
.	O
      
as	O
well	O
as	O
atropine	B-Drug
and	O
phosphorous	B-Drug_n
insecticides	I-Drug_n
.	O
      
Norepinephrine	B-Drug
      
It	O
is	O
recommended	O
that	O
in	O
patients	O
taking	O
anticoagulants	B-Group
prothrombin	O
time	O
be	O
determined	O
before	O
starting	O
lovastatin	B-Drug
and	O
frequently	O
enough	O
during	O
early	O
therapy	O
to	O
insure	O
that	O
no	O
significant	O
alteration	O
of	O
prothrombin	O
time	O
occurs	O
.	O
      
When	O
amiloride	B-Drug
HCl	O
is	O
administered	O
concomitantly	O
with	O
an	O
angiotensin	B-Group
-	O
converting	I-Group
enzyme	I-Group
inhibitor	I-Group
the	O
risk	O
of	O
hyperkalemia	O
may	O
be	O
increased	O
.	O
      
If	O
these	O
drugs	O
are	O
to	O
be	O
used	O
in	O
the	O
initial	O
treatment	O
of	O
severe	O
malaria	O
Mefloquine	B-Drug
administration	O
should	O
be	O
delayed	O
at	O
least	O
9	O
hours	O
after	O
the	O
last	O
dose	O
.	O
      
Alcohol	B-Drug
in	O
particular	O
has	O
been	O
found	O
to	O
exhibit	O
additive	O
effects	O
of	O
this	O
variety	O
.	O
      
Tetracyclines	B-Group
:	O
Concomitant	O
treatment	O
with	O
Accutane	B-Brand
and	O
tetracyclines	B-Group
should	O
be	O
avoided	O
because	O
Accutane	B-Brand
use	O
has	O
been	O
associated	O
with	O
a	O
number	O
of	O
cases	O
of	O
pseudotumor	O
cerebri	O
(	O
benign	O
intracranial	O
hypertension	O
)	O
some	O
of	O
which	O
involved	O
concomitant	O
use	O
of	O
tetracyclines	B-Group
      
Valdecoxib	B-Drug
caused	O
a	O
statistically	O
significant	O
increase	O
in	O
plasma	O
exposures	O
of	O
R	B-Drug
-	O
warfarin	I-Drug
and	O
S	B-Drug
-	O
warfarin	I-Drug
(	O
9	O
%	O
and	O
9	O
%	O
respectively	O
)	O
and	O
in	O
the	O
pharmacodynamic	O
effects	O
(	O
prothrombin	O
time	O
measured	O
as	O
INR	O
)	O
of	O
warfarin	B-Drug
.	O
      
Coadministration	O
of	O
Itraconazole	B-Drug
and	O
drugs	O
primarily	O
metabolized	O
by	O
the	O
cytochrome	O
P9	O
9A9	O
enzyme	O
system	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
the	O
drugs	O
that	O
could	O
increase	O
or	O
prolong	O
both	O
therapeutic	O
and	O
adverse	O
effects	O
.	O
      
Population	O
pharmacokinetic	O
studies	O
showed	O
higher	O
concentrations	O
of	O
cilostazol	B-Drug
among	O
patients	O
concurrently	O
treated	O
with	O
diltiazem	B-Drug
an	O
inhibitor	O
of	O
C.P.A..	O
      
Cholestyramine	B-Drug
:	O
Cholestyramine	B-Drug
binds	O
both	O
T9	B-Drug
and	O
T9	B-Drug
in	O
the	O
intestine	O
thus	O
impairing	O
absorption	O
of	O
these	O
thyroid	B-Group
hormones	I-Group
.	O
      
Cyclosporine	B-Drug
tacrolimus	B-Drug
and	O
digoxin	B-Drug
concentrations	O
should	O
be	O
monitored	O
at	O
the	O
initiation	O
of	O
Itraconazole	B-Drug
therapy	O
and	O
frequently	O
thereafter	O
and	O
the	O
dose	O
of	O
these	O
three	O
drug	O
products	O
adjusted	O
appropriately	O
.	O
      
Preliminary	O
clinical	O
data	O
suggest	O
that	O
the	O
incidence	O
of	O
nephrolithiasis	O
is	O
higher	O
in	O
patients	O
receiving	O
indinavir	B-Drug
in	O
combination	O
with	O
ritonavir	B-Drug
than	O
those	O
receiving	O
CRIXIVAN	B-Brand
9	O
mg	O
q9h	O
.	O
      
The	O
interaction	O
between	O
lomefloxacin	B-Drug
and	O
cimetidine	B-Drug
has	O
not	O
been	O
studied	O
.	O
      
The	O
physician	O
is	O
advised	O
to	O
monitor	O
the	O
plasma	O
concentrations	O
of	O
itraconazole	B-Drug
when	O
any	O
of	O
these	O
drugs	O
is	O
taken	O
concurrently	O
and	O
to	O
increase	O
the	O
dose	O
of	O
Itraconazole	B-Drug
if	O
necessary	O
.	O
      
Proquin	B-Brand
XR	I-Brand
should	O
be	O
administered	O
at	O
least	O
9	O
hours	O
before	O
or	O
9	O
hours	O
after	O
these	O
products	O
.	O
      
Dose	O
adjustments	O
of	O
either	O
class	O
of	O
agents	O
may	O
be	O
necessary	O
.	O
      
A	O
multiple	O
dose	O
drug	O
-	O
drug	O
interaction	O
study	O
demonstrated	O
that	O
ketoconazole	B-Drug
approximately	O
doubled	O
paricalcitol	B-Drug
AUC9	O
-	O
.	O
Since	O
paricalcitol	B-Drug
is	O
partially	O
metabolized	O
by	O
CYP9A	O
and	O
ketoconazole	B-Drug
le	O
is	O
known	O
to	O
be	O
a	O
strong	O
inhibitor	O
of	O
cytochrome	O
P9	O
9A	O
enzyme	O
care	O
should	O
be	O
taken	O
while	O
dosing	O
paricalcitol	B-Drug
with	O
ketoconazole	B-Drug
and	O
other	O
strong	O
P9	O
9A	O
inhibitors	O
including	O
atazanavir	B-Drug
clarithromycin	B-Drug
indinavir	B-Drug
itraconazole	B-Drug
nefazodone	B-Drug
nelfinavir	B-Drug
ritonavir	B-Drug
saquinavir	B-Drug
telithromycin	B-Drug
or	O
voriconazole	B-Drug
.	O
      
However	O
reports	O
suggest	O
that	O
NSAIDs	B-Group
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	B-Group
inhibitors	I-Group
.	O
      
Concomitant	O
administration	O
of	O
other	O
sympathomimetic	B-Group
agents	I-Group
may	O
potentiate	O
the	O
undesirable	O
effects	O
of	O
FORADIL	B-Brand
.	O
      
CRIXIVAN	B-Brand
may	O
not	O
be	O
effective	O
due	O
to	O
decreased	O
indinavir	B-Drug
concentrations	O
in	O
patients	O
taking	O
these	O
agents	O
concomitantly	O
.	O
      
Thus	O
it	O
is	O
recommended	O
not	O
to	O
use	O
such	O
methods	O
for	O
9	O
-	O
9	O
hours	O
after	O
administration	O
of	O
Omniscan	B-Brand
.	O
      
Ketoconazole	B-Drug
      
Cimetidine	B-Drug
treatment	O
should	O
be	O
stopped	O
during	O
treatment	O
with	O
ELLENCE	B-Brand
.	O
      
astemizole	B-Drug
bepridil	B-Drug
sparfloxacin	B-Drug
and	O
terodiline	B-Drug
.	O
      
Tricyclic	B-Group
Antidepressants	I-Group
:	O
Use	O
of	O
thyroid	B-Group
products	I-Group
with	O
imipramine	B-Drug
and	O
other	O
tricyclic	B-Group
antidepressants	I-Group
may	O
increase	O
receptor	O
sensitivity	O
and	O
enhance	O
antidepressant	O
activity	O
transient	O
cardiac	O
arrhythmias	O
have	O
been	O
observed	O
.	O
      
Lovastatin	B-Drug
      
These	O
cephalosporins	B-Group
are	O
inhibitors	O
of	O
hepatic	O
vitamin	O
K	O
epoxide	O
reductase	O
.	O
      
This	O
diminution	O
is	O
not	O
sufficient	O
to	O
preclude	O
effectiveness	O
of	O
the	O
pressor	O
agent	O
for	O
therapeutic	O
use	O
.	O
      
When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
DIABINESE	B-Brand
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O
      
Therefore	O
if	O
concomitant	O
use	O
of	O
such	O
agents	O
is	O
indicated	O
they	O
should	O
be	O
given	O
with	O
caution	O
and	O
the	O
patient	O
's	O
serum	O
potassium	O
should	O
be	O
monitored	O
.	O
      
(	O
May	O
inhibit	O
gastrointestinal	O
absorption	O
of	O
the	O
thiazide	B-Group
diuretics	I-Group
;	O
      
INH	B-Drug
(	O
Isoniazid	B-Drug
)	O
is	O
also	O
reported	O
to	O
affect	O
ketoconazole	B-Drug
concentrations	O
adversely	O
.	O
      
Caution	O
should	O
be	O
used	O
when	O
EVISTA	B-Brand
is	O
coadministered	O
with	O
other	O
highly	O
protein	O
-	O
bound	O
drugs	O
such	O
as	O
clofibrate	B-Drug
indomethacin	B-Drug
naproxen	B-Drug
ibuprofen	B-Drug
diazepam	B-Drug
and	O
diazoxide	B-Drug
.	O
      
The	O
ratios	O
of	O
the	O
AUCs	O
of	O
unbound	O
valproate	B-Drug
to	O
the	O
AUCs	O
of	O
the	O
total	O
valproate	B-Drug
were	O
9	O
%	O
9	O
%	O
and	O
9	O
%	O
with	O
coadministration	O
of	O
9	O
9	O
and	O
9	O
mg	O
/	O
day	O
of	O
Felbatol	B-Brand
respectively	O
.	O
      
Cyclosporine	B-Drug
:	O
Administration	O
of	O
nonsteroial	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
concomitantly	O
with	O
cyclosporine	B-Drug
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
cyclosporine	B-Drug
-	O
induced	O
toxicity	O
possibly	O
due	O
to	O
decreased	O
synthesis	O
of	O
renal	O
prostacyclin	O
.	O
      
CELEBREX	B-Brand
should	O
be	O
introduced	O
at	O
the	O
lowest	O
recommended	O
dose	O
in	O
patients	O
receiving	O
fluconazole	B-Drug
.	O
      
A	O
9	O
to	O
9	O
%	O
increase	O
in	O
AUC	O
and	O
Cmax	O
of	O
nisoldipine	B-Drug
was	O
observed	O
with	O
concomitant	O
administration	O
of	O
cimetidine	B-Drug
9	I-Drug
mg	I-Drug
twice	O
daily	O
.	O
      
These	O
increases	O
in	O
concentration	O
may	O
lead	O
to	O
increased	O
effects	O
(	O
lower	O
blood	O
pressure	O
and	O
increased	O
heart	O
rate	O
)	O
.	O
      
However	O
antacids	B-Group
can	O
decrease	O
the	O
peak	O
concentration	O
reached	O
by	O
9	O
%	O
to	O
9	O
%	O
but	O
have	O
no	O
detectable	O
effect	O
on	O
the	O
time	O
-	O
to	O
-	O
peak	O
.	O
      
In	O
the	O
long	O
-	O
term	O
safety	O
studies	O
guanfacine	B-Drug
was	O
given	O
concomitantly	O
with	O
many	O
drugs	O
without	O
evidence	O
of	O
any	O
interactions	O
.	O
      
Because	O
of	O
the	O
potential	O
for	O
adverse	O
reactions	O
from	O
the	O
drugs	O
in	O
nursing	O
infants	O
a	O
decision	O
must	O
be	O
made	O
whether	O
to	O
discontinue	O
nursing	O
or	O
discontinue	O
PEGASYS	B-Brand
and	O
COPEGUS	B-Brand
treatment	O
.	O
      
Because	O
the	O
potential	O
interaction	O
of	O
efavirenz	B-Drug
with	O
oral	O
contraceptives	B-Group
has	O
not	O
been	O
fully	O
characterized	O
a	O
reliable	O
method	O
of	O
barrier	O
contraception	O
should	O
be	O
used	O
in	O
addition	O
to	O
oral	O
contraceptives	B-Group
.	O
      
Some	O
drug	O
interactions	O
are	O
:	O
-	O
birth	O
control	O
pills	O
-	O
corticosteroids	B-Group
-	O
medicines	O
for	O
angina	O
or	O
high	O
blood	O
pressure	O
-	O
medicines	O
for	O
pain	O
-	O
medicines	O
to	O
control	O
seizures	O
such	O
as	O
phenytoin	B-Drug
or	O
carbamazepine	B-Drug
-	O
certain	O
antibiotics	B-Group
given	O
by	O
injection	O
-	O
cisplatin	B-Drug
-	O
edrophonium	B-Drug
-	O
neostigmine	B-Drug
-	O
polymyxin	B-Drug
B	I-Drug
or	O
bacitracin	B-Drug
-	O
local	O
anesthetics	B-Group
such	O
as	O
procaine	B-Drug
-	O
general	O
anesthetics	B-Group
-	O
succinylcholine	B-Drug
or	O
other	O
muscle	B-Group
relaxants	I-Group
      
Quinidine	B-Drug
at	O
9	O
mg	O
bid	O
decreased	O
the	O
bioavailability	O
(	O
AUC	O
)	O
of	O
nisoldipine	B-Drug
by	O
9	O
%	O
but	O
not	O
the	O
peak	O
concentration	O
.	O
      
INDOCIN	B-Brand
and	O
triamterene	B-Drug
should	O
not	O
be	O
administered	O
together	O
.	O
      
therefore	O
patients	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
such	O
an	O
action	O
should	O
be	O
carefully	O
observed	O
.	O
      
Caution	O
should	O
be	O
used	O
when	O
alosetron	B-Drug
and	O
ketoconazole	B-Drug
are	O
administered	O
concomitantly	O
.	O
      
CNS	O
Toxicity	O
Brain	O
hemorrhage	O
was	O
seen	O
in	O
a	O
female	O
dog	O
treated	O
for	O
9	O
months	O
at	O
9	O
mg	O
/	O
kg	O
/	O
day	O
.	O
      
Also	O
in	O
vitro	O
experiments	O
demonstrated	O
a	O
lack	O
of	O
interaction	O
between	O
dirithromycin	B-Drug
and	O
terfenadine	B-Drug
.	O
      
Both	O
the	O
sedative	O
and	O
anticholinergic	O
effects	O
of	O
the	O
major	B-Group
tranquilizers	I-Group
are	O
also	O
additive	O
to	O
those	O
of	O
desipramine	B-Drug
.	O
      
Caution	O
should	O
be	O
exercised	O
when	O
CYP9A9	O
inhibitors	O
are	O
coadministered	O
.	O
      
Other	O
than	O
with	O
probenecid	B-Drug
no	O
specific	O
clinical	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
      
Sulfamethoxazole	B-Drug
may	O
inhibit	O
the	O
hepatic	O
metabolism	O
of	O
phenytoin	B-Drug
.	O
      
Serum	O
potassium	O
levels	O
and	O
cardiac	O
function	O
should	O
be	O
closely	O
monitored	O
and	O
any	O
deficit	O
promptly	O
corrected	O
.	O
      
Read	O
the	O
circular	O
for	O
lithium	B-Drug
preparations	O
.	O
      
monitor	O
cyclosporine	B-Drug
levels	O
.	O
      
Concurrent	O
use	O
with	O
vasoconstrictor	B-Group
agents	I-Group
including	O
ergot	B-Group
alkaloids	I-Group
sumatriptan	B-Drug
and	O
nicotine	B-Drug
(	O
e.g	O
.	O
smoking	O
)	O
may	O
result	O
in	O
enhanced	O
vasoconstriction	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
The	O
administration	O
of	O
ceftazidime	B-Drug
may	O
result	O
in	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
when	O
using	O
CLINITEST	O
tablets	O
Benedicts	O
solution	O
or	O
Fehlings	O
solution	O
.	O
      
Johns	O
Wort	O
may	O
decrease	O
SUTENT	B-Brand
plasma	O
concentrations	O
unpredictably	O
.	O
      
as	O
such	O
it	O
may	O
impair	O
intestinal	O
absorption	O
of	O
any	O
of	O
vitamin	B-Group
D	I-Group
.	O
      
it	O
is	O
possible	O
that	O
larger	O
theophylline	B-Drug
doses	O
could	O
have	O
a	O
greater	O
effect	O
.	O
      
The	O
concomitant	O
use	O
of	O
Sanctura	B-Brand
with	O
other	O
anticholinergic	B-Group
agents	I-Group
that	O
produce	O
dry	O
mouth	O
constipation	O
and	O
other	O
anticholinergic	O
pharmacological	O
effects	O
may	O
increase	O
the	O
frequency	O
and	O
/	O
or	O
severity	O
of	O
such	O
effects	O
.	O
      
Few	O
systemic	O
data	O
have	O
been	O
collected	O
on	O
the	O
metabolism	O
of	O
WELLBUTRIN	B-Brand
following	O
concomitant	O
administration	O
with	O
other	O
drugs	O
or	O
alternatively	O
the	O
effect	O
of	O
concomitant	O
administration	O
of	O
WELLBUTRIN	B-Brand
on	O
the	O
metabolism	O
of	O
other	O
drugs	O
.	O
      
No	O
differences	O
in	O
safety	O
or	O
efficacy	O
were	O
observed	O
between	O
older	O
and	O
younger	O
patients	O
but	O
there	O
were	O
not	O
sufficient	O
data	O
to	O
exclude	O
important	O
differences	O
.	O
      
monitor	O
and	O
adjust	O
anticoagulant	B-Group
dosage	O
accordingly	O
.	O
      
Additives	O
may	O
be	O
incompatible	O
.	O
      
Potential	O
Terfenadine	B-Drug
Astemizole	B-Drug
and	O
Cisapride	B-Drug
Interactions	O
      
Pharmacokinetic	O
properties	O
of	O
abacavir	B-Drug
were	O
not	O
altered	O
by	O
the	O
addition	O
of	O
either	O
lamivudine	B-Drug
or	O
zidovudine	B-Drug
or	O
the	O
combination	O
of	O
lamivudine	B-Drug
and	O
zidovudine	B-Drug
.	O
      
Medication	O
such	O
as	O
digitalis	B-Group
may	O
also	O
influence	O
serum	O
electrolytes	O
.	O
      
Symptoms	O
resolved	O
when	O
clonidine	B-Drug
was	O
withdrawn	O
and	O
recurred	O
when	O
the	O
patient	O
was	O
rechallenged	O
with	O
clonidine	B-Drug
.	O
      
Tolbutamide	B-Drug
:	O
In	O
in	O
vitro	O
studies	O
M9	O
was	O
shown	O
to	O
cause	O
increases	O
ranging	O
from	O
9	O
-	O
9	O
%	O
in	O
the	O
free	O
fraction	O
of	O
tolbutamide	B-Drug
at	O
concentrations	O
in	O
the	O
clinical	O
range	O
.	O
      
It	O
is	O
recommended	O
that	O
if	O
CASODEX	B-Brand
is	O
started	O
in	O
patients	O
already	O
receiving	O
coumarin	B-Group
anticoagulants	I-Group
prothrombin	O
times	O
should	O
be	O
closely	O
monitored	O
and	O
adjustment	O
of	O
the	O
anticoagulant	B-Group
dose	O
may	O
be	O
necessary	O
.	O
      
Preliminary	O
evidence	O
suggests	O
that	O
cimetidine	B-Drug
inhibits	O
mebendazole	B-Drug
metabolism	O
and	O
may	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
concentrations	O
of	O
mebendazole	B-Drug
.	O
      
Notably	O
systemic	O
exposure	O
(	O
AUC9	O
-	O
9	O
)	O
of	O
dapsone	B-Drug_n
hydroxylamine	I-Drug_n
(	O
DHA	B-Drug_n
)	O
was	O
more	O
than	O
doubled	O
in	O
the	O
presence	O
of	O
TMP	B-Drug
/	O
SMX	B-Drug
.	O
      
In	O
vivo	O
studies	O
:	O
Nitrates	B-Group
:	O
The	O
blood	O
pressure	O
lowering	O
effects	O
of	O
sublingual	O
nitrates	B-Group
(	O
9	O
mg	O
)	O
taken	O
9	O
and	O
9	O
hours	O
after	O
vardenafil	B-Drug
and	O
increases	O
in	O
heart	O
rate	O
when	O
taken	O
at	O
9	O
9	O
and	O
9	O
hours	O
were	O
potentiated	O
by	O
a	O
9	O
mg	O
dose	O
of	O
Vardenafil	B-Drug
in	O
healthy	O
middle	O
-	O
aged	O
subjects	O
.	O
      
When	O
such	O
drugs	O
are	O
administered	O
to	O
a	O
patient	O
receiving	O
glipizide	B-Drug
the	O
patient	O
should	O
be	O
closely	O
observed	O
for	O
loss	O
of	O
control	O
.	O
      
There	O
have	O
been	O
reports	O
of	O
QTc	O
prolongation	O
with	O
or	O
without	O
TdP	O
in	O
patients	O
taking	O
amiodarone	B-Drug
when	O
fluoroquinolones	B-Drug
macrolide	B-Drug
antibiotics	I-Drug
or	O
azoles	O
were	O
administered	O
concomitantly	O
.	O
      
There	O
is	O
no	O
information	O
on	O
the	O
effect	O
of	O
other	O
highly	O
plasma	O
protein	O
bound	O
drugs	O
on	O
doxazosin	B-Drug
binding	O
.	O
      
9%	O
9%	O
9%	O
9%	O
      
-	O
Medicinal	O
or	O
dietary	O
iodine	B-Group
interferes	O
with	O
all	O
in	O
vivo	O
tests	O
of	O
radio	O
-	O
iodine	O
uptake	O
producing	O
low	O
uptakes	O
which	O
may	O
not	O
be	O
reflective	O
of	O
a	O
true	O
decrease	O
in	O
hormone	O
synthesis	O
      
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
drug	O
interactions	O
when	O
erythromycin	B-Drug
is	O
coadministered	O
with	O
cisapride	B-Drug
resulting	O
in	O
QT	O
prolongation	O
cardiac	O
arrythmias	O
ventricular	O
tachycardia	O
ventricular	O
fibrulation	O
and	O
torsades	O
de	O
pointes	O
most	O
like	O
due	O
to	O
inhibition	O
of	O
hepatic	O
metabolism	O
of	O
cisapride	B-Drug
by	O
erythromycin	B-Drug
.	O
      
One	O
case	O
of	O
hypertensive	O
crisis	O
has	O
been	O
reported	O
in	O
a	O
patient	O
taking	O
the	O
recommended	O
doses	O
of	O
selegiline	B-Drug
and	O
a	O
sympathomimetic	B-Group
medication	I-Group
(	O
ephedrine	B-Drug
)	O
.	O
      
Chlorotrianisene	B-Drug
may	O
interact	O
with	O
antidepressants	B-Group
aspirin	B-Brand
barbiturates	B-Group
bromocriptine	B-Drug
calcium	B-Drug
supplements	O
corticosteroids	B-Group
corticotropin	B-Drug
cyclosporine	B-Drug
dantrolene	B-Drug
nicotine	B-Drug
somatropin	B-Drug
tamoxifen	B-Drug
and	O
warfarin	B-Drug
.	O
      
False	O
-	O
positive	O
direct	O
Coombs	O
tests	O
have	O
been	O
reported	O
during	O
treatment	O
with	O
other	O
cephalosporins	B-Group
.	O
      
The	O
concomitant	O
use	O
of	O
diflunisal	B-Drug
tablets	O
and	O
other	O
NSAIDs	B-Group
is	O
not	O
recommended	O
due	O
to	O
the	O
increased	O
possibility	O
of	O
gastrointestinal	O
toxicity	O
with	O
little	O
or	O
no	O
increase	O
in	O
efficacy	O
.	O
      
However	O
this	O
has	O
not	O
been	O
investigated	O
in	O
human	O
studies	O
.	O
      
The	O
effect	O
of	O
theophylline	B-Drug
on	O
the	O
pharmacokinetics	O
of	O
citalopram	B-Drug
was	O
not	O
evaluated	O
.	O
      
This	O
observation	O
should	O
be	O
considered	O
in	O
clinical	O
decisions	O
to	O
prescribe	O
VESIcare	B-Brand
for	O
patients	O
with	O
a	O
known	O
history	O
of	O
QT	O
prolongation	O
or	O
patients	O
who	O
are	O
taking	O
medications	O
known	O
to	O
prolong	O
the	O
QT	O
interval	O
.	O
      
Effect	O
of	O
other	O
drugs	O
on	O
Vardenafil	B-Drug
      
Concomitant	O
use	O
with	O
other	O
calcium	B-Drug
-	O
containing	O
medicines	O
(	O
including	O
antacids	B-Group
)	O
may	O
cause	O
too	O
much	O
calcium	B-Drug
in	O
the	O
blood	O
or	O
urine	O
which	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
.	O
      
A	O
9	O
-	O
fold	O
increase	O
was	O
seen	O
in	O
another	O
9	O
patients	O
.	O
      
BREVIBLOC	B-Brand
concentrations	O
were	O
equivocally	O
higher	O
when	O
given	O
with	O
warfarin	B-Drug
but	O
this	O
is	O
not	O
likely	O
to	O
be	O
clinically	O
important	O
.	O
      
Caution	O
however	O
is	O
advised	O
in	O
patients	O
taking	O
tricyclic	B-Group
antidepressants	I-Group
which	O
can	O
affect	O
the	O
metabolism	O
and	O
uptake	O
of	O
circulating	O
amines	O
.	O
      
Conversely	O
the	O
administration	O
of	O
STADOL	B-Brand
NS	I-Brand
(	O
9	O
mg	O
butorphanol	B-Drug
QID	O
)	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
a	O
9	O
-	O
mg	O
dose	O
of	O
cimetidine	B-Drug
.	O
      
Thus	O
cimetidine	B-Drug
appeared	O
to	O
alter	O
the	O
renal	O
excretion	O
of	O
both	O
gabapentin	B-Drug
and	O
creatinine	O
an	O
endogenous	O
marker	O
of	O
renal	O
function	O
.	O
      
Significant	O
increases	O
In	O
AUC	O
(	O
9	O
%	O
)	O
and	O
Cmax	O
(	O
9	O
%	O
)	O
and	O
decreases	O
in	O
tmax	O
(	O
9	O
%	O
)	O
of	O
propranolol	B-Drug
were	O
noted	O
in	O
this	O
study	O
.	O
      
Probenecid	B-Drug
:	O
Probenecid	B-Drug
a	O
renal	O
tubular	O
secretion	O
blocking	O
agent	O
administered	O
at	O
a	O
dose	O
of	O
9	O
mg	O
four	O
times	O
a	O
day	O
did	O
not	O
change	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B-Drug
9	O
mg	O
twice	O
daily	O
.	O
      
Antifungals	B-Group
      
Drugs	O
such	O
as	O
erythromycin	B-Drug
diltiazem	B-Drug
verapamil	B-Drug
ketoconazole	B-Drug
fluconazole	B-Drug
and	O
itraconazole	B-Drug
were	O
shown	O
to	O
significantly	O
increase	O
the	O
C	O
max	O
and	O
AUC	O
of	O
orally	O
administered	O
midazolam	B-Drug
.	O
      
carbamazepine	B-Drug
;	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
None	O
known	O
.	O
      
Some	O
cases	O
presented	O
with	O
features	O
resembling	O
neuroleptic	O
malignant	O
syndrome	O
.	O
      
Dosage	O
adjustments	O
of	O
BROVANA	B-Brand
are	O
not	O
necessary	O
when	O
the	O
drug	O
is	O
given	O
concomitantly	O
with	O
potent	O
CYP9D9	O
inhibitors	O
.	O
      
Thus	O
careful	O
monitoring	O
of	O
clinical	O
status	O
is	O
warranted	O
when	O
rifampin	B-Drug
is	O
administered	O
or	O
discontinued	O
in	O
haloperidol	B-Drug
-	O
treated	O
patients	O
.	O
      
The	O
magnitude	O
of	O
interaction	O
at	O
other	O
doses	O
is	O
not	O
known	O
.	O
      
DIDREX	B-Brand
should	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
CNS	B-Group
stimulants	I-Group
.	O
      
Starlix	B-Brand
is	O
a	O
potential	O
inhibitor	O
of	O
the	O
CYP9C9	O
isoenzyme	O
in	O
vivo	O
as	O
indicated	O
by	O
its	O
ability	O
to	O
inhibit	O
the	O
in	O
vitro	O
metabolism	O
of	O
tolbutamide	B-Drug
.	O
      
Coadministration	O
of	O
CRIXIVAN	B-Brand
and	O
other	O
drugs	O
that	O
inhibit	O
CYP9A9	O
may	O
decrease	O
the	O
clearance	O
of	O
indinavir	B-Drug
and	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
indinavir	B-Drug
.	O
      
Volatile	O
Anesthetic	B-Drug
Agents	O
:	O
.	O
      
Fulvestrant	B-Drug
is	O
metabolized	O
by	O
CYP	O
9A9	O
in	O
vitro	O
.	O
      
Theophylline	B-Drug
:	O
A	O
single	O
9	O
mg	O
dose	O
of	O
tiagabine	B-Drug
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
theophylline	B-Drug
at	O
steady	O
state	O
.	O
      
Fat	B-Group
-	O
soluble	I-Group
Vitamin	I-Group
Supplements	I-Group
and	O
Analogues	O
:	O
A	O
pharmacokinetic	O
interaction	O
study	O
showed	O
a	O
9	O
%	O
reduction	O
in	O
beta	B-Drug
-	O
carotene	I-Drug
supplement	O
absorption	O
when	O
concomitantly	O
administered	O
with	O
XENICAL	B-Brand
.	O
      
Tubocurarine	B-Drug
      
The	O
effect	O
of	O
alosetron	B-Drug
on	O
monoamine	O
oxidases	O
and	O
on	O
intestinal	O
first	O
pass	O
secondary	O
to	O
high	O
intraluminal	O
concentrations	O
have	O
not	O
been	O
examined	O
.	O
      
Another	O
oral	O
azole	B-Group
antifungal	I-Group
ketoconazole	B-Drug
inhibits	O
the	O
metabolism	O
of	O
astemizole	B-Drug
resulting	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
astemizole	B-Drug
and	O
its	O
active	O
metabolite	O
desmethylastermizole	B-Drug_n
which	O
may	O
prolong	O
QT	O
intervals	O
.	O
      
Methotrexate	B-Drug
:	O
Ketoprofen	B-Drug
like	O
other	O
NSAIDs	B-Group
may	O
cause	O
changes	O
in	O
the	O
elimination	O
of	O
methotrexate	B-Drug
leading	O
to	O
elevated	O
serum	O
levels	O
of	O
the	O
drug	O
and	O
increased	O
toxicity	O
.	O
      
Therefore	O
patients	O
with	O
COPD	O
should	O
not	O
normally	O
be	O
treated	O
with	O
beta	B-Group
-	O
blockers	I-Group
.	O
      
It	O
is	O
possible	O
that	O
the	O
cardiovascular	O
action	O
of	O
other	O
calcium	B-Group
channel	I-Group
blockers	I-Group
could	O
be	O
enhanced	O
by	O
the	O
addition	O
of	O
Nimotop	B-Brand
.	O
      
Plasma	O
concentrations	O
of	O
azole	B-Group
antifungal	I-Group
agents	I-Group
are	O
reduced	O
when	O
given	O
concurrently	O
with	O
isoniazid	B-Drug
.	O
      
In	O
an	O
uncontrolled	O
study	O
of	O
over	O
9	O
patients	O
with	O
congestive	O
heart	O
failure	O
during	O
which	O
digoxin	B-Drug
blood	O
levels	O
were	O
not	O
measured	O
digitalis	O
toxicity	O
was	O
not	O
observed	O
.	O
      
When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
MICRONASE	B-Brand
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
loss	O
of	O
control	O
.	O
      
Bosentan	B-Drug
is	O
an	O
inducer	O
of	O
CYP9A9	O
and	O
CYP9C9	O
.	O
      
The	O
pharmacokinetics	O
of	O
praziquantel	B-Drug
were	O
unchanged	O
following	O
coadministration	O
with	O
albendazole	B-Drug
(	O
9	O
mg	O
)	O
.	O
      
.	O
      
The	O
pharmacokinetic	O
interaction	O
between	O
cimetidine	B-Drug
and	O
FLOMAX	B-Brand
capsules	O
was	O
investigated	O
.	O
      
.	O
      
Acetaminophen	B-Drug
:	O
Rimantadine	B-Drug
HCl	I-Drug
9	O
mg	O
was	O
given	O
twice	O
daily	O
for	O
9	O
days	O
to	O
9	O
healthy	O
volunteers	O
.	O
      
Fluconazole	B-Drug
an	O
inhibitor	O
of	O
P9	O
9C9	O
decreased	O
active	O
metabolite	O
concentration	O
and	O
increased	O
losartan	B-Drug
concentration	O
.	O
      
chymotrypsin	B-Drug
;	O
      
When	O
administering	O
other	O
drugs	O
for	O
which	O
alterations	O
in	O
blood	O
levels	O
could	O
have	O
a	O
clinically	O
significant	O
effect	O
on	O
safety	O
or	O
efficacy	O
physicians	O
should	O
consider	O
monitoring	O
drug	O
levels	O
or	O
effects	O
.	O
      
(	O
g	O
)	O
There	O
may	O
be	O
small	O
changes	O
in	O
lipid	O
profiles	O
.	O
      
In	O
vitro	O
studies	O
suggest	O
that	O
coadministration	O
of	O
cytochrome	O
P9	O
inhibitors	O
to	O
PMs	O
will	O
not	O
increase	O
the	O
plasma	O
concentrations	O
of	O
atomoxetine	B-Drug
.	O
      
Indinavir	B-Drug
      
In	O
patients	O
in	O
whom	O
CYP9A9	O
inducers	O
(	O
eg	O
dexamethasone	B-Drug
phenytoin	B-Drug
carbamazepine	B-Drug
rifampicin	B-Drug
phenobarbital	B-Drug
)	O
are	O
indicated	O
alternative	O
agents	O
with	O
less	O
enzyme	O
induction	O
potential	O
should	O
be	O
used	O
.	O
      
An	O
evaluation	O
of	O
prothrombin	O
time	O
and	O
an	O
adjustment	O
of	O
anticoagulant	B-Group
dosage	O
are	O
recommended	O
      
In	O
another	O
drug	O
interaction	O
study	O
co	O
-	O
administration	O
of	O
orally	O
inhaled	O
ciclesonide	B-Drug
and	O
oral	O
ketoconazole	B-Drug
a	O
potent	O
inhibitor	O
of	O
cytochrome	O
P9	O
9A9	O
increased	O
the	O
exposure	O
(	O
AUC	O
)	O
of	O
des	B-Drug
-	O
ciclesonide	I-Drug
by	O
approximately	O
9	O
-	O
fold	O
at	O
steady	O
state	O
while	O
levels	O
of	O
ciclesonide	B-Drug
remained	O
unchanged	O
.	O
      
Patients	O
treated	O
concurrently	O
with	O
BREVIBLOC	B-Brand
(	O
esmolol	B-Drug
HCl	I-Drug
)	O
and	O
a	O
catecholamine	O
depletor	O
should	O
therefore	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
or	O
marked	O
bradycardia	O
which	O
may	O
result	O
in	O
vertigo	O
syncope	O
or	O
postural	O
hypotension	O
.	O
      
If	O
glucocorticoid	B-Group
replacement	O
is	O
required	O
the	O
glucocorticoid	B-Group
dose	O
should	O
be	O
carefully	O
adjusted	O
.	O
      
however	O
during	O
the	O
period	O
of	O
treatment	O
physicians	O
should	O
monitor	O
blood	O
cell	O
counts	O
.	O
      
Dose	O
adjustment	O
of	O
Sensipar	B-Brand
may	O
be	O
required	O
and	O
PTH	O
and	O
serum	O
calcium	O
concentrations	O
should	O
be	O
closely	O
monitored	O
if	O
a	O
patient	O
initiates	O
or	O
discontinues	O
therapy	O
with	O
a	O
strong	O
CYP9A9	O
inhibitor	O
(	O
e.g.	O
ketoconazole	B-Drug
erythromycin	B-Drug
itraconazole	B-Drug
;	O
      
Information	O
on	O
concurrent	O
usage	O
of	O
atenolol	B-Drug
and	O
aspirin	B-Brand
is	O
limited	O
.	O
      
The	O
risk	O
of	O
using	O
bromocriptine	B-Drug
mesylate	I-Drug
in	O
combination	O
with	O
other	O
drugs	O
has	O
not	O
been	O
systematically	O
evaluated	O
but	O
alcohol	B-Drug
may	O
potentiate	O
the	O
side	O
effects	O
of	O
bromocriptine	B-Drug
mesylate	I-Drug
.	O
      
Loratadine	B-Drug
Descarboethoxyloratadine	B-Drug
      
-	O
a	O
steroid	B-Group
medicine	I-Group
such	O
as	O
prednisone	B-Drug
(	O
Deltasone	B-Brand
Orasone	B-Brand
others	O
)	O
methylprednisolone	B-Drug
(	O
Medrol	B-Brand
others	O
)	O
prednisolone	B-Drug
(	O
Prelone	B-Brand
Pediapred	B-Brand
others	O
)	O
and	O
others	O
;	O
      
For	O
example	O
diuretics	B-Group
(	O
e.g.	O
thiazides	B-Group
)	O
may	O
activate	O
the	O
renin	O
-	O
angiotensin	O
-	O
aldosterone	O
system	O
.	O
      
In	O
patients	O
where	O
rifampin	B-Drug
or	O
other	O
CYP9A9	O
inducers	O
are	O
indicated	O
alternative	O
therapeutic	O
agents	O
with	O
less	O
enzyme	O
induction	O
potential	O
should	O
be	O
considered	O
.	O
      
Potential	O
for	O
serious	O
reactions	O
such	O
as	O
risk	O
of	O
myopathy	O
including	O
rhabdomyolysis	O
.	O
      
Oral	O
Hypoglycemics	B-Group
:	O
Diclofenac	B-Drug
does	O
not	O
alter	O
glucose	O
metabolism	O
in	O
normal	O
subjects	O
nor	O
does	O
it	O
alter	O
the	O
effects	O
of	O
oral	O
hypoglycemic	B-Group
agents	I-Group
.	O
      
The	O
mechanism	O
of	O
this	O
pharmacodynamic	O
interaction	O
is	O
not	O
known	O
.	O
      
-	O
Antidiabetic	B-Group
drugs	I-Group
:	O
(	O
Oral	O
agents	O
and	O
insulin	B-Drug
)	O
Dosage	O
adjustment	O
of	O
the	O
antidiabetic	B-Group
drug	I-Group
may	O
be	O
required	O
      
Antihypertensives	B-Group
:	O
Amphetamines	B-Group
may	O
antagonize	O
the	O
hypotensive	O
effects	O
of	O
antihypertensives	B-Drug
.	O
      
Diltiazem	B-Drug
is	O
both	O
a	O
substrate	O
and	O
an	O
inhibitor	O
of	O
the	O
cytochrome	O
P	O
-	O
9	O
9A9	O
enzyme	O
system	O
.	O
      
No	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
depo	B-Brand
-	O
subQ	I-Brand
provera	I-Brand
9	I-Brand
.	O
      
-	O
Gold	B-Drug
salts	O
(	O
medicine	O
for	O
arthritis	O
)	O
or	O
      
free	O
T9	O
concentration	O
is	O
unaltered	O
      
Lithium	B-Drug
:	O
Increased	O
serum	O
lithium	B-Drug
and	O
symptoms	O
of	O
lithium	B-Drug
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
lithium	B-Drug
and	O
ACE	O
inhibitor	O
therapy	O
.	O
      
In	O
vitro	O
human	O
liver	O
microsome	O
studies	O
and	O
an	O
in	O
vivo	O
metabolic	O
probe	O
study	O
demonstrated	O
that	O
alosetron	B-Drug
did	O
not	O
inhibit	O
CYP	O
enzymes	O
9D9	O
9A9	O
9C9	O
or	O
9C9	O
.	O
      
If	O
these	O
products	O
are	O
needed	O
they	O
should	O
be	O
given	O
at	O
least	O
9	O
hours	O
before	O
cimetidine	B-Drug
administration	O
.	O
      
Amprenavir	B-Drug
does	O
not	O
inhibit	O
CYP9D9	O
CYP9A9	O
CYP9C9	O
CYP9C9	O
CYP9E9	O
or	O
uridine	O
glucuronosyltransferase	O
(	O
UDPGT	O
)	O
.	O
      
Additionally	O
paroxetine	B-Drug
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
Sonata	B-Brand
reflecting	O
the	O
absence	O
of	O
a	O
role	O
of	O
CYP9D9	O
in	O
zaleplon	B-Drug
metabolism	O
.	O
      
Antacids	B-Group
containing	O
magnesium	B-Drug
trisilicate	I-Drug
when	O
administered	O
concomitantly	O
with	O
nitrofurantoin	B-Drug
reduce	O
both	O
the	O
rate	O
and	O
extent	O
of	O
absorption	O
.	O
      
Similar	O
decreases	O
in	O
Cmax	O
and	O
AUC	O
were	O
seen	O
after	O
the	O
first	O
dose	O
.	O
      
Because	O
oral	O
anticoagulants	B-Group
may	O
interfere	O
with	O
the	O
hepatic	O
metabolism	O
of	O
phenytoin	B-Drug
toxic	O
levels	O
of	O
the	O
anticonvulsant	B-Group
may	O
occur	O
when	O
an	O
oral	O
anticoagulant	B-Group
and	O
phenytoin	B-Drug
are	O
administered	O
concurrently	O
.	O
      
Pediatric	O
Use	O
The	O
safety	O
and	O
effectiveness	O
of	O
PEGASYS	B-Brand
alone	O
or	O
in	O
combination	O
with	O
COPEGUS	B-Brand
in	O
patients	O
below	O
the	O
age	O
of	O
9	O
years	O
have	O
not	O
been	O
established	O
.	O
      
iv	O
.	O
      
In	O
some	O
cases	O
where	O
serious	O
ventricular	O
arrhythmias	O
QT	O
prolongation	O
and	O
torsades	O
de	O
pointes	O
have	O
occurred	O
when	O
cisapride	B-Drug
was	O
taken	O
in	O
conjunction	O
with	O
one	O
of	O
the	O
cytochrome	O
P9	O
9A9	O
inhibitors	O
elevated	O
blood	O
cisapride	B-Drug
levels	O
were	O
noted	O
at	O
the	O
time	O
of	O
the	O
QT	O
prolongation	O
.	O
      
In	O
a	O
study	O
involving	O
healthy	O
subjects	O
receiving	O
TAMBOCOR	B-Brand
and	O
propranolol	B-Drug
concurrently	O
plasma	O
flecainide	B-Drug
levels	O
were	O
increased	O
about	O
9	O
%	O
and	O
propranolol	B-Drug
levels	O
were	O
increased	O
about	O
9	O
%	O
compared	O
to	O
control	O
values	O
.	O
      
There	O
is	O
usually	O
complete	O
cross	O
-	O
resistance	O
between	O
PURINETHOL	B-Brand
(	O
mercaptopurine	B-Drug
)	O
and	O
TABLOID	B-Brand
brand	O
Thioguanine	B-Drug
.	O
      
No	O
dosage	O
adjustment	O
of	O
either	O
drug	O
is	O
recommended	O
when	O
azithromycin	B-Drug
is	O
co	O
administered	O
with	O
any	O
of	O
the	O
above	O
agents	O
.	O
      
unreliable	O
prothrombin	O
time	O
determinations	O
;	O
      
Cyclosporine	B-Drug
:	O
Increased	O
activity	O
of	O
both	O
cyclosporine	B-Drug
and	O
corticosteroids	B-Group
may	O
occur	O
when	O
the	O
two	O
are	O
used	O
concurrently	O
.	O
      
Studies	O
have	O
demonstrated	O
that	O
pretreatment	O
with	O
isoniazid	B-Drug
potentiates	O
a	O
cetaminophen	O
hepatoxicity	O
in	O
rats	O
.	O
      
The	O
use	O
of	O
MIVACRON	B-Brand
before	O
succinylcholine	B-Drug
to	O
attenuate	O
some	O
of	O
the	O
side	O
effects	O
of	O
succinylcholine	B-Drug
has	O
not	O
been	O
studied	O
.	O
      
Pilocarpine	B-Drug
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
taking	O
beta	B-Group
adrenergic	I-Group
antagonists	I-Group
because	O
of	O
the	O
possibility	O
of	O
conduction	O
disturbances	O
.	O
      
In	O
vitro	O
studies	O
show	O
that	O
tiludronate	B-Drug
does	O
not	O
displace	O
warfarin	B-Drug
from	O
its	O
binding	O
site	O
on	O
protein	O
.	O
      
It	O
is	O
recommended	O
that	O
these	O
tests	O
be	O
performed	O
prior	O
to	O
initiation	O
of	O
Soriatane	B-Brand
therapy	O
at	O
9	O
-	O
to	O
9	O
-	O
week	O
intervals	O
until	O
stable	O
and	O
thereafter	O
at	O
intervals	O
as	O
clinically	O
indicated	O
.	O
      
Concurrent	O
administration	O
of	O
dyphylline	B-Drug
and	O
probenecid	B-Drug
which	O
competes	O
for	O
tubular	O
secretion	O
has	O
been	O
shown	O
to	O
increase	O
the	O
plasma	O
half	O
-	O
life	O
of	O
dyphylline	B-Drug
.	O
      
Patients	O
should	O
be	O
cautioned	O
against	O
engaging	O
in	O
hazardous	O
activities	O
requiring	O
complete	O
mental	O
alertness	O
such	O
as	O
operating	O
machinery	O
or	O
driving	O
a	O
motor	O
vehicle	O
.	O
      
this	O
can	O
cause	O
headaches	O
and	O
other	O
signs	O
of	O
hypertensive	O
crisis	O
.	O
      
Interactions	O
may	O
occur	O
between	O
EPA	B-Drug
supplements	O
and	O
aspirin	B-Brand
and	O
other	O
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
and	O
herbs	O
such	O
as	O
garlic	O
(	O
Allium	O
sativum	O
)	O
and	O
ginkgo	B-Drug
(	O
Ginkgo	B-Drug
biloba	I-Drug
)	O
.	O
      
indinavir	B-Drug
concentration	O
      
Clinical	O
studies	O
with	O
celecoxib	B-Drug
have	O
identified	O
potentially	O
significant	O
interactions	O
with	O
fluconazole	B-Drug
and	O
lithium	B-Drug
.	O
      
Barbiturates	B-Group
phenytoin	B-Drug
or	O
rifampin	B-Drug
increased	O
metabolic	O
clearance	O
of	O
fludrocortisone	B-Drug
acetate	I-Drug
because	O
of	O
the	O
induction	O
of	O
hepatic	O
enzymes	O
.	O
      
These	O
agents	O
may	O
increase	O
the	O
anesthetic	O
or	O
sedative	O
effects	O
of	O
DIPRIVAN	B-Brand
Injectable	O
Emulsion	O
and	O
may	O
also	O
result	O
in	O
more	O
pronounced	O
decreases	O
in	O
systolic	O
diastolic	O
and	O
mean	O
arterial	O
pressures	O
and	O
cardiac	O
output	O
.	O
      
Corresponding	O
values	O
for	O
free	O
valproate	B-Drug
Cmin	O
concentrations	O
were	O
9	O
9	O
9	O
9	O
and	O
9	O
9	O
micrograms	O
/	O
mL	O
for	O
9	O
9	O
and	O
9	O
mg	O
/	O
day	O
Felbatol	B-Brand
respectively	O
.	O
      
In	O
studies	O
in	O
female	O
rats	O
at	O
doses	O
9	O
mg	O
/	O
kg	O
/	O
day	O
(	O
IM	O
;	O
      
Oral	O
Contraceptives	B-Group
Rofecoxib	B-Drug
did	O
not	O
have	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
norethindrone	B-Drug
.	O
      
This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O
      
Caution	O
should	O
be	O
exercised	O
when	O
anticoagulants	B-Group
are	O
given	O
in	O
conjunction	O
with	O
Atromid	B-Brand
-	O
S	I-Brand
.	O
      
A	O
pharmacokinetic	O
interaction	O
between	O
diltiazem	B-Drug
and	O
cyclosporine	B-Drug
has	O
been	O
observed	O
during	O
studies	O
involving	O
renal	O
and	O
cardiac	O
transplant	O
patients	O
.	O
      
Phosphate	O
-	O
Binding	O
Agents	O
:	O
Since	O
vitamin	B-Group
D	I-Group
also	O
has	O
an	O
effect	O
on	O
phosphate	O
transport	O
in	O
the	O
intestine	O
kidneys	O
and	O
bones	O
the	O
dosage	O
of	O
phosphate	O
-	O
binding	O
agents	O
must	O
be	O
adjusted	O
in	O
accordance	O
with	O
the	O
serum	O
phosphate	O
concentration	O
.	O
      
Aminosalicylic	B-Drug
acid	I-Drug
may	O
also	O
decrease	O
the	O
absorption	O
of	O
vitamin	B-Drug
B9	I-Drug
which	O
can	O
lead	O
to	O
a	O
deficiency	O
.	O
      
adjust	O
dosage	O
of	O
antidiabetic	B-Group
drug	I-Group
accordingly	O
.	O
      
Based	O
on	O
in	O
vitro	O
inhibition	O
information	O
coadministration	O
of	O
mifepristone	B-Drug
may	O
lead	O
to	O
an	O
increase	O
in	O
serum	O
levels	O
of	O
drugs	O
that	O
are	O
CYP	O
9A9	O
substrates	O
.	O
      
Drugs	O
that	O
induce	O
hepatic	O
enzymes	O
such	O
as	O
phenobarbital	B-Drug
phenytoin	B-Drug
and	O
rifampin	B-Drug
may	O
increase	O
the	O
clearance	O
of	O
corticosteroids	B-Group
and	O
may	O
require	O
increases	O
in	O
corticosteroid	B-Group
dose	O
to	O
achieve	O
the	O
desired	O
response	O
.	O
      
Patients	O
receiving	O
these	O
drugs	O
concurrently	O
should	O
be	O
monitored	O
for	O
a	O
potential	O
drug	O
interaction	O
.	O
      
When	O
used	O
concurrently	O
with	O
such	O
drugs	O
the	O
dose	O
of	O
butorphanol	B-Drug
should	O
be	O
the	O
smallest	O
effective	O
dose	O
and	O
the	O
frequency	O
of	O
dosing	O
reduced	O
as	O
much	O
as	O
possible	O
when	O
administered	O
concomitantly	O
with	O
drugs	O
that	O
potentiate	O
the	O
action	O
of	O
opioids	B-Group
.	O
      
The	O
concurrent	O
use	O
of	O
anticholinergics	B-Group
with	O
hydrocodone	B-Drug
may	O
produce	O
paralytic	O
ileus	O
.	O
      
A	O
single	O
dose	O
of	O
pravastatin	B-Drug
had	O
no	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
fenofibric	B-Drug_n
acid	I-Drug_n
.	O
      
In	O
patients	O
receiving	O
treatment	O
with	O
SPRYCEL	B-Brand
close	O
monitoring	O
for	O
toxicity	O
and	O
a	O
SPRYCEL	B-Brand
dose	O
reduction	O
should	O
be	O
considered	O
if	O
systemic	O
administration	O
of	O
a	O
potent	O
CYP9A9	O
inhibitor	O
can	O
not	O
be	O
avoided	O
.	O
      
Cholestyramine	B-Drug
and	O
Charcoal	B-Drug
Administration	O
of	O
cholestyramine	B-Drug
or	O
activated	B-Drug
charcoal	I-Drug
in	O
patients	O
(	O
n=9	O
)	O
and	O
volunteers	O
(	O
n=9	O
)	O
resulted	O
in	O
a	O
rapid	O
and	O
significant	O
decrease	O
in	O
plasma	O
M9	O
(	O
the	O
active	O
metabolite	O
of	O
leflunomide	B-Drug
)	O
concentration	O
.	O
      
vitamin	B-Drug
C	I-Drug
;	O
      
The	O
hypotensive	O
effect	O
of	O
sodium	B-Drug
nitroprusside	I-Drug
is	O
augmented	O
by	O
that	O
of	O
most	O
other	O
hypotensive	B-Group
drugs	I-Group
including	O
ganglionic	B-Group
blocking	I-Group
agents	I-Group
negative	O
inotropic	O
agents	O
and	O
inhaled	O
anesthetics	B-Group
.	O
      
Interaction	O
of	O
GABITRIL	B-Brand
with	O
Highly	O
Protein	O
Bound	O
Drugs	O
:	O
In	O
vitro	O
data	O
showed	O
that	O
tiagabine	B-Drug
is	O
9	O
%	O
bound	O
to	O
human	O
plasma	O
protein	O
and	O
therefore	O
has	O
the	O
potential	O
to	O
interact	O
with	O
other	O
highly	O
protein	O
bound	O
compounds	O
.	O
      
Potassium	B-Group
-	O
depleting	I-Group
diuretics	I-Group
are	O
a	O
major	O
contributing	O
factor	O
to	O
digitalis	B-Group
toxicity	O
.	O
      
However	O
because	O
nafarelin	B-Drug
acetate	I-Drug
is	O
a	O
peptide	O
that	O
is	O
primarily	O
degraded	O
by	O
peptidase	O
and	O
not	O
by	O
cytochrome	O
P	O
-	O
9	O
enzymes	O
and	O
the	O
drug	O
is	O
only	O
about	O
9	O
%	O
bound	O
to	O
plasma	O
proteins	O
at	O
9	O
C	O
drug	O
interactions	O
would	O
not	O
be	O
expected	O
to	O
occur	O
.	O
      
Concomitant	O
administration	O
of	O
gemfibrozil	B-Drug
with	O
Targretin	B-Brand
capsules	O
is	O
not	O
recommended	O
.	O
      
A	O
9	O
-	O
week	O
dietary	O
carcinogenicity	O
study	O
with	O
ezetimibe	B-Drug
was	O
also	O
conducted	O
in	O
mice	O
at	O
doses	O
up	O
to	O
9	O
mg	O
/	O
kg	O
/	O
day	O
(	O
>	O
9	O
times	O
the	O
human	O
exposure	O
at	O
9	O
mg	O
daily	O
based	O
on	O
AUC9	O
-	O
9hr	O
for	O
total	O
ezetimibe	B-Drug
)	O
.	O
      
Antibiotics	B-Group
(	O
ampicillin	B-Drug
tetracycline	B-Drug
)	O
:	O
Pregnancy	O
has	O
been	O
reported	O
following	O
concomitant	O
use	O
however	O
pharmacokinetic	O
studies	O
have	O
not	O
shown	O
consistent	O
effects	O
with	O
these	O
antibiotics	B-Group
on	O
plasma	O
concentrations	O
of	O
synthetic	B-Group
steroids	I-Group
.	O
      
This	O
may	O
lead	O
to	O
reduced	O
clearance	O
of	O
caffeine	B-Drug
and	O
the	O
prolongation	O
of	O
its	O
plasma	O
half	O
-	O
life	O
.	O
      
Pharmacokinetic	O
studies	O
have	O
demonstrated	O
that	O
omeprazole	B-Drug
and	O
erythromycin	B-Drug
significantly	O
increased	O
the	O
systemic	O
exposure	O
of	O
cilostazol	B-Drug
and	O
/	O
or	O
its	O
major	O
metabolites	O
.	O
      
Use	O
of	O
Anticoagulants	B-Group
and	O
Antiplatelet	B-Group
Agents	I-Group
-	O
-	O
Streptase	B-Brand
Streptokinase	B-Drug
alone	O
or	O
in	O
combination	O
with	O
antiplatelet	B-Group
agents	I-Group
and	O
anticoagulants	B-Group
may	O
cause	O
bleeding	O
complications	O
.	O
      
Imidazoles	B-Group
(	O
e.	O
g.	O
ketoconazole	B-Drug
miconazole	B-Drug
clotrimazole	B-Drug
fluconazole	B-Drug
etc	O
.	O
)	O
:	O
in	O
vitro	O
and	O
animal	O
studies	O
with	O
the	O
combination	O
of	O
amphotericin	B-Drug
B	I-Drug
and	O
imidazoles	B-Group
suggest	O
that	O
imidazoles	B-Group
may	O
induce	O
fungal	O
resistance	O
to	O
amphotericin	B-Drug
B	I-Drug
.	O
      
9	O
.	O
      
Inhibitors	O
of	O
CYP9A9	O
:	O
Concomitant	O
use	O
of	O
duloxetine	B-Drug
with	O
fluvoxamine	B-Drug
an	O
inhibitor	O
of	O
CYP9A9	O
results	O
in	O
approximately	O
a	O
9	O
-	O
fold	O
increase	O
in	O
AUC	O
and	O
about	O
a	O
9	O
-	O
fold	O
increase	O
in	O
Cmax	O
of	O
duloxetine	B-Drug
.	O
      
Skin	O
tests	O
:	O
Corticosteroids	B-Group
may	O
suppress	O
reactions	O
to	O
skin	O
tests	O
.	O
      
Because	O
tetracyclines	B-Group
have	O
been	O
shown	O
to	O
depress	O
plasma	O
prothrombin	O
activity	O
patients	O
who	O
are	O
on	O
anticoagulant	B-Group
therapy	O
may	O
require	O
downward	O
adjustment	O
of	O
their	O
anticoagulant	B-Group
dosage	O
.	O
      
If	O
co	O
-	O
administration	O
is	O
essential	O
close	O
monitoring	O
may	O
be	O
appropriate	O
.	O
      
If	O
iron	B-Group
supplements	I-Group
are	O
required	O
during	O
OMNICEF	B-Brand
therapy	O
OMNICEF	B-Brand
should	O
be	O
taken	O
at	O
least	O
9	O
hours	O
before	O
or	O
after	O
the	O
supplement	O
.	O
      
Colestipol	B-Drug
      
.	O
      
In	O
a	O
pharmacokinetic	O
interaction	O
study	O
with	O
warfarin	B-Drug
bioavailability	O
parameters	O
the	O
degree	O
of	O
protein	O
binding	O
and	O
the	O
anticoagulant	O
effect	O
(	O
measured	O
by	O
prothrombin	O
time	O
)	O
of	O
warfarin	B-Drug
were	O
not	O
significantly	O
changed	O
.	O
      
Agents	O
Causing	O
Renin	O
Release	O
Captopril	B-Drug
's	O
effect	O
will	O
be	O
augmented	O
by	O
antihypertensive	B-Group
agents	I-Group
that	O
cause	O
renin	O
release	O
.	O
      
Doxazosin	B-Drug
mesylate	I-Drug
has	O
been	O
administered	O
without	O
any	O
evidence	O
of	O
an	O
adverse	O
drug	O
interaction	O
to	O
patients	O
receiving	O
thiazide	B-Group
diuretics	I-Group
beta	B-Group
-	O
blocking	I-Group
agents	I-Group
and	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
.	O
      
therefore	O
coadministration	O
of	O
Aprepitant	B-Drug
with	O
drugs	O
that	O
inhibit	O
CYP9A9	O
activity	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
aprepitant	B-Drug
.	O
      
Methotrexate	B-Drug
:	O
HUMIRA	B-Brand
has	O
been	O
studied	O
in	O
rheumatoid	O
arthritis	O
patients	O
taking	O
concomitant	O
MTX	B-Drug
.	O
      
It	O
is	O
likely	O
that	O
experience	O
significantly	O
underestimates	O
the	O
degree	O
of	O
accumulation	O
that	O
might	O
occur	O
with	O
repealed	O
diazepam	B-Drug
administration	O
.	O
      
Drugs	O
that	O
are	O
contraindicated	O
specifically	O
due	O
to	O
the	O
expected	O
magnitude	O
of	O
interaction	O
and	O
potential	O
for	O
serious	O
adverse	O
events	O
are	O
listed	O
CONTRAINDICATIONS	O
.	O
      
Routine	O
administration	O
of	O
vaccines	B-Group
or	O
toxoids	O
should	O
be	O
deferred	O
until	O
corticosteroid	B-Group
therapy	O
is	O
discontinued	O
if	O
possible	O
.	O
      
Serum	O
concentrations	O
of	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P9	O
system	O
should	O
be	O
monitored	O
closely	O
in	O
patients	O
concurrently	O
receiving	O
erythromycin	B-Drug
.	O
      
Appropriate	O
doses	O
for	O
this	O
combination	O
arenot	O
established	O
but	O
an	O
increase	O
in	O
thedosage	O
of	O
saquinavir	B-Drug
may	O
be	O
required	O
.	O
      
Thalidomide	B-Drug
has	O
been	O
reported	O
to	O
enhance	O
the	O
sedative	O
activity	O
of	O
barbiturates	B-Group
alcohol	B-Drug
chlorpromazine	B-Drug
and	O
reserpine	B-Drug
.	O
      
Cyclosporin	B-Drug
:	O
After	O
introduction	O
of	O
chloroquine	B-Drug
(	O
oral	O
form	O
)	O
a	O
sudden	O
increase	O
in	O
serum	O
cyclosporin	B-Drug
level	O
has	O
been	O
reported	O
.	O
      
Dofetilide	B-Drug
is	O
not	O
an	O
inhibitor	O
of	O
CYP9A9	O
nor	O
of	O
other	O
cytochrome	O
P9	O
isoenzymes	O
(	O
e.g.	O
CYP9C9	O
CYP9D9	O
)	O
and	O
is	O
not	O
expected	O
to	O
increase	O
levels	O
of	O
drugs	O
metabolized	O
by	O
CYP9A9	O
.	O
      
Effects	O
of	O
sympathomimetics	B-Group
are	O
increased	O
with	O
MAO	B-Group
inhibitors	I-Group
and	O
beta	B-Group
adrenergic	I-Group
blockers	I-Group
.	O
      
However	O
if	O
the	O
patients	O
thyroid	O
gland	O
has	O
sufficient	O
function	O
the	O
decreased	O
free	O
thyroxine	B-Drug
will	O
result	O
in	O
a	O
compensatory	O
increase	O
in	O
thyroxin	O
output	O
by	O
the	O
thyroid	O
.	O
      
Aspirin	B-Brand
:	O
Rimantadine	B-Drug
HCl	I-Drug
9	O
mg	O
was	O
given	O
twice	O
daily	O
fro	O
9	O
days	O
to	O
9	O
healthy	O
volunteers	O
.	O
      
Danazol	B-Drug
:	O
The	O
risk	O
of	O
myopathy	O
/	O
rhabdomyolysis	O
is	O
increased	O
by	O
concomitant	O
administration	O
of	O
danazol	B-Drug
particularly	O
with	O
higher	O
doses	O
of	O
lovastatin	B-Drug
(	O
see	O
WARNINGS	O
Myopathy	O
/	O
Rhabdomyolysis	O
)	O
.	O
      
This	O
medicine	O
should	O
not	O
be	O
taken	O
with	O
MAO	B-Group
inhibitors	I-Group
.	O
      
Drugs	O
Affecting	O
Hepatic	O
Metabolism	O
The	O
metabolism	O
and	O
pharmacokinetics	O
of	O
REMERON	B-Brand
SolTab	I-Brand
(	O
mirtazapine	B-Drug
)	O
Orally	O
Disintegrating	O
Tablets	O
may	O
be	O
affected	O
by	O
the	O
induction	O
or	O
inhibition	O
of	O
drug	O
-	O
metab	O
-	O
olizing	O
enzymes	O
.	O
      
Monoamine	B-Drug
Oxidase	I-Drug
Inhibitors	I-Drug
:	O
Guanethidine	B-Drug
or	O
similarly	O
acting	O
compounds	O
;	O
      
The	O
peripheral	O
vasoconstriction	O
caused	O
by	O
high	O
doses	O
of	O
dopamine	B-Drug
HCl	I-Drug
is	O
antagonized	O
by	O
alpha	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
.	O
      
Prospective	O
studies	O
on	O
the	O
potential	O
for	O
hydroxyurea	B-Drug
to	O
interact	O
with	O
other	O
drugs	O
have	O
not	O
been	O
performed	O
.	O
      
Agents	O
Affecting	O
Cytochrome	O
P9	O
9A9	O
Isoenzyme	O
System	O
Fentanyl	B-Drug
is	O
metabolized	O
mainly	O
via	O
the	O
human	O
cytochrome	O
P9	O
9A9	O
isoenzyme	O
system	O
(	O
CYP9A9	O
)	O
therefore	O
potential	O
interactions	O
may	O
occur	O
when	O
DURAGESIC	B-Brand
is	O
given	O
concurrently	O
with	O
agents	O
that	O
affect	O
CYP9A9	O
activity	O
.	O
      
Cimetidine	B-Drug
Ranitidine	B-Drug
:	O
In	O
normal	O
volunteers	O
(	O
n=9	O
)	O
pretreatment	O
with	O
cimetidine	B-Drug
or	O
ranitidine	B-Drug
did	O
not	O
affect	O
flurbiprofen	B-Drug
pharmacokinetics	O
except	O
that	O
a	O
small	O
(	O
9	O
%	O
)	O
but	O
statistically	O
significant	O
increase	O
in	O
the	O
area	O
under	O
the	O
serum	O
concentration	O
curve	O
of	O
flurbiprofen	B-Drug
resulted	O
with	O
cimetidine	B-Drug
.	O
      
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
DOXIL	B-Brand
.	O
      
multivitamins	B-Group
containing	O
zinc	B-Drug
;	O
      
Consequently	O
estazolam	B-Drug
should	O
be	O
avoided	O
in	O
patients	O
receiving	O
ketoconazole	B-Drug
and	O
itraconazole	B-Drug
which	O
are	O
very	O
potent	O
inhibitors	O
of	O
CYP9A	O
.	O
      
While	O
in	O
vitro	O
studies	O
indicate	O
that	O
CYP9D9	O
and	O
CYP9A9	O
may	O
be	O
minimally	O
involved	O
in	O
paliperidone	B-Drug
metabolism	O
in	O
vivo	O
studies	O
do	O
not	O
show	O
decreased	O
elimination	O
by	O
these	O
isozymes	O
and	O
they	O
contribute	O
to	O
only	O
a	O
small	O
fraction	O
of	O
total	O
body	O
clearance	O
.	O
      
Additionally	O
saquinavir	B-Drug
is	O
a	O
substrate	O
for	O
P	O
-	O
Glycoprotein	O
(	O
Pgp	O
)	O
.	O
      
In	O
clinical	O
trials	O
FLOLAN	B-Brand
was	O
used	O
with	O
digoxin	B-Drug
diuretics	B-Group
anticoagulants	B-Group
oral	O
vasodilators	B-Group
and	O
supplemental	O
oxygen	B-Drug
.	O
In	O
a	O
pharmacokinetic	O
substudy	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
receiving	O
furosemide	B-Drug
or	O
digoxin	B-Drug
in	O
whom	O
therapy	O
with	O
FLOLAN	B-Brand
was	O
initiated	O
apparent	O
oral	O
clearance	O
values	O
for	O
furosemide	B-Drug
(	O
n	O
=	O
9	O
)	O
and	O
digoxin	B-Drug
(	O
n	O
=	O
9	O
)	O
were	O
decreased	O
by	O
9	O
%	O
and	O
9	O
%	O
respectively	O
on	O
the	O
second	O
day	O
of	O
therapy	O
and	O
had	O
returned	O
to	O
baseline	O
values	O
by	O
day	O
9	O
.	O
      
Because	O
of	O
its	O
primary	O
CNS	O
effect	O
caution	O
should	O
be	O
used	O
when	O
EQUETROTM	B-Brand
is	O
taken	O
with	O
other	O
centrally	B-Group
acting	I-Group
drugs	I-Group
and	O
alcohol	B-Drug
.	O
      
Greater	O
sensitivity	O
of	O
some	O
older	O
individuals	O
can	O
not	O
be	O
ruled	O
out	O
.	O
      
Fluvoxamine	B-Drug
is	O
a	O
known	O
strong	O
inhibitor	O
of	O
CYP9A9	O
and	O
also	O
inhibits	O
CYP9A9	O
CYP9C9	O
and	O
CYP9C9	O
.	O
      
Cyclosporine	B-Drug
:	O
Combination	O
hormonal	B-Group
contraceptives	I-Group
may	O
inhibit	O
the	O
metabolism	O
of	O
cyclosporine	B-Drug
leading	O
to	O
increased	O
plasma	O
concentrations	O
;	O
      
Valproate	B-Drug
:	O
Tiagabine	B-Drug
causes	O
a	O
slight	O
decrease	O
(	O
about	O
9	O
%	O
)	O
in	O
steady	O
-	O
state	O
valproate	B-Drug
concentrations	O
.	O
      
inhalation	O
anesthetics	B-Group
;	O
      
Though	O
individual	O
theophylline	B-Drug
levels	O
fluctuated	O
there	O
were	O
no	O
clinically	O
significant	O
symptoms	O
of	O
drug	O
inter	O
-	O
action	O
.	O
      
This	O
could	O
lead	O
to	O
decreased	O
salicylate	B-Group
serum	O
levels	O
or	O
increase	O
the	O
risk	O
of	O
salicylate	B-Group
toxicity	O
when	O
methylprednisolone	B-Drug
is	O
withdrawn	O
.	O
      
Ergot	B-Group
-	O
containing	O
drugs	O
have	O
been	O
reported	O
to	O
cause	O
prolonged	O
vasospastic	O
reactions	O
.	O
      
Coumarin	B-Group
-	O
Type	I-Group
Anticoagulants	I-Group
:	O
Several	O
short	O
-	O
term	O
controlled	O
studies	O
failed	O
to	O
wshow	O
that	O
ibuprofen	B-Drug
significantly	O
affected	O
prothrombin	O
times	O
or	O
a	O
variety	O
of	O
other	O
clotting	O
factors	O
when	O
administered	O
to	O
individuals	O
on	O
coumarin	B-Group
-	O
type	I-Group
anticoagulants	I-Group
.	O
      
When	O
such	O
combined	O
therapy	O
is	O
contemplated	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
significantly	O
reduced	O
.	O
      
All	O
HMG	B-Group
-	O
CoA	I-Group
reductase	I-Group
inhibitors	I-Group
are	O
contraindicated	O
in	O
pregnant	O
and	O
nursing	O
women	O
.	O
      
.	O
      
indinavir	B-Drug
concentration	O
      
Norepinephrine	B-Drug
:	O
Amphetamines	B-Group
enhance	O
the	O
adrenergic	O
effect	O
of	O
norepinephrine	B-Drug
.	O
      
There	O
was	O
no	O
evidence	O
of	O
clinically	O
important	O
adverse	O
interactions	O
.	O
      
Use	O
of	O
barrier	O
form	O
of	O
contraception	O
is	O
suggested	O
while	O
on	O
griseofulvin	B-Drug
therapy	O
.	O
      
Clinical	O
Comment	O
      
The	O
effects	O
of	O
PEGASYS	B-Brand
on	O
male	O
fertility	O
have	O
not	O
been	O
studied	O
.	O
      
This	O
increase	O
was	O
observed	O
at	O
the	O
first	O
test	O
point	O
which	O
was	O
the	O
second	O
day	O
after	O
starting	O
Mexitil	B-Brand
.	O
Theophylline	B-Drug
plasma	O
levels	O
returned	O
to	O
pre	O
-	O
Mexitil	B-Brand
values	O
within	O
9	O
hours	O
after	O
discontinuing	O
Mexitil	B-Brand
.	O
If	O
Mexitil	B-Brand
and	O
theophylline	B-Drug
are	O
to	O
be	O
used	O
concurrently	O
theophylline	B-Drug
blood	O
levels	O
should	O
be	O
monitored	O
particularly	O
when	O
the	O
Mexitil	B-Brand
dose	O
is	O
changed	O
.	O
      
Mutagenesis	O
PEGASYS	B-Brand
did	O
not	O
cause	O
DNA	O
damage	O
when	O
tested	O
in	O
the	O
Ames	O
bacterial	O
mutagenicity	O
assay	O
and	O
in	O
the	O
in	O
vitro	O
chromosomal	O
aberration	O
assay	O
in	O
human	O
lymphocytes	O
either	O
in	O
the	O
presence	O
or	O
absence	O
of	O
metabolic	O
activation	O
.	O
      
Antidepressants	B-Group
:	O
In	O
vitro	O
data	O
indicate	O
that	O
nefazodone	B-Drug
inhibits	O
the	O
metabolism	O
of	O
cisapride	B-Drug
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	B-Drug
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O
      
Theophylline	B-Drug
:	O
Twelve	O
healthy	O
male	O
volunteers	O
were	O
administered	O
one	O
9	O
-	O
mg	O
ceftibuten	B-Drug
capsule	O
twice	O
daily	O
for	O
9	O
days	O
.	O
      
Erythromycin	B-Drug
:	O
In	O
healthy	O
individuals	O
plasma	O
concentrations	O
of	O
atorvastatin	B-Drug
increased	O
approximately	O
9	O
%	O
with	O
coadministration	O
of	O
atorvastatin	B-Drug
and	O
erythromycin	B-Drug
a	O
known	O
inhibitor	O
of	O
cytochrome	O
P9	O
9A9	O
.	O
      
Interactions	O
with	O
Fruit	O
Juices	O
Fruit	O
juices	O
such	O
as	O
grapefruit	O
orange	O
and	O
apple	O
may	O
reduce	O
the	O
bioavailability	O
and	O
exposure	O
of	O
fexofenadine	B-Drug
.	O
      
Cytokines	B-Group
(	O
interferon	B-Group
interleukin	B-Group
)	O
:	O
Cytokines	B-Group
have	O
been	O
reported	O
to	O
induce	O
both	O
hyperthyroidism	O
and	O
hypothyroidism	O
.	O
      
Human	O
pharmacokinetics	O
data	O
indicate	O
that	O
oral	O
ketoconazole	B-Drug
potently	O
inhibits	O
the	O
metabolism	O
of	O
cisapride	B-Drug
resulting	O
in	O
an	O
eight	O
-	O
fold	O
increase	O
in	O
the	O
mean	O
AUC	O
of	O
cisapride	B-Drug
.	O
      
Theophylline	B-Drug
-	O
related	O
adverse	O
effects	O
have	O
occurred	O
in	O
patients	O
when	O
theophylline	B-Drug
and	O
enoxacin	B-Drug
were	O
coadministered	O
.	O
      
Meclofenamate	B-Drug
sodium	I-Drug
does	O
not	O
affect	O
serum	O
salicylate	B-Group
levels	O
.	O
      
In	O
addition	O
the	O
beneficial	O
effects	O
of	O
levodopa	B-Drug
in	O
Parkinsons	O
disease	O
have	O
been	O
reported	O
to	O
be	O
reversed	O
by	O
phenytoin	B-Drug
and	O
papaverine	B-Drug
.	O
      
or	O
-	O
over	O
-	O
the	O
-	O
counter	O
cough	O
cold	O
allergy	O
or	O
weight	O
loss	O
medications	O
.	O
      
However	O
due	O
to	O
possible	O
pharmacodynamic	O
interactions	O
when	O
co	O
-	O
administered	O
with	O
PRECEDEX	B-Brand
a	O
reduction	O
in	O
dosage	O
of	O
PRECEDEX	B-Brand
on	O
the	O
concomitant	O
anesthetic	B-Group
sedative	B-Group
hypnotic	B-Group
or	O
opioid	B-Group
may	O
be	O
required	O
.	O
      
Interactions	O
attributed	O
to	O
the	O
combined	O
use	O
of	O
baclofen	B-Drug
injection	O
and	O
epidural	O
morphine	B-Drug
include	O
hypotension	O
and	O
dyspnea	O
.	O
      
Co	O
-	O
administration	O
of	O
probenecid	B-Drug
with	O
acyclovir	B-Drug
has	O
been	O
shown	O
to	O
increase	O
the	O
mean	O
half	O
-	O
life	O
and	O
the	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
.	O
      
Anticoagulants	B-Group
:	O
Flurbiprofen	B-Drug
like	O
other	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
has	O
been	O
shown	O
to	O
affect	O
bleeding	O
parameters	O
in	O
patients	O
receiving	O
anti	B-Group
-	O
coagulants	I-Group
and	O
serious	O
clinical	O
bleeding	O
has	O
been	O
reported	O
.	O
      
No	O
interactions	O
have	O
been	O
observed	O
between	O
nizatidine	B-Drug
and	O
theophylline	B-Drug
chlordiazepoxide	B-Drug
lorazepam	B-Drug
lidocaine	B-Drug
phenytoin	B-Drug
and	O
warfarin	B-Drug
.	O
      
Mutagenesis	O
Impairment	O
of	O
Fertility	O
PEGASYS	B-Brand
may	O
impair	O
fertility	O
in	O
women	O
.	O
      
Physicians	O
should	O
be	O
aware	O
that	O
interaction	O
studies	O
with	O
medications	O
other	O
than	O
those	O
listed	O
in	O
the	O
<	O
a	O
href=	O
``	O
flucon_cp.htm	O
#	O
CP	O
''	O
>	O
CLINICAL	O
PHARMACOLOGY	O
section	O
have	O
not	O
been	O
conducted	O
but	O
such	O
interactions	O
may	O
occur	O
.	O
      
A	O
study	O
in	O
9	O
normal	O
male	O
and	O
female	O
volunteers	O
suggests	O
that	O
coadministration	O
of	O
cisapride	B-Drug
and	O
ketoconazole	B-Drug
can	O
result	O
in	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O
      
Check	O
serum	O
potassium	O
levels	O
at	O
frequent	O
intervals	O
;	O
      
In	O
such	O
cases	O
of	O
combined	O
treatment	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O
      
Therefore	O
it	O
is	O
recommended	O
that	O
Fluvoxamine	B-Drug
Tablets	O
not	O
be	O
used	O
in	O
combination	O
with	O
MAOIs	B-Group
or	O
within	O
9	O
days	O
of	O
discontinuing	O
treatment	O
with	O
a	O
MAOI	B-Group
.	O
      
Anticholinergics	B-Group
:	O
Concurrent	O
administration	O
of	O
certain	O
anticholinergic	B-Group
compounds	I-Group
such	O
as	O
belladonna	B-Group
alkaloids	I-Group
and	O
dicyclomine	B-Drug
would	O
be	O
expected	O
to	O
compromise	O
the	O
beneficial	O
effects	O
of	O
cisapride	B-Drug
.	O
      
Anticoagulants	B-Group
oral	O
:	O
Co	O
-	O
administration	O
of	O
corticosteroids	B-Group
and	O
warfarin	B-Drug
usually	O
results	O
in	O
inhibition	O
of	O
response	O
to	O
warfarin	B-Drug
although	O
there	O
have	O
been	O
some	O
conflicting	O
reports	O
.	O
      
Therefore	O
erlotinib	B-Drug
exposure	O
may	O
be	O
increased	O
in	O
patients	O
with	O
hepatic	O
dysfunction	O
.	O
      
Pyrantel	B-Drug
(	O
e.g.	O
Antiminth	B-Drug
)	O
-	O
Taking	O
piperazine	B-Drug
and	O
pyrantel	B-Drug
together	O
may	O
decrease	O
the	O
effects	O
of	O
piperazine	B-Drug
.	O
      
In	O
some	O
patients	O
combined	O
use	O
of	O
INDOCIN	B-Brand
and	O
diflunisal	B-Drug
has	O
been	O
associated	O
with	O
fatal	O
gastrointestinal	O
hemorrhage	O
.	O
      
Plasma	O
concentrations	O
decreased	O
by	O
SUSTIVA	B-Brand
;	O
      
Although	O
specific	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
ALPHAGAN	B-Brand
P	I-Brand
the	O
possibility	O
of	O
an	O
additive	O
or	O
potentiating	O
effect	O
with	O
CNS	B-Group
depressants	I-Group
(	O
alcohol	B-Drug
barbiturates	B-Group
opiates	B-Group
sedatives	B-Group
or	O
anesthetics	B-Group
)	O
should	O
be	O
considered	O
.	O
      
When	O
patients	O
have	O
received	O
such	O
drugs	O
the	O
dose	O
of	O
INAPSINE	B-Brand
required	O
will	O
be	O
less	O
than	O
usual	O
.	O
      
Fluoroquinolones	B-Drug
macrolide	B-Drug
antibiotics	I-Drug
and	O
azoles	O
are	O
known	O
to	O
cause	O
QTc	O
prolongation	O
.	O
      
d	B-Drug
-	O
amphetamine	I-Drug
with	O
desipramine	B-Drug
or	O
protriptyline	B-Drug
and	O
possibly	O
other	O
tricyclics	B-Group
cause	O
striking	O
and	O
sustained	O
increases	O
in	O
the	O
concentration	O
of	O
d	B-Drug
-	O
amphetamine	I-Drug
in	O
the	O
brain	O
;	O
      
Sulfacetamide	B-Drug
preparations	O
are	O
incompatible	O
with	O
silver	B-Drug
preparations	O
.	O
      
Digoxin	O
When	O
given	O
concomitantly	O
with	O
PLENDIL	B-Drug
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
in	O
patients	O
with	O
heart	O
failure	O
were	O
not	O
significantly	O
altered	O
.	O
      
These	O
agents	O
include	O
medications	O
such	O
as	O
:	O
anticoagulants	B-Group
platelet	B-Group
inhibitors	I-Group
including	O
acetylsalicylic	B-Drug
acid	I-Drug
sali	O
-	O
cylates	O
NSAIDs	B-Group
(	O
including	O
ketorolac	B-Drug
tromethamine	I-Drug
)	O
dipyridamole	B-Drug
or	O
sulfinpyrazone	B-Drug
.	O
      
Furosemide	B-Drug
:	O
When	O
aliskiren	B-Drug
was	O
co	O
-	O
administered	O
with	O
furosemide	B-Drug
the	O
AUC	O
and	O
Cmax	O
of	O
furosemide	B-Drug
were	O
reduced	O
by	O
about	O
9	O
%	O
and	O
9	O
%	O
respectively	O
.	O
      
The	O
net	O
effect	O
of	O
these	O
interactions	O
is	O
summarized	O
in	O
the	O
following	O
table	O
:	O
AED	B-Group
AED	B-Group
Felbatol	B-Brand
      
substrates	O
in	O
vitro	O
data	O
suggest	O
similar	O
effects	O
of	O
grepafloxacin	B-Drug
in	O
CYP9A9	O
mediated	O
metabolism	O
and	O
theophylline	B-Drug
metabolism	O
.	O
      
No	O
formal	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O
      
When	O
INDOCIN	B-Brand
is	O
given	O
to	O
patients	O
receiving	O
probenecid	B-Drug
the	O
plasma	O
levels	O
of	O
indomethacin	B-Drug
are	O
likely	O
to	O
be	O
increased	O
.	O
      
This	O
could	O
lead	O
to	O
an	O
increase	O
in	O
blood	O
pressure	O
.	O
      
Paliperidone	B-Drug
is	O
therefore	O
not	O
expected	O
to	O
inhibit	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
transport	O
of	O
other	O
drugs	O
in	O
a	O
clinically	O
relevant	O
manner	O
.	O
      
quinine	B-Drug
;	O
      
Alcohol	B-Drug
-	O
Although	O
LEXAPRO	B-Brand
did	O
not	O
potentiate	O
the	O
cognitive	O
and	O
motor	O
effects	O
of	O
alcohol	B-Drug
in	O
a	O
clinical	O
trial	O
as	O
with	O
other	O
psychotropic	B-Group
medications	I-Group
the	O
use	O
of	O
alcohol	B-Drug
by	O
patients	O
taking	O
LEXAPRO	B-Brand
is	O
not	O
recommended	O
.	O
      
In	O
vitro	O
methotrexate	B-Drug
did	O
not	O
displace	O
meloxicam	B-Drug
from	O
its	O
human	O
serum	O
binding	O
sites	O
.	O
      
ZEBETA	B-Brand
should	O
not	O
be	O
combined	O
with	O
other	O
beta	B-Group
-	O
blocking	I-Group
agents	I-Group
.	O
      
Exacerbation	O
or	O
the	O
initial	O
presentation	O
of	O
a	O
number	O
of	O
autoimmune	O
and	O
inflammatory	O
disorders	O
has	O
been	O
observed	O
following	O
concurrent	O
use	O
of	O
interferon	B-Drug
-	O
alfa	I-Drug
and	O
PROLEUKIN	B-Brand
including	O
crescentic	O
IgA	O
glomerulonephritis	O
oculo	O
-	O
bulbar	O
myasthenia	O
gravis	O
inflammatory	O
arthritis	O
thyroiditis	O
bullous	O
pemphigoid	O
and	O
Stevens	O
-	O
Johnson	O
syndrome	O
.	O
      
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
cardiac	O
arrhythmias	O
.	O
      
SINCE	O
THE	O
CONCOMITANT	O
ADMINISTRATION	O
OF	O
THESE	O
TWO	O
DRUGS	O
CAN	O
LEAD	O
TO	O
PHENYTOIN	B-Drug
INTOXICATION	O
PRIOR	O
TO	O
ADMINISTERING	O
DISULFIRAM	B-Drug
TO	O
A	O
PATIENT	O
ON	O
PHENYTOIN	B-Drug
THERAPY	O
A	O
BASELINE	O
PHENYTOIN	B-Drug
SERUM	O
LEVEL	O
SHOULD	O
BE	O
OBTAINED	O
.	O
      
In	O
many	O
of	O
these	O
cases	O
buprenorphine	B-Drug
was	O
misused	O
by	O
self	O
-	O
injection	O
of	O
crushed	O
SUBUTEX	B-Brand
tablets	O
.	O
      
Patients	O
receiving	O
the	O
two	O
drugs	O
concomitantly	O
should	O
be	O
carefully	O
monitored	O
.	O
      
MAO	B-Group
inhibitors	I-Group
and	O
beta	B-Group
adrenergic	I-Group
blockers	I-Group
increase	O
the	O
effects	O
of	O
pseudoephedrine	B-Drug
.	O
      
antibody	O
      
This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O
      
Potassium	B-Drug
Supplements	O
and	O
Potassium	B-Group
-	O
Sparing	I-Group
Diuretics	I-Group
Lotensin	O
can	O
attenuate	O
potassium	O
loss	O
caused	O
by	O
thiazide	B-Group
diuretics	I-Group
.	O
      
Positive	O
direct	O
and	O
indirect	O
antiglobulin	O
(	O
Coombs	O
)	O
tests	O
have	O
occurred	O
;	O
      
No	O
studies	O
have	O
been	O
conducted	O
at	O
intermediate	O
doses	O
of	O
cimetidine	B-Drug
.	O
      
There	O
is	O
no	O
pharmacokinetic	O
interaction	O
between	O
zaleplon	B-Drug
and	O
diphenhydramine	B-Drug
following	O
the	O
administration	O
of	O
a	O
single	O
dose	O
(	O
9	O
mg	O
and	O
9	O
mg	O
respectively	O
)	O
of	O
each	O
drug	O
.	O
      
Amitriptyline	B-Drug
:	O
Concurrent	O
administration	O
of	O
9	O
mg	O
or	O
9	O
mg	O
cinacalcet	B-Drug
with	O
9	O
mg	O
amitriptyline	B-Drug
increased	O
amitriptyline	B-Drug
exposure	O
and	O
nortriptyline	B-Drug_n
(	O
active	O
metabolite	O
)	O
exposure	O
by	O
approximately	O
9	O
%	O
in	O
CYP9D9	O
extensive	O
metabolizers	O
.	O
      
Depending	O
on	O
clinical	O
circumstances	O
consideration	O
should	O
be	O
given	O
to	O
increasing	O
the	O
dose	O
of	O
DIFLUCAN	B-Brand
when	O
it	O
is	O
administered	O
with	O
rifampin	B-Drug
.	O
      
Theoretically	O
the	O
naproxen	B-Drug
anion	O
itself	O
could	O
likewise	O
be	O
displaced	O
.	O
      
MAO	B-Group
inhibitors	I-Group
narcotic	B-Group
analgesics	I-Group
(	O
e.g.	O
meperidine	B-Drug
)	O
nitrates	B-Group
and	O
nitrites	B-Group
sympathomimetic	B-Group
agents	I-Group
tricyclic	B-Group
antidepressants	I-Group
and	O
other	O
drugs	O
having	O
anticholinergic	O
activity	O
.	O
      
Maalox	B-Brand
*	O
Coadministration	O
of	O
Maalox	B-Brand
TC	I-Brand
had	O
no	O
effect	O
on	O
nicardipine	B-Drug
HCl	I-Drug
absorption	O
.	O
      
The	O
absorption	O
of	O
lymecycline	B-Drug
may	O
be	O
affected	O
by	O
the	O
simultaneous	O
administration	O
of	O
indigestion	O
remedies	O
iron	B-Drug
or	O
zinc	B-Drug
supplements	O
.	O
      
A	O
few	O
spontaneous	O
accounts	O
of	O
QT	O
interval	O
prolongation	O
with	O
ventricular	O
arrhythmia	O
including	O
torsades	O
de	O
pointes	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
erythromycin	B-Drug
or	O
troleandomycin	B-Drug
.	O
      
In	O
situations	O
when	O
concurrent	O
therapy	O
is	O
necessary	O
careful	O
patient	O
monitoring	O
is	O
essential	O
.	O
      
Insulin	B-Drug
requirements	O
in	O
diabetic	O
patients	O
may	O
be	O
increased	O
decreased	O
or	O
unchanged	O
.	O
      
In	O
the	O
first	O
study	O
concomitant	O
administration	O
of	O
9	O
mg	O
cerivastatin	B-Drug
sodium	I-Drug
and	O
9	O
g	O
cholestyramine	B-Drug
resulted	O
in	O
decreases	O
of	O
more	O
than	O
9	O
%	O
for	O
AUC	O
and	O
9	O
%	O
for	O
Cmax	O
when	O
compared	O
to	O
dosing	O
cerivastatin	B-Drug
sodium	I-Drug
alone	O
.	O
      
The	O
absorption	O
of	O
oral	O
gemifloxacin	B-Drug
is	O
significantly	O
reduced	O
by	O
the	O
concomitant	O
administration	O
of	O
an	O
antacid	B-Group
containing	O
aluminum	B-Drug
and	O
magnesium	B-Drug
.	O
      
If	O
the	O
two	O
drugs	O
are	O
coadministered	O
the	O
beta	B-Group
blocker	I-Group
should	O
be	O
withdrawn	O
several	O
days	O
before	O
the	O
gradual	O
withdrawal	O
of	O
clonidine	B-Drug
.	O
      
Warfarin	B-Drug
:	O
Eszopiclone	B-Drug
9	O
mg	O
administered	O
daily	O
for	O
9	O
days	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
R	B-Drug
-	O
or	O
S	B-Drug
-	O
warfarin	I-Drug
nor	O
were	O
there	O
any	O
changes	O
in	O
the	O
pharmacodynamic	O
profile	O
(	O
prothrombin	O
time	O
)	O
following	O
a	O
single	O
9	O
mg	O
oral	O
dose	O
of	O
warfarin	B-Drug
      
The	O
clinical	O
significance	O
of	O
these	O
in	O
vitro	O
interactions	O
is	O
unknown	O
;	O
      
Dose	O
reduction	O
of	O
rifabutin	B-Drug
to	O
half	O
the	O
standard	O
dose	O
and	O
a	O
dose	O
increase	O
of	O
CRIXIVAN	B-Brand
to	O
9	O
mg	O
(	O
three	O
9	O
-	O
mg	O
capsules	O
)	O
every	O
9	O
hours	O
are	O
recommended	O
when	O
rifabutin	B-Drug
and	O
CRIXIVAN	B-Brand
are	O
coadministered	O
.	O
      
Warfarin	B-Drug
:	O
When	O
fluvoxamine	B-Drug
maleate	I-Drug
(	O
9	O
mg	O
tid	O
)	O
was	O
administered	O
concomitantly	O
with	O
warfarin	B-Drug
for	O
two	O
weeks	O
warfarin	B-Drug
plasma	O
concentrations	O
increased	O
by	O
9	O
%	O
and	O
prothrombin	O
times	O
were	O
prolonged	O
.	O
      
Dose	O
adjustment	O
of	O
lapatinib	B-Drug
should	O
be	O
considered	O
for	O
patients	O
who	O
must	O
receive	O
concomitant	O
strong	O
inhibitors	O
or	O
concomitant	O
strong	O
inducers	O
of	O
CYP9A9	O
enzymes	O
.	O
      
Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
None	O
known	O
.	O
      
Food	O
:	O
Isoniazid	B-Drug
should	O
not	O
be	O
administered	O
with	O
food	O
.	O
      
However	O
it	O
should	O
be	O
noted	O
that	O
both	O
products	O
are	O
capable	O
of	O
producing	O
transient	O
increases	O
in	O
blood	O
pressure	O
.	O
      
Patients	O
taking	O
Acamprosate	B-Drug
concomitantly	O
with	O
antidepressants	B-Group
more	O
commonly	O
reported	O
both	O
weight	O
gain	O
and	O
weight	O
loss	O
compared	O
with	O
patients	O
taking	O
either	O
medication	O
alone	O
.	O
      
These	O
six	O
volunteers	O
received	O
terfenadine	B-Drug
alone	O
(	O
9	O
mg	O
twice	O
daily	O
)	O
for	O
9	O
days	O
followed	O
by	O
terfenadine	B-Drug
in	O
combination	O
with	O
dirithromycin	B-Drug
(	O
9	O
mg	O
once	O
daily	O
)	O
for	O
9	O
days	O
.	O
      
Catecholamine	O
-	O
depleting	O
drugs	O
(	O
e.g.	O
reserpine	B-Drug
)	O
:	O
additive	O
effect	O
;	O
      
9	O
.	O
      
9	O
.	O
      
Clinical	O
studies	O
of	O
PEGASYS	B-Brand
alone	O
or	O
in	O
combination	O
with	O
COPEGUS	B-Brand
did	O
not	O
include	O
sufficient	O
numbers	O
of	O
subjects	O
aged	O
9	O
or	O
over	O
to	O
determine	O
whether	O
they	O
respond	O
differently	O
from	O
younger	O
subjects	O
.	O
      
The	O
concomitant	O
use	O
of	O
alcohol	B-Drug
or	O
other	O
central	B-Group
nervous	I-Group
system	I-Group
depressants	I-Group
may	O
have	O
an	O
additive	O
effect	O
.	O
      
Antigout	B-Group
medications	I-Group
      
Amiodarone	B-Drug
is	O
metabolized	O
to	O
desethylamiodarone	B-Drug
by	O
the	O
cytochrome	O
P9	O
(	O
CYP9	O
)	O
enzyme	O
group	O
specifically	O
cytochromes	O
P9	O
9A9	O
(	O
CYP9A9	O
)	O
and	O
CYP9C9	O
.	O
      
MOBIC	B-Brand
is	O
not	O
a	O
substitute	O
for	O
aspirin	B-Brand
for	O
cardiovascular	O
prophylaxis	O
.	O
      
Concurrent	O
administration	O
of	O
a	O
TNF	B-Group
antagonist	I-Group
with	O
ORENCIA	B-Brand
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	O
and	O
no	O
significant	O
additional	O
efficacy	O
over	O
use	O
of	O
the	O
TNF	B-Group
antagonists	I-Group
alone	O
.	O
      
In	O
separate	O
single	O
or	O
multiple	O
dose	O
pharmacokinetic	O
interaction	O
studies	O
with	O
chlorthalidone	B-Drug
nifedipine	B-Drug
propanolol	B-Drug
hydrochlorothiazide	B-Drug
cimetidine	B-Drug
metoclopramide	B-Drug
propantheline	B-Drug
digoxin	B-Drug
and	O
warfarin	B-Drug
the	O
bioavailability	O
of	O
fosinoprilat	B-Drug_n
was	O
not	O
altered	O
by	O
coadministration	O
of	O
fosinopril	B-Drug
with	O
any	O
one	O
of	O
these	O
drugs	O
.	O
      
increased	O
serum	O
digoxin	B-Drug
concentrations	O
may	O
result	O
.	O
      
Non	B-Group
-	O
selective	I-Group
MAO	I-Group
inhibitors	I-Group
including	O
tranylcypromine	B-Drug
sulfate	I-Drug
phenelzine	B-Drug
sulfate	I-Drug
and	O
pargyline	B-Drug
HC9	O
:	O
Concomitant	O
use	O
of	O
L	B-Drug
-	O
tyrosine	I-Drug
and	O
non	O
-	O
selective	O
MAO	B-Group
inhibitors	I-Group
may	O
cause	O
hypertension	O
.	O
      
Lithium	B-Drug
:	O
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B-Group
.	O
      
Co	O
-	O
administration	O
of	O
oral	O
ketoconazole	B-Drug
9	O
mg	O
twice	O
daily	O
increased	O
retapamulin	B-Drug
geometric	O
mean	O
AUC	O
(	O
9	O
-	O
9	O
)	O
and	O
Cmax	O
by	O
9	O
%	O
after	O
topical	O
application	O
of	O
retapamulin	B-Drug
ointment	O
9	O
%	O
on	O
the	O
abraded	O
skin	O
of	O
healthy	O
adult	O
males	O
.	O
      
Cholestyramine	B-Drug
increases	O
enterohepatic	O
elimination	O
of	O
amiodarone	B-Drug
and	O
may	O
reduce	O
its	O
serum	O
levels	O
and	O
t9	B-Drug
/	O
9	O
.	O
      
CYP	O
9A9	O
Inhibitors	O
(	O
e.g	O
.	O
Macrolide	B-Group
Antibiotics	I-Group
and	O
Protease	B-Group
Inhibitors	I-Group
)	O
There	O
have	O
been	O
rare	O
reports	O
of	O
serious	O
adverse	O
events	O
in	O
connection	O
with	O
the	O
coadministration	O
of	O
certain	O
ergot	B-Group
alkaloid	I-Group
drugs	I-Group
(	O
e.g	O
.	O
dihydroergotamine	B-Drug
and	O
ergotamine	B-Drug
)	O
and	O
potent	O
CYP	O
9A9	O
inhibitors	O
resulting	O
in	O
vasospasm	O
leading	O
to	O
cerebral	O
ischemia	O
and	O
/	O
or	O
ischemia	O
of	O
the	O
extremities	O
.	O
      
Blunting	O
of	O
the	O
antihypertensive	O
effect	O
of	O
beta	B-Group
-	O
adrenoceptor	I-Group
blocking	I-Group
agents	I-Group
by	O
nonsteroidal	B-Group
anti	I-Group
-	O
inflammatory	I-Group
drugs	I-Group
has	O
been	O
reported	O
.	O
      
Itraconazole	B-Drug
decreases	O
busulfan	B-Drug
clearance	O
by	O
up	O
to	O
9	O
%	O
and	O
may	O
produce	O
AUCs	O
9	O
M	O
min	O
in	O
some	O
patients	O
.	O
      
Studies	O
with	O
famotidine	B-Drug
in	O
man	O
in	O
animal	O
models	O
and	O
in	O
vitro	O
have	O
shown	O
no	O
significant	O
interference	O
with	O
the	O
disposition	O
of	O
compounds	O
metabolized	O
by	O
the	O
hepatic	O
microsomal	O
enzymes	O
e.g.	O
cytochrome	O
P9	O
system	O
.	O
      
Salicylic	B-Drug
acid	I-Drug
:	O
Combination	O
hormonal	B-Group
contraceptives	I-Group
may	O
increase	O
the	O
clearance	O
of	O
salicylic	B-Drug
acid	I-Drug
.	O
      
Since	O
FOSCAVIR	B-Brand
decreases	O
serum	O
concentrations	O
of	O
ionized	O
calcium	O
concurrent	O
treatment	O
with	O
other	O
drugs	O
known	O
to	O
influence	O
serum	O
calcium	O
concentrations	O
should	O
be	O
used	O
with	O
particular	O
caution	O
.	O
      
Antidepressants	B-Group
tricyclic	B-Group
:	O
Amphetamines	B-Group
may	O
enhance	O
the	O
activity	O
of	O
tricyclic	B-Group
or	O
sympathomimetic	B-Group
agents	I-Group
;	O
      
Glyburide	B-Drug
:	O
In	O
9	O
normal	O
-	O
weight	O
subjects	O
receiving	O
orlistat	B-Drug
9	O
mg	O
three	O
times	O
a	O
day	O
for	O
9	O
days	O
orlistat	B-Drug
did	O
not	O
alter	O
the	O
pharmacokinetics	O
or	O
pharmacodynamics	O
(	O
blood	O
glucose	O
-	O
lowering	O
)	O
of	O
glyburide	B-Drug
.	O
      
Diclofenac	B-Drug
:	O
Administration	O
of	O
morning	O
and	O
lunch	O
doses	O
of	O
Starlix	B-Brand
9	O
mg	O
in	O
combination	O
with	O
a	O
single	O
9	O
-	O
mg	O
dose	O
of	O
diclofenac	B-Drug
in	O
healthy	O
volunteers	O
resulted	O
in	O
no	O
significant	O
changes	O
to	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O
      
Therefore	O
when	O
chlorothiazide	B-Drug
and	O
non	B-Group
-	O
steroidal	I-Group
anti	I-Group
-	O
inflammatory	I-Group
agents	I-Group
are	O
used	O
concomitantly	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-Group
is	O
obtained	O
      
Paroxetine	B-Drug
:	O
Coadministration	O
of	O
once	O
daily	O
doses	O
of	O
aprepitant	B-Drug
as	O
a	O
tablet	O
formulation	O
comparable	O
to	O
9	O
mg	O
or	O
9	O
mg	O
of	O
the	O
capsule	O
formulation	O
with	O
paroxetine	B-Drug
9	O
mg	O
once	O
daily	O
resulted	O
in	O
a	O
decrease	O
in	O
AUC	O
by	O
approximately	O
9	O
%	O
and	O
Cmax	O
by	O
approximately	O
9	O
%	O
of	O
both	O
aprepitant	B-Drug
and	O
paroxetine	B-Drug
.	O
      
Because	O
CYP	O
9A9	O
inhibitors	O
may	O
increase	O
plasma	O
concentrations	O
of	O
buprenorphine	B-Drug
patients	O
already	O
on	O
CYP	O
9A9	O
inhibitors	O
such	O
as	O
azole	B-Group
antifungals	I-Group
(	O
e.g	O
.	O
      
When	O
administered	O
concurrently	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
adrenal	B-Group
corticosteroids	I-Group
.	O
      
However	O
appropriate	O
monitoring	O
of	O
blood	O
glucose	O
should	O
be	O
performed	O
when	O
initiating	O
EXTRANEAL	B-Brand
in	O
diabetic	O
patients	O
and	O
insulin	B-Drug
dosage	O
should	O
be	O
adjusted	O
if	O
needed	O
.	O
      
thyroid	B-Drug
medication	O
;	O
      
Co	O
-	O
administration	O
of	O
anastrozole	B-Drug
and	O
tamoxifen	B-Drug
resulted	O
in	O
a	O
reduction	O
of	O
anastrozole	B-Drug
plasma	O
levels	O
by	O
9	O
%	O
compared	O
with	O
those	O
achieved	O
with	O
anastrozole	B-Drug
alone	O
.	O
      
Doxazosin	B-Drug
mesylate	I-Drug
tablets	O
have	O
been	O
used	O
with	O
the	O
following	O
drugs	O
or	O
drug	O
classes	O
:	O
9	O
.	O
      
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
pharmacodynamic	O
effect	O
of	O
warfarin	B-Drug
administered	O
alone	O
and	O
warfarin	B-Drug
administered	O
with	O
Lodine	B-Brand
as	O
measured	O
by	O
prothrombin	O
time	O
.	O
      
Because	O
of	O
the	O
potential	O
for	O
additive	O
or	O
synergistic	O
depressant	O
effects	O
on	O
the	O
SA	O
and	O
AV	O
nodes	O
however	O
Adenocard	B-Brand
should	O
be	O
used	O
with	O
caution	O
in	O
the	O
presence	O
of	O
these	O
agents	O
.	O
      
On	O
the	O
basis	O
of	O
the	O
metabolism	O
of	O
bexarotene	B-Drug
by	O
cytochrome	O
P9	O
9A9	O
ketoconazole	B-Drug
itraconazole	B-Drug
erythromycin	B-Drug
gemfibrozil	B-Drug
grapefruit	O
juice	O
and	O
other	O
inhibitors	O
of	O
cytochrome	O
P9	O
9A9	O
would	O
be	O
expected	O
to	O
lead	O
to	O
an	O
increase	O
in	O
plasma	O
bexarotene	B-Drug
concentrations	O
.	O
      
Therefore	O
simultaneous	O
use	O
of	O
creams	O
ointments	O
or	O
oils	O
should	O
be	O
avoided	O
.	O
      
No	O
separate	O
information	O
available	O
      
In	O
order	O
to	O
monitor	O
the	O
occurrence	O
of	O
myelotoxicity	O
it	O
is	O
recommended	O
that	O
frequent	O
peripheral	O
blood	O
cell	O
counts	O
be	O
performed	O
on	O
all	O
patients	O
receiving	O
TAXOL	B-Brand
.	O
      
Propantheline	B-Drug
and	O
diphenoxylate	B-Drug
by	O
decreasing	O
gut	O
motility	O
may	O
increase	O
digoxin	B-Drug
absorption	O
.	O
      
A	O
dose	O
adjustment	O
may	O
be	O
required	O
.	O
      
The	O
pharmacokinetics	O
of	O
fenofibric	B-Drug_n
acid	I-Drug_n
were	O
not	O
significantly	O
affected	O
by	O
atorvastatin	B-Drug
      
certain	O
antibiotics	B-Group
especially	O
the	O
aminoglycosides	B-Group
and	O
polymyxins	B-Group
;	O
      
In	O
a	O
placebo	O
-	O
controlled	O
trial	O
in	O
normal	O
volunteers	O
the	O
administration	O
of	O
a	O
single	O
9	O
mg	O
dose	O
of	O
doxazosin	B-Drug
on	O
day	O
9	O
of	O
a	O
four	O
-	O
day	O
regimen	O
of	O
oral	O
cimetidine	B-Drug
(	O
9	O
mg	O
twice	O
daily	O
)	O
resulted	O
in	O
a	O
9	O
%	O
increase	O
in	O
mean	O
AUC	O
of	O
doxazosin	B-Drug
(	O
p=9	O
)	O
and	O
a	O
slight	O
but	O
not	O
statistically	O
significant	O
increase	O
in	O
mean	O
Cmax	O
and	O
mean	O
half	O
-	O
life	O
of	O
doxazosin	B-Drug
.	O
      
Other	O
Agents	O
:	O
No	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
occurred	O
when	O
UNIVASC	B-Brand
was	O
administered	O
concomitantly	O
with	O
hydrochlorothiazide	B-Drug
digoxin	B-Drug
or	O
cimetidine	B-Drug
.	O
      
It	O
is	O
recommended	O
to	O
avoid	O
concurrent	O
administration	O
of	O
ethambutol	B-Drug
with	O
aluminum	B-Drug
hydroxide	I-Drug
containing	O
antacids	B-Group
for	O
at	O
least	O
9	O
hours	O
following	O
ethambutol	B-Drug
administration	O
.	O
      
During	O
administration	O
of	O
multiple	O
oral	O
doses	O
of	O
TAMBOCOR	B-Brand
to	O
healthy	O
subjects	O
stabilized	O
on	O
a	O
maintenance	O
dose	O
of	O
digoxin	B-Drug
a	O
9	O
%	O
-	O
9	O
%	O
increase	O
in	O
plasma	O
digoxin	B-Drug
levels	O
occurred	O
at	O
six	O
hours	O
postdose	O
.	O
      
Patients	O
should	O
take	O
other	O
drugs	O
at	O
least	O
one	O
hour	O
before	O
or	O
four	O
hours	O
after	O
COLESTID	B-Brand
Tablets	O
to	O
avoid	O
impeding	O
their	O
absorption	O
.	O
      
In	O
diabetic	O
patients	O
the	O
metabolic	O
effects	O
of	O
androgens	B-Group
may	O
decrease	O
blood	O
glucose	O
and	O
therefore	O
insulin	B-Drug
requirements	O
.	O
      
Similarly	O
nateglinide	B-Drug
had	O
no	O
influence	O
on	O
the	O
serum	O
protein	O
binding	O
of	O
propranolol	B-Drug
glyburide	B-Drug
nicardipine	B-Drug
warfarin	B-Drug
phenytoin	B-Drug
acetylsalicylic	B-Drug
acid	I-Drug
and	O
tolbutamide	B-Drug
in	O
vitro	O
.	O
      
Monoamine	B-Group
Oxidase	I-Group
Inhibitors	I-Group
(	O
MAOIs	B-Group
)	O
      
TAMBOCOR	B-Brand
has	O
been	O
administered	O
to	O
patients	O
receiving	O
digitalis	B-Group
preparations	I-Group
or	O
beta	B-Group
-	O
adrenergic	I-Group
blocking	I-Group
agents	I-Group
without	O
adverse	O
effects	O
.	O
      
Co	O
-	O
administration	O
of	O
lovastatin	B-Drug
atenolol	B-Drug
warfarin	B-Drug
furosemide	B-Drug
digoxin	B-Drug
celecoxib	B-Drug
hydrochlorothiazide	B-Drug
ramipril	B-Drug
valsartan	B-Drug
metformin	B-Drug
and	O
amlodipine	B-Drug
did	O
not	O
result	O
in	O
clinically	O
significant	O
increases	O
in	O
aliskiren	B-Drug
exposure	O
.	O
      
However	O
neuromuscular	O
paralysis	O
may	O
be	O
potentiated	O
by	O
co	O
-	O
administration	O
or	O
overlapping	O
administration	O
of	O
different	O
botulinum	B-Group
toxin	I-Group
serotypes	O
.	O
      
Patients	O
receiving	O
concurrent	O
administration	O
of	O
substrates	O
of	O
C.P.A	O
.	O
were	O
not	O
excluded	O
from	O
clinical	O
trials	O
of	O
grepafloxacin	B-Drug
.	O
      
Diazepam	B-Drug
:	O
Diazepam	B-Drug
(	O
Valium	B-Brand
)	O
is	O
a	O
CYP	O
9A9	O
and	O
CYP	O
9C9	O
substrate	O
.	O
      
Single	O
doses	O
of	O
either	O
cholestyramine	B-Drug
or	O
colestipol	B-Drug
resins	B-Group
bind	O
the	O
hydrochlorothiazide	B-Drug
and	O
reduce	O
its	O
absorption	O
from	O
the	O
gastrointestinal	O
tract	O
by	O
up	O
to	O
9	O
and	O
9	O
percent	O
respectively	O
.	O
      
The	O
physician	O
should	O
be	O
notified	O
immediately	O
if	O
any	O
of	O
the	O
following	O
situations	O
occur	O
which	O
may	O
be	O
a	O
sign	O
of	O
seriously	O
worsening	O
asthma	O
:	O
Decreased	O
effectiveness	O
of	O
short	B-Group
-	O
acting	I-Group
inhaled	I-Group
beta9	I-Group
-	O
agonists	I-Group
;	O
      
These	O
drugs	O
should	O
be	O
coadministered	O
with	O
caution	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	B-Drug
levels	O
is	O
recommended	O
.	O
      
Probenecid	B-Drug
competes	O
with	O
meropenem	B-Drug
for	O
active	O
tubular	O
secretion	O
and	O
thus	O
inhibits	O
the	O
renal	O
excretion	O
of	O
meropenem	B-Drug
.	O
      
Vasopressors	B-Group
particularly	O
metaraminol	B-Drug
may	O
cause	O
serious	O
cardiac	O
arrhythmias	O
during	O
halothane	B-Drug
anesthesia	O
and	O
therefore	O
should	O
be	O
used	O
only	O
with	O
great	O
caution	O
or	O
not	O
at	O
all	O
.	O
      
Coadministration	O
of	O
SULAR	B-Brand
with	O
phenytoin	B-Drug
or	O
any	O
known	O
CYP9A9	O
inducer	O
should	O
be	O
avoided	O
and	O
alternative	O
antihypertensive	B-Group
therapy	O
should	O
be	O
considered	O
.	O
      
for	O
adult	O
-	O
onset	O
diabetics	O
dosage	O
adjustment	O
of	O
hypoglycemic	B-Group
medications	I-Group
may	O
be	O
necessary	O
during	O
and	O
after	O
thiazide	B-Group
diuretic	I-Group
therapy	O
;	O
      
Propoxyphene	B-Drug
:	O
In	O
cases	O
of	O
propoxyphene	B-Drug
overdosage	O
amphetamine	B-Drug
CNS	O
stimulation	O
is	O
potentiated	O
and	O
fatal	O
convulsions	O
can	O
occur	O
.	O
      
clofibrate	B-Drug
;	O
      
lithium	B-Drug
;	O
      
However	O
the	O
impairment	O
of	O
motor	O
skills	O
produced	O
by	O
REMERON	B-Brand
has	O
been	O
shown	O
to	O
be	O
additive	O
with	O
those	O
caused	O
by	O
diazepam	B-Drug
.	O
      
Specific	O
Effects	O
of	O
Felbatol	B-Brand
on	O
Other	O
Antiepileptic	B-Group
Drugs	I-Group
Phenytoin	B-Drug
:	O
Felbatol	B-Brand
causes	O
an	O
increase	O
in	O
steady	O
-	O
state	O
phenytoin	B-Drug
plasma	O
concentrations	O
.	O
      
This	O
is	O
based	O
on	O
the	O
results	O
from	O
9	O
clinical	O
studies	O
using	O
histamine	B-Drug
induced	O
skin	O
wheals	O
and	O
flares	O
coupled	O
with	O
population	O
pharmacokinetic	O
analysis	O
.	O
      
no	O
other	O
specific	O
drug	O
interaction	O
studies	O
were	O
performed	O
.	O
      
Patients	O
receiving	O
sirolimus	B-Drug
or	O
nifedipine	B-Drug
in	O
combination	O
with	O
MYCAMINE	B-Brand
should	O
be	O
monitored	O
for	O
sirolimus	B-Drug
or	O
nifedipine	B-Drug
toxicity	O
and	O
sirolimus	B-Drug
or	O
nifedipine	B-Drug
dosage	O
should	O
be	O
reduced	O
if	O
necessary	O
.	O
      
Alternate	O
treatments	O
lacking	O
CYP9A9	O
inducing	O
activity	O
should	O
be	O
considered	O
.	O
      
